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Dyspepsia suggests impaired digestion but when chronic, implies recurrent upper abdomi‐
nal pain or fullness that may follow a meal. Functional dyspepsia lacks evidence of a struc‐
tural basis, yet is a common disorder that often profoundly impacts the patient’s quality of
life. Many clinicians have a relatively poor understanding of factors that play a role in this
disorder. Differentiation between organic disease and functional dyspepsia is often difficult.
Further confounding this is their occasional co-existence. Management of patients with func‐
tional dyspepsia can be frustrating, particularly as symptoms are frequently refractory.
This textbook is specifically written for clinicians involved in managing patients with dys‐
pepsia. It is a practical guide with up-to-date suggestions on evaluation, diagnosis, and
management from experts from around the world. Each chapter is a succinct review of cur‐
rent topics that play a role in the pathogenesis and management of this disorder. Special
populations such as pediatrics, those with cardiovascular disease and women’s health are
specifically examined.
Dyspepsia: Advances in Understanding and Management is essential reading for those who wish
to advance their understanding of this complex and often challenging disorder.
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1. Introduction
Dyspepsia is defined as predominantly midline pain or discomfort located in the upper
abdomen [1]. Discomfort refers to a subjective, negative feeling that is not “painful”. Dyspepsia
can incorporate a variety of symptoms including early satiety or upper abdominal fullness.
Although the term implies a relationship with eating and the majority of patients have
symptoms worsened by food, this is no longer necessary to diagnose dyspepsia [2]. During
the investigation of dyspepsia, three major structural causes are readily identifiable: peptic
ulcer disease (10%), gastroesophageal reflux (20%) (with or without esophagitis), and malig‐
nancy (2%) [3]. Thus, most (50%-70%) patients with chronic dyspepsia do not have a significant
focal or structural lesion found at endoscopy. When symptoms are chronic or recurrent (table
1) but without an identifiable structural cause using standard diagnostic tests (usually
endoscopy), the condition is usually labelled functional or functional dyspepsia [4, 5]. Hence
functional dyspepsia is a diagnosis of exclusion, the implication being that symptoms have
been investigated without demonstrating an organic or anatomical cause [5].
Functional dyspepsia is not life-threatening and is not associated with any increase in mortal‐
ity. However, the impact of this condition on patients and health care services is considerable.
In a recent community survey of several European and North American populations, 20% of
people with dyspeptic symptoms had consulted either primary care physicians or hospital
specialists; more than 50% of dyspepsia sufferers were on medication most of the time and
approximately 30% reported taking days off from work or school due to their symptoms [5,
6]. Patients with functional dyspepsia have a significantly reduced quality of life when
compared to the general population [7].
The Rome III criteria for diagnosing functional dyspepsia are persistent or recurrent upper
abdominal pain or discomfort for a period of 12 weeks, which need not be consecutive, in the
preceding 12 months, with symptoms present more than 25 percent of the time, and an absence
© 2013 Sabih and Rahim; licensee InTech. This is a paper distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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of clinical, biochemical, endoscopic, and ultrasonographic evidence of organic disease that
would account for the symptoms [1] (Table 2).
12 weeks minimum, that need not be consecutive, in the preceding 12 months of:
• Persistent or recurrent symptoms (pain or discomfort centred in the upper abdomen);
• No evidence of organic disease (including at upper GI endoscopy) that is likely to explain the symptoms;
• No evidence that dyspepsia is exclusively relieved by defecation or associated with the onset of a change in stool
frequency or stool form (i.e., not irritable bowel).
Table 2. Rome III diagnostic criteria for functional dyspepsia [1, 9]
On the basis of the most bothersome or predominant single symptom, identified by the patient,
functional dyspepsia is further classified into various subgroups [4, 9]:
1. Ulcer-like dyspepsia
Pain centred in the upper abdomen is the predominant (most bothersome) symptom [9].
2. Dysmotility-like dyspepsia
An unpleasant or troublesome non-painful sensation (discomfort) centred in the upper
abdomen is the predominant symptom; this sensation may be characterized by or associated
with upper abdominal fullness, early satiety, bloating, or nausea [9].
3. Unspecified (non-specific) dyspepsia
Symptoms do not fulfil the criteria for ulcer-like or dysmotility-like dyspepsia [9].
Symptom Definition
Pain centered in the upper
abdomen
Pain refers to a subjective, unpleasant sensation; some patients may feel that tissue
damage is occurring. Other pain sensations could be throbbing, shooting, stabbing,
cramping, gnawing, burning or aching. By questioning the patient, pain should be
distinguished from discomfort.
Discomfort centered in the
upper abdomen
A subjective, unpleasant sensation or feeling that is not interpreted as pain according to
the patient and which, if fully assessed, can include any of the symptoms below.
Early satiety A feeling that the stomach is overfilled soon after starting to eat, out of




Unpleasant sensations like the persistence of food in the stomach; this
may or may not occur post-prandially (slow digestion).
Bloating in the
upper abdomen
Tightness located in the upper abdomen; it should be distinguished
from visible abdominal distension.
Nausea Queasiness or sick sensation; a feeling of the need to vomit.
Table 1. The spectrum of dyspepsia symptoms and recommended definitions [4, 5]
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2. Functional dyspepsia: Pathophysiologic mechanisms and their relation
to symptom pattern
Several pathophysiologic mechanisms explain underlie dyspeptic symptoms. These include
delayed gastric emptying, impaired gastric accommodation to a meal, and hypersensitivity to
gastric distension, H. pylori infection, altered response to duodenal lipids or acid, abnormal
duodenojejunal motility, or central nervous system dysfunction. At present, the pathophysiol‐
ogy of functional dyspepsia is only partially elucidated. However, there is growing evidence
that functional dyspepsia is in fact a very heterogeneous disorder and different subgroups can
be identified based on different demographic, clinical, and pathophysiologic features [2].
1. Delayed gastric emptying
Delayed gastric emptying is traditionally considered a major pathophysiologic mechanism
underlying symptoms in functional dyspepsia and idiopathic gastroparesis [10]. Several large
single-centre studies from Europe found association between delayed gastric emptying and
the prevalence and severity of symptoms like post-prandial fullness, nausea, and vomiting
[10]. Similarly, other reports have investigated the relationship between delayed gastric
emptying and symptom pattern and severity [2]. Depending on the study, the percentage of
dyspeptic patients with delayed gastric emptying ranges from 20% to 50%. In a meta-analysis
of 17 studies involving 868 dyspeptic patients and 397 controls, significant delay of solid gastric
emptying was present in almost 40% of patients with functional dyspepsia [11]. Various causes
of delayed gastric emptying are summarized in table 3.
2. Impaired gastric accommodation to a meal
The motor functions of the proximal and distal stomach differ remarkably. The proximal
stomach (body) serves mainly as a reservoir. In contrast, the distal stomach (antrum) regulates
gastric emptying of solids by grinding and sieving the contents until the particles are small
enough to pass the pylorus. The stomach accommodates to a meal by relaxing of the proximal
stomach, providing the meal with a reservoir and enabling an increase in volume without an
increase in pressure. Scintigraphic and ultrasonographic studies have shown an abnormal
intragastric distribution of food in patients with functional dyspepsia, with preferential
accumulation in the distal stomach. These findings suggest defective postprandial accommo‐
dation of the proximal stomach [12, 13].
3. Hypersensitivity to gastric distension
Physiologic stimuli during the digestive process are not normally perceived but in some
circumstances may induce conscious sensations. Patients with functional gastrointestinal
diseases may have a sensory dysfunction of the gut (termed visceral hypersensitivity), with
normal physiological stimuli perceived as discomfort or pain [14]. Patients with functional
dyspepsia appear to have enhanced sensitivity to gastric distension [10, 15, 16].
4. Altered duodenal sensitivity to lipids or acid
The symptoms of dyspepsia are usually exacerbated by meals which are rich in fat [20].
Similarly the duodenum is more sensitive to acid in those with functional dyspepsia. The
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duodenal motor response to acid is decreased in patients with functional dyspepsia, resulting
in reduced clearance of exogenous duodenal acid [21].
5. Inflammation
About a third of patients with irritable bowel syndrome or dyspepsia describe the onset of
symptoms after an acute enteric infection. It is possible that mucosal inflammation may have
a part in the creation of the visceral hypersensitivity.
6. H. Pylori infection
The discovery of H. pylori led to uncovering a causal relationship between H. pylori infection
and the occurrence of duodenal and gastric ulcers [17]. The role of H. pylori is less clear in
functional dyspepsia. Systematic reviews of the epidemiologic evidence on a relationship
between H. pylori infection and functional dyspepsia have found no evidence for a strong
association [18, 19].
*The alarm features are unintended weight loss, progressive dysphagia, recurrent or persistent vomiting, evidence of
gastrointestinal bleeding, anemia, fever, family history of gastric cancer, new onset dyspepsia in the subjects over 40
years of age in population with high prevalence of upper gastrointestinal malignancy and over 45 and 50 years in
populations with intermediate and low prevalence, respectively. **Adapted from reference [22]
Figure 1. Diagnostic algorithm for functional (functional) dyspepsia**
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3. Causes of delayed gastric emptying




Cigarette smoking, Alcohol, Viral gastroenteritis, Hyperglycemia,
Acidosis, Hypokalemia, Immobilization, Myxoedema, Hypocalcaemia,




Gastric ulcer disease, Functional dyspepsia, Gastroesophageal reflux
disease, Diabetes Mellitus, Hypothyroidism, Post gastric surgery,
Addison’s diseases, Pernicious anaemia, Achlorhydria, Connective
tissue diseases, Anorexia nervosa, Depression, Neurologic disorders
(Multiple sclerosis, Parkinsonism, paraneoplastic syndrome etc).
Pharmacological Agents and
Hormones
Antacids (aluminium hydroxide), Opiates, Anticholinergics, Tricyclic
antidepressants, Beta adrenergic agonists, Levodopa, Calcium channel
blockers, Progesterone, Birth control pills, Gastrin, Cholecystokinin,
Somatostatin
Table 3. Causes of Delayed Gastric Emptying [23].
4. Diagnostic investigations of dyspepsia
Functional dyspepsia is usually a diagnosis of exclusion; the diagnosis is made after eliminat‐
ing organic disease or a structural basis for symptoms. The physician must decide how many
investigations to order before deciding that the patient has a functional disorder (Table 4). The
heterogeneity of presentation and the extensive differential diagnosis including significant
organic disease mandates rapid exclusion of pathologies like peptic ulcer disease, reflux
esophagitis and malignancy of the stomach or esophagus. Another perspective is the test-and-
treat approach that includes acid suppression, treatment of H.pylori infection and early
endoscopy. Patients with “alarm features” (Fig 1), or those older than 40-50 years (depending
on ethnicity) require a more aggressive strategy such as early endoscopy. It must also be
understood that there are many patients who can have both organic as well as functional
components of dyspepsia.
Initial investigations may include blood counts, electrolytes, fasting blood sugar, renal function
tests and thyroid function tests. Testing for celiac disease and stool examination for occult
blood or parasites may also be considered. H.pylori infection can be diagnosed by serology,
breath or stool testing.
Gastric accommodation can be assessed by gastric barotest. The barotest measures gastric tone
and comprises of a bag that can be maintained at a constant pressure by feedback mechanisms
(termed a barostat). Volume changes in the bag thus represent variation in gut - the bag
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treat approach that includes acid suppression, treatment of H.pylori infection and early
endoscopy. Patients with “alarm features” (Fig 1), or those older than 40-50 years (depending
on ethnicity) require a more aggressive strategy such as early endoscopy. It must also be
understood that there are many patients who can have both organic as well as functional
components of dyspepsia.
Initial investigations may include blood counts, electrolytes, fasting blood sugar, renal function
tests and thyroid function tests. Testing for celiac disease and stool examination for occult
blood or parasites may also be considered. H.pylori infection can be diagnosed by serology,
breath or stool testing.
Gastric accommodation can be assessed by gastric barotest. The barotest measures gastric tone
and comprises of a bag that can be maintained at a constant pressure by feedback mechanisms
(termed a barostat). Volume changes in the bag thus represent variation in gut - the bag
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becomes bigger with gut relaxation and smaller with contraction. “Barotesting” is the “gold
standard” for visceral hypersensitivity, but is invasive and uncomfortable, so non-invasive
means have been developed that include SPECT (Single Photon Emission Tomography)
imaging and 3-D ultrasound.
SPECT can be used to assess intragastric volume although correlation with barotest has not
been consistently established and the volumes determined do not reflect muscle activity of the
stomach. 3D ultrasound can also be used for volume determination of the stomach but this
remains a highly operator dependent technique and there is limited data available in the
literature.
Chemical hypersensitivity tests can be done by a duodenal infusion of lipid to provoke early
symptoms of gastric distension in patients with functional dyspepsia and relief by adminis‐
tering a cholecystokinin receptor antagonist (loxiglumide). CCK-8 (cholecystokinin octapep‐
tide) intravenously can be used instead of the lipid infusion to provoke symptoms in patients
with functional dyspepsia, but this does not affect normal individuals.
Scintigraphic imaging lends itself elegantly to the evaluation of functional-dyspepsia due to
the inherent strength of dynamic imaging and generating physiological data. Currently, it
remains the only method to quantitatively measure the rate of gastric emptying.
Gastric scintigraphy employs a radiolabeled meal to measure emptying [24]. Gastric scintig‐
raphy has evolved to include an evaluation of compartmental or antral motility, and more
recently to SPECT to evaluate postprandial gastric accommodation. As a physiologic, quanti‐
tative, and non-invasive test, gastric emptying scintigraphy is well suited for evaluating
patients before and after medical or surgical treatment. This procedure is now widely consid‐
ered the gold standard for evaluating gastric emptying. The advantages of radionuclide
imaging are:
1. The method is simple and non-invasive from the patient’s point of view, requiring a single
oral administration of the radionuclide.
2. The meal used in this method is physiological and does not alter the normal physiology
of the gut.
3. Reaction to the radiopharmaceutical is rare.
4. Both solid and liquid meals can be studied and the gastric emptying can be quantified.
5. The radiation dose is very low so that repeated studies can be done to follow the progress
of the disease or the response to treatment and the method can therefore be used as a
research tool.
6. This method can be used to assess the amount of original meal in the stomach irrespective
of the gastric secretions or the duodenal reflux.
7. There is no documented complication reported as the result of the gastric emptying
studies.
8. There are different protocols with a 2, 3 or 4 hour end points (3 and 4 hour end points are
emerging as more diagnostic).
Dyspepsia - Advances in Understanding and Management6





• Gastroparesis can be diagnosed with barium
meal
• Contraindicated in acid peptic disease and
partial intestinal obstruction
• Can cause barium appendicitis
Ultrasonography
• Non invasive
• Does not involve ionizing radiation
• Equipment used is available in most of the
hospitals
• Operator dependent
• Relatively time consuming as it requires
repeated and prolonged observations
Endoscopy
• Permits direct visualization of the oesophagus,
gastric and duodenal mucosa
• First-line diagnostic procedure for patients with
alarm features
• Invasive procedure
• Not well accepted by patients
• Requires trained personnel
• Limited availability of equipment
Gastric emptying
scintigraphy
• Simple and non-invasive
• Physiological meal used
• No reaction to pharmaceutical
• No documented complication
• Ionizing radiation used
• Time consuming
• Equipment widely available
• Degree of delayed gastric emptying does not
correlate well with symptomatology
C-13 Acetate breath test
• Non invasive
• No radiation involved
• Can be adapted for solid or liquid emptying
(C-13 sodium acetate for liquid and C-13 octanoic
acid for solids)
• Variability similar to other tests
• Good reproducibility
• Needs special equipment (mass
spectrophotometer) but cheaper alternates have
been developed (NDIRS* and LARA**)
*NDIRS Non-dispersive isotope-selective infrared spectroscopy
**LARA Laser-assisted ratio analysis
Table 4. Investigations for the work-up of functional dyspepsia with their strengths and weaknesses
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Figure 3. Figure Dynamic images and time–activity curves of a normal person.
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Figure 4. Dynamic images and time–activity curves of a patient with impaired gastric emptying.
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Functional dyspepsia is a common problem with a significant impact on individuals and
society. A variety of diagnostic tests are available to exclude organic disease and characterize
underlying pathophysiologic abnormalities. Further work is needed to validate existing
diagnostic tests in different populations. The goal of having an objective test that correlates
with the symptom severity remains elusive. Physicians must remain cognisant that functional
disorders create the same or perhaps even more distress in the patient when compared to
conditions that can yield evidence of organic pathology.
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1. Introduction
Dyspepsia is currently defined by Rome III criteria for the diagnosis of functional gastroin‐
testinal disorders (FGIDs), as the presence of one or more of the following symptoms: both‐
ersome postprandial fullness, early satiation, epigastric pain and epigastric burning [1] These
are symptoms thought to originate from the gastroduodenal region. Bloating and nausea often
coexist with dyspepsia but are considered nonspecific and are thus not included in the Rome
III criteria. However, there have been attempts by some researchers to broaden this definition
to include more symptoms. The Asian consensus guideline includes bloating, nausea, vomit‐
ing and belching in the definition of dyspepsia [2]
Dyspeptic patients who have not undergone any investigations are defined as having unin‐
vestigated dyspepsia. An organic cause is found in only a minority who seek medical care [3,
4]. The remaining group is labeled as having functional dyspepsia (FD). Organic dyspepsia
means there is a clear anatomic or pathophysiologic reason for the dyspeptic complaints, such
as peptic ulcer or cancer. In contrast, when a diagnosis of functional dyspepsia has been made,
it means that a number of investigations were performed including upper gastrointestinal
endoscopy, and were found to be normal [5].
The need for more systematic description of FGIDs gave rise to the Rome process, which has
evolved from Rome I in 1991 [6], Rome II in 1999 [7], to the most recent, which is Rome III [1].
According to Rome I and Rome II definitions, FD was defined as the presence of pain or
discomfort centered in the upper abdomen, in the absence of organic disease that readily
explained the symptoms [7]. While the meaning of pain is readily understood, the lack of an
accurate definition for discomfort was a major limitation of Rome I. Rome I also included reflux
symptoms in FD, and recognized a subgroup called “reflux-like dyspepsia”. Rome II tried to
correct this by excluding patients with predominant heartburn from the definition of FD. Rome
© 2013 Nwokediuko; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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I and Rome II criteria did not account for meal-related symptoms and this was the fundamental
change in Rome III criteria [8, 9].
Rome III criteria made a distinction between meal-induced symptoms and meal-unrelated
symptoms, and this forms the basis of newly defined subcategories of FD:
1. Meal-induced dyspeptic symptoms (postprandial distress syndrome, which is character‐
ized by postprandial fullness and early satiation)
2. Epigastric pain syndrome or EPS, characterized by epigastric pain and epigastric burning.
The traditional definition of FD portrays it as an idiopathic condition [10]. However, recent
studies suggest that this condition have some pathophysiologic correlates. A diversity of
changes in gastrointestinal structure and function has been described in this heterogeneous
disorder. In this chapter, the author attempts to provide an overview of structural and
physiological alterations in FD beyond those demonstrable by conventional tests used to
separate organic dyspepsia from its functional counterpart.
2. Current definition of Functional Dyspepsia
According to Rome III criteria, FD must include one or more of the following symptoms:
bothersome postprandial fullness, early satiation, epigastric pain and epigastric burning; with
no evidence of structural disease, including use of upper gastrointestinal endoscopy, which is
likely to explain the symptoms. Criteria should be fulfilled for at least 3 months with symptom
onset at least 6 months previously [1].
Older terms that represent FD are non-ulcer dyspepsia, idiopathic or essential dyspepsia. The
term non ulcer dyspepsia is still popular but no longer recommended because it implies that
the patient has symptoms similar to peptic ulcer disease without having an actual ulcer on
endoscopic examination. The spectrum of symptoms in FD includes epigastric pain syndrome
and postprandial distress syndrome
At least 3 months, with onset at least 6 months previously, of one or more of the following:





No evidence of structural disease (including upper endoscopy) that is likely to explain the symptoms.
Table 1. Rome III diagnostic criteria for functional dyspepsia [1]
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3. Definitions of functional dyspepsia symptoms [1]
The Rome III committee proposed a distinction between meal-induced symptoms and meal-
unrelated symptoms to be pathophysiologically, clinically and therapeutically relevant.
Epigastric pain syndrome:
1. Epigastric pain
Epigastric refers to the region between the umbilicus and lower end of the sternum, and
marked by the midclavicular lines. Pain refers to a subjective, unpleasant sensation; some
patients may feel that tissue damage is occurring.
2. Epigastric burning
Epigastric refers to the region between the umbilicus and lower end of the sternum, and
marked by the midclavicular lines. Burning refers to an unpleasant subjective sensation of heat.
Postprandial distress syndrome:
1. Postprandial fullness: An unpleasant sensation like the prolonged persistence of food in
the stomach.
2. Early satiation: A feeling that the stomach is overfilled soon after starting to eat, out of
proportion to the size of the meal being eaten, so that the meal cannot be finished.
Previously, the term ‘early satiety’ was used, but satiation is the correct term for the
disappearance of the sensation of appetite during food ingestion.
Recent research findings indicate that postprandial distress syndrome and epigastric pain
syndrome overlap in majority of patients with FD [11]. The implication of this is that the value
of dividing FD into the subgroups of postprandial distress syndrome and epigastric pain
syndrome is thus questionable [11]
4. Evaluating a patient with dyspepsia
4.1. Symptom-based diagnosis
The introduction of Rome criteria and Rome process was a milestone in the management of
FGIDs. However, the high turnover of Rome criteria is a testimony to the fact that symptom-
based diagnosis has limitations. Symptoms may be perceived differently within different
cultures and languages. It has been recommended that the current Rome III questionnaire be
translated into local languages [12]. Symptoms are poor predictors of FD and significant
overlaps are often seen with functional disorders including functional heartburn and irritable
bowel syndrome. [13-22].
One of the difficulties encountered in evaluating a patient with dyspepsia is that symptoms
are nonspecific and cannot accurately differentiate an organic process from a functional
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physiological alterations in FD beyond those demonstrable by conventional tests used to
separate organic dyspepsia from its functional counterpart.
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no evidence of structural disease, including use of upper gastrointestinal endoscopy, which is
likely to explain the symptoms. Criteria should be fulfilled for at least 3 months with symptom
onset at least 6 months previously [1].
Older terms that represent FD are non-ulcer dyspepsia, idiopathic or essential dyspepsia. The
term non ulcer dyspepsia is still popular but no longer recommended because it implies that
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At least 3 months, with onset at least 6 months previously, of one or more of the following:





No evidence of structural disease (including upper endoscopy) that is likely to explain the symptoms.
Table 1. Rome III diagnostic criteria for functional dyspepsia [1]
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3. Definitions of functional dyspepsia symptoms [1]
The Rome III committee proposed a distinction between meal-induced symptoms and meal-
unrelated symptoms to be pathophysiologically, clinically and therapeutically relevant.
Epigastric pain syndrome:
1. Epigastric pain
Epigastric refers to the region between the umbilicus and lower end of the sternum, and
marked by the midclavicular lines. Pain refers to a subjective, unpleasant sensation; some
patients may feel that tissue damage is occurring.
2. Epigastric burning
Epigastric refers to the region between the umbilicus and lower end of the sternum, and
marked by the midclavicular lines. Burning refers to an unpleasant subjective sensation of heat.
Postprandial distress syndrome:
1. Postprandial fullness: An unpleasant sensation like the prolonged persistence of food in
the stomach.
2. Early satiation: A feeling that the stomach is overfilled soon after starting to eat, out of
proportion to the size of the meal being eaten, so that the meal cannot be finished.
Previously, the term ‘early satiety’ was used, but satiation is the correct term for the
disappearance of the sensation of appetite during food ingestion.
Recent research findings indicate that postprandial distress syndrome and epigastric pain
syndrome overlap in majority of patients with FD [11]. The implication of this is that the value
of dividing FD into the subgroups of postprandial distress syndrome and epigastric pain
syndrome is thus questionable [11]
4. Evaluating a patient with dyspepsia
4.1. Symptom-based diagnosis
The introduction of Rome criteria and Rome process was a milestone in the management of
FGIDs. However, the high turnover of Rome criteria is a testimony to the fact that symptom-
based diagnosis has limitations. Symptoms may be perceived differently within different
cultures and languages. It has been recommended that the current Rome III questionnaire be
translated into local languages [12]. Symptoms are poor predictors of FD and significant
overlaps are often seen with functional disorders including functional heartburn and irritable
bowel syndrome. [13-22].
One of the difficulties encountered in evaluating a patient with dyspepsia is that symptoms
are nonspecific and cannot accurately differentiate an organic process from a functional
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disorder. Neither clinical impression, nor computer models incorporating patient demograph‐
ics, risk factors, history items, and symptoms can distinguish between organic and functional
disease in patients referred for endoscopic evaluation of dyspepsia( [23].
There is also a high degree of overlap between FD symptoms and those of gastroparesis [1,
24-29]. In FD, the predominant sensation of early satiety was found to be closely associated
with impaired accommodation, although it was also present in more than 30% of patients with
delayed gastric emptying [26]. Nausea and vomiting, thought to be cardinal symptoms of
gastroparesis, are present in at least 20-50% of patients with FD [25, 30, 31]. Epigastric pain
thought to be a cardinal symptom of FD is also present in up to 90% of patients with gastro‐
paresis (GP) [32, 33]. Generally, common symptoms of gastric neuromuscular dysfunction are
nonspecific and cannot reliably predict the underlying pathophysiology [24-26, 34]. Further‐
more, recent research data indicate that rapid gastric emptying has been implicated in
functional dyspepsia symptoms, especially in the postprandial distress syndrome [35, 36].
Enhanced antral contractility, decreased duodenal feedback inhibition and impaired accom‐
modation represent the underlying mechanisms [37, 38].
The current approach is to view functional dyspepsia and idiopathic gastroparesis, not as
completely distinct disorders, but as a broad, continuous spectrum, with significant overlap.
It has been proposed that these 2 entities be reclassified under the umbrella term of functional
dyspepsia with or without disordered gastric emptying [39], to enable clinicians and research‐
ers to focus on predominant symptoms expressed by the majority of patients with this disorder.
4.2. Age
Older age is an important predictor for the presence of organic disease. The American
Gastroenterological Association recommends proceeding directly to endoscopy in patients
older than 55 years [40], however, there has been debate about a lower cut-off age of 35 to 45
years in men [41]. The optimal age threshold for endoscopy is unclear but 55 years seems a
reasonable cut-off because cancer is rare in younger patients but no age threshold is absolute
[42] Age specific thresholds to trigger endoscopic evaluation may differ by sex and locality [43,
44] Prompt endoscopy in patients over 50 years regardless of alarm status has been shown to
increase the proportion of curable cases of upper gastrointestinal malignancies by as much as
30% [45-47], but the cost-effectiveness of initial endoscopy in this age group for improving
survival of cancer patients is uncertain [47, 48]. Distinct upper gastrointestinal malignancy
incidence rates and various distributions of its topographical types in different populations
[49-52], as well as differences in Helicobacter pylori infection rates [53, 54] could partly explain
the variable results.
4.3. Alarm features
Alarm features include unintended weight loss, family history of upper gastrointestinal
cancer, gastrointestinal bleeding, progressive dysphagia, odynophagia, unexplained iron
deficiency anemia, persistent vomiting, palpable mass, lymphadenopathy and jaundice. These
features are useful in identifying high risk patients who need early endoscopy. The absence
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of alarm features makes the likelihood of finding important structural causes for dyspepsia
very low. However, a meta-analysis found that negative predictive value of alarm features
was poor (6%) [55]. Worse still, subjects with organic pathologies may also have FD. [56]
4.4. Helicobacter pylori testing
Testing for Helicobacter pylori in dyspepsia may be used to select the subgroup of dyspeptic
patients who have Helicobacter-related dyspepsia. The Asian consensus guideline posits that
this is strictly not a form of FD. Proponents of this argue that gastritis can now be identified
easily with advanced endoscopic techniques, and that Helicobacter pylori-dyspepsia is a form
of post-infectious FD [2]. Exclusion of Helicobacter pylori infection should be an important
part of diagnostic exercise in parts of the world where the burden of infection is high [2]. The
effect of Helicobacter pylori eradication on the amelioration of symptoms in patients with FD
has been evaluated in several large, well-designed, randomized controlled trials, but the results
were conflicting [57-61]. Eradication of Helicobacter pylori in FD appears to improve dyspeptic
symptoms more in the Chinese population than in Western populations [2]
4.5. Gastric accommodation and visceral hypersensitivity
The accommodation reflex is a vagally mediated volume response of the upper part of the
stomach after a meal. After ingestion of food, the gastric fundus spontaneously dilates and
begins to store food [62]. Impairment of this accommodation reflex is known to correlate well
with dyspeptic symptoms especially early satiation [63, 64]. Enhanced perception of physio‐
logical signals arising from the stomach (visceral hypersensitivity) is considered a hallmark of
functional gastrointestinal disorders including FD [65]. Such hypersensitivity can be repro‐
duced acutely by different types of mechanical gastric distension [66, 67]. However, it has not
been possible to conclusively identify the site and mechanisms underlying visceral hypersen‐
sitivity in FD.
Gastric barostat is gold standard for investigating gastric accommodation. It is however,
invasive, time-consuming and uncomfortable to patients. Newer techniques include single
photon emission computed tomography (SPECT) [64], 2- and 3- dimensional gastric ultra‐
sound [68] and magnetic resonance imaging [69]. These are noninvasive but their high cost,
sophistication and radiation exposure make them less attractive.
Drinking test is simpler [70]. It is based on the assumption that gastric volume is reduced with
impaired accommodation and therefore limits the drinking volume. This test has been
validated against the gastric barostat but the reproducibility is limited due to differences in
types of drink and rates of drinking. In general these tests are poorly associated with dyspeptic
symptoms and cannot predict a response to treatment in FD. Therefore they are not yet
available for routine clinical use.
4.6. Gastric emptying
Gastroparesis is a syndrome characterized by delayed gastric emptying in absence of me‐
chanical obstruction. Its causes include diabetes mellitus, post-surgical and idiopathic [71].
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patients who have Helicobacter-related dyspepsia. The Asian consensus guideline posits that
this is strictly not a form of FD. Proponents of this argue that gastritis can now be identified
easily with advanced endoscopic techniques, and that Helicobacter pylori-dyspepsia is a form
of post-infectious FD [2]. Exclusion of Helicobacter pylori infection should be an important
part of diagnostic exercise in parts of the world where the burden of infection is high [2]. The
effect of Helicobacter pylori eradication on the amelioration of symptoms in patients with FD
has been evaluated in several large, well-designed, randomized controlled trials, but the results
were conflicting [57-61]. Eradication of Helicobacter pylori in FD appears to improve dyspeptic
symptoms more in the Chinese population than in Western populations [2]
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The accommodation reflex is a vagally mediated volume response of the upper part of the
stomach after a meal. After ingestion of food, the gastric fundus spontaneously dilates and
begins to store food [62]. Impairment of this accommodation reflex is known to correlate well
with dyspeptic symptoms especially early satiation [63, 64]. Enhanced perception of physio‐
logical signals arising from the stomach (visceral hypersensitivity) is considered a hallmark of
functional gastrointestinal disorders including FD [65]. Such hypersensitivity can be repro‐
duced acutely by different types of mechanical gastric distension [66, 67]. However, it has not
been possible to conclusively identify the site and mechanisms underlying visceral hypersen‐
sitivity in FD.
Gastric barostat is gold standard for investigating gastric accommodation. It is however,
invasive, time-consuming and uncomfortable to patients. Newer techniques include single
photon emission computed tomography (SPECT) [64], 2- and 3- dimensional gastric ultra‐
sound [68] and magnetic resonance imaging [69]. These are noninvasive but their high cost,
sophistication and radiation exposure make them less attractive.
Drinking test is simpler [70]. It is based on the assumption that gastric volume is reduced with
impaired accommodation and therefore limits the drinking volume. This test has been
validated against the gastric barostat but the reproducibility is limited due to differences in
types of drink and rates of drinking. In general these tests are poorly associated with dyspeptic
symptoms and cannot predict a response to treatment in FD. Therefore they are not yet
available for routine clinical use.
4.6. Gastric emptying
Gastroparesis is a syndrome characterized by delayed gastric emptying in absence of me‐
chanical obstruction. Its causes include diabetes mellitus, post-surgical and idiopathic [71].
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Delayed gastric emptying occurs in 23-59% of patients with FD [72]. Research has shown that
delayed gastric emptying may be related to postprandial fullness and vomiting with symp‐
toms being more frequently found in female patients than in males [73-75]. Other studies have
failed to confirm any difference in the occurrence of FD symptoms between patients with
normal or delayed gastric emptying [76, 77]
Assessment of gastric emptying is commonly performed for such indications as nausea,
vomiting and dyspepsia. However, there is a poor correlation of symptoms to observed
abnormalities.
Techniques of gastric emptying include scintigraphy, which is the standard method in clinical
practice, but is associated with radiation exposure. Newer non-invasive methods include
wireless motility capsule and gastric emptying breath testing. Ultrasound, single-photon
emission computed tomography (SPECT) and magnetic resonance imaging (MRI) are pre‐
dominantly research tools.
4.7. Chemical hypersensitivity test
The duodenum is implicated in the pathophysiology of FD. Duodenal hypersensitivity and
abnormal responses to various substances have been observed in FD.
Duodenal hypersensitivity to lipid: Duodenal infusion of lipid in subjects with FD increased
gastric distension and symptoms in a dose-dependent fashion [78]. Symptom relief is achieved
with administration of Loxiglumide, a cholecystokinin A receptor antagonist and this suggests
that cholecystokinin release following a lipid stimulus is the mediator of gastric hypersensi‐
tivity in FD [79] Using cholecystokinin infusion as a challenge test is appealing [80] but is not
yet available for clinical use.
Buspirone challenge test [81] is another chemical hypersensitivity test. This chemical is a
serotonin 1A agonist that acts at the hypothalamic level to stimulate prolactin release. The
extent of prolactin release following Buspirone challenge is a reliable measure of central 5HT
sensitivity which can be impaired in patients with FD [82, 83].
Duodenal sensitivity to acid infusion: Studies on the presence of duodenal hypersensitivity
to acid in FD patients and its role in the pathophysiology of FD remain controversial. Samson
et al [84] reported that duodenal acid infusion induced nausea in a subset of FD patients, but
not in healthy controls, suggesting the presence of duodenal hypersensitivity to acid in FD
patients. However, other studies found that dyspeptic symptoms such as nausea could be
induced by duodenal acidification in healthy volunteers [85].
5. Empirical treatment
Therapeutic trial may be employed as a means of diagnosis. This has proved successful in the
management of GERD but the story in FD is entirely different because its pathogenesis is poorly
understood and there is no effective treatment. Also, there is often a substantial placebo effect.
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The new drug, Acotiamide, an acetylcholinesterase inhibitor is promising and has been shown
to be efficacious and safe in the elimination of meal-related FD symptoms [86]. Though not yet
approved for treatment of FD, it holds high promise as no adverse events were recorded.
5.1. Duodenal eosinophilia
Eosinophils and mast cells may be specifically recruited to the duodenum, altering sensation
and motility [87]. The duodenum, which is often ignored in the search for pathophysiologic
explanations for FD may be key to the symptom experience in FD. Mast cells induce eosinophil
migration and eosinophils activate mast cells [88]. Degranulation from mast cells and eosino‐
phils leads to neural stimulation and smooth muscle contraction, which in turn results in
gastrointestinal symptoms, such as abdominal pain and bloating [89]. While a significant
increase in mast cells has not been observed in the duodenum of patients with FD, duodenal
eosinophilia in FD has been described [90, 91]. This finding is exciting, because, in patients
undergoing endoscopy, duodenal biopsy is safe and easy to perform. This finding also has a
potential therapeutic implication which further research would unravel.
Putative test/Abnormality Comments/Pitfalls
Helicobacter pylori testing Useful in identifying patients who have Helicobacter pylori
– associated dyspepsia
Gastric accommodation test Several tests have been developed. Invasiveness, high cost,
patient discomfort and radiation exposure remain
challenges
Gastric emptying test Scintigraphy is currently available for clinical use.
Empirical treatment Not a viable option because of poorly understood
pathogenesis and lack of effective treatment
Duodenal eosinophilia Initial studies promising. Larger studies needed.
Duodenal acid infusion Results controversial
Duodenal lipid infusion Duodenal hypersensitivity to lipids consistently obtained
from most studies
Chemical hypersensitivity tests Several candidate chemicals at various stages of
development
Table 2. Summary of structural and functional abnormalities of the gastrointestinal tract in functional dyspepsia
In conclusion, dyspepsia is a very common clinical problem globally. Majority of patients with
this problem have FD, defined traditionally as dyspepsia in which investigations, including
upper gastrointestinal endoscopy fail to reveal a structural, biochemical or other pathophy‐
siologic reason for the symptom. The pathophysiology of FD remains poorly understood.
Recent information from research shows that there are structural and physiological changes
in FD that may hold the key to further understanding of the pathogenesis of this disease. These
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include Helicobacter pylori infection, abnormalities of gastric accommodation, abnormalities
of gastric emptying, duodenal eosinophilia duodenal hypersensitivity to acid and lipids. These
changes have prospects of being deployed in future for the diagnostic evaluation of FD. The
implication of this is that FD may not be idiopathic after all. Research is likely to shed more
light on this in future.
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In the late 1980s, a group of experts met in Rome to establish symptom-based diagnostic criteria
for functional gastrointestinal disorders (FGIDs). This first set of “Rome criteria,” published
in 1989, focused exclusively on adults [1]. In 1999, when these criteria were revised, a pediatric
committee established a parallel set of diagnostic criteria for FGIDs in children and adolescents
[2]. The Rome II pediatric subcommittee defined four pediatric disorders related to abdominal
pain: functional dyspepsia (FD), irritable bowel syndrome (IBS), abdominal migraine, and
functional abdominal pain. With Rome II, FD was defined as persistent or recurrent pain or
discomfort centered in the upper abdomen (above the umbilicus) that was unrelated to a
change in stool frequency or form and not exclusively relieved by defecation. Further, there
had to be no evidence of an inflammatory, anatomic, metabolic, or neoplastic process to explain
the patient’s symptoms. Importantly, the committee determined that mild, chronic inflamma‐
tory changes on mucosal biopsies should not preclude the diagnosis of FD. Similar to the adult
criteria on which they were based, the Rome II pediatric criteria for FD included 3 subtypes:
1) ulcer-like, in which pain was the predominant symptom; 2) dysmotility-like, in which
discomfort (e.g., bloating, early satiety, postprandial fullness) was the predominant symptom;
and, 3) unspecified.
In 2006, the same process of expert committees again revised the criteria, yielding the current
Rome III criteria [3,4]. In adults, the previous FD subtypes were eliminated while two new
subtypes were identified based on new studies generally utilizing factor analysis. The first
subtype, postprandial distress syndrome, was defined as bothersome postprandial fullness
occurring after ordinary sized meals and/or early satiation that prevents finishing a regular
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meal. The second subtype, epigastric pain syndrome, was defined as intermittent pain or
burning localized to the epigastrium (i.e., not generalized or localized to other abdominal or
chest regions) and of at least moderate severity. The Rome III pediatric subcommittee also
eliminated the old subtypes, but did not adopt the new adult subtypes because of a lack of
existing data to support their existence in children and adolescents. However, recent evidence
suggests that the adult subtypes actually may have meaningful associations with mucosal
inflammation and psychosocial functioning in pediatric FD [5].
1.2. Prevalence and presentation
Most pediatric gastroenterologists may not routinely use Rome criteria and differences exist
in how the criteria are interpreted. Nevertheless, there is agreement that a strong majority of
children with chronic abdominal pain presenting to pediatric gastroenterology practices fulfill
criteria for an FGID, with the two most common being FD and IBS [6-9]. Community preva‐
lence for FD is estimated at 3.5-27% in children/adolescents compared to 20-30% in adults [3,4].
In both pediatric and adult gastroenterology practices, FD frequently overlaps with IBS or
gastroesophageal reflux [7,10]. Adult IBS overlap is associated with more psychological
dysfunction including anxiety and depression, compared to “pure” FD, but this association
does not appear to be present in pediatric overlap [11,12]. Pediatric FD is associated with lower
quality of life, increased functional disability, and increased likelihood of meeting criteria for
an anxiety disorder relative to healthy children [13]. In adults with FD, the association with
anxiety appears to be specific to patients with postprandial distress syndrome, with this
relationship also apparent in children/adolescents with symptoms consistent with postpran‐
dial distress syndrome [5,14].
1.3. Etiology
FD, like all FGIDs, is probably best understood through a biopsychosocial model (see Figure
1). This model states that symptoms are likely the result of varying contributions from, and
interactions between, biological/physiological factors (e.g. inflammation, mechanical distur‐
bances, hypersensitivity), psychological factors (e.g. anxiety, depression, somatization), and
social factors (e.g. interactions with parents, teachers, or peers). Within this model, there is less
emphasis on the “cause” of symptoms than on “contributors” to its emergence and mainte‐
nance. This model would suggest that there is value in identifying and targeting all of the
factors which might be contributing to symptom generation in children with FD. It also would
suggest that there is value in understanding the mechanisms by which the factors interact with
one another, as these mechanisms represent additional opportunities for clinical intervention.
2. The role of inflammation in functional dyspepsia
Inflammation has the potential to contribute to the development of FGIDs via the release of
specific mediators that impact mechanisms known to play a role in the pathogenesis of these
conditions. Acute gastrointestinal inflammation and injury are associated with both peripheral
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and central sensitization of the nervous system, which results in visceral hyperalgesia [15].
Neuroplastic changes may occur that affect the response thresholds of enteric nerves, thereby
negatively impacting both sensitivity and motility [16]. Both motility and sensitivity responses
to acute inflammation in adults generally are reversible; however, animal model responses
suggest that, if inflammation occurs in neonates, neuroplastic changes and sensitivity may
persist into adulthood [17,18]. Visceral sensitization may be even more relevant in instances
where there is chronic inflammation with ongoing mediator release, as there may be subse‐
quent effects on visceral sensitivity that compound and prolong the issue.
Figure 1. The Biopsychosocial Model of FD
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The role of inflammation in FD has historically been controversial. However, emerging
evidence supports its role as a contributing factor in the biopsychosocial model of FD. In fact,
inflammation may be of particular importance in this model, as it interacts with a number of
other factors and may actually mediate the relationship between psychologic and physiologic
factors. The remainder of this chapter focuses on examination of inflammation within the
biopsychosocial model of FD, laying out the current evidence for its prevalence, mechanisms
of action, relationship with other important factors, and implications for evaluation and
treatment.
2.1. Chronic inflammation
Upper endoscopy is commonly performed in children with chronic abdominal pain in general
and children with functional dyspepsia in particular. Histologic inflammation is common in
these patients. In children with chronic abdominal pain, esophagitis is common and would
implicate gastroesophageal reflux as a contributor or cause of pain [19]. In one study of children
with FD, specifically, histologic esophagitis was found in 18%, gastritis in 21%, and duodenitis
in 13% [10]. Higher prevalences for gastritis, ranging from 43% to 71%, have been reported by
others [20,21]. For the broader group of children with chronic abdominal pain, histologic
inflammation has been documented in up to 79%, with an increase in mononuclear cells
(indicative of chronic inflammation) in the antrum of 55% and in the duodenum of 16% of
these children [19].
Most of these patients have chronic inflammation of which the clinical significance is unknown.
Chronic gastritis is not associated with electrogastrographic abnormalities, delayed gastric
emptying, or psychologic dysfunction in children with FD [5,22]. Despite this, chronic active
gastritis (manifest as lymphocytic and neutrophilic inflammation) has been associated with a
higher prevalence of nocturnal pain [21]. Chronic gastritis has been associated with an
increased prevalence of postprandial pain [5].
2.2. Mast cells
Increased mucosal mast cell density has been demonstrated in the gastric corpus and antrum
in adults with FD [23,24]. In adults with gastritis, mast cell density is significantly increased
and generally correlates with the intensity of the inflammation [25]. Though findings have
been variable, increased mast cell density appears isolated to the stomach in adults with FD;
increased duodenal mast cell density is more associated with IBS [24,26]. In addition, increased
mast cells in the proximal stomach in adults with FD have been associated with hypersensi‐
tivity; these mast cells will degranulate with balloon distension of the proximal stomach [27].
Due to a lack of normal control data, it is not known if gastric mast cells are elevated in pediatric
FD. However, antral mast cells do appear to be actively degranulating in children with FD,
with a mean degranulation index of 67% and greater than 50% degranulation in over 80% of
patients [28]. In children with FD, mast cell density positively correlates with slower gastric
emptying and increased gastric dysrhythmia (primarily preprandial bradycardia) in children
with FD [28]. Further, this dysrhythmia is associated with increased postprandial pain [29].
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2.3. Eosinophils
Ethical considerations preclude undertaking studies that assess eosinophil density in healthy
pediatric controls. However, the available pediatric literature indicates that it is reasonable to
consider eosinophil densities ≥10/hpf in the antrum and >20/hpf in the duodenum to be
abnormal. In a pediatric autopsy study, eosinophil density was <10/hpf in the antrum of all
subjects and ≤20/hpf in the duodenum of 82%, even though symptoms could not be docu‐
mented [30]. Another study reviewed biopsies from 682 presumably symptomatic children
referred for endoscopy, documenting eosinophil density ≤10/hpf in the antrum in 90% and
≤20/hpf in the duodenum in 93% [31].
While certain cut-off points for density seem reasonable, eosinophil density may not be
completely informative. Eosinophil biologic activity occurs through mediator release or
degranulation, and the effects are generally concentration-dependent. Important to consider
is the fact that density and activation are not correlated events [32]. In one study involving 20
children with FD, eosinophil density >20/hpf was present in only 15%; however, moderate to
extensive degranulation was demonstrated by electron microscopy in 95% [33].
Adult population studies have demonstrated increased duodenal eosinophil density in those
with dyspepsia compared to controls, whereas antral eosinophils did not differ between the
groups [34,35]. Higher eosinophil density and a higher prevalence of duodenal eosinophilia
(as defined by application of the cut points outlined above) have been specifically associated
with the postprandial distress syndrome subtype of FD in adults [36]. Duodenal biopsies from
adults with FD also have revealed more extensive degranulation, including documentation of
extracellular major basic protein; this corresponds to a similar finding of degranulation and
release of major basic protein previously demonstrated in pediatric patients with FD [33,35].
Although no information is available for healthy children, tissue eosinophilia has been
evaluated in the broad group of children with chronic abdominal pain, which provides some
limited basis for comparison. In a study of 1191 children with chronic abdominal pain,
eosinophilia was identified in the antrum or duodenum in 11.4% [37]. In another study, gastric
eosinophilia was reported in 19% and duodenal eosinophilia in 32% of children with unspe‐
cified chronic abdominal pain [19]. In contrast, duodenal eosinophilia has been demonstrated
in 79% of children specifically fulfilling FD criteria [38].
Antral eosinophil density does not appear to have any direct relationship to gastric electro‐
mechanical function in children with FD [28]. However, in patients with elevated mucosal
eosinophils, antral CD3+ cell density does correlate with preprandial tachygastria, indicating
that it may result from the interaction between different cell types [28].
3. Specific Conditions Associated with Mucosal Inflammation
There are a number of triggers or inciting events which may initiate an inflammatory response
in the gastrointestinal tract, particularly with regard to recruitment and activation of mast cells
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that it may result from the interaction between different cell types [28].
3. Specific Conditions Associated with Mucosal Inflammation
There are a number of triggers or inciting events which may initiate an inflammatory response
in the gastrointestinal tract, particularly with regard to recruitment and activation of mast cells
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and eosinophils. These include stress/anxiety, infection (including H. pylori), and allergy, as
detailed below.
3.1. Stress/Anxiety
The involvement of inflammation in the biopsychosocial model is best illustrated by examining
the stress response. Corticotropin releasing hormone (CRH), produced by the hypothalamus
(as well as immune cells including lymphocytes and mast cells) is a major mediator of the stress
response in the hypothalamic-pituitary-adrenal axis and, subsequently, within the brain-gut
axis. CRH has central nervous system (CNS) effects which may alter central processing of
nociceptive messages, leading to anxiogenic and depressive effects. The stress response also
results in physiologic effects which may be relevant to FGIDs, including inflammation and
alterations of sensorimotor function such as altered gastric accommodation, gastric dysmotil‐
ity, and visceral hypersensitivity.
The relationship between the CNS and gastrointestinal pathophysiology appears bidirectional.
In a rodent model, gastric irritation in the neonatal period induces a long lasting increase in
depression- and anxiety-like behaviors. This, in turn, is associated with an increased expres‐
sion of CRH in the hypothalamus and increased sensitivity of the hypothalamic-pituitary-
adrenal axis to stress [39]. CRH stress systems may be activated by afferent nerves from
inflamed sites or via cytokines including TNF-α, IL-1, IL-6, and IL-12 [40]. The majority of
studies support an enhanced hypothalamic-pituitary-adrenal axis in at least some adults with
IBS, although results have been variable [41-45].
Corticotropin releasing hormone receptors are widely expressed including within the gastro‐
intestinal tract and immune cells. Mast cells express both CRH1 and CRH2 receptor subtypes
at their surface [46]. Most of the inflammatory cell actions, including those on mast cells, occur
via CRH2 receptors. Once mast cells are activated, they release mediators which recruit and
activate eosinophils. Both of these cell types are interactive in a bi-directional fashion with T
helper cells (Th; see Figure 2).
In addition to this indirect pathway, there also may be a direct effect for CRH on eosinophils.
In a rodent model, psychologic stress results in eosinophils expressing CRH [47]. CRH is not
expressed on eosinophils in the intestines of the mice except under psychologic stress and
decreases after the stress is removed, with the reversion requiring longer periods of time as
the length of the stressor increases [47]. A high correlation exists between anxiety scores and
mucosal eosinophil density in children with FD [48]. Antral mast cell density also correlates
with anxiety scores in children with FD [5]. Stress appears to shift the relative proportion and
trafficking of T helper lymphocytes towards a Th2 or “allergic” phenotype [40]. This shift is
driven by central and peripheral CRH, catecholamines, and histamine via H2 receptors. The
Th2 phenotype is associated with release of IL-4, IL-10, and IL-13, which stimulate growth and
activation of mast cells and eosinophils [40]. Shifting from a Th1 to a Th2 response may be the
mechanism through which low grade inflammation leads to visceral sensitivity and motility
disturbances; eosinophils and mast cells represent the key effector cells [49].
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Once activated by CRH, mast cells may release pre-formed and newly synthesized cytokines,
including interleukins (IL-4, IL-5, IL-6) and tumor necrosis factor (TNF-α) among others
[50,51]. In adults, there is selective luminal release of tryptase and histamine from jejunal mast
cells under cold stress; the magnitude of release is similar to that induced by antigen exposure
in food allergic patients [52]. Once released, mast cell and eosinophil mediators can stimulate
afferent nerves sending a “pain” message, sensitize afferent nerves resulting in visceral
hypersensitivity, and alter electromechanical function (see Figure 2). Histamine also can
stimulate afferent sensory nerves via H2 receptors [53]. Consistent with this, experimental
anxiety decreases gastric compliance and accommodation and increases epigastric symptom
scores during a standard nutrient challenge [54].
3.2. Infection
FD has been reported at a higher prevalence following both bacterial and parasitic infections
[55]. It seems likely that FD may also be induced by viral gastroenteritis similar to what has
been reported with IBS. In a large cohort of adults that were evaluated 8 years after bacterial
Figure 2. The Relationship between CRH Activation and Inflammatory Cells in FD Symptom Generation
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and eosinophils. These include stress/anxiety, infection (including H. pylori), and allergy, as
detailed below.
3.1. Stress/Anxiety
The involvement of inflammation in the biopsychosocial model is best illustrated by examining
the stress response. Corticotropin releasing hormone (CRH), produced by the hypothalamus
(as well as immune cells including lymphocytes and mast cells) is a major mediator of the stress
response in the hypothalamic-pituitary-adrenal axis and, subsequently, within the brain-gut
axis. CRH has central nervous system (CNS) effects which may alter central processing of
nociceptive messages, leading to anxiogenic and depressive effects. The stress response also
results in physiologic effects which may be relevant to FGIDs, including inflammation and
alterations of sensorimotor function such as altered gastric accommodation, gastric dysmotil‐
ity, and visceral hypersensitivity.
The relationship between the CNS and gastrointestinal pathophysiology appears bidirectional.
In a rodent model, gastric irritation in the neonatal period induces a long lasting increase in
depression- and anxiety-like behaviors. This, in turn, is associated with an increased expres‐
sion of CRH in the hypothalamus and increased sensitivity of the hypothalamic-pituitary-
adrenal axis to stress [39]. CRH stress systems may be activated by afferent nerves from
inflamed sites or via cytokines including TNF-α, IL-1, IL-6, and IL-12 [40]. The majority of
studies support an enhanced hypothalamic-pituitary-adrenal axis in at least some adults with
IBS, although results have been variable [41-45].
Corticotropin releasing hormone receptors are widely expressed including within the gastro‐
intestinal tract and immune cells. Mast cells express both CRH1 and CRH2 receptor subtypes
at their surface [46]. Most of the inflammatory cell actions, including those on mast cells, occur
via CRH2 receptors. Once mast cells are activated, they release mediators which recruit and
activate eosinophils. Both of these cell types are interactive in a bi-directional fashion with T
helper cells (Th; see Figure 2).
In addition to this indirect pathway, there also may be a direct effect for CRH on eosinophils.
In a rodent model, psychologic stress results in eosinophils expressing CRH [47]. CRH is not
expressed on eosinophils in the intestines of the mice except under psychologic stress and
decreases after the stress is removed, with the reversion requiring longer periods of time as
the length of the stressor increases [47]. A high correlation exists between anxiety scores and
mucosal eosinophil density in children with FD [48]. Antral mast cell density also correlates
with anxiety scores in children with FD [5]. Stress appears to shift the relative proportion and
trafficking of T helper lymphocytes towards a Th2 or “allergic” phenotype [40]. This shift is
driven by central and peripheral CRH, catecholamines, and histamine via H2 receptors. The
Th2 phenotype is associated with release of IL-4, IL-10, and IL-13, which stimulate growth and
activation of mast cells and eosinophils [40]. Shifting from a Th1 to a Th2 response may be the
mechanism through which low grade inflammation leads to visceral sensitivity and motility
disturbances; eosinophils and mast cells represent the key effector cells [49].
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Once activated by CRH, mast cells may release pre-formed and newly synthesized cytokines,
including interleukins (IL-4, IL-5, IL-6) and tumor necrosis factor (TNF-α) among others
[50,51]. In adults, there is selective luminal release of tryptase and histamine from jejunal mast
cells under cold stress; the magnitude of release is similar to that induced by antigen exposure
in food allergic patients [52]. Once released, mast cell and eosinophil mediators can stimulate
afferent nerves sending a “pain” message, sensitize afferent nerves resulting in visceral
hypersensitivity, and alter electromechanical function (see Figure 2). Histamine also can
stimulate afferent sensory nerves via H2 receptors [53]. Consistent with this, experimental
anxiety decreases gastric compliance and accommodation and increases epigastric symptom
scores during a standard nutrient challenge [54].
3.2. Infection
FD has been reported at a higher prevalence following both bacterial and parasitic infections
[55]. It seems likely that FD may also be induced by viral gastroenteritis similar to what has
been reported with IBS. In a large cohort of adults that were evaluated 8 years after bacterial
Figure 2. The Relationship between CRH Activation and Inflammatory Cells in FD Symptom Generation
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dysentery, an increased prevalence of FD was found compared to non-infected controls [56].
Consistent with the biopsychosocial model, anxiety and depression were independent risk
factors for developing post-infectious FD [56]. In another study, 82 adults were identified with
persistent abdominal symptoms following Giardia infection; 24.3% of these met criteria for FD,
while 80.5% met criteria for IBS [57]. Over half of these patients reported exacerbation due to
specific foods and nearly half reported exacerbations with physical or mental stress [57]. Rates
of post-infectious FD appear similar in pediatric populations. In a study of 88 children with a
previous positive bacterial stool culture, FD was present in 24% and IBS in 87% [58]. Fifty-six
percent of these patients reported the onset of abdominal pain after the acute infection.
Post-infectious FD appears to represent an impaired ability to terminate the inflammatory
response after the offending pathogen has been eliminated, but also may involve neuroplastic
changes in visceral and central afferent pathways as it is associated with impaired accommo‐
dation and increased sensitivity to distension [59-61]. Post-infectious FD patients frequently
demonstrate histologic duodenitis, with a severe grade in 57% [62]. Post-infectious FD is
associated with increased macrophages and may be associated with increased CD8+ cells [62,
63]. Findings regarding CD8+ cells however have been variable [62,63]. Duodenal eosinophilia
has also been described in post-infectious FD [49]. In addition, gastric mast cells are signifi‐
cantly increased in post-infectious FD as compared to healthy controls [64]. Post-infectious FD
is associated with increased gastric release of histamine and 5HT, as well as increased number
of mast cells within 5 μm of nerve fibers as compared to healthy controls or patients with FD
that is not post-infectious [64].
H. pylori. The role of Helicobacter pylori (H. pylori) in FD remains incompletely defined and,
as such, deserves particular attention within the scope of infectious organisms. Given that most
people never demonstrate symptoms at all when colonized with H. pylori, it is possible that
H. pylori has little to no contributory value for a significant subset of the population with FD.
However, it is possible that H. pylori may generate symptoms as a primary chronic infection
or, alternatively, patients may experience post-infectious FD once H. pylori has cleared in the
much the same way as seen in other bacterial and parasitic infections.
Several studies have demonstrated efficacy in reducing FD symptoms with H. pylori eradica‐
tion; however, others have found only a moderate (but statistically significant) effect or no
clinical benefit to eradication at all [65-69]. A Cochrane review concluded that eradication was
significantly better than placebo [69]. Response rates may be dependent on the specific
symptom. For example, one study documented a positive response to H. pylori eradication,
but only for the symptoms of epigastric pain and burning, indicating that efficacy may be
restricted to patients with the epigastric pain syndrome subtype of FD [67]. A large number
of patients with FD continue to experience symptoms following H. pylori eradication. These
may be patients in whom H. pylori had no pathologic role, or may represent a group of patients
who should be classified as post-infectious FD given that complete resolution of submucosal
inflammation requires a prolonged period [70].
H. pylori colonization is generally associated with gastric and duodenal histologic inflamma‐
tion. Histologic duodenitis has been associated with more severe symptoms when histologic
gastritis also is present [71]. However, this finding has not been consistent, with others actually
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reporting an inverse relation between severity of symptoms and gastric inflammation [72]. H.
pylori colonization in children is associated with increased mucosal lymphocytes, plasma cells,
neutrophils, and eosinophils, which decrease with eradication [20]. H. pylori colonization may
also be associated with increased antral mast cell density, though this may be H. pylori strain
specific [73]. In the setting of nodular gastritis associated with HP colonization, eosinophils
may be of particular significance. Nodularity is associated with the presence and density of
eosinophils [74]. Patients with nodular gastritis have a higher incidence of FD symptoms which
resolve with eradication therapy and improvement of gross endoscopic appearance [70]. Even
in the absence of nodularity, H. pylori colonization is associated with increased antral
eosinophils, as well as increased gastric fluid eosinophil cationic protein indicating eosino‐
philic activation [20,75,76]. These findings suggest a possible pathophysiologic role for
eosinophils in contributing to symptoms in patients with H. pylori colonization or possibly
following eradication.
Similar to post-infectious FD, H. pylori may be associated with electromechanical dysfunction
which, in turn, can contribute to FD symptom generation. Though studies are conflicting, H.
pylori has not consistently been associated with delayed gastric emptying or visceral hyper‐
sensitivity [77]. However, treatment with a prokinetic was found to be as effective as eradica‐
tion at 12 months [78]. H. pylori also has been associated with an abnormal electrogastrogram
that normalized in 83% with eradication [79]. H. pylori does not appear to have any effect on
accommodation [60].
3.3. Allergy
The role of allergy in the development of FD has not been greatly studied. However, allergy
may be important given the observed increases in, and activation of, mast cells and eosinophils
in FD. FGIDs occur more commonly in children with a history of cow’s milk allergy as infants
[80]. In children with FD in association with cow’s milk allergy, mucosal application of cow’s
milk is associated with increased eosinophils and mast cells, as well as rapid degranulation,
within 10 minutes of application [81]. In addition, cow’s milk exposure is associated with
increased mast cells within 5 μm of nerves [81]. Adult FD patients with a history of allergy
have increased duodenal eosinophil density [36]. In addition, lymphoid hyperplasia is
significantly more frequent in children with abdominal pain associated with food allergies [19].
Lymphoid hyperplasia is associated with food hypersensitivity although this reaction may be
local reactivity only as it is associated with normal skin prick tests and normal serum IgE levels
[82,83].
Food allergy, similar to post-infectious FD and H. pylori colonization, also may cause electro‐
mechanical dysfunction. Exposure to cow’s milk in allergic FD children resulted in increased
bradygastria [81]. In infants with cow’s milk allergy, exposure results in gastric arrhythmias
and delayed gastric emptying [84].
Whether food allergy accounts for a substantial portion of children with FD is not clear. One
study found no significant increase in immunoreactivity to common food allergens in FD
children with duodenal eosinophilia, although it is possible that the reaction was localized to
the mucosa [85]. It is also possible that environmental allergens may be playing a role. Antigen
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dysentery, an increased prevalence of FD was found compared to non-infected controls [56].
Consistent with the biopsychosocial model, anxiety and depression were independent risk
factors for developing post-infectious FD [56]. In another study, 82 adults were identified with
persistent abdominal symptoms following Giardia infection; 24.3% of these met criteria for FD,
while 80.5% met criteria for IBS [57]. Over half of these patients reported exacerbation due to
specific foods and nearly half reported exacerbations with physical or mental stress [57]. Rates
of post-infectious FD appear similar in pediatric populations. In a study of 88 children with a
previous positive bacterial stool culture, FD was present in 24% and IBS in 87% [58]. Fifty-six
percent of these patients reported the onset of abdominal pain after the acute infection.
Post-infectious FD appears to represent an impaired ability to terminate the inflammatory
response after the offending pathogen has been eliminated, but also may involve neuroplastic
changes in visceral and central afferent pathways as it is associated with impaired accommo‐
dation and increased sensitivity to distension [59-61]. Post-infectious FD patients frequently
demonstrate histologic duodenitis, with a severe grade in 57% [62]. Post-infectious FD is
associated with increased macrophages and may be associated with increased CD8+ cells [62,
63]. Findings regarding CD8+ cells however have been variable [62,63]. Duodenal eosinophilia
has also been described in post-infectious FD [49]. In addition, gastric mast cells are signifi‐
cantly increased in post-infectious FD as compared to healthy controls [64]. Post-infectious FD
is associated with increased gastric release of histamine and 5HT, as well as increased number
of mast cells within 5 μm of nerve fibers as compared to healthy controls or patients with FD
that is not post-infectious [64].
H. pylori. The role of Helicobacter pylori (H. pylori) in FD remains incompletely defined and,
as such, deserves particular attention within the scope of infectious organisms. Given that most
people never demonstrate symptoms at all when colonized with H. pylori, it is possible that
H. pylori has little to no contributory value for a significant subset of the population with FD.
However, it is possible that H. pylori may generate symptoms as a primary chronic infection
or, alternatively, patients may experience post-infectious FD once H. pylori has cleared in the
much the same way as seen in other bacterial and parasitic infections.
Several studies have demonstrated efficacy in reducing FD symptoms with H. pylori eradica‐
tion; however, others have found only a moderate (but statistically significant) effect or no
clinical benefit to eradication at all [65-69]. A Cochrane review concluded that eradication was
significantly better than placebo [69]. Response rates may be dependent on the specific
symptom. For example, one study documented a positive response to H. pylori eradication,
but only for the symptoms of epigastric pain and burning, indicating that efficacy may be
restricted to patients with the epigastric pain syndrome subtype of FD [67]. A large number
of patients with FD continue to experience symptoms following H. pylori eradication. These
may be patients in whom H. pylori had no pathologic role, or may represent a group of patients
who should be classified as post-infectious FD given that complete resolution of submucosal
inflammation requires a prolonged period [70].
H. pylori colonization is generally associated with gastric and duodenal histologic inflamma‐
tion. Histologic duodenitis has been associated with more severe symptoms when histologic
gastritis also is present [71]. However, this finding has not been consistent, with others actually
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reporting an inverse relation between severity of symptoms and gastric inflammation [72]. H.
pylori colonization in children is associated with increased mucosal lymphocytes, plasma cells,
neutrophils, and eosinophils, which decrease with eradication [20]. H. pylori colonization may
also be associated with increased antral mast cell density, though this may be H. pylori strain
specific [73]. In the setting of nodular gastritis associated with HP colonization, eosinophils
may be of particular significance. Nodularity is associated with the presence and density of
eosinophils [74]. Patients with nodular gastritis have a higher incidence of FD symptoms which
resolve with eradication therapy and improvement of gross endoscopic appearance [70]. Even
in the absence of nodularity, H. pylori colonization is associated with increased antral
eosinophils, as well as increased gastric fluid eosinophil cationic protein indicating eosino‐
philic activation [20,75,76]. These findings suggest a possible pathophysiologic role for
eosinophils in contributing to symptoms in patients with H. pylori colonization or possibly
following eradication.
Similar to post-infectious FD, H. pylori may be associated with electromechanical dysfunction
which, in turn, can contribute to FD symptom generation. Though studies are conflicting, H.
pylori has not consistently been associated with delayed gastric emptying or visceral hyper‐
sensitivity [77]. However, treatment with a prokinetic was found to be as effective as eradica‐
tion at 12 months [78]. H. pylori also has been associated with an abnormal electrogastrogram
that normalized in 83% with eradication [79]. H. pylori does not appear to have any effect on
accommodation [60].
3.3. Allergy
The role of allergy in the development of FD has not been greatly studied. However, allergy
may be important given the observed increases in, and activation of, mast cells and eosinophils
in FD. FGIDs occur more commonly in children with a history of cow’s milk allergy as infants
[80]. In children with FD in association with cow’s milk allergy, mucosal application of cow’s
milk is associated with increased eosinophils and mast cells, as well as rapid degranulation,
within 10 minutes of application [81]. In addition, cow’s milk exposure is associated with
increased mast cells within 5 μm of nerves [81]. Adult FD patients with a history of allergy
have increased duodenal eosinophil density [36]. In addition, lymphoid hyperplasia is
significantly more frequent in children with abdominal pain associated with food allergies [19].
Lymphoid hyperplasia is associated with food hypersensitivity although this reaction may be
local reactivity only as it is associated with normal skin prick tests and normal serum IgE levels
[82,83].
Food allergy, similar to post-infectious FD and H. pylori colonization, also may cause electro‐
mechanical dysfunction. Exposure to cow’s milk in allergic FD children resulted in increased
bradygastria [81]. In infants with cow’s milk allergy, exposure results in gastric arrhythmias
and delayed gastric emptying [84].
Whether food allergy accounts for a substantial portion of children with FD is not clear. One
study found no significant increase in immunoreactivity to common food allergens in FD
children with duodenal eosinophilia, although it is possible that the reaction was localized to
the mucosa [85]. It is also possible that environmental allergens may be playing a role. Antigen
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exposure in adults with birch pollen allergy results in an increase in mucosal major basic
protein positive eosinophils and IgE-bearing cells, as well as in FD symptoms, in the majority
of patients [86]. Information in this area remains quite limited.
4. Implications for Care
4.1. Evaluation
The current approach to the pediatric FD patient has not been thoroughly studied. Based on
existing small studies in children and large studies in adults, however, it appears reasonable
to treat empirically with acid reducing medications and proceed with endoscopy with biopsies
for non-responders. There may be value in evaluating mucosal biopsies for eosinophil density,
particularly those obtained from the duodenum. A reasonable standard would be to consider
antral eosinophil density >10/hpf and duodenal eosinophil density >20/hpf as abnormal.
Despite current information implicating a role for mucosal mast cells, particularly in the
antrum, it is less clear if there is value in determining mast cell density. The latter would require
special immunohistochemical stains and the standard for normal is even less well defined than
for eosinophils.
4.2. Treatment
Medications targeting mast cells or eosinophils could offer benefit by decreasing either cell
density or activation. Such agents include corticosteroids and mast cell stabilizers. In addition,
medications potentially could provide relief by targeting receptors for specific mediators once
released by either cell. Although there is no current means for identifying the specific media‐
tors generating symptoms in a particular patient, antagonists are available for some mediators,
such as histamine, cysteinyl leukotrienes, and TNF- α. Finally, other treatments exist that may
provide relief by targeting other factors, such as CRH, that may play an important role in
activation and/or maintenance of inflammation. Consistent with a biopsychosocial model,
combining treatments that address inflammation from different perspectives ultimately
should be most beneficial.
Corticosteroids. Corticosteroids have not been evaluated in treating FD, but are commonly used
in the treatment of eosinophilic gastroenteritis, although there are no placebo-controlled
studies evaluating efficacy. The extensive side effect profile represents a significant draw back
in considering their use long term. Budesonide may represent a safer alternative. Budesonide
is a synthetic corticosteroid with high topical activity and substantial first pass elimination,
limiting systemic exposure [87]. The literature regarding budesonide and eosinophilic
gastroenteritis is limited, consisting of only case reports where budesonide therapy has been
reported to be effective against eosinophilia in the duodenum and jejunum [88-90].
Mast Cell Stabilizers. Mast cell stabilizers, including cromolyn and ketotifen, would represent
an attractive potential therapy given data implicating mast cells in the generation of FD
symptoms as previously discussed. These agents would have the potential to prevent release
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of a variety of mediators with downstream effects. In one open-label observational study of
children with FD in association duodenal eosinophilia, resolution of pain was demonstrated
with use of oral cromolyn in 89% of patients who had previously failed to respond to H2 and
combined H1/H2 antagonism [91]. There have been no other pediatric or adult studies on the
use of mast cell stabilizers in patients with FD. Benefit has been demonstrated in adults with
IBS and may be related to blocking allergic or immunologic reactions to foods [92-94].
Ketotifen, specifically, has been shown to significantly decrease pain in adults with IBS and to
increase the threshold for discomfort in patients with visceral hypersensitivity [95]. Ketotifen
also acts as an H1 antagonist, so the effects may not be directly, or completely, related to mast
cell stabilization.
Antihistamine Medications and Proton Pump Inhibitors (PPI). Acid reduction remains the most
common treatment prescribed empirically by pediatric gastroenterologists for children with
FD [9]. While there are numerous adult studies to support this practice, pediatric studies are
limited. In children with chronic abdominal pain, famotidine (H2 recptor antagonist - H2RA)
was superior to placebo in global improvement, with clear benefit to those with FD [96]. In a
large pediatric study, omeperazole was shown to have a very modest advantage in the relief
of all symptoms as compared to either famotidine or ranitidine; however, there was no
significant difference between the three with regard to resolution of abdominal pain, epigastric
pain, nausea, or vomiting specifically [97].
In adults, H2 antagonism has been shown to improve at least some symptoms associated with
FD, including abdominal pain, indigestion, belching, and gastroesophageal reflux symptoms
[98,99]. H2 antagonists have been shown to be superior to prokinetic medications and short
term use of an anxiolytic [100,101]. A meta-analysis evaluating the use of PPIs in adult FD
determined that they were superior to placebo in symptom reduction [102]. Studies of
omeperazole, lansoprazole, and pantoprazole have demonstrated a modest superiority to
placebo in symptom reduction which is limited to patients with ulcer-like or reflux-like FD
[103-105]. Whether PPIs are superior to H2 antagonism is not completely clear. Omeperazole
was found to have a modest increase in efficacy as compared to ranitidine at 4 weeks (51% vs.
36%), but there was no additional benefit at 6 months [101].
Given the response to PPIs, it would appear that at least some of the clinical improvement
from H2 antagonism or PPIs is related directly to acid suppression. A significant portion of
responders may derive benefit from treatment of overlap GERD, or possibly from peptic
gastritis or duodenitis. Conversely, the benefit may be due to removing exposure to acid in
patients with acid hypersensitivity. PPIs do not appear to have other benefits with regard to
gastric emptying or myoelectrical function [106].
The benefit of H2 antagonism may be unrelated to acid reduction, at least in part. Histamine
has direct gastric myogenic actions, modulates afferent enteric nerve excitability, and acts as
an immunomodulating agent [53,107-111]. There may be additional benefit from H1 antago‐
nism, as well. Combining an H1 antagonist with an H2 antagonist has been reported to relieve
symptoms in 50% of children with FD associated with duodenal eosinophilia and in 79% of
adults with FD associated with increased antral mast cell density who had previously failed
to respond to acid reduction therapy [91,112]. H1 receptors affect smooth muscle contraction
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exposure in adults with birch pollen allergy results in an increase in mucosal major basic
protein positive eosinophils and IgE-bearing cells, as well as in FD symptoms, in the majority
of patients [86]. Information in this area remains quite limited.
4. Implications for Care
4.1. Evaluation
The current approach to the pediatric FD patient has not been thoroughly studied. Based on
existing small studies in children and large studies in adults, however, it appears reasonable
to treat empirically with acid reducing medications and proceed with endoscopy with biopsies
for non-responders. There may be value in evaluating mucosal biopsies for eosinophil density,
particularly those obtained from the duodenum. A reasonable standard would be to consider
antral eosinophil density >10/hpf and duodenal eosinophil density >20/hpf as abnormal.
Despite current information implicating a role for mucosal mast cells, particularly in the
antrum, it is less clear if there is value in determining mast cell density. The latter would require
special immunohistochemical stains and the standard for normal is even less well defined than
for eosinophils.
4.2. Treatment
Medications targeting mast cells or eosinophils could offer benefit by decreasing either cell
density or activation. Such agents include corticosteroids and mast cell stabilizers. In addition,
medications potentially could provide relief by targeting receptors for specific mediators once
released by either cell. Although there is no current means for identifying the specific media‐
tors generating symptoms in a particular patient, antagonists are available for some mediators,
such as histamine, cysteinyl leukotrienes, and TNF- α. Finally, other treatments exist that may
provide relief by targeting other factors, such as CRH, that may play an important role in
activation and/or maintenance of inflammation. Consistent with a biopsychosocial model,
combining treatments that address inflammation from different perspectives ultimately
should be most beneficial.
Corticosteroids. Corticosteroids have not been evaluated in treating FD, but are commonly used
in the treatment of eosinophilic gastroenteritis, although there are no placebo-controlled
studies evaluating efficacy. The extensive side effect profile represents a significant draw back
in considering their use long term. Budesonide may represent a safer alternative. Budesonide
is a synthetic corticosteroid with high topical activity and substantial first pass elimination,
limiting systemic exposure [87]. The literature regarding budesonide and eosinophilic
gastroenteritis is limited, consisting of only case reports where budesonide therapy has been
reported to be effective against eosinophilia in the duodenum and jejunum [88-90].
Mast Cell Stabilizers. Mast cell stabilizers, including cromolyn and ketotifen, would represent
an attractive potential therapy given data implicating mast cells in the generation of FD
symptoms as previously discussed. These agents would have the potential to prevent release
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of a variety of mediators with downstream effects. In one open-label observational study of
children with FD in association duodenal eosinophilia, resolution of pain was demonstrated
with use of oral cromolyn in 89% of patients who had previously failed to respond to H2 and
combined H1/H2 antagonism [91]. There have been no other pediatric or adult studies on the
use of mast cell stabilizers in patients with FD. Benefit has been demonstrated in adults with
IBS and may be related to blocking allergic or immunologic reactions to foods [92-94].
Ketotifen, specifically, has been shown to significantly decrease pain in adults with IBS and to
increase the threshold for discomfort in patients with visceral hypersensitivity [95]. Ketotifen
also acts as an H1 antagonist, so the effects may not be directly, or completely, related to mast
cell stabilization.
Antihistamine Medications and Proton Pump Inhibitors (PPI). Acid reduction remains the most
common treatment prescribed empirically by pediatric gastroenterologists for children with
FD [9]. While there are numerous adult studies to support this practice, pediatric studies are
limited. In children with chronic abdominal pain, famotidine (H2 recptor antagonist - H2RA)
was superior to placebo in global improvement, with clear benefit to those with FD [96]. In a
large pediatric study, omeperazole was shown to have a very modest advantage in the relief
of all symptoms as compared to either famotidine or ranitidine; however, there was no
significant difference between the three with regard to resolution of abdominal pain, epigastric
pain, nausea, or vomiting specifically [97].
In adults, H2 antagonism has been shown to improve at least some symptoms associated with
FD, including abdominal pain, indigestion, belching, and gastroesophageal reflux symptoms
[98,99]. H2 antagonists have been shown to be superior to prokinetic medications and short
term use of an anxiolytic [100,101]. A meta-analysis evaluating the use of PPIs in adult FD
determined that they were superior to placebo in symptom reduction [102]. Studies of
omeperazole, lansoprazole, and pantoprazole have demonstrated a modest superiority to
placebo in symptom reduction which is limited to patients with ulcer-like or reflux-like FD
[103-105]. Whether PPIs are superior to H2 antagonism is not completely clear. Omeperazole
was found to have a modest increase in efficacy as compared to ranitidine at 4 weeks (51% vs.
36%), but there was no additional benefit at 6 months [101].
Given the response to PPIs, it would appear that at least some of the clinical improvement
from H2 antagonism or PPIs is related directly to acid suppression. A significant portion of
responders may derive benefit from treatment of overlap GERD, or possibly from peptic
gastritis or duodenitis. Conversely, the benefit may be due to removing exposure to acid in
patients with acid hypersensitivity. PPIs do not appear to have other benefits with regard to
gastric emptying or myoelectrical function [106].
The benefit of H2 antagonism may be unrelated to acid reduction, at least in part. Histamine
has direct gastric myogenic actions, modulates afferent enteric nerve excitability, and acts as
an immunomodulating agent [53,107-111]. There may be additional benefit from H1 antago‐
nism, as well. Combining an H1 antagonist with an H2 antagonist has been reported to relieve
symptoms in 50% of children with FD associated with duodenal eosinophilia and in 79% of
adults with FD associated with increased antral mast cell density who had previously failed
to respond to acid reduction therapy [91,112]. H1 receptors affect smooth muscle contraction
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and visceral sensitivity [53]. In addition, some benefit from H1 antagonism may be due to an
anxiolytic effect [113].
Cysteinyl Leukotriene (cysLT) Antagosists. CysLTs are another potential therapeutic target. The
pattern of eosinophil degranulation in pediatric FD is consistent with the release of major basic
protein, which is known to enhance the synthesis of cysLT; cysLT, in turn, stimulates smooth
muscle contraction and recruitment of eosinophils [114]. CysLTs have been shown to alter mast
cell function. CysLTs can induce IL-5 and TNF-α production in primed mast cells, an effect
blocked by cysLT inhibition [115]. Leukotrienes (LTs) have the potential to increase intestinal
sensory nerve sensitivity during inflammation. CysLTs have been shown to stimulate enteric
neurons and to have a pro-contactile effect on the esophagus, stomach, small intestine, colon,
and gallbladder [116-123].
Montelukast, a cysLT receptor antagonist, was superior to placebo with regard to relief of pain
in a double-blind, placebo-controlled, cross-over trial of children with FD associated with
duodenal eosinophilia [124]. The response rate was 84% in patients with eosinophil densities
between 20 and 29/hpf versus 42% receiving placebo. A second study confirmed this high
response rate [125]. In the latter study, the short term clinical response did not result from a
decrease in eosinophil density or activation. This suggests that the effect of montelukast may
be mediated through an enteric nerve effect on motility or sensitivity, something that remains
to be demonstrated.
Anti-TNF-α. TNF-α would represent another potential therapeutic target. Mast cells are an
important source of intestinal mucosal TNF-α in humans. CysLTs induce TNF-α production.
TNF-α can recruit and prolong survival of eosinophils, as well promote a Th2 response
depending on other chemokines present in the microenvironment [126-128]. Serum TNF-α
concentration prior to treatment correlates negatively with the subsequent clinical response to
montelukast in pediatric FD associated with duodenal eosinophilia, indicating that TNF-α may
represent an alternative pathway for symptom generation in these patients. Although there
are no controlled studies, anti-TNF-α has been reported to be effective in a series of children
with resistant eosinophil disease, including patients with FD [129].
Biofeedback-Assisted Relaxation Training. The biopsychosocial model and CRH physiology
would suggest a potential role for CRH antagonism or for controlling CRH secretion by
controlling anxiety and the stress response. There are no previous studies evaluating CRH-
antagonists in FD. Stress management would have the potential to control CRH secretion and,
thereby, decrease inflammation. Biofeedback is a technique where individuals are trained to
relieve physical or emotional symptoms using signals from their bodies that are displayed
visually or aurally. It can be paired with relaxation training to yield biofeedback-assisted
relaxation training. Biofeedback-assisted relaxation training may be considered as a solo
therapy or, consistent with the biopsychosocial model, a stronger effect may occur in combin‐
ing relaxation with medications targeting biologic factors such as inflammation. The combi‐
nation of biofeedback-assisted relaxation training and fiber is superior to fiber alone in children
with non-specific abdominal pain [130]. The effect of biofeedback-assisted relaxation training
on inflammation has not been studied directly, but biofeedback-assisted relaxation training
has been studied as adjunctive treatment in children with FD in association with duodenal
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eosinophilia [131]. Children receiving medication plus biofeedback-assisted relaxation
training demonstrated better outcomes with regard to pain intensity, duration of pain
episodes, and global clinical improvement as compared to children receiving medications
alone [131].
5. Conclusions
Current evidence implicates inflammation, particularly mast cells and eosinophils, in the
pathophysiology of FD. FD in adults is associated with an increase in antral mast cell density
and an increase in duodenal eosinophil density; elevated duodenal eosinophil density is
frequently present in children with FD. Active degranulation of both cell types in children with
FD suggests a pathophysiologic role. In children with FD, higher antral mast cell density is
associated with gastric electromechanical dysfunction, psychologic dysfunction, and symp‐
toms consistent with the postprandial distress syndrome subtype of FD defined for adults.
Duodenal eosinophil density appears associated with anxiety in children with FD, but
relationships with electromechanical dysfunction appear less direct. Both mast cells and
eosinophils may have key roles in conditions that are associated with FD, including anxiety,
infection (including H. pylori), and allergy. Ultimately, inflammation appears to be of
particular importance in FD. Inflammation interacts with a number of other factors and may
even mediate the relationship between psychologic and physiologic factors.
There may be efficacy in utilizing medications directed at inflammation, particularly mast cells
and eosinophils. Most reports on treatment response consist of case series using H1/H2
antagonists, mast cell stabilizers, and anti-TNF-α. Consistent with a biopsychosocial model,
some evidence exists to suggest that combining treatments targeting different components of
the model that may influence inflammation can increase rates of symptom resolution in
pediatric FD. There remains a need for placebo-controlled trials of the various medications
and other treatments targeting inflammation which have been suggested to have efficacy, both
alone and in thoughtful combination. Treatment for pediatric FD must continue to evolve if
we are to prevent the significant downstream costs to the individual and society and, in this
goal, inflammation appears an important primary target.
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protein, which is known to enhance the synthesis of cysLT; cysLT, in turn, stimulates smooth
muscle contraction and recruitment of eosinophils [114]. CysLTs have been shown to alter mast
cell function. CysLTs can induce IL-5 and TNF-α production in primed mast cells, an effect
blocked by cysLT inhibition [115]. Leukotrienes (LTs) have the potential to increase intestinal
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TNF-α can recruit and prolong survival of eosinophils, as well promote a Th2 response
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montelukast in pediatric FD associated with duodenal eosinophilia, indicating that TNF-α may
represent an alternative pathway for symptom generation in these patients. Although there
are no controlled studies, anti-TNF-α has been reported to be effective in a series of children
with resistant eosinophil disease, including patients with FD [129].
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would suggest a potential role for CRH antagonism or for controlling CRH secretion by
controlling anxiety and the stress response. There are no previous studies evaluating CRH-
antagonists in FD. Stress management would have the potential to control CRH secretion and,
thereby, decrease inflammation. Biofeedback is a technique where individuals are trained to
relieve physical or emotional symptoms using signals from their bodies that are displayed
visually or aurally. It can be paired with relaxation training to yield biofeedback-assisted
relaxation training. Biofeedback-assisted relaxation training may be considered as a solo
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ing relaxation with medications targeting biologic factors such as inflammation. The combi‐
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alone [131].
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and an increase in duodenal eosinophil density; elevated duodenal eosinophil density is
frequently present in children with FD. Active degranulation of both cell types in children with
FD suggests a pathophysiologic role. In children with FD, higher antral mast cell density is
associated with gastric electromechanical dysfunction, psychologic dysfunction, and symp‐
toms consistent with the postprandial distress syndrome subtype of FD defined for adults.
Duodenal eosinophil density appears associated with anxiety in children with FD, but
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eosinophils may have key roles in conditions that are associated with FD, including anxiety,
infection (including H. pylori), and allergy. Ultimately, inflammation appears to be of
particular importance in FD. Inflammation interacts with a number of other factors and may
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some evidence exists to suggest that combining treatments targeting different components of
the model that may influence inflammation can increase rates of symptom resolution in
pediatric FD. There remains a need for placebo-controlled trials of the various medications
and other treatments targeting inflammation which have been suggested to have efficacy, both
alone and in thoughtful combination. Treatment for pediatric FD must continue to evolve if
we are to prevent the significant downstream costs to the individual and society and, in this
goal, inflammation appears an important primary target.
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1. Introduction
Helicobacter pylori (H. pylori) was first observed over 100 years ago yet its association with
clinical diseases was not fully understanding until 1982 when Marshall and Warren identified
and subsequently cultured the gastric bacterium. At their first attempt to culture the bacteria
was not successful. Colonies finally grew when they accidentally left some culture plates over
the Easter holiday. Dr. Barry Marshall subsequently inoculated himself with culture broth
containing more than 1 billion organism to prove that this bacterium would cause peptic ulcers
supporting Koch’s postulate. He developed acute gastritis 1 week after the inoculation. H.
pylori is a microaerophilic, spiral shaped, gram negative bacterium measuring about 3.5
microns in length and 0.5 microns in width. In vitro, this bacterium is a gradually growing
organism that can be cultured on blood agar incubated at 37ºC in a microaerophilic condition
(5% oxygen) for 4-7 days. The colony of this bacteria is tiny, uniformly sized and translucence
(fig 2A).
H. pylori is a Gram-negative, spiral shaped, bacterium about 3.5 microns long and 0.5 microns
wide. (fig 2B). This bacterium uses its 2-7 unipolar flagella to escape the harsh luminal acidity
by burrowing into the mucus layer that covers the gastric mucosa and so reside in close
proximity to the more neutral pH of the epithelial cell surface of the gastric mucosa. It can
convert from a highly motile, helical (spiral) shape to a more dormant coccoidal form, perhaps
a survival benefit depending upon its local environment. Being microaerophilic, H. pylori
requires oxygen. H. pylori is biochemically characterized as positive for catalase, oxidase, and
urease. The urease enzyme, which has been located on the surface of the bacteria, is important
and likely to be vital for bacterial survival and colonization in the highly acidity milieu of the
stomach. Urease breaks down the luminal urea normally produced by the gastric mucosa,
yielding carbon dioxide and ammonia.
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Figure 1. or 14C-urea is hydrolyzed by the H pylori urease enzyme and can be detected by CO2 in breath samples
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Figure 2. A) H. pylori colonies; (B). H. pylori detected by gram stain
Ammonia then accepts a proton (H+), lessening the nearby acidity and forming protective
surroundings that allow its survival. Furthermore, urease activity is clinically relevance in the
form of several tests to diagnose infection such as rapid urease test and urea breath test. [1-4]
The ammonia produced however is toxic to the epithelium, and aided by other products like
proteases, vacuolating cytotoxin A (associated with cytotoxin-associated gene A ), and certain
phospholipases damages the mucosa. H. pylori infection also increases gastric acid secretion
(suppressing somatostatin to allow increased gastrin), down regulates mucosal defense
mechanisms and elicits an inflammatory response.
H. pylori infects the gastric mucosa in 20-80 % of humans throughout the world, making it a
very common bacterial infection. In developing countries, the infection tends to be acquired
via the fecal-oral or oral-oral route during childhood and subsequently persists through
adulthood. In developed countries, childhood infection is no longer common (rare under 10
years of age) though prevalence does increase during adulthood (>50% if over 50 years); the
latter cohort likely acquired H. pylori during childhood. This bacteria is the major pathologic
agent in the development of gastritis, gastric ulcer, duodenal ulcer, MALT lymphoma and
gastric cancer. The International Agency for Research into Cancer has classified H. pylori as a
class 1 carcinogen which is in the same class as cigarette smoke. [1-3]
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Functional dyspepsia (FD) is one of the most common causes of dyspeptic symptoms. FD
is recognized as heterogeneous group of symptoms located in the center of upper abdo‐
men. The prevalence of dyspepsia is variable in different populations and environmental
factors.  In 2006 the Rome III  provides the diagnostic criteria,  which are included one or
more of the following [5, 6]




The FD patient must not have any evidence of structural disease to explain the dyspeptic
symptoms. Symptom onset should occur at least 6 months prior to diagnosis while the criteria
must be fulfilled for the last 3 months. FD also can be divided into two major syndromes: the
postprandial distress syndrome and the epigastric pain syndrome. The postprandial distress
syndrome type of FD constitutes bothersome postprandial fullness and early satiation,
occurring after meal and at least several times per week. Upper abdominal bloating or
postprandial nausea or excessive belching might be present. In contrast, the epigastric pain
syndrome type of FD mostly suffers with intermittent epigastric pain or burning at least once
a week. The pain should not refer to other abdominal or chest regions, and should not be
relieved by defecation of passage of flatus. [5]
2. Epidemiology of H. pylori infection and FD
H. pylori is a global bacterial infection. Its prevalence varies greatly from 10-80% between
countries, being quite elevated in developing countries in Asia, Africa, and South America but
rather low in North America and Western Europe. In developed countries, approximately 20%
of the population under the age of 40 years and 50% of those over the age of 60 years carry the
infection. [6]
The prevalence of H. pylori infection also varies depending on age, socioeconomic status,
sanitation and ethnic group [4, 7-9]. Typically, the infection is acquired in childhood before
the age of 10 and the rate of acquisition is related inversely to household hygiene and the
general levels of sanitation; wherever sanitation and standards of living have improved, the
incidence of transmission has declined. The low prevalence in middle and upper socioeco‐
nomic populations in Western Europe and North America reflect better sanitation and quality
of living. In the United States, the prevalence rate is approximately 50% in African Americans,
60% in Mexican Americans, and 26% in whites. [4] In developing countries, the prevalence
among adult people is between 50-80%.
H. pylori infection may be evident in 20-60% of patients with functional dyspepsia, but the
clinical  relevance  in  most  instances  is  confounded by the  background frequency of  this
bacteria in the general population. A large scale nationwide community-based endoscopic
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survey of 2,488 adult subjects identified an overall H. pylori infection at 40.2% that was no
different  in  dyspeptic  subjects  compared to  asymptomatic  persons.  Differences  amongst
geographic  regions  likely  related to  differences  in  socioeconomic  status  and community
hygiene during childhood period. [8] The frequency of functional dyspepsia is common in
Asia,  varying  between  8-23% in  most  reported  studies.  [10]  In  fact,  given  the  common
frequency of H. pylori infection and challenges in obtaining endoscopy to eliminate organic
causes of dyspepsia, it is difficult to discern the extent this microorganism is the basis for
dyspepsia in Asia. [10, 11]
There are many FD patients in Asian as well as Western countries. The reported prevalence of
H. pylori infection in patients with FD varies from 39% to 87%. [14] Several epidemiological
studies have shown that H. pylori infection occurs more frequently in FD than in matched
control populations. A meta-analysis published in 1999 reported a summary odds ratio for H.
pylori infection in FD of 1.6 (95% CI, 1.4 to 1.8). [15]
3. Pathogenesis of functional dyspepsia associated with H. pylori infection
The pathophysiological disturbances generally responsible for the dyspepsia focus on
hyperacidity, impaired gastric accommodation (the “stiff fundus”) and delayed gastric
emptying. FD patients who are infected with H. pylori have higher stimulated gastric acid
secretion than H. pylori-negative healthy volunteers. [16] Impaired accommodation to a meal
may be common in functional dyspepsia and early satiety, but is not particularly associated
with H. pylori positivity or delayed gastric emptying. There is no constituent disturbance of
sensory or motor function yet reported in H. pylori-infected persons. Another factor possibly
responsible for the dyspepsia associated with H. pylori infection is the gut hormone, ghrelin.
Secreted from oxyntic cells, ghrelin normally stimulates gastric motility and food intake.
Patients with H. pylori may have reduction in ghrelin secretion that might lead to impaired
gastric emptying and symptoms of postprandial dyspepsia.
Recent study demonstrated that metronidazole resistant strains of H. pylori infection were
significantly higher in PDS than those of EPS patients. This study also indicated more specific
of cagA genotype that presence of cagA 2a gene of H. pylori infection was significantly higher
in metronidazole resistant than those of metronidazole sensitive strains especially in EPS
patients. This finding might be helpful to identify metronidazole resistant by using cagA
genotype in dyspeptic patients. [17]
CagA is a highly immunogenic protein encoded by the cagA gene, located at end of the cag
pathogenicity island (PAI). Infection with cagA-positive strains was associated with a greater
inflammatory response and an increased risk of adverse clinical outcomes than with cagA-
negative strains. [7, 18-20] Taneike et al recently reported that the metronidazole resistant rate
in cagA negative group was significantly higher than in cagA positive group and suggested
that absence of cagA might be a risk factor in development of metronidazole resistance. [21]
Unlike many countries such as European countries and United State of America, nearly all of
H. pylori strains in Thailand possess cagA-positive strains. [16] These different results might be
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explained by variation in cagA between the Asian- and Western-types. CagA genotype can be
divided into cagA 1a and 2a [17] and cagA 1a strain of H. pylori demonstrated more virulence
and associated with more gastric inflammation due to activation of proinflammatory cytokines
such as increased production of IL-1β and IL-8 in the gastric mucosa. [21] Previous meta-
analysis study reported that cagA-positive strain increases the likelihood of successful
eradication. [22] The mechanism for the effect of cagA on eradication outcome might be
explained by the presence of cagA induces secretion of inflammatory cytokine in gastric
epithelial cells and increased gastric inflammatory response. [22] Consequently, the increase
blood flow may help in the diffusion of antibiotics. [23] Another possibility might be explained
by the density of H. pylori in gastric mucosa which has been reported to be higher in cagA-
positive strains than cagA-negative strains, thus cagA-positive strains might be proliferative
faster than cagA-negative strains. [24, 25] As antibiotics are more active on rapidly growing
bacteria, cagA-positive strains would be more susceptible to antibiotic activity [23].
The effect of H. pylori eradication on dyspeptic symptoms in FD patients has revealed incon‐
clusive results in several studies, both in developed countries and in Asia. [26, 27, 28, 29]
Dyspeptic patients who are infected with H. pylori often have functional dyspepsia rather than
peptic ulcer disease, yet the outcome of eradicating H. pylori infection may be suboptimal in
FD compared with that for established duodenal ulcer disease. [30] Nevertheless, at a popu‐
lation level, a Cochrane systemic review indicated that there was a 10% relative risk reduction
of persistent symptoms in the H. pylori-eradication group compared to placebo; the number
needed to treat to cure one case of dyspepsia was 14. [31] A recent meta-analysis of the Chinese
literature showed that dyspepsia symptoms in FD improved after H. pylori eradication with
an odds ratio of 3.61, suggesting that this infection might have a greater role in Asian than in
Western countries. [32] Thus, H. pylori eradication overall does improve dyspepsia, particu‐
larly in regions with high prevalence.
4. H. pylori diagnostic tests in FD
Tests to diagnosis H pylori infection are divided into those that are invasive requiring endos‐
copy versus those that are noninvasive, not requiring endoscopy. The choice of test depends
on issues such as cost (variable in each country), availability, clinical situation, prevalence of
infection, pretest probability of infection, and presence of confounding factors (eg, the use of
PPI and antibiotics) that may influence test results.
a. Noninvasive tests for H. pylori
The noninvasive tests available in clinical practice include serologic tests, urea breath tests,
and stool antigen tests. The choice of test is important in terms of validity
1. Serological tests
IgM and IgA antibody tests have not proven to be useful clinically, whereas anti–H pylori IgG
has a better result. anti–H pylori IgG usually can be detected by 3-4 weeks after infection. The
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dyspepsia in Asia. [10, 11]
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control populations. A meta-analysis published in 1999 reported a summary odds ratio for H.
pylori infection in FD of 1.6 (95% CI, 1.4 to 1.8). [15]
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may be common in functional dyspepsia and early satiety, but is not particularly associated
with H. pylori positivity or delayed gastric emptying. There is no constituent disturbance of
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Patients with H. pylori may have reduction in ghrelin secretion that might lead to impaired
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significantly higher in PDS than those of EPS patients. This study also indicated more specific
of cagA genotype that presence of cagA 2a gene of H. pylori infection was significantly higher
in metronidazole resistant than those of metronidazole sensitive strains especially in EPS
patients. This finding might be helpful to identify metronidazole resistant by using cagA
genotype in dyspeptic patients. [17]
CagA is a highly immunogenic protein encoded by the cagA gene, located at end of the cag
pathogenicity island (PAI). Infection with cagA-positive strains was associated with a greater
inflammatory response and an increased risk of adverse clinical outcomes than with cagA-
negative strains. [7, 18-20] Taneike et al recently reported that the metronidazole resistant rate
in cagA negative group was significantly higher than in cagA positive group and suggested
that absence of cagA might be a risk factor in development of metronidazole resistance. [21]
Unlike many countries such as European countries and United State of America, nearly all of
H. pylori strains in Thailand possess cagA-positive strains. [16] These different results might be
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analysis study reported that cagA-positive strain increases the likelihood of successful
eradication. [22] The mechanism for the effect of cagA on eradication outcome might be
explained by the presence of cagA induces secretion of inflammatory cytokine in gastric
epithelial cells and increased gastric inflammatory response. [22] Consequently, the increase
blood flow may help in the diffusion of antibiotics. [23] Another possibility might be explained
by the density of H. pylori in gastric mucosa which has been reported to be higher in cagA-
positive strains than cagA-negative strains, thus cagA-positive strains might be proliferative
faster than cagA-negative strains. [24, 25] As antibiotics are more active on rapidly growing
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lation level, a Cochrane systemic review indicated that there was a 10% relative risk reduction
of persistent symptoms in the H. pylori-eradication group compared to placebo; the number
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an odds ratio of 3.61, suggesting that this infection might have a greater role in Asian than in
Western countries. [32] Thus, H. pylori eradication overall does improve dyspepsia, particu‐
larly in regions with high prevalence.
4. H. pylori diagnostic tests in FD
Tests to diagnosis H pylori infection are divided into those that are invasive requiring endos‐
copy versus those that are noninvasive, not requiring endoscopy. The choice of test depends
on issues such as cost (variable in each country), availability, clinical situation, prevalence of
infection, pretest probability of infection, and presence of confounding factors (eg, the use of
PPI and antibiotics) that may influence test results.
a. Noninvasive tests for H. pylori
The noninvasive tests available in clinical practice include serologic tests, urea breath tests,
and stool antigen tests. The choice of test is important in terms of validity
1. Serological tests
IgM and IgA antibody tests have not proven to be useful clinically, whereas anti–H pylori IgG
has a better result. anti–H pylori IgG usually can be detected by 3-4 weeks after infection. The
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three mains methods of commercial kits are ELISA ($90–$95/correct diagnosis),, immunochro‐
matography, and Western blotting.
Most serologic tests carries a high sensitivity (~90 to 100%), but variable specificity (under
85-90%). Their positive and negative predicative values depend upon the background
prevalence of H. pylori infection in the population at risk. In areas where infection is common,
a negative test is likely to be a false negative. Conversely, a positive test amongst those in whom
H pylori is infrequent is more likely to be a false positive. In developed countries with low
prevalence of H. pylori infection (<20%), for example, a positive serological test signals active
infection only about half the time. Hence, serology should be validated locally. Further,
antibody tests can remain positive for years after H pylori eradication and have limited value
to confirm eradication of H pylori infection4.
2. Urea breath test (UBT)
The urea breath test provides a reliable noninvasive method for H pylori detection with
sensitivity and specificity of 88-95% and 95%-100% respectively. [33] Urea breath testing is not
only sensitive and specific but has an important advantage to confirm H pylori eradication.
Following ingestion of 13C- or 14C-urea, H pylori-produced urease enzyme that is resident in
the stomach hydrolyzes this labeled urea to 14CO2 or 13CO2, which can be detected in breath
samples [34] (fig. 1). The nonradioactive13C (a stable label) test and the radioactive 14C test have
received US Food and Drug Administration (FDA) approval for H pylori diagnosis. The dose
of radiation in the 14C-urea test however is not approved for use in children and pregnant
women [4].
3. Fecal H. pylori detection
H. pylori in the stomach also appears in the stool, allowing the development of fecal assays: H
pylori culture, DNA detected by polymerase chain reaction (PCR), or H pylori antigen testing.
Only stool antigen has proven to be clinical useful with sensitivities and specificities of more
than 90%. Stool antigen assay is advantageous to confirm eradication. To avoid false negative
results, it is generally recommended that post-treatment testing with the UBT, histology, stool
antigen test or culture be delayed for 4 weeks and the patients should discontinue proton pump
inhibitors (PPI) and antibiotic such as amoxicillin, clarithromycin and quinolone groups to
ensure that any remaining organisms can repopulate the stomach [4].
b. Invasive tests
Invasive testing which requires endoscopy should be limited to patients who require endos‐
copy for diagnostic or therapeutic evaluation. Invasive tests available in clinical practice
include: gastric biopsies for culture (fig. 2A), gram stain (fig. 2B), histology (fig. 3A), or rapid
urease testing (fig. 3B). Rapid urease test such as CLO test plus upper GI endoscopy usually
cost between 276-502 (average 389) US dollars. H pylori culture is the absolute gold standard
to diagnose H. pylori but culture generally is not available in most hospitals. Good quality
laboratories are capable to culture H. pylori from gastric biopsies in more than 80% of instances
and also offer susceptibility testing such as E-test.
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Figure 3. A.) H pylori detected by histology; (B.) H pylori detected by rapid urease test
Histological examination has an advantage over other diagnostic tests by providing morpho‐
logical information such as severity of gastritis, and evidence for dysplasia. The accuracy of
histological examination however may be variable due to density of H. pylori and sampling
error, and is dependent upon histopathogical interpretation. The accuracy of histological
diagnosis of H pylori infection can be improved by adequate biopsies from the antrum and
body and by special staining such as a silver staining and the Diff-Quik stain [35].
Rapid urease tests contain a solution or gel with urea and a pH indicator reagent. The presence
of urease from H pylori results in hydrolysis of neutral urea to alkaline ammonia, which is then
visualized by a change in color of the pH indicator. The rapid urease test has a high sensitivity
(95%) and specificity (95%), [36] making it an excellent primary diagnostic test.
Any concomitant use of antibiotics or PPI however will reduces bacterial load, and may lead
to false negative tests such as rapid urease tests, urea breath test and histology. [4]
4. Test-and-Treat Strategy for H. pylori
Proposed strategies based on the noninvasive diagnosis of H. pylori infection so-called ‘‘test-
and-treat’’ strategy. This strategy has been proposed for clinical practice in developed
countries which has low prevalence of H. pylori infection. Test-and-treat is based on the test
of the presence of H. pylori and its subsequent eradication when detected.13 The test-and-
scope strategy performing a test to detect H. pylori in all patients and endoscopy only in those
who are shown to be infected has been considered useful in clinical practice in some developing
countries which has high prevalence of H. pylori infection such as Asia.
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5. Management of H. pylori infection in FD
Both European (Maastricht IV/ Florence Consensus Report) and Asian consensus reports
endorse H. pylori testing and eradication as a key management strategy for patients with
dyspepsia to produce long-term relief of symptoms. [37,38]
6. Antibiotics use for H. pylori eradication
6.1. Amoxicillin
Amoxicillin is a popular antibiotic for treating H pylori infection because it is inexpensive and
well tolerated, while resistance is rare. [39, 40] Amoxicillin acts by inhibiting the synthesis of
the bacterial cell wall and can act locally when delivered into the gastric lumen and systemi‐
cally once absorbed into the bloodstream. Amoxicillin is pH-dependent; its bactericidal activity
increases as the pH rises. As a single agent antibiotic use is not capable of curing H. pylori
infection, amoxicillin must be combined with other antibiotics such as clarithromycin and
metronidazole. [4]
6.2. Clarithromycin
Clarithromycin, a 14-membered ring macrolide antibiotic, is a derivative of erythromycin,
sharing a close spectrum and clinical application. Clarithromycin is one of the most acid-stable
macrolide with a low minimum inhibitory concentration (MIC) for H. pylori treatment. The
antimicrobial activity results from its binding to bacterial ribosomes and disrupting bacterial
proteinsynthesis. [4] Currently, Clarithromycin resistance is increasing and resulting in a
marked reduction in treatment success. [4, 8, 41] Increasing the clarithromycin dosage does
not overcome the problem of resistance. This antibiotic frequently causes a bitter taste that
causes some patients will stop treatment.
6.3. Metronidazole
Metronidazole is a nitroimidazole group, which is toxic to microaerophilic organisms.
Metronidazole is secreted into gastric juice and saliva, and is active after absorption with a
half-life of 8 to 12 hours. [4] Metronidazoleis is a pH-independent. [42] After entry into the
bacterial cell, metronidazole changes into a toxic form that alters the bacterial enzymes
required for transformation. Unlike clarithromycin, metronidazole resistance can be overcome
by increasing the dosage. The side effects of short-term use of metronidazole include interac‐
tions with alcohol (disulfiram like effect) and gastrointestinal symptoms such as nausea and
vomiting. [4]
6.4. Tetracycline
Tetracycline, a derivative of polycyclic naphtacenecarboxamides, is a fine anti–H. pylori
antimicrobial because it is inexpensive and pH-independent. [4] Tetracycline inhibits bacterial
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protein synthesis and seems to act luminal or locally. [43] The site of action of tetracycline is
the bacterial ribosome, resulting in the interruption of protein biosynthesis. This antibiotic
should not be given to pregnant women or children because it causes permanent staining of
developing teeth. [4]
6.5. Fluoroquinolones
Fluoroquinolones have been used more popularly for H pylori treatment. These drugs block
DNA gyrase and DNA synthesis  in the organism. Resistance to fluoroquinolones devel‐
ops rapidly, so that prior use of these medications is associated with a significant rate of
resistance. [4]
6.6. Furazolidone
Furazolidone is a monoamine oxidase inhibitor with widely antibacterial activity based on
interference with bacterial enzymes. This antibiotic has proven to be an effective part of
triple therapy while the development of resistance is rare. Furazolidone is an underused
antimicrobial. [44]
6.7. Rifabutin
Rifabutin is a semisynthetic ansamycin antibiotic with low MIC level for H pylori infection.
This antibiotic is becoming more common and primarily used in combination with PPI and
amoxicillin. [4] Rifabutin-based triple therapy for 10 days has been tested as salvage therapy
and found to have high eradication rate of over 80%. Ritabutin can have cross-resistance with
antimycobacterium. [8]
6.8. Other antimicrobial agent
Bismuth compounds are topically active pH-independent antimicrobial drugs that disrupt the
integrity of bacterial cell walls. Bismuth is directly bactericidal, even though its MIC is high
for H pylori. Bismuth is available in two forms (bismuth subsalicylate and bismuth subcitrate),
which have equivalent effect as anti–H pylori therapy. H pylori resistance has not been reported
for this agent. [4]
Regimens available
In recent years, the efficacy of legacy triple therapy for H. pylori eradication has declined
worldwide to an unacceptable level. The average success rate of triple therapy has also
declined to about 70%. [4, 8, 41] Bismuth-based quadruple therapy containing metronidazole
is more effective than triple therapy with overall eradication rate of 83% and the eradication
rate is higher in metronidazole sensitive group than those of the resistant group. [45] A recent
study from Thailand demonstrated that a ten-day sequential therapy is highly effective for H.
pylori infection with eradication rate of 95% but its efficacy affected by clarithromycin resist‐
ance. [41] A study from concomitant therapy evaluated and compared the efficacy of 10-day
and 5-day therapy for H. pylori eradication using PPI with three antibiotics and found that 10-
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5. Management of H. pylori infection in FD
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day regimen is highly effective with eradication rate of 96% and the 5-day regimen yielded
eradication rate of 88%. [46] The available treatment regimens was summarized in table 1. [4]
Legacy therapies
Triple therapy: A PPI plus amoxicillin, 1 g , plus clarithromycin, 500 mg, or metronidazole/tinidazole, 500 mg, twice a
day for 14 days
Quadruple therapy: Bismuth, metronidazole, 500 mg, tetracycline, 500 mg, three times a day plus a PPI twice a day for
14 days
Concomitant triple therapies
A PPI plus amoxicillin, 1 g, plus clarithromycin, 500 mg, and metronidazole/tinidazole, 500 mg, twice a day for 14 days
Sequential therapy
A PPI plus 1 g amoxicillin, twice a day for 5 days. On day 6 stop amoxicillin and add clarithromycin, 250 or 500 mg and
metronidazole/tinidazole, 500 mg, twice a day to complete the 10-day course.
Table 1. Treatment regimens for Helicobacter pylori infections4
There are many factors that could influence the eradication rate of H. pylori. Compliance is a
major concern and how to make the regimen conveniently used by all patients is important.
Impact of drug metabolism and CYP2C19 on eradication rate is a new point of concern and
needs further research to elucidate this question. The choice of a second-line therapy depends
on local antibiotic resistance pattern, previous treatment, drug availability and cost. Second-
line salvage therapy after primary therapy failure, levofloxacin based triple therapy resulted
in eradication rate of over 80% in patients after failed triple therapy. The accumulation
eradication rate after first-line and second-line therapy becomes nearly 90%. This regimen is
convenient and well-tolerated but antibiotic resistance to levofloxacin needs to be monitored.
Rifabutin-based triple therapy for 10 days has been tested as salvage therapy and found to
have high eradication rate of over 80%. Ritabutin can have cross-resistance with antimyco‐
bacterium. Furazotidone can also be used as salvage therapy but the use is limited by its
availability. The summarized efficacy of H. pylori treatment regimens is: [8]
• Triple therapy containing PPI plus amoxicillin and clarithromycin or metronidazole has
limited efficacy for H. pylori eradication with expected eradication rate of 70%.
• Sequential therapy and concomitant therapy yield high eradication rate of over 90% and
could be used as first - line therapy.
• Bismuth based quadruple therapy could be used as alternative first - line therapy with high
eradication rate.
• Levofloxacin based- triple therapy and concomitant therapy can be used as a second line
salvage therapy after failed first - line therapy.
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1. Introduction
Helicobacter pylori  ubiquitously infects the human gastric mucosa since time immemorial,
predictably  before  the  man’s  diaspora  out  of  East  Africa  around  58,000  years  ago  [1].
Colonization  may  have  been  somehow  beneficial  for  human  carriers,  allowing  the  co-
evolution  of  this  gram-negative  bacterium and  its  host  over  the  centuries.  Yet,  at  least
nowadays  [2],  this  may  not  be  a  peaceful  association,  with  infection  almost  invariably
causing an acute host  immune response.  However,  in a fully adapted manner,  H. pylori
avoids recognition and, thus, clearance, by the host immune system, with both infection
and the consequent gastritis persisting throughout the patients’ life. The clinical outcome
of  this  persistence  is  dependent  on  a  sophisticated  crosstalk  between  the  host  and  the
pathogen. If often asymptomatic, the H. pylori-associated non-ulcer dyspepsia is clearly the
strongest aetiological factor for severe gastric diseases that will develop late in adult life in
a minority of infected patients, i.e., peptic ulcer disease, both gastric and duodenal ulcers,
and  gastric  cancer,  namely,  adenocarcinoma  and  mucosa  associated  lymphoid  tissue
(MALT) lymphoma (reviewed in [3]). Peptic ulcer disease rarely occurs soon after H. pylori
infection [4-8] that generally starts in childhood; this presumably reflects marked differen‐
ces in the virulence [9-16] and/or in the susceptibility of young patients [17-19].
This chapter, focussing on the paediatric population, seeks to explore: the prevalence of H.
pylori infection; the molecular mechanism used by H. pylori during colonization and infection;
the role of this bacterium in the development of peptic ulcer-related organic dyspepsia; and
the genetic/proteome profile of the H. pylori-strains associated with peptic ulcer disease.
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1.1. Prevalence of infection
H. pylori is one of the most common gastrointestinal bacterial infections among humans,
affecting more than 50% of the world's population [1,20]. Infection is usually acquired during the
first years of life in both developing and industrialized countries, with intra-familial spread playing
a central role in transmission of the infection [21,22]. The prevalence of H. pylori is markedly
variable between developing and developed countries, and even among individuals living in
the same country, varying according to ethnicity, place of birth and socioeconomic factors.
Besides geographic area, age is also significantly and independently associated with an
increase in H. pylori prevalence, a phenomenon known as birth cohort effect, which is a
progressive reduction of the infection rate in successive birth cohorts, due to the improvements
in general living conditions (reviewed in [23]). In less developed countries the infection rate
reaches almost 50% in very young children and more than 90% in adults, whereas in indus‐
trialized countries H. pylori infects 20-50% of adults and less than 10% of children, and has been
declining over time [23,24]. Indeed, the prevalence of H. pylori infection is showing a decreased
trend worldwide that is directly associated with an improvement in the socioeconomic status and
hygienic conditions of the populations.
Accordingly, in Europe and North America, the epidemiology of H. pylori infection in children has
changed in recent decades. Nowadays, low incidence rates are found in the northern and western
European countries, resulting in prevalence far below 10% in children and adolescents. In contrast, the
infection is still common in certain geographic areas such as southern or eastern Europe, Mexico, and
certain immigrant populations from South America, Africa, most Asian countries, and first-nation
(aboriginal) people in North America [25-27]. In Portugal with the worst scenario of Europe, the
prevalence of H. pylori infection is closer to the situation observed in developing countries,
reaching 80% among the adult population in their early nineties, and, more recently, varying
from approximately 20% in young children (less than 5 years old) to 50% in children 10 to 15
years old [28,29].
The absence of effective vaccines [30] and of efficient alternatives to antibiotics [31-34] renders
difficult the worldwide prevention of H. pylori infection-associated diseases through massive
eradication of the bacterium. The current antibiotic therapy against H. pylori infection fails in
about 20% of the patients; depending on the therapeutic schema and strain resistance pattern,
the failure rate may reach 70%. Antibiotic resistance, mainly to clarithromycin, is the major
factor affecting the efficacy of standard triple therapy of H. pylori infection (co-administration
of two antibiotics and a proton pump inhibitor or ranitidine bismuth for seven to ten days). In
fact, the resistance rates to this and other second line antibiotics, such as the fluoroquinolones,
are increasing in many geographical areas [34-36].
Several studies reveal a similar or higher resistance rate to clarithromycin among paediatric
isolates as compared to those obtained from adults, especially in southern European countries,
reflecting the recognized overuse of macrolides in children in these countries [31,34,37,38]. As
an example, Portugal displays one of the highest rates of H. pylori primary resistance to
clarithromycin in Europe, similarly high in children as among adults (≈33%) [34]. Moreover,
resistance to second line antibiotics has rapidly increased over the last decade and is a matter
of concern [31-34]. This places the research on disease-specific bacterial biomarkers and their
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associated molecular mechanisms as a top priority to define disease-risk and to target H.
pylori eradication in high-risk individuals. Ultimately, it may provide novel bacterial and/or
host’s therapeutic or vaccine targets.
1.2. Molecular mechanisms of H. pylori colonization and infection
1.2.1. Acid resistance and motility
In a fully adapted manner, during colonization and persistence, this neutralophile bacterium
resists gastric acidity mainly through its urease activity. Its urease enzyme, a Ni2+-containing
dodecameric protein of approximately 1100 kDa, composed of 12 small subunits, UreA (27
kDa), and 12 large subunits, UreB (62 kDa), catalyzes the hydrolysis of urea into ammonia and
carbon dioxide, buffering both the bacteria cytoplasm and periplasm [39]. Accounting for
5-10% of the total protein content, urease is one of the most abundant proteins in the H.
pylori proteome [16,30]. Probably due to the toxicity of ammonia, urease activity is known to
be dependent on low pH and/or Ni2+ concentration conditions [39,40], being essential for
bacteria survival only under acidic conditions. In the early stages of colonization, H. pylori
seeks parts of the stomach with higher pH, such as the antrum (the distal part of the stomach).
Indeed, this bacterium uses the pH gradient as chemotactic signal to achieve regions of neutral
pH, since its spatial orientation is lost in the absence of the mucus pH gradient [41]. Thus, the
acid-producing parietal cells may protect the corpus region from initial invasion.
Efficient colonization of the gastric niche by H. pylori is also dependent on how fast it escapes
from the lumen of the stomach and reaches the mucus layer, avoiding elimination by gastric
peristalsis [42]. Its helical shape and the two to six polar, sheathed flagella provide swimming
abilities. According to a longstanding theory [43], the helical shape allows H. pylori to have a
corkscrew motion which, although not being essential for motility, enhances its ability to swim
through the viscous mucus layer. The machinery that gives rise to the spiral shape of this
bacterium remains largely unknown, but seems dependent on the coordinated action of
multiple proteins in a shape-generating pathway that leads to the relaxation of the peptido‐
glycan crosslinking [44]. Flagella are, however, essential for H. pylori motility. Indeed, aflagel‐
lated strains (obtained by elimination of both flaA and flaB, genes encoding the two major
components of flagellar filament, flagellins A and B) [45], as well as strains presenting non-
functional flagella (in knockout motB models lacking the gene that encodes the MotB flagellar
motor protein), are non-motile [42]. Such mutants are able to establish only transient coloni‐
zation in animal models [42,46]. Moreover, lower-motility strains are long known to induce
in vitro reduced inflammation levels, when compared to higher motility strains [47]. Once in
the mucus layer of the stomach, H. pylori resides here thereafter, either freely swimming [43]
or attached to host’s extracellular mucins [41], getting closer to the host’s gastric epithelial
surface whenever necessary. Occasionally H. pylori also can be internalized, entering the gastric
epithelial cells [48]. Invasion beyond the epithelial layer is, however, is a rare event.
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In the human stomach, the vast majority of H. pylori cells exist in their motile form within the
mucus layer lining; only a small portion (≈30%) are adherent to the surfaces of epithelial cells
[41]. Nevertheless, adherence to the gastric epithelium is important for the ability of H. pylori
to cause disease because this intimate attachment facilitates: 1) persistence, by preventing the
bacteria from being eliminated from the stomach through mucus turnover and gastric
peristalsis, and also by enabling the bacteria to replicate; 2) evasion from the human immune
system; 3) efficient delivery of the bacterial toxic proteins; and 4) acquiring nutrients released
from the damaged host cells.
H. pylori expresses a multitude of different adhesins. Best characterized is the blood group
antigen-binding adhesin (BabA), a ligand of ABO (of the blood group system) Lewis b (Leb)
antigens [49]. Sequence analyses reveals the existence of two allelic variants of babA, the babA1
and babA2 alleles, which are identical except for a 10 base pair insertion that results in a
translational initiation codon present in babA2 but absent in babA1, and of a highly homologous
gene, babB. Of these, only babA2 allele encodes a functional Leb adhesin [49]. BabA is not likely
to be essential for the colonization; BabA-expressing strains are no different in this step
compared to BabA-non-expressing strains [50]. BabA, being an adhesin, however likely plays
an important role in the induction of host inflammatory response. Indeed, babA2 allele is
clinically important, namely in a vacA/cagA-positive genetic background (two additional
important virulence factors discussed in section 1.2.3. of this chapter), which is associated with
peptic ulcer disease and gastric cancer [51]. BabA-expressing strains induces change in the
glycosylation pattern of the gastric mucosa of humans and animal models [50].
The second best characterized H. pylori adhesin is the sialic acid binding adhesin (SabA) which
mediates attachment to the inflammation-associated (sialylated Lewisx and Lewisa) antigens
[52]. In fact, gastric tissue inflammation and malignant transformation promote synthesis of
sialylated glycoconjugates, which are rare in healthy human stomachs [52, 53]. Accordingly,
high levels of sialylated glycoconjugates are found in H. pylori infected persons; these decrease
after eradication of the infection and resolution of the gastritis [54]. H. pylori can agglutinate
erythrocytes and neutrophils in vitro. The SabA adhesin is the hemagglutinin of H. pylori and
allows bacterial adherence to blood cells; this may result in systemic dissemination of the
pathogen [55]. Moreover, the binding of SabA to sialic acid carries neutrophil receptors,
essential for the nonopsonic activation of human neutrophils [56]. Neutrophils play a major
role in the epithelium injury, since these cells have direct toxic effects on the epithelial cells,
through the induction of an oxidative burst, with the release of reactive oxygen and nitrogen
species. Thus, the neutrophil activating capacity of SabA makes this protein an additional
virulence factor that is important in the pathogenesis of H. pylori infection.
The outer membrane inflammatory protein (OipA), a member of the Hop family of proteins,
is another H. pylori membrane protein with an active role in bacterial adherence, for which no
host receptors are known. Its encoding gene (oipA) is present in all H. pylori strains but it is
only expressed in those presenting the oipA “on” (i.e., functional) genotype. This is regulated
by slipped-strand mispairing, depending on the number of CT repeats in the 5’ region of the
gene [57]. OipA expression by H. pylori is associated with high bacterial densities, severe
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neutrophil infiltration and, ultimately, with peptic ulceration and gastric cancer [58,59].
Supporting the later association, the inactivation of oipA results in a reduced nuclear translo‐
cation of β-catenin, a known factor involved in the transcriptional up-regulation of genes
implicated in carcinogenesis [59].
1.2.3. Delivery and virulence factors
After adherence, H. pylori delivers its virulence factors into the cytoplasm of the host’s cells by
using a type IV secretion system (T4SS) and/or outer membrane vesicles. The genes encoding
the components of the T4SS, which is a syringe-like pilus protruding from the bacterial surface
used to inject virulence factors in host target cells’ cytoplasm, are located in the cag pathoge‐
nicity island (PAI) [60]. This is an approximately 40 kpb chromosomal insertion that is thought
to have been incorporated into the H. pylori genome by horizontal transfer from an unknown
source [61]. As a result, strains are heterogenic regarding the presence of this chromosomal
region, varying between those that contain the intact cag PAI to those that completely lack it.
For those lacking an intact T4SS, the delivery of their virulence factors is totally dependent on
the secretion of outer membrane vesicles with a still poorly known content; these are endocy‐
tosed by the host epithelial cells (reviewed in [62]).
Encoded by cytotoxin associated gene A, one of the 32 genes of the cag PAI region, CagA is
perhaps the most extensively studied translocated protein, the only known effector protein
injected by the T4SS. Once injected into cytoplasm of target cells, CagA interferes with several
host cell signalling cascades, ultimately inducing abnormal proliferation, cytoskeleton
rearrangements and inflammation through the release of cytokines, such as interleukin-1β
(IL-1β), IL-8 and tumour necrosis factor-α (TNF-α) (reviewed in [63]). There are two types of
clinical isolates regarding CagA: those producing this protein (cagA-positive H. pylori strains),
and the CagA-nonproducing strains (cagA-negative H. pylori strains). The cagA-positive strains
are considerably more virulent [60]. In Western countries, individuals carriers of cagA-positive
strains are thus at higher risk of peptic ulcer disease and/or gastric cancer [64,65], leading to
the classification of CagA as a bacterium-derived oncogenic protein [66]. In a not fully
undisclosed manner, the virulence of the cagA-positive strains is associated with the number
and the type of the phosphorylation motifs of the C-terminal variable region of the protein. Of
these motifs, defined as EPIYA (Glu-Pro-Ile-Tyr-Ala) A, B, C and D according to different
flanking amino acids, CagA protein nearly always possesses EIPYA-A and B segments,
followed by none, one, two or three C segments in Western-strains or a D segment in strains
of East Asian countries. The East Asian-type of CagA (ABD) is known to be more carcinogenic
than the Western-type; within the latter, the variants possessing multiple EPIYA-C motifs
(ABCC or ABCCC) are more virulent compared with those with a single segment (ABC)
(reviewed in [63]). Moreover, the association of CagA expression levels with polymorphisms
in the cagA promoter region may further contribute to differences in virulence among cagA-
positive strains and different disease-associated risks [67]. The virulence of the strain must also
be dependent on additional bacterial factors, since in East Asia most strains are cagA-positive
irrespective of the patient disease.
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through the induction of an oxidative burst, with the release of reactive oxygen and nitrogen
species. Thus, the neutrophil activating capacity of SabA makes this protein an additional
virulence factor that is important in the pathogenesis of H. pylori infection.
The outer membrane inflammatory protein (OipA), a member of the Hop family of proteins,
is another H. pylori membrane protein with an active role in bacterial adherence, for which no
host receptors are known. Its encoding gene (oipA) is present in all H. pylori strains but it is
only expressed in those presenting the oipA “on” (i.e., functional) genotype. This is regulated
by slipped-strand mispairing, depending on the number of CT repeats in the 5’ region of the
gene [57]. OipA expression by H. pylori is associated with high bacterial densities, severe
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neutrophil infiltration and, ultimately, with peptic ulceration and gastric cancer [58,59].
Supporting the later association, the inactivation of oipA results in a reduced nuclear translo‐
cation of β-catenin, a known factor involved in the transcriptional up-regulation of genes
implicated in carcinogenesis [59].
1.2.3. Delivery and virulence factors
After adherence, H. pylori delivers its virulence factors into the cytoplasm of the host’s cells by
using a type IV secretion system (T4SS) and/or outer membrane vesicles. The genes encoding
the components of the T4SS, which is a syringe-like pilus protruding from the bacterial surface
used to inject virulence factors in host target cells’ cytoplasm, are located in the cag pathoge‐
nicity island (PAI) [60]. This is an approximately 40 kpb chromosomal insertion that is thought
to have been incorporated into the H. pylori genome by horizontal transfer from an unknown
source [61]. As a result, strains are heterogenic regarding the presence of this chromosomal
region, varying between those that contain the intact cag PAI to those that completely lack it.
For those lacking an intact T4SS, the delivery of their virulence factors is totally dependent on
the secretion of outer membrane vesicles with a still poorly known content; these are endocy‐
tosed by the host epithelial cells (reviewed in [62]).
Encoded by cytotoxin associated gene A, one of the 32 genes of the cag PAI region, CagA is
perhaps the most extensively studied translocated protein, the only known effector protein
injected by the T4SS. Once injected into cytoplasm of target cells, CagA interferes with several
host cell signalling cascades, ultimately inducing abnormal proliferation, cytoskeleton
rearrangements and inflammation through the release of cytokines, such as interleukin-1β
(IL-1β), IL-8 and tumour necrosis factor-α (TNF-α) (reviewed in [63]). There are two types of
clinical isolates regarding CagA: those producing this protein (cagA-positive H. pylori strains),
and the CagA-nonproducing strains (cagA-negative H. pylori strains). The cagA-positive strains
are considerably more virulent [60]. In Western countries, individuals carriers of cagA-positive
strains are thus at higher risk of peptic ulcer disease and/or gastric cancer [64,65], leading to
the classification of CagA as a bacterium-derived oncogenic protein [66]. In a not fully
undisclosed manner, the virulence of the cagA-positive strains is associated with the number
and the type of the phosphorylation motifs of the C-terminal variable region of the protein. Of
these motifs, defined as EPIYA (Glu-Pro-Ile-Tyr-Ala) A, B, C and D according to different
flanking amino acids, CagA protein nearly always possesses EIPYA-A and B segments,
followed by none, one, two or three C segments in Western-strains or a D segment in strains
of East Asian countries. The East Asian-type of CagA (ABD) is known to be more carcinogenic
than the Western-type; within the latter, the variants possessing multiple EPIYA-C motifs
(ABCC or ABCCC) are more virulent compared with those with a single segment (ABC)
(reviewed in [63]). Moreover, the association of CagA expression levels with polymorphisms
in the cagA promoter region may further contribute to differences in virulence among cagA-
positive strains and different disease-associated risks [67]. The virulence of the strain must also
be dependent on additional bacterial factors, since in East Asia most strains are cagA-positive
irrespective of the patient disease.
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The vacuolating toxin (VacA), another important virulence factor (reviewed in [68]), is
synthesized as a pro-toxin of ≈140 kDa, which contains a N-terminal signal sequence, a
passenger domain and C-terminal autotransporter domain. The passenger toxin domain (≈88
kDa) is cleaved and processed at some point during its secretion into the extracellular milieu
through the autotransporter that functions as a type V secretion system. This 88 kDa toxin is
further proteolytically cleaved, creating a N-terminal fragment of ≈33 kDa (p33) and a C-
terminal fragment of ≈55 kDa (p55) that remain non-covalently associated. Required for the
cytotoxic activity, the p33 subunit is postulated to be involved in the formation of anionic
membrane channels, while p55 subunit seems to mediate VacA binding to host cells (reviewed
in [68]). These functions are, however, highly dependent of the tridimensional structure of
both subunits [69,70]. Once secreted by the bacterial cells, VacA triggers various responses in
the host, resulting in the cellular vacuolation, pore formation in the cell membrane, disruption
of endosomal ⁄ lysosomal structure and function, apoptosis by toxin trafficking to mitochon‐
dria, and immunomodulation [71-73]. Virtually all H. pylori strains have a functional VacA.
However, the amount of toxin produced is related to the allelic variation of the encoding gene,
especially in its signal and middle regions (reviewed in [74]). Therefore, an association between
particular vacA allele types and peptic ulcer disease has been reported worldwide..
The ancient association between H. pylori and the modern humans [1,20] has determined the
abnormal high diversity in both their genetic background and the virulence observed among
strains. This generates complex scenario that creates difficulty in understanding the contribu‐
tion of each individual factor. Nevertheless, H. pylori strains presenting the association of these
two virulence factors, i.e., cagA-positive and vacA-toxigenic alleles, are considered to be more
virulent and thus more associated with severe organic dyspepsia inducers of a high production
of proinflammatory cytokines in the gastric mucosa and thus more severe non-ulcer dyspepsia.
Even so, these virulence factors do not appear to determine the overall pattern of gastro-
duodenal disease and a complex interplay between host bacterial factors and environment
seems to be involved in the development of gastric pathology [75].
1.2.4. Evasion
Upon colonization, H. pylori-infected patients experience a strong and complex immune
response in the gastric mucosa, both at the humoral and cellular levels; despite this response,
nevertheless the infection fails to clear. Therefore, in the absence of effective treatment,
infection becomes chronic, persists, and contributes to the immunopathology. The persistence
of infection throughout the life of its host is guaranteed by a set of molecular mechanisms used
by H. pylori to constantly evade the host immune response (reviewed in [76]). Bacterial mimicry
and genetic diversity play a central role in such successful strategies.
Mimicking the cell surfaces of the host, the lipopolysaccharide of the H. pylori cell wall is
relatively anergic compared to other gram-negative bacteria. In fact, the variable part of the
O-antigen chain of H. pylori lipopolysaccharide is composed of host-related Lewis antigens,
making it unrecognizable to the host immune system [77]. Therefore, this pathogen not only
binds to human Lewis antigens through BabA and SabA, but it also expresses Lewis-like
antigens facilitating the escape from the host immune system. Another ingenious camouflage
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used by H. pylori is the expression of proteins at its surface, which specifically bind to host-
secreted proteins, e.g., bacterial plasminogen-binding proteins (PgbA and PgbB). This allows
the bacterium to be coated with host proteins [78]. H. pylori also avoids immune recognition
through the in vitro and in vivo impairment of the expression of host’s specific heat shock
proteins, thus, inactivating both the innate and adaptive immune response [79].
Allelic diversification of its virulence factors encoding genes allows H. pylori to occupy
different microenvironments within the human stomach and to adapt to the varying conditions
in the niche over time. This is even more efficient, considering that the expression of different
variants of those genes may switch through mechanisms of phase variation. Indeed, several
in vitro studies have demonstrated that H. pylori Lewis-like antigens can undergo phase
variation (reviewed in [76]). Moreover, in animal models, persistent infection leads to the loss
of expression of babA. This occurs either by phase variation switching between an “on” and
an “off” status in a manner similar to that described for oipA (see section 1.2.2 of this chapter),
or by nonreciprocal gene conversion of babA to babB [80].
The existence of a small subpopulation of H. pylori within gastric epithelial cells (as briefly
discussed in section 1.2.1 of this chapter) may represent a sanctuary site that protects bacteria
against immune clearance [48].
1.3. Peptic Ulcer — Related organic dyspepsia in paediatrics, a rare event
Although rarely associated with severe forms of organic dyspepsia (namely peptic ulcer
disease) in the paediatric age group, H. pylori is clearly linked with acute gastric inflammation
in childhood and occurs frequently in children with dyspepsia [81]. This important association
gains relevance when considering that: a) gastric colonization by H. pylori occurring in
childhood and the consequent inflammation continues for life if left untreated; and b) this
lifelong persistence of inflammation after decades of infection is the main etiology for peptic
ulceration and/or cancer in adulthood. Moreover, some studies suggest a possible impact of
H. pylori-associated dyspepsia on anthropometry, as children with dyspepsia and H. pylori
infection are shorter and lighter than children with similar symptoms but no infection [82,83].
Evidence for the importance of H. pylori infection as a factor for dyspepsia in childhood comes
from H. pylori eradication resulting in a significant long-term improvement of dyspeptic
symptoms [84]. The symptoms of H. pylori-associated paediatric dyspepsia however do not
differ from those of non-infected dyspeptic children [85], raising questions about which
approach should be adopted in children with dyspepsia, in terms of H. pylori testing. According
to current guidelines for the management of H. pylori infection at pediatric age [86,87], the
primary goal of diagnostic interventions should be to determine the cause of the presenting
gastrointestinal symptoms (“scope and treat” strategy) and not just the presence of H. pylori
infection (“test and treat” strategy). Indeed, recurrent abdominal pain is not an indication for
a “test and treat” strategy concerning H. pylori infection in children, as evidence regarding the
association with H. pylori infection has been so far inconclusive (even in the presence of peptic
ulcer). Indeed, several studies using different noninvasive tests for H pylori infection compared
the prevalence of positive results in children with recurrent abdominal pain and controls and
found no significant difference in infection rates between cases and controls [88,89]. On the
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further proteolytically cleaved, creating a N-terminal fragment of ≈33 kDa (p33) and a C-
terminal fragment of ≈55 kDa (p55) that remain non-covalently associated. Required for the
cytotoxic activity, the p33 subunit is postulated to be involved in the formation of anionic
membrane channels, while p55 subunit seems to mediate VacA binding to host cells (reviewed
in [68]). These functions are, however, highly dependent of the tridimensional structure of
both subunits [69,70]. Once secreted by the bacterial cells, VacA triggers various responses in
the host, resulting in the cellular vacuolation, pore formation in the cell membrane, disruption
of endosomal ⁄ lysosomal structure and function, apoptosis by toxin trafficking to mitochon‐
dria, and immunomodulation [71-73]. Virtually all H. pylori strains have a functional VacA.
However, the amount of toxin produced is related to the allelic variation of the encoding gene,
especially in its signal and middle regions (reviewed in [74]). Therefore, an association between
particular vacA allele types and peptic ulcer disease has been reported worldwide..
The ancient association between H. pylori and the modern humans [1,20] has determined the
abnormal high diversity in both their genetic background and the virulence observed among
strains. This generates complex scenario that creates difficulty in understanding the contribu‐
tion of each individual factor. Nevertheless, H. pylori strains presenting the association of these
two virulence factors, i.e., cagA-positive and vacA-toxigenic alleles, are considered to be more
virulent and thus more associated with severe organic dyspepsia inducers of a high production
of proinflammatory cytokines in the gastric mucosa and thus more severe non-ulcer dyspepsia.
Even so, these virulence factors do not appear to determine the overall pattern of gastro-
duodenal disease and a complex interplay between host bacterial factors and environment
seems to be involved in the development of gastric pathology [75].
1.2.4. Evasion
Upon colonization, H. pylori-infected patients experience a strong and complex immune
response in the gastric mucosa, both at the humoral and cellular levels; despite this response,
nevertheless the infection fails to clear. Therefore, in the absence of effective treatment,
infection becomes chronic, persists, and contributes to the immunopathology. The persistence
of infection throughout the life of its host is guaranteed by a set of molecular mechanisms used
by H. pylori to constantly evade the host immune response (reviewed in [76]). Bacterial mimicry
and genetic diversity play a central role in such successful strategies.
Mimicking the cell surfaces of the host, the lipopolysaccharide of the H. pylori cell wall is
relatively anergic compared to other gram-negative bacteria. In fact, the variable part of the
O-antigen chain of H. pylori lipopolysaccharide is composed of host-related Lewis antigens,
making it unrecognizable to the host immune system [77]. Therefore, this pathogen not only
binds to human Lewis antigens through BabA and SabA, but it also expresses Lewis-like
antigens facilitating the escape from the host immune system. Another ingenious camouflage
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used by H. pylori is the expression of proteins at its surface, which specifically bind to host-
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through the in vitro and in vivo impairment of the expression of host’s specific heat shock
proteins, thus, inactivating both the innate and adaptive immune response [79].
Allelic diversification of its virulence factors encoding genes allows H. pylori to occupy
different microenvironments within the human stomach and to adapt to the varying conditions
in the niche over time. This is even more efficient, considering that the expression of different
variants of those genes may switch through mechanisms of phase variation. Indeed, several
in vitro studies have demonstrated that H. pylori Lewis-like antigens can undergo phase
variation (reviewed in [76]). Moreover, in animal models, persistent infection leads to the loss
of expression of babA. This occurs either by phase variation switching between an “on” and
an “off” status in a manner similar to that described for oipA (see section 1.2.2 of this chapter),
or by nonreciprocal gene conversion of babA to babB [80].
The existence of a small subpopulation of H. pylori within gastric epithelial cells (as briefly
discussed in section 1.2.1 of this chapter) may represent a sanctuary site that protects bacteria
against immune clearance [48].
1.3. Peptic Ulcer — Related organic dyspepsia in paediatrics, a rare event
Although rarely associated with severe forms of organic dyspepsia (namely peptic ulcer
disease) in the paediatric age group, H. pylori is clearly linked with acute gastric inflammation
in childhood and occurs frequently in children with dyspepsia [81]. This important association
gains relevance when considering that: a) gastric colonization by H. pylori occurring in
childhood and the consequent inflammation continues for life if left untreated; and b) this
lifelong persistence of inflammation after decades of infection is the main etiology for peptic
ulceration and/or cancer in adulthood. Moreover, some studies suggest a possible impact of
H. pylori-associated dyspepsia on anthropometry, as children with dyspepsia and H. pylori
infection are shorter and lighter than children with similar symptoms but no infection [82,83].
Evidence for the importance of H. pylori infection as a factor for dyspepsia in childhood comes
from H. pylori eradication resulting in a significant long-term improvement of dyspeptic
symptoms [84]. The symptoms of H. pylori-associated paediatric dyspepsia however do not
differ from those of non-infected dyspeptic children [85], raising questions about which
approach should be adopted in children with dyspepsia, in terms of H. pylori testing. According
to current guidelines for the management of H. pylori infection at pediatric age [86,87], the
primary goal of diagnostic interventions should be to determine the cause of the presenting
gastrointestinal symptoms (“scope and treat” strategy) and not just the presence of H. pylori
infection (“test and treat” strategy). Indeed, recurrent abdominal pain is not an indication for
a “test and treat” strategy concerning H. pylori infection in children, as evidence regarding the
association with H. pylori infection has been so far inconclusive (even in the presence of peptic
ulcer). Indeed, several studies using different noninvasive tests for H pylori infection compared
the prevalence of positive results in children with recurrent abdominal pain and controls and
found no significant difference in infection rates between cases and controls [88,89]. On the
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other hand, pediatric studies are limited by the lack of a clear definition for recurrent abdomi‐
nal pain or by the use of nonspecific criteria for the diagnosis of chronic abdominal pain [90].
Nevertheless, in patients with persistent abdominal pain (after exclusion of other causes, such
as lactose intolerance, giardiasis, celiac disease, inflammatory bowel disease, among others) and/
or severe upper abdominal symptoms (namely suggesting peptic ulcer disease, such as
nocturnal pain), upper endoscopy with biopsy should be performed (diagnostic investigation
of choice). Furthermore, testing for H. pylori in children/adolescents should be considered if
there is a family history of gastric cancer and in children/adolescents with refractory iron
deficiency anemia, when no other cause is found. In these settings, when upper endoscopy is
performed, the presence of H. pylori should be systematically sought through histological
examination and, whenever feasible, culture and antibiotic susceptibility testing; treatment
should be offered in the presence of H. pylori positivity. Population screening for H. pylori in
asymptomatic children to prevent gastric cancer is not warranted. Although 13C-urea breath
testing is a validated noninvasive diagnostic test for H. pylori infection in children, a “test and
treat” strategy including this tool should not be indiscriminately adopted in clinical practice
at this age group, considering the fact that this test merely identifies H. pylori presence but not
necessarily the causality of symptoms. Noninvasive tests for H.pylori include different methods
for the detection of bacterial antigens in stool, detection of antibodies (IgG, IgA) against H.
pylori in serum, urine, and oral samples, and the 13C-UBT. In the paediatric group, both fecal
antigens determination and respiratory test are reliable to determine whether H pylori has been
eradicated or not after antibiotic treatment, while tests based on the detection of antibodies
against H pylori are considered not reliable for use in the clinical setting, but may be useful in
epidemiological studies [91].
Therefore, H. pylori infection in childhood differs from adults not only in terms of the prevalence of the
infection and a higher rate of antibiotic resistance, but also with respect to the complication rate, age-
specific problems with diagnostic tests and drugs, and the near-absence of gastric malignancies [92].
Nevertheless, H. pylori-associated peptic ulcer disease may also occur shortly after infection
in childhood [4-8]. This rare event may be due to more virulent strains [9-16], and/or more
predisposed subjects [17-19]. The two forms of H. pylori-associated peptic ulcers, i.e., gastric
ulcer and duodenal ulcers, are divergent in prevalence and physiopathology, but both cause
considerable patients’ morbidity entailing high annual costs of treatment [93].
1.3.1. Prevalence of H. pylori-associated gastric and duodenal ulcers in childhood
In general, about 10-15% of the H. pylori infected patients suffer from duodenal ulcer disease and 2-5%
with gastric ulcer and/or gastric cancer late in the adulthood [3]. Population-based studies in patients
with organic dyspepsia suggest that peptic ulcer disease related to H. pylori infection is decreasing in
prevalence in Western countries, along with a decrease in the prevalence of infection [94]. The former
should be a direct consequence of the second; with improved living standards, cohorts of children became
progressively less likely to acquire the organism and thus suffer from H. pylori-associated diseases.
Nevertheless, specific populations such as immigrants and rural communities may have a high
prevalence of infection and peptic ulcer disease; these individuals should be separately reviewed even in
areas where the general prevalence of H. pylori infection has declined below 15% [95]. Despite changing
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prevalence trends, H. pylori-induced gastritis causing mucosal ulceration either in the stomach
(gastric ulcer) or the proximal duodenum (duodenal ulcer) is a relatively uncommon event in
children, compared with adults [4-8]. In fact, during childhood, H. pylori is associated with
predominant antral gastritis or with pangastritis [96]. In children, few studies have yet investigated
the actual trend of H. pylori prevalence in peptic ulcer disease [5-8] and the available data are more
difficult to interpret, considering that the rates of peptic ulcer diagnosis depend also on the
clinical setting (endoscopy versus outpatient clinic or hospital admissions) [97,98]. For
example, in Italy the detection rate of ulcer disease was 7.8% out of an average of 180 paediatric
gastrointestinal endoscopies performed each year [99]. Similarly, a retrospective review (from
1998 to 2006) showed that 43 (6.9%) out of 619 Chinese children who underwent upper
endoscopy for investigation of upper gastrointestinal symptoms had peptic ulcer [7]; and
another retrospective study (from 2003 to 2006) have also reported a high incidence of peptic
ulcer (6.8%) in Israeli children submitted to upper endoscopy [100]. In Canada, however, the
approximate incidence of peptic ulcer was 1 case per 2,500 hospital admissions [92]. In a recent
large European multicenter study, including 1233 symptomatic children with H. pylori
infection, peptic ulcer disease was diagnosed in less than 5% of children younger than 12 years
of age and in ≈10% of teenagers [8]. Interestingly, other studies indicate a higher association
of H. pylori with peptic ulcer in adolescents than in younger children [100,101]. But, the
prevalence of H. pylori-positive ulcers in children also differs between countries and this is
not completely explained by the prevalence of the infection in the population studied. This is
easily demonstrated from data collected from January 2001 to December 2002 on 518 children
from the paediatric European register for treatment of H. pylori [5]. At endoscopy, 454 of those
patients had H. pylori-associated gastritis and 64 had a peptic ulcer (12.3%). This series also
included children from Russia, who had a significantly higher prevalence of peptic ulcer (35%)
compared to that of the remainder of European children (6.7%) [6]. In another report, school-
aged children with chronic abdominal complaints living in the rural area of Russia had a high
prevalence rate of H. pylori infection (80%) and also of peptic ulcer disease (24%) [102].
In adults, the prevalence of H. pylori infection is higher than 95% in duodenal ulcer cases and
around 60% to 80% in gastric ulcer cases [103]. This scenario is similar in children i.e. when H.
pylori-associated ulcers occur in children, duodenal ulceration is much more frequently
identified than gastric ulcers [104]. In fact, pooled analysis of early reports (from 1983 to 1994)
has demonstrated that the prevalence of H. pylori in children with duodenal ulcer was
relatively higher (ranging from 33% to 100%, with a median value of 92%), compared with
children with gastric ulcer (ranging from 11% to 75%, with a median value of 25%) [104]. A
more recent retrospective study (from 1995 to 2001) from Japan confirmed a very high
prevalence of H. pylori in antral gastritis and duodenal ulcer (98.5% and 83%, respectively),
also identifying H. pylori as a risk factor for the development of gastric ulcer although with a
lower prevalence of infection (less than 50%) [101]. Finally, in a Chinese study, it was reported
that among 43 Chinese children suffering with peptic ulcer disease, 37 had duodenal ulcer, of
which 21 were H. pylori positive, while only six had gastric ulcer, of which only two were
positive for the infection [7]. In summary, H. pylori infection is much more associated to
duodenal ulcer than to gastric ulcer, in both children and adults.
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included children from Russia, who had a significantly higher prevalence of peptic ulcer (35%)
compared to that of the remainder of European children (6.7%) [6]. In another report, school-
aged children with chronic abdominal complaints living in the rural area of Russia had a high
prevalence rate of H. pylori infection (80%) and also of peptic ulcer disease (24%) [102].
In adults, the prevalence of H. pylori infection is higher than 95% in duodenal ulcer cases and
around 60% to 80% in gastric ulcer cases [103]. This scenario is similar in children i.e. when H.
pylori-associated ulcers occur in children, duodenal ulceration is much more frequently
identified than gastric ulcers [104]. In fact, pooled analysis of early reports (from 1983 to 1994)
has demonstrated that the prevalence of H. pylori in children with duodenal ulcer was
relatively higher (ranging from 33% to 100%, with a median value of 92%), compared with
children with gastric ulcer (ranging from 11% to 75%, with a median value of 25%) [104]. A
more recent retrospective study (from 1995 to 2001) from Japan confirmed a very high
prevalence of H. pylori in antral gastritis and duodenal ulcer (98.5% and 83%, respectively),
also identifying H. pylori as a risk factor for the development of gastric ulcer although with a
lower prevalence of infection (less than 50%) [101]. Finally, in a Chinese study, it was reported
that among 43 Chinese children suffering with peptic ulcer disease, 37 had duodenal ulcer, of
which 21 were H. pylori positive, while only six had gastric ulcer, of which only two were
positive for the infection [7]. In summary, H. pylori infection is much more associated to
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The causative role of H. pylori in gastric ulcers in children and adolescents is, therefore, less
certain when compared to adults, possibly reflecting the fact that a large proportion of gastric
ulcers are secondary in nature in children. Characteristically, in children younger than 10 years
of age, peptic ulcers are usually due to noxious agents (such as corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs)) or occur after major stresses (such as burns,
trauma, and systemic illness). In these settings, upper gastrointestinal tract haemorrhage,
vomiting and perforation are frequent presenting features. The ulcers tend not to recur after
healing. In older children and adolescents, the clinical presentation and natural history of
peptic ulcers are similar to that observed in adults, presenting as epigastric and nocturnal
abdominal pain and being usually associated with H. pylori infection [8,100,101]. In this setting,
even though the acute ulcer is likely to heal, the natural history is for ulcer recurrence.
Moreover, the complication rate of peptic ulceration is important. The estimated incidence of
peptic ulcer bleeding in the US paediatric population also has ranged from 0.5 to 4.4/100,000
individuals in 2008 [105].
These and other differences explain why some of the recommendations for adults may not
apply in children [87,96]. Few randomized, placebo-controlled treatment trials are available
in children for the different outcomes (gastritis or peptic ulcer), and often consist of only small
numbers of cases [86,106]. Clearly in children as in adults, successful eradication of H. pylori
markedly reduces the risk of ulcer recurrence [107-110]. Thus, there is general consensus
worldwide to treat H. pylori infection when there is endoscopic evidence of peptic ulceration.
Triple therapy is the treatment of choice in children for endoscopically proven duodenal ulcer
and histologically proven H. pylori antral gastritis [91, 96, 111, 112].
1.3.2. Differences in the physiopathology of H. pylori-associated gastric and duodenal ulcers
Peptic ulceration is a multifactorial disease ultimately explained by disequilibrium between
aggressive injurious factors and defensive gastroduodenal mucosa-protective factors, which
raises the vulnerability of this mucosa to luminal secretions. H. pylori infection is considered
the major causative factor for peptic ulceration. Nevertheless, there are other injurious
mechanisms jeopardizing the mucosal integrity: some viral infections (e.g. cytomegalovirus
and herpes simplex); drug-induced injury, particularly acetylsalicylic acid, NSAIDs and
chemotherapy; vascular disorders interfering with perfusion; major stresses; and syndromes
in which a marked overproduction of gastric acid occurs, as is the case of the Zollinger-Ellison
syndrome and, more commonly in children, antral G cell hyperplasia (also referred to as
pseudo-Zollinger Ellison syndrome) [113].
Although differing in their pathogenesis, both H. pylori-associated duodenal ulcers and gastric
ulcers are intimately related to changes in the acid production by the gastric mucosa [113,
114]. Indeed, H. pylori infection can result in increased, decreased or no overall change in the
level of gastric acid secretion. Duodenal ulcers arise on a background of H. pylori–induced
antral-predominant gastritis with sparing of the oxyntic mucosa, resulting in hypergastrine‐
mia and consequent high levels of acid production from the healthy gastric corpus following
meal or hormonal stimulation. In response to the excessive acid secretion, the duodenum
develops gastric metaplasia. This, unlike the normal duodenal mucosa, can be colonized by
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H. pylori with consequent inflammation and ulceration [113]. Eradication of the H. pylori
infection corrects the hypergastrinemia and decreases the basal acid secretory rate, heals any
peptic ulcer and ameliorates any symptoms of gastroesophageal reflux [115]. Conversely,
gastric ulcers are associated with H. pylori–induced pan- or corpus-predominant gastritis,
resulting in multifocal atrophy of acid-secreting mucosa and reduced acid secretion. These
ulcers usually arise at the junction of the antral and corpus mucosa, an area of intense inflam‐
mation [113]. Thus, the non-acidophilic nature of H. pylori (see section 1.2.1) explains how those
with low acid secretory capacity are more susceptible to spread of infection through the corpus
mucosa and to gastric ulceration. With their somewhat common pathobiology, gastric ulcer
disease precedes the development of gastric cancer [93,116,117]. Gastric and duodenal ulcers
have marked differences in their basis, placing them on opposite ends of disease spectrum. H.
pylori-induced duodenal ulcer conveys a lower risk of developing a gastric cancer [117]. But,
what makes it possible for H. pylori to be involved in both ends of disease spectrum? Although
the mechanisms are unclear, the infecting strain itself may play a crucial role on the diverging
point of this disease spectrum [16,93]. Moreover, the similarity between the phenotype of
gastric ulcer and gastric cancer raises questions about the carcinogenic potential of the
associated H. pylori strains [93]. Certainly the etiology for H. pylori-associated peptic ulcer in
adults depends on the complex interplay of gastritis phenotype and of progressive physio‐
logical gastro-duodenal alterations through childhood until adulthood, a result of environ‐
mental factors, bacterial virulence factors and host genetic background.
Despite epidemiological evidence that infection during childhood is seldom associated with
peptic ulceration or gastric atrophy, the mechanisms underlying differences in histopathology
and clinical expression of H. pylori infection when compared to the adult, are still poorly
identified. Theoretically, such differences might be explained by qualitative and/or quantita‐
tive differences in induced immune response, possibly age-related. Indeed, adults exhibit a
predominantly neutrophil infiltrate, whereas H. pylori-associated gastritis in children is
usually mild and superficial with a predominantly mononuclear infiltrate, a paucity of
neutrophils and a higher degree of lymphoid follicular hyperplasia [118]. Therefore, different
immunopathology and different patterns of cytokine expression would be anticipated for
children when compared to adults [18]. There may be differences in adaptive component of
gastric mucosa immune response in children compared to the adult host; a clear Th1 response
has not always been demonstrated for young patients. The lower gastritis scores in children
may also be a reflection of such a skewed Th1/Th2 balance, which may result in their lower
risk for developing ulcer disease [18, 19]. These findings could indicate that the host humoral
and cellular responses differ depending on the age at which the gastric infection is first
acquired and might explain the varying rates of disease outcomes that are evident in different
parts of the world. Nevertheless, higher anti-H. pylori IgG antibody titres occur in paediatric
patients with duodenal ulcer compared to those without ulceration, suggesting that local
humoral immune responses contribute to the development of peptic ulceration in these young
patients [102,119,120]. This is not surprising, given the fact that the more severe inflammation,
the greater the chance of ulcer formation [121] with increased IgG production leading to
mucosal damage similar to an Arthus reaction [2].
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predominantly neutrophil infiltrate, whereas H. pylori-associated gastritis in children is
usually mild and superficial with a predominantly mononuclear infiltrate, a paucity of
neutrophils and a higher degree of lymphoid follicular hyperplasia [118]. Therefore, different
immunopathology and different patterns of cytokine expression would be anticipated for
children when compared to adults [18]. There may be differences in adaptive component of
gastric mucosa immune response in children compared to the adult host; a clear Th1 response
has not always been demonstrated for young patients. The lower gastritis scores in children
may also be a reflection of such a skewed Th1/Th2 balance, which may result in their lower
risk for developing ulcer disease [18, 19]. These findings could indicate that the host humoral
and cellular responses differ depending on the age at which the gastric infection is first
acquired and might explain the varying rates of disease outcomes that are evident in different
parts of the world. Nevertheless, higher anti-H. pylori IgG antibody titres occur in paediatric
patients with duodenal ulcer compared to those without ulceration, suggesting that local
humoral immune responses contribute to the development of peptic ulceration in these young
patients [102,119,120]. This is not surprising, given the fact that the more severe inflammation,
the greater the chance of ulcer formation [121] with increased IgG production leading to
mucosal damage similar to an Arthus reaction [2].




Endoscopy is the only method to accurately diagnose peptic ulceration in children [87,122]. A
nodular mucosa in the gastric antrum or duodenal bulb and/or gastric or duodenal erosions
or ulcerations are specific (but not sensitive) features, suggesting active H. pylori infection. For
those with suspected infection, biopsies should be obtained for histopathology, as well as
complementary tests for detection of H. pylori including rapid urease test, histopathology with
Giemsa stain and, if available, culture. The rationale for the recommendation to perform more
than one diagnostic test is based on their sensitivity results in children, which range from 66%
to 100% for histology and from 75% to 100% for rapid urease tests [91]. In all paediatric age
groups, for patients receiving therapy with a proton pump inhibitor, biopsies should be
performed on the body and cardia (and, possibly, transition zones) of the stomach as well as
from the antrum to reduce the chances of false-negative results. Follow-up endoscopy is rarely
necessary, except in the setting of peptic ulceration associated with complications (such as
haemorrhage or perforation).
1.3.4. Host susceptibility
The multifactorial nature of peptic ulcer disease reflects its dependence on the patients’ genetic
susceptibility and habits (alcohol and/or non-steroid anti-inflammatory drug consumption,
diet, smoking and stress) [20]. Paediatric peptic ulcer disease is significantly more frequent in
boys than in girls (63.6% versus 36.4%, p<0.025) [32]. Although female hormones may have a
protective role against developing peptic ulcerations [123], the true nature of this susceptibility
of the male gender remains unclear.
Mucins, glycoproteins secreted by the gastric mucosa, form a gel layer that is essential to
maintain a stable neutral pH adjacent to epithelium. This mucus barrier affords protection
from attack by acid-pepsin and other luminal noxious agents [124]. H. pylori has a complex
relationship with different gastric mucins’ subtypes. Infected children for example have a
decreased mucin in their gastric mucosa presumably weakening this important defense barrier
[125]. The highly diverse carbohydrate structure of the gastric mucins, functioning as binding
sites for H. pylori, should also play a role in the outcome of infection, with genetic and epigenetic
changes in the mucin molecules influencing the susceptibility of the patient for H. pylori-
associated peptic ulcer disease. Recently, it was shown that H. pylori-infected children
presented a normal pattern of expression and glycosylation of mucin 5AC (MUC5AC) in the
surface mucous cells, and MUC6 in the gland mucous cells, contrasting with the aberrant
expression of MUC6 and MUC2 found in infected adults. Additionally, it was shown that the
pattern of Lewis blood group antigens in the surface epithelium of children was significantly
correlated with H. pylori load, however no correlation with gastritis, nodularity, and gastric or
duodenal ulcer was found [17].
In children and teenagers, as in adults, the severity of antral inflammation strongly correlates
with the risk of duodenal ulcer disease. Among the host factors, polymorphisms in cytokines
encoding genes, or in their promoters, that affect cytokine transcription, are good risk candi‐
dates. Indeed, polymorphisms in the IL-1 gene cluster play an important role in modulating
the risk for H. pylori-induced hypochlorhydria and, thus, for gastric ulceration and cancer. The
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IL-1 cluster, located on chromosome 2q12-22 region, includes the genes IL-1A, IL-1B and
IL-1RN that code for the proinflammatory cytokines IL-1α, IL-1β and their endogenous
receptor antagonist IL-1RA, respectively. The less common alleles of IL-1B, i.e., IL-1B-31C and
IL-1B-511T (representing, respectively, T-C and C-T transitions at positions 31 and 511 of the
IL-1B promoter) are associated with a higher risk of hypochlorhydria [116]. This association
can be explained considering that such polymorphisms lead to increased IL-1β expression/
secretion that, upon H. pylori-infection, amplifies the host inflammatory response. Also the less
common allele of IL-1RA, i.e., the IL-1RN*2 (representing one of the five known 86 base pair
tandem repeat polymorphisms in intron 2) is associated with a higher risk of gastric cancer in
adults [116]. The risk is potentiated when in association with infection by cagA/vacA-positive
H. pylori strains, highlighting the interplay between host and bacterial factors that seems to be
involved in the development of gastric pathology [126]. Children presenting the IL1RN*2 allele
and infected by cagA-positive H. pylori strains are at higher risk of duodenal ulceration,
emphasizing differences in the physiopathology of the disease between adult and paediatric
patients [124]. Also at higher risk of developing duodenal ulcer are children presenting the
transition G-A at position 238 of the TNF-α coding gene when infected by iceA1-positive H.
pylori strains [127].
Other  putative  host  risk  factors  for  H.  pylori-severe  gastroduodenal  diseases  are  the
polymorphisms in the genes coding for Toll-like receptors (TLRs) that might influence the
innate and adaptive immune response to the infection. Indeed, the presence of the TLR4
allele in combination with infection by cagA-positive strains, leads to increased gastric levels
of IL-8 and IL-10 [128].
1.4. Molecular profile of ulcerogenic paediatric H. pylori strains
The co-evolution between H. pylori and the modern humans has determined the extremely
high diversity of the bacterium in both its genetic background and virulence. Thus, it is likely
that bacterial determinants may influence the clinical outcome, an association that is well
established for cagA, vacA and babA genes (see sections 1.2.2 and 1.2.3 of this chapter). Never‐
theless, this topic is far from being fully clarified, and the identification of other factors
responsible for the enhanced virulence of the bacteria leading to the development of more
severe diseases remains pertinent. For that purpose, the study of H. pylori strains isolated in
specific clinical situations, such as the paediatric peptic ulcer disease, can be useful. Indeed,
H. pylori paediatric infection may be regarded as a privileged natural study model of the
interaction of this bacterium with human host, as the child is usually not exposed to injurious
factors as is the adult and represents a different stage of H. pylori infection in a immunologically
maturing host. Comparative genomic studies of the rare paediatric ulcerogenic H. pylori strains
and of the non-ulcerogenic strains show a distinctive genotype virulence pattern, suggesting
a potential pathogenic role for new markers [9-15]. Two putative virulence determinants are
associated with peptic ulceration, mostly duodenal ulcer, in children and with other H.
pylori-virulence factors: jhp0562, involved in lipopolysaccharide biosynthesis and in the
regulation of Lewis antigen expression [13]; and homB, a putative outer membrane protein,
involved in bacterial adherence [9,11,12,14,15]. HomB contributes to the proinflammatory




Endoscopy is the only method to accurately diagnose peptic ulceration in children [87,122]. A
nodular mucosa in the gastric antrum or duodenal bulb and/or gastric or duodenal erosions
or ulcerations are specific (but not sensitive) features, suggesting active H. pylori infection. For
those with suspected infection, biopsies should be obtained for histopathology, as well as
complementary tests for detection of H. pylori including rapid urease test, histopathology with
Giemsa stain and, if available, culture. The rationale for the recommendation to perform more
than one diagnostic test is based on their sensitivity results in children, which range from 66%
to 100% for histology and from 75% to 100% for rapid urease tests [91]. In all paediatric age
groups, for patients receiving therapy with a proton pump inhibitor, biopsies should be
performed on the body and cardia (and, possibly, transition zones) of the stomach as well as
from the antrum to reduce the chances of false-negative results. Follow-up endoscopy is rarely
necessary, except in the setting of peptic ulceration associated with complications (such as
haemorrhage or perforation).
1.3.4. Host susceptibility
The multifactorial nature of peptic ulcer disease reflects its dependence on the patients’ genetic
susceptibility and habits (alcohol and/or non-steroid anti-inflammatory drug consumption,
diet, smoking and stress) [20]. Paediatric peptic ulcer disease is significantly more frequent in
boys than in girls (63.6% versus 36.4%, p<0.025) [32]. Although female hormones may have a
protective role against developing peptic ulcerations [123], the true nature of this susceptibility
of the male gender remains unclear.
Mucins, glycoproteins secreted by the gastric mucosa, form a gel layer that is essential to
maintain a stable neutral pH adjacent to epithelium. This mucus barrier affords protection
from attack by acid-pepsin and other luminal noxious agents [124]. H. pylori has a complex
relationship with different gastric mucins’ subtypes. Infected children for example have a
decreased mucin in their gastric mucosa presumably weakening this important defense barrier
[125]. The highly diverse carbohydrate structure of the gastric mucins, functioning as binding
sites for H. pylori, should also play a role in the outcome of infection, with genetic and epigenetic
changes in the mucin molecules influencing the susceptibility of the patient for H. pylori-
associated peptic ulcer disease. Recently, it was shown that H. pylori-infected children
presented a normal pattern of expression and glycosylation of mucin 5AC (MUC5AC) in the
surface mucous cells, and MUC6 in the gland mucous cells, contrasting with the aberrant
expression of MUC6 and MUC2 found in infected adults. Additionally, it was shown that the
pattern of Lewis blood group antigens in the surface epithelium of children was significantly
correlated with H. pylori load, however no correlation with gastritis, nodularity, and gastric or
duodenal ulcer was found [17].
In children and teenagers, as in adults, the severity of antral inflammation strongly correlates
with the risk of duodenal ulcer disease. Among the host factors, polymorphisms in cytokines
encoding genes, or in their promoters, that affect cytokine transcription, are good risk candi‐
dates. Indeed, polymorphisms in the IL-1 gene cluster play an important role in modulating
the risk for H. pylori-induced hypochlorhydria and, thus, for gastric ulceration and cancer. The
Dyspepsia - Advances in Understanding and Management80
IL-1 cluster, located on chromosome 2q12-22 region, includes the genes IL-1A, IL-1B and
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adults [116]. The risk is potentiated when in association with infection by cagA/vacA-positive
H. pylori strains, highlighting the interplay between host and bacterial factors that seems to be
involved in the development of gastric pathology [126]. Children presenting the IL1RN*2 allele
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H. pylori paediatric infection may be regarded as a privileged natural study model of the
interaction of this bacterium with human host, as the child is usually not exposed to injurious
factors as is the adult and represents a different stage of H. pylori infection in a immunologically
maturing host. Comparative genomic studies of the rare paediatric ulcerogenic H. pylori strains
and of the non-ulcerogenic strains show a distinctive genotype virulence pattern, suggesting
a potential pathogenic role for new markers [9-15]. Two putative virulence determinants are
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regulation of Lewis antigen expression [13]; and homB, a putative outer membrane protein,
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characteristics of H. pylori. Strains that are also positive for both homB and jhp562 are related
to a higher risk of paediatric peptic ulcer disease. Thus, it is likely that these new markers
acting together with the well-established virulence markers will promote a more severe antral
inflammation, a phenomenon strongly associated with duodenal ulceration.
Other pathogenic genes interact synergistically to induce peptic ulcer in young patients. There
is no gene or protein that acts alone to establish the virulence of H. pylori [74]. Accordingly, we
investigated further virulence-associated genes by comparing the proteome of a group of
genetically/epidemiologically-unlinked H. pylori strains, all isolated from Portuguese children,
half suffering with peptic ulcer disease, and the other presenting only active gastritis [16].
Despite the typical proteome profile of all the H. pylori strains grown under the same labora‐
torial conditions [129], the ulcerogenic paediatric H. pylori strains presented differences
suggestive of higher motility, better antioxidant defences and a metabolism favouring the
biosynthesis of aromatic amino acids. As already mentioned in this chapter (see section 1.2.1
of this chapter) motility is a long known virulence-related trait [46], with lower-motility
associated reduced inflammation levels [47] and with non-motile strains unable to establish a
robust infection [42,45,46]. Moreover, it was more recently shown that higher motility enhances
H. pylori density and inflammatory response in dyspeptic patients [130].
The differences in the abundance of antioxidant proteins observed between paediatric
ulcerogenic and non-ulcerogenic strains may be important in conferring resistance to inflam‐
mation; the enzymes involved in key steps in the metabolism of glucose, amino acids and urea
may be advantageous to respond to fluctuations of nutrients [16].
Additionally, by comparing the duodenal ulcer-associated paediatric strains with the one
studied strain associated with gastric ulcer, we observed differences on the abundance of
proteins associated with acid resistance and motility. These suggest that the former are better
prepared to survive to the abnormal low levels of pH observed in duodenal ulceration, in
contrast to the gastric ulcer strain which is a better swimmer, supporting the proximal spread
of infection characteristic of this disease [16]. Overall, our data supports the idea that the
infecting strain may be determinant in the divergence between duodenal and gastric ulcer [93].
2. Conclusions
The prevalence of H. pylori infection remains high worldwide despite a progressive decline
over time, attributed to improved overall living conditions and hygiene. Although often
asymptomatic, most infected patients suffer from persistent non-ulcer dyspepsia that, usually
later in adulthood, may further progress to more severe conditions. The most common severe
complication H. pylori is duodenal ulcer, affecting 10 to 15% of the infected adults. Although
less frequent, 2 to 5% of the infected adults with non-ulcer dyspepsia progress to gastric
ulceration and some ultimately to gastric cancer. These two forms of peptic ulcer-related
(organic) dyspepsia differ in prevalence and physiopathology; those suffering with duodenal
ulcer are at low risk of developing a gastric ulcer/gastric cancer. The onset of peptic ulcers in
childhood is a rare event that may occur shortly after infection, suggesting more virulent H.
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pylori strains and more susceptible young patients. H. pylori-associated paediatric peptic ulcer
disease is, therefore, a privileged natural study model to search for ulcerogenic-specific
bacterial biomarkers and implicated molecular mechanisms, a required step to better address
this important public health problem. This includes enhanced virulence of the paediatric
ulcerogenic H. pylori strains that also may have a natural ability to better adapt to the hostility
of their niche.
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half suffering with peptic ulcer disease, and the other presenting only active gastritis [16].
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torial conditions [129], the ulcerogenic paediatric H. pylori strains presented differences
suggestive of higher motility, better antioxidant defences and a metabolism favouring the
biosynthesis of aromatic amino acids. As already mentioned in this chapter (see section 1.2.1
of this chapter) motility is a long known virulence-related trait [46], with lower-motility
associated reduced inflammation levels [47] and with non-motile strains unable to establish a
robust infection [42,45,46]. Moreover, it was more recently shown that higher motility enhances
H. pylori density and inflammatory response in dyspeptic patients [130].
The differences in the abundance of antioxidant proteins observed between paediatric
ulcerogenic and non-ulcerogenic strains may be important in conferring resistance to inflam‐
mation; the enzymes involved in key steps in the metabolism of glucose, amino acids and urea
may be advantageous to respond to fluctuations of nutrients [16].
Additionally, by comparing the duodenal ulcer-associated paediatric strains with the one
studied strain associated with gastric ulcer, we observed differences on the abundance of
proteins associated with acid resistance and motility. These suggest that the former are better
prepared to survive to the abnormal low levels of pH observed in duodenal ulceration, in
contrast to the gastric ulcer strain which is a better swimmer, supporting the proximal spread
of infection characteristic of this disease [16]. Overall, our data supports the idea that the
infecting strain may be determinant in the divergence between duodenal and gastric ulcer [93].
2. Conclusions
The prevalence of H. pylori infection remains high worldwide despite a progressive decline
over time, attributed to improved overall living conditions and hygiene. Although often
asymptomatic, most infected patients suffer from persistent non-ulcer dyspepsia that, usually
later in adulthood, may further progress to more severe conditions. The most common severe
complication H. pylori is duodenal ulcer, affecting 10 to 15% of the infected adults. Although
less frequent, 2 to 5% of the infected adults with non-ulcer dyspepsia progress to gastric
ulceration and some ultimately to gastric cancer. These two forms of peptic ulcer-related
(organic) dyspepsia differ in prevalence and physiopathology; those suffering with duodenal
ulcer are at low risk of developing a gastric ulcer/gastric cancer. The onset of peptic ulcers in
childhood is a rare event that may occur shortly after infection, suggesting more virulent H.
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pylori strains and more susceptible young patients. H. pylori-associated paediatric peptic ulcer
disease is, therefore, a privileged natural study model to search for ulcerogenic-specific
bacterial biomarkers and implicated molecular mechanisms, a required step to better address
this important public health problem. This includes enhanced virulence of the paediatric
ulcerogenic H. pylori strains that also may have a natural ability to better adapt to the hostility
of their niche.
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1. Introduction
Functional  dyspepsia  (FD) is  a  highly prevalent  disorder,  characterized by persistent  or
recurrent pain or discomfort centered in the upper abdomen without evidence of organic
disease that might explain the symptoms [1]. Epidemiologic surveys suggest that 15 – 20
% of the general population in Western countries experience dyspepsia over the course of
one year.
The options for managing functional dyspepsia are limited and far from ideal [2]. Limit‐
ed information concerning the underlying pathophysiologic mechanisms has hampered the
development of effective management strategies and specific therapeutic agents.
Several factors have been proposed to play a role in functional dyspepsia: delayed gastric
emptying, Helicobacter pylori infection, hypersensitivity to gastric distention, impaired gastric
accommodation to a meal, altered duodenal sensitivity to lipids or acids, abnormal duodeno-
jejunal motility, and central nervous dysfunction. None of these abnormalities are able to
completely account for the dyspepsia symptom complex [3].
Abnormal gastric motility and visceral hypersensitivity are generally thought to be directly
linked  to  FD  symptoms.  Other  factors  that  directly  affect  physiologic  function  include
lifestyle, diet and genetics. [4,5]
The purpose of this chapter is to provide more specific dietary patterns and avoidances of
certain food items in managing functional dyspepsia
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2. Physiology of human feeding
The gastrointestinal tract processes ingested food via a complex series of actions in specific
organs.
The esophagus propels food into the stomach though a relaxed lower esophageal sphincter
that subsequently contracts to prevent gastroesophageal reflux. The functions of the proximal
and distal stomach differ remarkably. Initially, the proximal stomach relaxes, providing a
reservoir function. The distal stomach regulates the gastric emptying of solids by grinding and
sieving the contents until the particles are small enough to pass the pylorus. The small intestine
also regulates the gastric emptying rate through a feedback mechanism mediated by vagal
nerves, and by physiological changes, such as gastric relaxation and the release of gastroin‐
testinal hormones [3].
The overall process of digestion is coordinated by interactions between the gut and brain.
Hunger is the sensation that leads us to seek and consume food, whereas satiety notifies us
when to stop feeding.
Food intake is influenced by several types of gastrointestinal signals. These signals, when
elicited by receptors in the stomach, provide information to the brain via the vagus nerve [6].
The stomach functions as a food reservoir; its capacity limits food intake. The gastric distention
associated with ingestion of food activates tension mechanoreceptors and this generates a
feeling of satiety. Pyloric chemoreceptors have an important role in regulating gastric motility,
a fixed energy load being emptied into the duodenum at a constant rate regardless of meal
composition. Conversely, gastrointestinal peptides, secreted by the stomach and small
intestine with meals, primarily exert short–term effects on food intake. The gut peptides that
reduce meal size are cholecystokinin (CCK), glucagon, glucagon – like peptide 1, amylin,
somatostatin, peptide YY and bombesin. In contrast, ghrelin appears to have the opposite
effect, stimulating enhanced food intake [3].
3. Pathophysiology of functional dyspepsia
Abnormal gastric motility and visceral hypersensitivity are thought to be the phenomena that
are most closely related to the manifestation of FD symptoms.
Postprandial gastric motility may involve two possible sites: 1. the proximal stomach (fundus)
exhibiting a disordered accommodation reflex after food ingestion, and/or 2. the antrum
having abnormal gastric motor contractility. Proximal gastric distention, in fact, correlates very
well with dyspeptic symptoms [2, 7]. The accommodation reflex is regarded as an appropriate
response by which the stomach provides a reservoir facility for ingested food. In FD, this reflex
can be impaired, leading to early satiety [8]. Such impairment occurs in 40 to 50% of FD patients
[9]. In addition to impaired accommodation, delayed gastric emptying is also thought to
contribute to the pathogenesis of FD. Food that is delayed in leaving the stomach provides the
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sensation that the stomach feels heavy. Some reports have suggested that delayed gastric
emptying may be seen in up to 40% of FD patients [10].
Visceral hypersensitivity is also an important factor contributing to the feeling of dyspepsia.
When a balloon is distended in the stomach of an FD patient, the threshold at which pain is
perceived is significantly lower in FD patients compared to normal controls [11]. Such gastric
hypersensitivity relates to symptoms of postprandial pain, belching and weight loss.
4. Nutrients and gastrointestinal function
Different nutrients and food items may modulate gastrointestinal motor and sensory func‐
tions, and so provoke gastrointestinal symptoms. The three basic nutritional components
(carbohydrates, proteins and lipids) can contribute to disturbed gastrointestinal function. The
individual nutritional components impact gastric emptying and the sensation of fullness
differently. 1. Lipids (fat) and proteins exert a negative (“braking”) effect on gastric motility.
Fat releases enteric hormones (such as CCK) that increase pyloric sphincter tone and delay
gastric emptying. 2.
Proteins alter gastric motility, leading to a feeling of fullness and this provides satiety. 3.
Carbohydrates and some food chemicals (like salicylates and amines) give rise to an osmotic
effect with increased luminal volume. This can result in a sensation of fullness particularly in
patients with visceral hypersensitivity.
In addition to the individual nutrients, the caloric content, the physical form, and the ingested
volume of food affect the sensation of satiety and fullness. High meal viscosity has a greater
effect on the sense of satiety, whereas high caloric foods delay gastric emptying. [12,13].
Dietary nutrients influence gastrointestinal function and seem to be related to symptom
generation. Thus, it seems logical that disturbances of gastrointestinal motor and sensory
functions can lead to generation of gastrointestinal symptoms after food ingestion. However,
usually mixtures of food items are eaten, creating difficulties when attempting to pinpoint the
individual responsible factor and limiting advice in terms of dietary restrictions in patients
with dyspepsia. Dietary measures are classically prescribed in the management of patients
with motility disorders, although they have not been systematically studied.
5. Role of meals in the generation of symptoms in functional dyspepsia
Epidemiologic studies, both in the USA and Europe, have shown that 50 to 80% of subjects
with functional dyspepsia indicate that their symptoms are meal-related [5]. Meal ingestion is
associated with diverse changes in the environment of the gastrointestinal lumen, the gastro‐
intestinal function and potential physiopathological mechanisms. The two most cited causes
of pathology are delayed gastric emptying and visceral hypersensitivity. After ingestion of a
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meal, patients with functional dyspepsia experience a marked rise in the intensity of their
symptoms (epigastric burning, epigastric pain, fullness, bloating, nausea and belching) that
persists for 4 hours [14]. Postprandial fullness is the most severe symptom that a meal
aggravates.
Disturbances in upper gastrointestinal motor functions in FD have received considerable
attention. Not surprisingly, current treatments such as prokinetics are primarily directed to
these abnormalities. Therapies for visceral hypersensitivity remain difficult to establish.
Factors such as eating patterns (meal size and frequency, nutrient composition, overall energy
intake) and intolerances to specific foods or food groups have received little attention so far.
6. Dietary factors in functional dyspepsia
6.1. Eating patterns
Patients with functional dyspepsia frequently report that they are able to tolerate only small
quantities of food [15], suggesting that their eating patterns differ from healthy subjects [8].
As a result of eating smaller quantities of food with lower energy intake, over half of FD
patients experience weight loss even with a tendency to snack [16]. Despite eating fewer meals
and consuming less total energy and fat, patients with FD experience fullness that is directly
related to the amount of fat ingested and overall energy intake, while inversely related to the
amount of carbohydrates ingested. Management of FD patients therefore might be improved
by consuming smaller meals with reduced fat content [17,18].
6.2. Food intolerances
Patients with functional dyspepsia appear to exhibit more food intolerances than healthy
persons, although studies are limited.
The belief that food is causing or at least triggering gut symptoms has led to the application
of investigations purporting to guide dietary design. Various tests for food “intolerances” are
widely available, such as skin prick (allergy) tests and assays for food specific immunoglobu‐
lins, but their value is unknown. Furthermore, various diets including wheat-free, anti-
candida, carbohydrate-free, and other complex exclusions diets are touted in books and on the
internet but evidence for any benefit is lacking.[19] The exception is the gluten-free diet, which
will be discussed later in the chapter.
Alternative health practitioners and some nutritionists have advocated many such diets and
intolerance-testing.
Therefore, gastroenterologists often are left with a defensive role when patients request dietary
interventions. Although gastroenterologists may appreciate that food is an undoubted trigger,
it is difficult to recognize the specific food item. Tests designed to this have a poor predictive
value, while the resulting diets are often overly restrictive with the potential to render the
patient nutritionally compromised [20].
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How Food Triggers Gastrointestinal Symptoms?
The enteric nervous system is a major controller of multiple gut functions, such as secretion,
motility, blood flow and mucosal growth. In a normal situation, low intensity stimuli from the
lumen have few discernible effects on motility (as occurs in association with minimal inflation
of the balloon during barostat studies).
In most patients with functional gastrointestinal disorders, there is a change in relationship
between stimulus intensity and perception (the hallmark of visceral hypersensitivity) and
efferent motility response. These people experience pain in response to low intensity stimuli;
abnormal motility responses may ensue.
Luminal events may be initiated via two main stimuli: mechanical (associated with distention
of the gut wall) and chemical stimuli. Chemical stimuli trigger specific enteroendocrine cells
of the gut, releasing serotonin, which stimulates primary afferents of the enteric nervous
system [21]. There is also evidence that some enteric neurons might directly respond to
mechanical stimuli: the transient receptor potential (TRP) cation channels seem to be involved
in most levels of control of gastrointestinal function, including visceral hypersensitivity [22].
The TRPV1 (vanilloid) channels appear to be central to the initiation and persistence of visceral
hypersensitivity in an animal model. Increased expression of TRPV1 channels in neurons of
the gut has been observed in patients with IBS; such expression correlates with visceral
hypersensitivity, and with abdominal pain [23,24].
Food stimulates the gut through the release of enteric hormones and particularly via the enteric
nervous system. A primary trigger is luminal distention, which results from the physical act
of ingesting food and from secondary events such as gas production (especially bacterial
fermentation). Food also contains potent chemicals. If the food constituents that stimulate the
enteric nervous system were to be identified, then these would become obvious targets for
dietary manipulation.
On the basis of these concepts (luminal distention, visceral hypersensitivity and chemical
stimuli of the enteric nervous system), three specific areas of proven or suspected food-induced
gut symptoms in patients with functional GI symptoms are important: a. FODMAPs (fer‐
mentable oligo-, di- and monosaccharides and polyols) that include luminal distention; b. food
chemicals (salicylates, amines) that potentially stimulates the enteric nervous system (ENS),
and c. gluten that may trigger symptoms by as yet unknown mechanisms.
a. Targeting luminal distention: The FODMAP approach
Carbohydrates occur across a range of foods regularly consumed including grains such as
wheat and rye, vegetables, fruit and legumes. Short-chain carbohydrates with chain lengths
up to 10 sugars vary in their digestibility and subsequent absorption. Those that are poorly
absorbed exert osmotic effects in the intestinal lumen increasing its water volume. They are
also rapidly fermented by bacteria yielding consequent gas production. These two effects may
underlie many of the gastrointestinal symptoms that follows their ingestion. Only monosac‐
charides (glucose, galactose) can be actively absorbed across the small intestinal epithelium.
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nervous system. A primary trigger is luminal distention, which results from the physical act
of ingesting food and from secondary events such as gas production (especially bacterial
fermentation). Food also contains potent chemicals. If the food constituents that stimulate the
enteric nervous system were to be identified, then these would become obvious targets for
dietary manipulation.
On the basis of these concepts (luminal distention, visceral hypersensitivity and chemical
stimuli of the enteric nervous system), three specific areas of proven or suspected food-induced
gut symptoms in patients with functional GI symptoms are important: a. FODMAPs (fer‐
mentable oligo-, di- and monosaccharides and polyols) that include luminal distention; b. food
chemicals (salicylates, amines) that potentially stimulates the enteric nervous system (ENS),
and c. gluten that may trigger symptoms by as yet unknown mechanisms.
a. Targeting luminal distention: The FODMAP approach
Carbohydrates occur across a range of foods regularly consumed including grains such as
wheat and rye, vegetables, fruit and legumes. Short-chain carbohydrates with chain lengths
up to 10 sugars vary in their digestibility and subsequent absorption. Those that are poorly
absorbed exert osmotic effects in the intestinal lumen increasing its water volume. They are
also rapidly fermented by bacteria yielding consequent gas production. These two effects may
underlie many of the gastrointestinal symptoms that follows their ingestion. Only monosac‐
charides (glucose, galactose) can be actively absorbed across the small intestinal epithelium.
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Di- and oligosaccharides must be hydrolyzed to their constituent hexoses for absorption to
occur. All these molecules are plentiful in the diet and have been termed FODMAPs1
FODMAPs are therefore poorly absorbed, highly osmotic and rapidly fermented by gastroin‐
testinal bacteria, leading to increased water and gas. The result is intestinal distention that also
effects changes in motility, leading to symptoms of bloating and discomfort [26]. FOPMAPs
induce functional symptoms in patients with IBS who have fructose malabsorption; reduction
of dietary FODMAPs produces a durable symptomatic response [27, 28].



































b. Targeting food chemicals
Plants produce a wide variety of chemicals, some of which have survival function (the bad
taste for protection, odors for reproduction), along with antibacterial or preservative proper‐
ties.
Potentially bioactive chemicals include salicylates (that have a protective role), amines and
glutamates (that are products of protein breakdown), and common food additives such as
benzoates, sulfites and, nitrates (as preservatives).
1 FODMAP is an acronym for different carbohydrates: F: fermentable; O: oligosaccharides (fructans , galacto-oligosac‐
charides); D: disaccharides (lactose); M: monosaccharides (fructose); A: and P: polyols (sorbitol , mannitol , xylitol ,
maltitol) [25].
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In general, the stronger the flavor of the food, the higher the chemical content will be. In clinical
practice, food chemicals have received some attention in the pathogenesis and management
of urticaria, headaches, asthma and anaphylactic reactions.
Food chemicals are major afferent stimuli to the enteric nervous system. In the presence of
visceral hypersensitivity, normal physiological stimulation by such chemicals might result in
exaggerated effector responses (luminal distention). [32] Plant chemicals are able to activate
TRP channels. Chronic exposure to certain chemicals will lead to increased expression of TRP
channels and this contributes to a higher sensitivity of the enteric nervous system, and thus to
the development of functional gut symptoms. Withdrawing the offending chemicals from the
diet may reverse the TRP channel overexpression with subsequent resolution of the gut
symptoms.
The only food chemicals that have been systematically studied with respect to gut symptoms
are salicylates and related molecules such as non-steroid anti-inflammatory drugs. 2 to 4 % of
patients with irritable bowel syndrome (IBS) or food allergies are salicylate-drug intolerant
[29]. Examples of food sources containing high amounts of potentially bioactive chemicals are
summarized in Table 2.
Salicylates Amines Glutamates
Fruits
Avocado, berries , cherry,
citrus , date, grape ,












Breakfast cereals , mueslis,














parmesan , tasty cheeses
Brie , camembert ,
parmesan
Legumes
Bean mixes , broad beans ,
canned baked beans in
sauce
Surimi, soy sauce , miso,
tempeh
Canned baked beans in
sauce , textured vegetable
protein
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Di- and oligosaccharides must be hydrolyzed to their constituent hexoses for absorption to
occur. All these molecules are plentiful in the diet and have been termed FODMAPs1
FODMAPs are therefore poorly absorbed, highly osmotic and rapidly fermented by gastroin‐
testinal bacteria, leading to increased water and gas. The result is intestinal distention that also
effects changes in motility, leading to symptoms of bloating and discomfort [26]. FOPMAPs
induce functional symptoms in patients with IBS who have fructose malabsorption; reduction
of dietary FODMAPs produces a durable symptomatic response [27, 28].
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are salicylates and related molecules such as non-steroid anti-inflammatory drugs. 2 to 4 % of
patients with irritable bowel syndrome (IBS) or food allergies are salicylate-drug intolerant
[29]. Examples of food sources containing high amounts of potentially bioactive chemicals are
summarized in Table 2.
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Avocado, berries , cherry,
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parmesan , tasty cheeses
Brie , camembert ,
parmesan
Legumes
Bean mixes , broad beans ,
canned baked beans in
sauce
Surimi, soy sauce , miso,
tempeh
Canned baked beans in
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Meat, fish , chicken
Beef : smoked , corned ,
dried
Chicken : nuggets , smoked
Meat pastes , fish pastes ,
salami
Ham , bacon , anchovies,
prawns tuna , fish : pickled ,
salted, smoked
Beef : billong, jerky
Chicken : pressed ,
seasoned , gravy
Fats and oils
Almond oil , extra virgin
olive oil , sesame , avocado
oil
Almond oil , extra virgin
olive oil , sesame oil
Almond oil , extra virgin
olive oil , sesame oil
Beverages
Flavored mineral waters,
spirits (except gin, tonic,
whisky, vodka) , wine, fruit
juices, ginger beer, beer ,
champagne , cider , herbal
tea , tea
Beer , champagne , cider ,
tea , herbal tea , wine
Chocolate drinks , cocoa
powder
Beer , champagne , cider ,
tea , herbal tea , wine
Other
Jam , marmalade , fruit
flavored syrup , yeast
extract , vinegar (cider , red
and white wine)
Honey , peppermints,
tomato sauce , soy sauce
Jam , marmalade , yeast
extract , vinegar ,
chocolate , sauces ,
Jam , fruit flavored sweets ,
yeast extract , fermented
products , chicken salt ,
sauces ( tomato , soy , fish
and oyster)
Table 2. Examples of food sources with very high amounts of salicylates, amines and glutamates (reference: http://
www.allergy.net.eu)
c. Targeting gluten: A suspected molecule without a known mechanism
A. Celiac disease in recent years has undergone a profound revision. Celiac disease (CD) is now
considered to be a systemic immune-mediated disorder elicited by gluten. The common
denominator for all patients with CD is the presence of a combination of gluten-dependent
clinical manifestations, specific autoantibodies (anti–tissue transglutaminase, anti-endomysial
antibodies plus serum IgA) and different degrees of enteropathy, ranging from lymphocytic
infiltration of the epithelium to complete villous atrophy. [33, 34] Nevertheless, CD remains
underdiagnosed in all age groups. The advent of serological testing has improved the detection
of celiac disease but typical endoscopic findings for villous atrophy such as scalloping of folds,
a mosaic pattern, or decreased folds are often not evident in less severe cases. Magnification
tools like confocal endomicroscopy or “water immersion” techniques help characterize the
abnormal duodenal mucosa and target biopsying. In many patients, particular adults, the
disease features atypical symptoms or is completely silent, the so-called “celiac iceberg”.
Upper abdominal symptoms, such as abdominal pain and dyspepsia, are a common primary
complaint in CD [36]. 30 to 40 % of celiac patients have dyspeptic symptoms. From a different
perspective, diagnostic testing for celiac disease in individuals with dyspepsia has some
advocates, because of a trend to a greater prevalence [35]. Nevertheless, the prevalence of
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biopsy-proven celiac disease in individuals with dyspepsia may be as low as 1%, a value similar
to that amongst individuals in the general population, or markedly higher at 6% to 9% [37].
Routine screening for celiac disease therefore seems useful through serological testing and
with distal duodenal biopsy during upper gastrointestinal endoscopy done to investigate
dyspepsia.
B. Gluten (wheat) sensitivity. Gluten may also induce other pathological conditions, such as a
wheat allergy. Wheat allergy is an immunoglobulin IgE–mediated disease and thus com‐
pletely unrelated to celiac disease. [33] Recent attention however has been given to another
entity: gluten or wheat sensitivity (also termed non-celiac gluten sensitivity). This disorder
misses one or more of the key criteria: enteropathy and the presence of specific autoantibod‐
ies that define celiac disease (CD). The current working definition of non-celiac gluten sensi‐
tivity is the occurrence of irritable bowel syndrome (IBS)-like symptoms after ingesting
gluten, and improvement after gluten withdrawal from the diet. Celiac disease must be ex‐
cluded by negative celiac serology or a normal intestinal architecture, while wheat allergy
should be negated by a negative IgE-mediated allergy test to wheat. Non-celiac gluten sensi‐
tivity (NCGS) thus encompasses a collection of medical conditions in which gluten leads to
an adverse food reaction, clinically similar to some features of celiac disease, but celiac test‐
ing is negative or inconclusive [38, 39]. Such non-celiac IBS patients, in whom celiac disease
is excluded, will improve on a gluten-free diet [30].
The key question is the mechanism by which gluten induces symptoms. Gluten may mediate
cholinergic activation, leading to increased smooth muscle contractility and indirectly have
effects on luminal water content. Another explanation might be the release of neutrally active
peptides from the gluten digestion that might potentially gain access to enteric nerve endings.
Gluten ingestion can precipitate duodenal tissue eosinophilia in those with wheat sensitivity
[39]. Although there is no well-established mechanism for NCGS, the gluten-free diet has
gained substantial popularity with the general public.
7. Dietary management strategies in functional dyspepsia
Because of the many patients with functional dyspepsia and its serious impairment to their
quality of life, this entity represents an important clinical challenge. Pharmacologic therapies
are limited, leaving patients and physicians to often use dietary strategies in managing FD.
Unfortunately most of the available information concerning the role of diet and food intake in
FD patients is inconclusive. Several studies fortunately have shown clear differences between
FD patients and healthy persons in the ability to tolerate certain types of foods including
fermentable carbohydrates (FODMAPs).
FD patients often maintain regular consumption of several foods despite these being impli‐
cated with the dyspepsia. Why these patients do not avoid the majority of food components,
which they link to dyspepsia, remains unclear. Possible reasons might be ignorance of this
association, a lack of alternatives to replace food items, or cultural habits such as the use of
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clinical manifestations, specific autoantibodies (anti–tissue transglutaminase, anti-endomysial
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underdiagnosed in all age groups. The advent of serological testing has improved the detection
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a mosaic pattern, or decreased folds are often not evident in less severe cases. Magnification
tools like confocal endomicroscopy or “water immersion” techniques help characterize the
abnormal duodenal mucosa and target biopsying. In many patients, particular adults, the
disease features atypical symptoms or is completely silent, the so-called “celiac iceberg”.
Upper abdominal symptoms, such as abdominal pain and dyspepsia, are a common primary
complaint in CD [36]. 30 to 40 % of celiac patients have dyspeptic symptoms. From a different
perspective, diagnostic testing for celiac disease in individuals with dyspepsia has some
advocates, because of a trend to a greater prevalence [35]. Nevertheless, the prevalence of
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biopsy-proven celiac disease in individuals with dyspepsia may be as low as 1%, a value similar
to that amongst individuals in the general population, or markedly higher at 6% to 9% [37].
Routine screening for celiac disease therefore seems useful through serological testing and
with distal duodenal biopsy during upper gastrointestinal endoscopy done to investigate
dyspepsia.
B. Gluten (wheat) sensitivity. Gluten may also induce other pathological conditions, such as a
wheat allergy. Wheat allergy is an immunoglobulin IgE–mediated disease and thus com‐
pletely unrelated to celiac disease. [33] Recent attention however has been given to another
entity: gluten or wheat sensitivity (also termed non-celiac gluten sensitivity). This disorder
misses one or more of the key criteria: enteropathy and the presence of specific autoantibod‐
ies that define celiac disease (CD). The current working definition of non-celiac gluten sensi‐
tivity is the occurrence of irritable bowel syndrome (IBS)-like symptoms after ingesting
gluten, and improvement after gluten withdrawal from the diet. Celiac disease must be ex‐
cluded by negative celiac serology or a normal intestinal architecture, while wheat allergy
should be negated by a negative IgE-mediated allergy test to wheat. Non-celiac gluten sensi‐
tivity (NCGS) thus encompasses a collection of medical conditions in which gluten leads to
an adverse food reaction, clinically similar to some features of celiac disease, but celiac test‐
ing is negative or inconclusive [38, 39]. Such non-celiac IBS patients, in whom celiac disease
is excluded, will improve on a gluten-free diet [30].
The key question is the mechanism by which gluten induces symptoms. Gluten may mediate
cholinergic activation, leading to increased smooth muscle contractility and indirectly have
effects on luminal water content. Another explanation might be the release of neutrally active
peptides from the gluten digestion that might potentially gain access to enteric nerve endings.
Gluten ingestion can precipitate duodenal tissue eosinophilia in those with wheat sensitivity
[39]. Although there is no well-established mechanism for NCGS, the gluten-free diet has
gained substantial popularity with the general public.
7. Dietary management strategies in functional dyspepsia
Because of the many patients with functional dyspepsia and its serious impairment to their
quality of life, this entity represents an important clinical challenge. Pharmacologic therapies
are limited, leaving patients and physicians to often use dietary strategies in managing FD.
Unfortunately most of the available information concerning the role of diet and food intake in
FD patients is inconclusive. Several studies fortunately have shown clear differences between
FD patients and healthy persons in the ability to tolerate certain types of foods including
fermentable carbohydrates (FODMAPs).
FD patients often maintain regular consumption of several foods despite these being impli‐
cated with the dyspepsia. Why these patients do not avoid the majority of food components,
which they link to dyspepsia, remains unclear. Possible reasons might be ignorance of this
association, a lack of alternatives to replace food items, or cultural habits such as the use of
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coffee in some populations. Nevertheless dietary recommendations are intrinsic for managing
FD. General advice should include consuming small, frequent meals that have a low-fat
content.
Although such recommendations are helpful, specific strategies more commonly become
necessary.
A well-trained nutritionist should direct the patient to record a 7-day food and symptom diary.
It is also important to record other variables such as stress levels and activity as these factors
can also impact symptomatology. The role of the dietitian is to explain the physiological basis
of the diet, provide a list of suitable alternative foods and so restrict specific FODMAPs, while
promoting a nutritionally adequate diet.
A low FODMAP diet is currently the first approach for many dietitians. This relatively complex
diet involves the reduction, but not the complete avoidance of FODMAPs. Foods have been
classified into high and low FODMAP content, and therefore knowledge of the FODMAP
status of foods is an important skill for patient education (see table below). Low FODMAP
foods that are suitable alternatives to foods high in FODMAP are encouraged. For example,
rather than completely restricting fruit, reduce the intake of high FODMAP fruit and encourage
the intake of FODMAP fruit [32]. After 6 to 8 weeks, the dietitian should undertake a review.
If there is a satisfactory improvement, then a re-challenge could be done. It is important to
determine the tolerance level, and also to increase variety in the diet. If the improvement is
partial or absent, than additional dietary triggers should be emphasized: avoidance of some
food chemicals such as salicylates, amines and glutamates, and last but not least a gluten-free
diet might be initiated.
Any diet that aims to reduce one group of components will affect other dietary components
with the potential to influence the same end point. This is certainly the case with a low
FODMAP diet. As gluten-containing cereals also contain a high FODMAP content, any
reduction of gluten intake would be accompanied by a decrease in other potentially symptom-
inducing, cereal-related proteins. Likewise, if lactose is avoided in a proportion of patients,
then the intake of dairy-associated proteins concomitantly may be reduced.
Type of food HIGH in FODMAP LOW in FODMAP
Milk
Milk : cow, sheep, goat, soy
Creamy soups with milk
Evaporated milk
Sweetened condensed milk
Milk : almond, coconut, hazelnut, rice
Lactose free cow’s milk









Hard cheeses : cheddar, Swiss, brie, blue
cheese, mozzarella, parmesan, feta
No more than 2 tablespoons ricotta or
cottage cheese
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Type of food HIGH in FODMAP LOW in FODMAP










Sorbet from FODMAPs friendly fruit
Fruit
Apples, pears
Cherries , raspberries, blackberries
Watermelon


















<1 tablespoon dried fruit





































Oats , oat bran
Quinoa
Corn
Gluten-free bread, cereals , pastas and
crackers without honey
Apple/pear juice , agave
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determine the tolerance level, and also to increase variety in the diet. If the improvement is
partial or absent, than additional dietary triggers should be emphasized: avoidance of some
food chemicals such as salicylates, amines and glutamates, and last but not least a gluten-free
diet might be initiated.
Any diet that aims to reduce one group of components will affect other dietary components
with the potential to influence the same end point. This is certainly the case with a low
FODMAP diet. As gluten-containing cereals also contain a high FODMAP content, any
reduction of gluten intake would be accompanied by a decrease in other potentially symptom-
inducing, cereal-related proteins. Likewise, if lactose is avoided in a proportion of patients,
then the intake of dairy-associated proteins concomitantly may be reduced.
Type of food HIGH in FODMAP LOW in FODMAP
Milk
Milk : cow, sheep, goat, soy
Creamy soups with milk
Evaporated milk
Sweetened condensed milk
Milk : almond, coconut, hazelnut, rice
Lactose free cow’s milk









Hard cheeses : cheddar, Swiss, brie, blue
cheese, mozzarella, parmesan, feta
No more than 2 tablespoons ricotta or
cottage cheese
Dyspepsia - Advances in Understanding and Management104
Type of food HIGH in FODMAP LOW in FODMAP










Sorbet from FODMAPs friendly fruit
Fruit
Apples, pears
Cherries , raspberries, blackberries
Watermelon


















<1 tablespoon dried fruit





































Oats , oat bran
Quinoa
Corn
Gluten-free bread, cereals , pastas and
crackers without honey
Apple/pear juice , agave
Diet in the Etiology and Management of Functional Dyspepsia
http://dx.doi.org/10.5772/57138
105
Type of food HIGH in FODMAP LOW in FODMAP
Legumes
Chickpeas , hummus





<1/3 cup green peas
Nuts and seeds Pistachios
1-2 tablespoons almonds, pecans, pine





High fructose corn syrup













Protein-rich food Fish, chicken, turkey, eggs, meat
Table 3. FODMAP status of food
8. Summary
Functional dyspepsia is a clinical problem of considerable magnitude for the health care system
due to its high prevalence and the chronic or recurrent nature of symptoms. The manifestation
of FD symptoms is directly caused by physiological abnormalities: abnormal gastroduodenal
motility and/or visceral hypersensitivity. The therapeutic options for a clinician are limited
and far from optimal: pharmacological therapies often fail. As food ingestion commonly
triggers gastrointestinal symptoms, a dietary approach would seem most effective. There is
reasonable evidence to suggest that a low FODMAP diet is beneficial, while gluten sensitivity
may benefit others particularly in patients with IBS features. Gastroenterologists should no
longer ignore specific dietary intervention for patients with functional dyspepsia.
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1. Introduction
Biliary-type abdominal pain is common and often presents a clinical challenge for physicians.
True biliary colic consists of episodes of steady pain across the right upper quadrant and
epigastric regions, lasting from 30 minutes to 6 hours [1]. Such abdominal pain, when it lasts
longer than 6 hours, is likely due to complications of gallstone disease such as acute cholecys‐
titis or acute pancreatitis, or represents a non-biliary source of pain [1].
1.1. Cholelithiasis, biliary pain and atypical dyspepsia
Classical biliary pain that occurs in the setting of gallstones represents symptomatic choleli‐
thiasis. The symptoms associated with gallstones however are frequently confusing. In fact,
only 13% of people with gallstones ever develop biliary pain when followed for 15–20 years
[2], meaning that most (70-90%) patients with gallstones never experience biliary symptoms.
Vague dyspeptic complaints like belching, bloating, flatulence, heartburn and nausea are not
characteristic for biliary disease [3, 4]. Therefore, it is not surprising that cholecystectomy often
fails to relieve such ambiguous symptoms in those with documented gallstones. In fact,
cholecystectomy fails to relieve symptoms in 10-33% of patients with documented gallstones
[5]. If the abdominal pain is misdiagnosed and instead due to functional gut disorders like
irritable bowel syndrome, cholecystectomy would not provide a favorable outcome [4, 5, 6].
1.2. Functional gallbladder disease
Biliary-type abdominal pain (also termed biliary colic) in the context of a structurally normal
gallbladder has been referred to as “biliary dyspepsia”. True biliary pain manifests as steady,
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severe epigastric or right upper quadrant pain that might radiate through to the back and right
infrascapular regions, lasting for at least thirty minutes but less than 6 hours. It can be
associated with symptoms of nausea and vomiting, and may awaken the patient from sleep
[8]. Episodes are recurrent but usually in a sporadic and quite erratic frequency. Its functional
nature should be supported by an absence of markers of organic disease: normal liver and
pancreatic biochemistries, and negative diagnostic imaging. No structural basis should be
evident to explain the pain.
Functional biliary pain has also been termed: gallbladder dyskinesia, chronic acalculous gallbladder
dysfunction, acalculous biliary disease and chronic acalculous cholecystitis [9]. “Biliary dyskinesia”
implies a motility disorder resulting from abnormal motor function of the gallbladder
(manifest as impaired emptying) and/or sphincter of Oddi (increased tone)[10].
1.3. Functional disorders of the biliary tract (Sphincter of Oddi dysfunction)
Following removal of the gallbladder, biliary pain has been attributed to sphincter of Oddi
dysfunction (SOD). SOD represents intermittent obstruction to the flow of biliopancreat‐
ic  secretions  through the  sphincter  of  Oddi  in  the  absence  of  biliary  stones  or  a  ductal
stricture [11].  The Rome III  Consensus has developed criteria  for  functional  biliary-type
pain (Table 1) [8].
2. Epidemiology
Dyspepsia overall is a common symptom in the general population with reported prevalence
rates ranging between 10-45% [12]. Such estimates are confounded by the use of differing
criteria for defining dyspepsia as well as a recurrent failure to exclude patients who primarily
report heartburn symptoms12. Nevertheless, dyspepsia remains a common issue with annual
incidence rates estimated between 1-6%[13]. In the United States, there were 4,007,198
outpatient visits for gastroenteritis or dyspepsia and 130,744 hospital admissions for functional
or motility disorders in 2009 [14]. This represents a 26% increase from the year 2000, which
suggests an upsurge in the overall incidence of dyspepsia14.
Epidemiology of functional gallbladder disease (i.e.; Frequency of biliary pain with a normal
appearing gallbladder e.g. without gallstones)
The true prevalence of biliary dyspepsia is unknown. Estimates are generally based on the
presence of non-specific clinical features and a lack of structural findings on ultrasonographic
investigation of the biliary system. In large Italian population-based studies, 7.6% of men and
20.7% of women experienced biliary pain yet lacked gallstones on abdominal ultrasonography
[15, 16].
With the advent of minimally invasive surgery, biliary dyskinesia has become a new indication
for laparoscopic cholecystectomy increasing 348% in adults [17] and escalating 700% in
pediatric patients over approximately a decade [18]. Large scale case series now list biliary
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dyskinesia as the primary indication for cholecystectomy in 10-20% of adults [17, 19-22] and
10-50% of pediatric patients [23-26].
Epidemiology of functional sphincter of Oddi disorders (i.e.; Frequency of biliary pain after the
gallbladder has been removed – postcholecystectomy).
In the US householder survey of presumably healthy adults, 69% expressed symptoms
indicating a functional gastrointestinal syndrome within the previous three months and 1.5%
had biliary dyspepsia following cholecystectomy [27]. Women were more commonly afflicted
at 2.3% than men at 0.6% [27]. Nevertheless, sphincter of Oddi dysfunction (SOD) is uncommon
in this population. SOD, when documented by ERCP manometry, occurs in less than 1% of
the patients who have had their gallbladders removed and accounts for the abdominal pain
in 14% of the patients with postcholecystectomy pain [28].
3. Pathophysiology
3.1. Acute biliary pain
The biliary tract normally is a low-pressure conduit though which bile secreted from the liver
reaches the duodenum. The gallbladder acts as a reservoir for decompression while storing
bile in the interdigestive periods overnight and throughout the day [29]. Even in the digestive
phase, gallbladder contraction does not elicit marked pressure spikes within the biliary tree
because the sphincter of Oddi effectively relaxes. The hormone cholecystokinin (CCK) is
primarily responsible for this reciprocity.
In the setting of cholelithiasis, biliary pain is assumed to originate from either an obstructive
event (the gallbladder contracting on a closed cystic duct which is blocked by a gallstone) that
increases intrabiliary pressure and/or inflammation (cholecystitis)10. Such obstruction also
appears to stimulate the gallbladder mucosa to produce a phospholipase, which then hydrol‐
yses fatty acids off lecithin to yield lysolecithin in bile. Lysolecithin, acting as a biological
detergent, might then initiate an inflammatory reaction (cholecystitis). Subsequently, inflam‐
matory mediators could trigger painful stimuli, while mechanoreceptor afferent fibers in the
gallbladder and biliary tree conduct visceral pain information to the spinal cord and the brain.
Thus, motor contraction, sensory afferents producing painful sensations and obstruction/
inflammation may all play a role in the perception of acute biliary-type pain.
3.2. Chronic functional biliary pain
The basis for chronic functional biliary pain appears to reside in visceral hypersensitivity,
altered central processing, and/or abnormal gastrointestinal motility. Prolonged or intense
noxious stimuli, particularly when repeated, lead to sensitization of visceral nociceptors. These
peripheral sensory neurons respond to potentially damaging stimuli by sending nerve signals
to the spinal cord (dorsal horn) and then projecting centrally to the brain – the thalamus and
cortex, the site of pain perception. Chronic irritation might then influence afferent input and
the release of neuroactive chemicals in the dorsal horn of the spinal cord. Even when the
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peripheral irritation ceases, synaptic changes in the spinal cord can persist, causing "pain
memory". Thus, irritation to the biliary tract can potentially sensitize the nervous system. In
some, the central nervous system becomes so sensitive that hyperalgesia results: severe pain
evoked by only mildly painful stimuli. Persistent central excitability might subsequently result
in allodynia: innocuous stimuli produce pain [30, 31]. Thus, the basis for abnormally heightened
biliary sensations can reside at any level: either altered receptor sensitivity of the viscus,
increased excitability of the neurons in the spinal cord dorsal horn, and/or altered central
modulation of sensation, including psychological influences that affect the interpretation of
these sensations. Further, central hyperexcitability can effect changes in the dorsal horn.
Acalculous biliary pain may represent a generalised motor disorder of the duct: the irritable
gallbladder/sphincter of Oddi10. The abnormalities identified by impaired gallbladder
emptying or increased tone in the sphincter of Oddi, for example, may reflect a more gener‐
alised motility disorder of the gut [32]. Moreover, biliary-type pain could originate from a
neighbouring structure: for example, abnormal small intestinal motility. Gut smooth muscle
in functional gut disorders exhibits altered sensitivity to regulatory peptides such as CCK,
precipitating abdominal pain in some patients and confounding the interpretation of intestinal
versus biliary pain.
Functional biliary disorders have been most prominently linked to abnormal motility of the
gallbladder and/or sphincter of Oddi, in part because techniques exist to detect them in clinical
practice. Biliary pain is construed to result in most instances from increased gallbladder
pressure from either abnormal gallbladder contraction (“dyskinesia”) and/or structural or
functional outlet obstruction either at the exit from the gallbladder (e.g.; abnormal cystic duct)
or at the sphincter of Oddi (“the fighting gallbladder”). Reduced emptying and pain however
may also reflect diminished gallbladder contractility (“hypokinesia”). Decreased gallbladder
emptying has been attributed to abnormal CCK release, decreased gallbladder CCK receptor
sensitivity or density, or increased cystic duct receptor sensitivity to CCK with impaired
smooth-muscle contractility producing outlet obstruction [33].
Impaired gallbladder emptying, however, is also an important pathogenetic component in
cholesterol gallstones. Cholesterol gallstone formation begins when the liver produces bile
supersaturated  with  cholesterol,  in  excess  of  the  solubilizing  agents,  bile  salts  and leci‐
thin.  In  this  first  stage,  the  liver  secretes  excess  cholesterol  into  bile  canaliculi  that  is
accompanied by lecithin as small,  unilamellar vesicles.  These fuse in this supersaturated
bile to become cholesterol-rich, multilamellar vesicles (liquid crystals).  Aided by nucleat‐
ing factors (biliary proteins), cholesterol microcrystals precipitate out of solution. Mucin, a
glycoprotein, secreted by the gallbladder mucosa, then acts as a matrix scaffold to retain
these  cholesterol  microcrystals.  Diminished  gallbladder  contractility  facilitates  retention,
providing the residence time that is necessary for these microcrystals to agglomerate and
grow into overt gallstones. Cholesterol constitutes the vast majority (>85%) of gallstones.
A  minority  of  gallstones  are  black  pigment  stones.  These  are  composed  of  calcium
bilirubinate  polymers  that  result  from  abnormal  bilirubin  metabolism.  Such  black  pig‐
ment stones tend to develop in advanced age,  Crohn's  disease,  extensive ileal  resection,
cirrhosis, cystic fibrosis, and chronic hemolytic states [34].
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Hence, a smooth muscle defect producing gallbladder hypomotility is intrinsic to cholesterol
gallstone formation and disease [35, 36] and also occurs in chronic acalculous disease [37]. Both
conditions yield biliary pain, creating a potentially confusing scenario. Evidence of microli‐
thiasis in the gallbladder bile in some patients with biliary dyskinesia [38] may merely indicate
that excessive cholesterol, likely a stage of stone formation in which macroscopic gallstones
were not evident, compromised signal transduction in the gallbladder and was the mechanism
for reduced emptying. Certainly any bile crystals or sludge may eventually result in calculous
disease, causing obstruction of the gallbladder and symptoms of biliary pain, but this must be
distinguished from functional gallbladder disease. The mechanism for chronic cholecystitis is
unclear [39], while cholesterolosis with its accumulation of lipid products (triglycerides and
cholesterol precursors and esters) is likely too common to have any clinical importance as a
cause of biliary pain [38].
Gallbladder dysmotility is also associated with other conditions including functional gastro‐
intestinal disorders, pregnancy, diabetes mellitus, obesity, cirrhosis [40], and the use of various
medications (including atropine, morphine, octreotide, nifedipine, and progesterone) [41].
Interestingly, gut smooth muscle in the irritable bowel syndrome (IBS) also exhibits altered
sensitivity to regulatory peptides such as CCK [42]. It is, therefore, not surprising that the
gallbladder empties abnormally in some patients with IBS [43-45].
Although in sphincter of Oddi dysfunction, pain has classically been attributed to abnormal
smooth muscle motility, there may also be a component of visceral hypersensitivity. Here, the
hypersensitivity might arise in a structure adjacent to the sphincter, the duodenum [46, 47].
3.3. Biliary dyspepsia and fatty food intolerance
Despite biliary dyspepsia suggesting impaired digestion, there is no consistent relationship to
eating. Historically, the abdominal discomfort and bloating that follow a heavy, fatty meal has
been termed “fatty food” intolerance, connoting an association between fat content in the diet
and biliary dyspepsia [48, 49, 59]. Patients with biliary dyspepsia may eat fewer meals, perhaps
because their symptoms onset after eating [51]. In some, the sensation of fullness experienced
relates to the amount of fat consumed. The presumed basis is fat releasing CCK and peptide
YY, which are gut hormones important in regulating hunger and satiety. Patients with biliary
dyspepsia, particularly those experiencing higher scores for nausea and pain, have higher
concentrations of fasting and postprandial CCK compared to healthy individuals50. However,
just as dyspepsia is not a particular manifestation of gallstone disease, fatty foods do not
necessarily precipitate attacks of biliary colic [3, 52].
4. Differential diagnoses
Structural causes affecting the gastrointestinal tract should be considered in any patient
presenting with dyspepsia (Table 2) [12]. Gallstones, biliary sludge and microlithiasis must be
eliminated [12]. As decreased gallbladder emptying is a key investigation leading to the
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peripheral irritation ceases, synaptic changes in the spinal cord can persist, causing "pain
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in functional gut disorders exhibits altered sensitivity to regulatory peptides such as CCK,
precipitating abdominal pain in some patients and confounding the interpretation of intestinal
versus biliary pain.
Functional biliary disorders have been most prominently linked to abnormal motility of the
gallbladder and/or sphincter of Oddi, in part because techniques exist to detect them in clinical
practice. Biliary pain is construed to result in most instances from increased gallbladder
pressure from either abnormal gallbladder contraction (“dyskinesia”) and/or structural or
functional outlet obstruction either at the exit from the gallbladder (e.g.; abnormal cystic duct)
or at the sphincter of Oddi (“the fighting gallbladder”). Reduced emptying and pain however
may also reflect diminished gallbladder contractility (“hypokinesia”). Decreased gallbladder
emptying has been attributed to abnormal CCK release, decreased gallbladder CCK receptor
sensitivity or density, or increased cystic duct receptor sensitivity to CCK with impaired
smooth-muscle contractility producing outlet obstruction [33].
Impaired gallbladder emptying, however, is also an important pathogenetic component in
cholesterol gallstones. Cholesterol gallstone formation begins when the liver produces bile
supersaturated  with  cholesterol,  in  excess  of  the  solubilizing  agents,  bile  salts  and leci‐
thin.  In  this  first  stage,  the  liver  secretes  excess  cholesterol  into  bile  canaliculi  that  is
accompanied by lecithin as small,  unilamellar vesicles.  These fuse in this supersaturated
bile to become cholesterol-rich, multilamellar vesicles (liquid crystals).  Aided by nucleat‐
ing factors (biliary proteins), cholesterol microcrystals precipitate out of solution. Mucin, a
glycoprotein, secreted by the gallbladder mucosa, then acts as a matrix scaffold to retain
these  cholesterol  microcrystals.  Diminished  gallbladder  contractility  facilitates  retention,
providing the residence time that is necessary for these microcrystals to agglomerate and
grow into overt gallstones. Cholesterol constitutes the vast majority (>85%) of gallstones.
A  minority  of  gallstones  are  black  pigment  stones.  These  are  composed  of  calcium
bilirubinate  polymers  that  result  from  abnormal  bilirubin  metabolism.  Such  black  pig‐
ment stones tend to develop in advanced age,  Crohn's  disease,  extensive ileal  resection,
cirrhosis, cystic fibrosis, and chronic hemolytic states [34].
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that excessive cholesterol, likely a stage of stone formation in which macroscopic gallstones
were not evident, compromised signal transduction in the gallbladder and was the mechanism
for reduced emptying. Certainly any bile crystals or sludge may eventually result in calculous
disease, causing obstruction of the gallbladder and symptoms of biliary pain, but this must be
distinguished from functional gallbladder disease. The mechanism for chronic cholecystitis is
unclear [39], while cholesterolosis with its accumulation of lipid products (triglycerides and
cholesterol precursors and esters) is likely too common to have any clinical importance as a
cause of biliary pain [38].
Gallbladder dysmotility is also associated with other conditions including functional gastro‐
intestinal disorders, pregnancy, diabetes mellitus, obesity, cirrhosis [40], and the use of various
medications (including atropine, morphine, octreotide, nifedipine, and progesterone) [41].
Interestingly, gut smooth muscle in the irritable bowel syndrome (IBS) also exhibits altered
sensitivity to regulatory peptides such as CCK [42]. It is, therefore, not surprising that the
gallbladder empties abnormally in some patients with IBS [43-45].
Although in sphincter of Oddi dysfunction, pain has classically been attributed to abnormal
smooth muscle motility, there may also be a component of visceral hypersensitivity. Here, the
hypersensitivity might arise in a structure adjacent to the sphincter, the duodenum [46, 47].
3.3. Biliary dyspepsia and fatty food intolerance
Despite biliary dyspepsia suggesting impaired digestion, there is no consistent relationship to
eating. Historically, the abdominal discomfort and bloating that follow a heavy, fatty meal has
been termed “fatty food” intolerance, connoting an association between fat content in the diet
and biliary dyspepsia [48, 49, 59]. Patients with biliary dyspepsia may eat fewer meals, perhaps
because their symptoms onset after eating [51]. In some, the sensation of fullness experienced
relates to the amount of fat consumed. The presumed basis is fat releasing CCK and peptide
YY, which are gut hormones important in regulating hunger and satiety. Patients with biliary
dyspepsia, particularly those experiencing higher scores for nausea and pain, have higher
concentrations of fasting and postprandial CCK compared to healthy individuals50. However,
just as dyspepsia is not a particular manifestation of gallstone disease, fatty foods do not
necessarily precipitate attacks of biliary colic [3, 52].
4. Differential diagnoses
Structural causes affecting the gastrointestinal tract should be considered in any patient
presenting with dyspepsia (Table 2) [12]. Gallstones, biliary sludge and microlithiasis must be
eliminated [12]. As decreased gallbladder emptying is a key investigation leading to the
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diagnosis of a functional gallbladder disorder, other causes of impaired gallbladder emptying
should be identified to obviate confounders (Table 3) [53].
Must include episodes of pain located in the epigastrium and/or right upper quadrant and all of the following:
1. Episodes lasting 30 minutes or longer
2. Recurrent symptoms occurring at different intervals (not daily)
3. The pain builds up to a steady level
4. The pain is moderate to severe enough to interrupt the patient’s daily activities or lead to
an emergency department visit
5. The pain is not relieved by bowel movements
6. The pain is not relieved by postural change
7. The pain is not relieved by antacids
8. Exclusion of other structural disease that would explain the symptoms
Supportive criteria:
The pain may present with 1 or more of the following:
1. Pain is associated with nausea and vomiting
2. Pain radiates to the back and/or right infrasubscapular region
3. Pain awakens from sleep in the middle of the night
Table 1. Rome III Diagnostic Criteria for Functional Gallbladder and Sphincter of Oddi Disorders [8]
Gastrointestinal Disorders
Gastroesophageal reflux disease


















Table 2. Organic Causes for Dyspepsia [12]
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Primary gallbladder disease
Cholesterol gallstones





Acute or chronic, with or without stones
Metabolic disorders
Obesity, diabetes, pregnancy, VIPoma, sickle hemoglobinopathy
Neuromuscular defects
Myotonia dystrophic
Denervation (spinal cord injury, vagotomy)





Anticholinergic agents, calcium channel blockers, opioids, ursodeoxycholic acid, octreotide, cholecystokinin-
A receptor antagonist, nitric oxide donors, female sex hormones (progestins)
Table 3. Causes of Impaired Gallbladder Emptying [52]
5. Diagnosis
The diagnosis of functional disorders of the gallbladder and sphincter of Oddi should be based
on the Rome III criteria for functional gallbladder and sphincter of Oddi disorders (Table 1).
5.1. Functional gallbladder disease
1. Preliminary investigations to rule out structural disease that might be the origin of the
pain must include liver and pancreatic biochemistries and esophagogastroduodenoscopy.
All should be normal in functional gallbladder disorder. The search for gallstones must
be scrupulous. Transabdominal ultrasound is critical in being capable of detecting stones
down to 3-5 mm in size. Endoscopic ultrasound (EUS) is more refined for microlithiasis:
tiny stones < 3mm and biliary sludge [10]. Microscopic examination of gallbladder bile
collected from the duodenum following IV CCK stimulation can detect deposits, either
cholesterol as birefringent crystals (Figure 1) or pigment in the form of dark red-brown
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6. The pain is not relieved by postural change
7. The pain is not relieved by antacids
8. Exclusion of other structural disease that would explain the symptoms
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The pain may present with 1 or more of the following:
1. Pain is associated with nausea and vomiting
2. Pain radiates to the back and/or right infrasubscapular region
3. Pain awakens from sleep in the middle of the night
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Table 3. Causes of Impaired Gallbladder Emptying [52]
5. Diagnosis
The diagnosis of functional disorders of the gallbladder and sphincter of Oddi should be based
on the Rome III criteria for functional gallbladder and sphincter of Oddi disorders (Table 1).
5.1. Functional gallbladder disease
1. Preliminary investigations to rule out structural disease that might be the origin of the
pain must include liver and pancreatic biochemistries and esophagogastroduodenoscopy.
All should be normal in functional gallbladder disorder. The search for gallstones must
be scrupulous. Transabdominal ultrasound is critical in being capable of detecting stones
down to 3-5 mm in size. Endoscopic ultrasound (EUS) is more refined for microlithiasis:
tiny stones < 3mm and biliary sludge [10]. Microscopic examination of gallbladder bile
collected from the duodenum following IV CCK stimulation can detect deposits, either
cholesterol as birefringent crystals (Figure 1) or pigment in the form of dark red-brown
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calcium bilirubinate. Both techniques are fairly specific (in the order of 90%). Detection of
microlithiasis by EUS however is more sensitive (96% versus 67%) than microscopic bile
examination [54, 55], and also more available in most centres. Regardless, the use of these
investigations in biliary dyskinesia is limited by their invasive nature.
Figure 1. Cholesterol microcrystals in aspirated duodenal bile following CCK stimulation. The collected golden brown
duodenal bile is first centrifuged and then examined under polarizing microscopy. As seen here, cholesterol is evident
as birefringent, rhomboid-shaped crystals, characteristically with a notch in one corner.
2. Assessment of gallbladder emptying by cholecystokinin-cholescintigraphy is currently
the key to diagnosing functional gallbladder disorder. The gallbladder ejection fraction
(GBEF) is best measured via a nuclear medicine hepatobiliary scan. The radiopharma‐
ceutical, technetium 99m-labelled iminodiacetic acid (HIDA), when infused intravenous‐
ly, is readily taken up by hepatocytes, excreted into the bile, and accumulates in the
gallbladder [37, 56, 57]. Infusion of the CCK analogue, Sincalide™ (the 8-amino acid C-
terminal fragment of cholecystokinin, CCK-8), then initiates gallbladder evacuation
(Figure 2). There has been a wide variation in methodology, leading to a consensus
recommendation: Sincalide™ should be infused at 0.02μg/kg over 60 minutes. Normal
gallbladder ejection fraction should be ≥ 38%, according to a recent consensus conference
[58]. In selected cases of recurrent biliary pain in which no structural cause is evident, no
stone disease is apparent and there exists no other associated cause for impaired gall‐
bladder emptying, cholecystectomy is a reasonable consideration when the gallbladder
ejection fraction is reduced at less than 35-40% [59].















































Figure 2. A. Normal gallbladder emptying on CCK-cholescintigraphy. The gallbladder is visualized 30 minutes after the
injection of the 99m-labelled technetium iminodiacetic acid radiopharmaceutical (HIDA scan). Cholecystokinin is then
infused (shown as arrow). Prompt gallbladder emptying (70% here) then ensues with the radiolabel ejected into the
small intestine. The gallbladder is depicted as GB, before and after the CCK infusion. [52], B. Abnormal gallbladder
emptying. Although the gallbladder fills, becoming well visualized at 30 minutes, the CCK infusion (arrow) has little
effect thirty minut s later at 60 minutes into the study or even with an additional thirty minutes a  90 minutes. The
liver washes out during this period of time. [52]
There is as yet no predictive value for CCK-cholescintigraphy in those with established yet
uncomplicated (‘silent”) gallstones. The influence of gallbladder evacuation on the develop‐
ment of biliary symptoms and on the severity of disease remains unclear [56]. The sluggish
gallbladder do s not protect n individual with stones from developing pain.
The use of a fat y meal to stimulate gallbladder contraction may be more physiological and
cheaper than CCK but does not enjoy an established protocol with normal values. Another
limitation is that endogenous CCK release depends upon gastric emptying of the meal;
gastroparesis often accompanies functional gastrointestinal disorders [58].
Real-time ultrasound has also been used to measure volume changes as the gallbladder
empties. Its advantage over a nuclear medicine scan obviates exposing the patient to ionizing
radiation. Quantitative ultrasonography, based on geometric assumptions, however is
operator-dependent, limiting its accuracy. Although 3-dimensional and 4-dimensional
ultrasounds appear to correlate reasonably well with HIDA scans in identifying reduced
gallbladder ejection fractions [60], CCK-cholescintigraphy is more precise and remains the
standard [56, 58, 60].
The CCK-provocation test aimed to reproduce the biliary pain following an infusion of CCK,
implicating the gallbladder as the culprit. This test has fallen out of favor due to lack of
objectivity and specificity for biliary dyskinesia [42, 61]. Rapid infusion of CCK can elicit
abdominal pain even in normal individuals [10].
The algorithm for diagnosing and managing functional gallbladder disorder is outlined in
Figure 3 [8].
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examination [54, 55], and also more available in most centres. Regardless, the use of these
investigations in biliary dyskinesia is limited by their invasive nature.
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as birefringent, rhomboid-shaped crystals, characteristically with a notch in one corner.
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terminal fragment of cholecystokinin, CCK-8), then initiates gallbladder evacuation
(Figure 2). There has been a wide variation in methodology, leading to a consensus
recommendation: Sincalide™ should be infused at 0.02μg/kg over 60 minutes. Normal
gallbladder ejection fraction should be ≥ 38%, according to a recent consensus conference
[58]. In selected cases of recurrent biliary pain in which no structural cause is evident, no
stone disease is apparent and there exists no other associated cause for impaired gall‐
bladder emptying, cholecystectomy is a reasonable consideration when the gallbladder
ejection fraction is reduced at less than 35-40% [59].
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liver washes out during this period of time. [52]
There is as yet no predictive value for CCK-cholescintigraphy in those with established yet
uncomplicated (‘silent”) gallstones. The influence of gallbladder evacuation on the develop‐
ment of biliary symptoms and on the severity of disease remains unclear [56]. The sluggish
gallbladder do s not protect n individual with stones from developing pain.
The use of a fat y meal to stimulate gallbladder contraction may be more physiological and
cheaper than CCK but does not enjoy an established protocol with normal values. Another
limitation is that endogenous CCK release depends upon gastric emptying of the meal;
gastroparesis often accompanies functional gastrointestinal disorders [58].
Real-time ultrasound has also been used to measure volume changes as the gallbladder
empties. Its advantage over a nuclear medicine scan obviates exposing the patient to ionizing
radiation. Quantitative ultrasonography, based on geometric assumptions, however is
operator-dependent, limiting its accuracy. Although 3-dimensional and 4-dimensional
ultrasounds appear to correlate reasonably well with HIDA scans in identifying reduced
gallbladder ejection fractions [60], CCK-cholescintigraphy is more precise and remains the
standard [56, 58, 60].
The CCK-provocation test aimed to reproduce the biliary pain following an infusion of CCK,
implicating the gallbladder as the culprit. This test has fallen out of favor due to lack of
objectivity and specificity for biliary dyskinesia [42, 61]. Rapid infusion of CCK can elicit
abdominal pain even in normal individuals [10].
The algorithm for diagnosing and managing functional gallbladder disorder is outlined in
Figure 3 [8].
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Figure 3. Algorithm for the diagnostic workup and management for biliary dyspepsia due to functional gallbladder
disorder [8]. Patients with biliary type abdominal pain should initially undergo non-invasive investigations including
relevant laboratory work and an abdominal ultrasound. An endogastroduodenoscopy (EGD) should then be per‐
formed and if any structural abnormalities, should be treated by medical, endoscopic or surgical management. A gall‐
bladder cholecystokinin (GB CCK) cholescintigraphy can be subsequently performed. If there is abnormal ejection, EUS
(endoscopic ultrasound) or bile microscopy can be used to further investigate for microlithiasis. Even in the absence of
microlithiasis, if the ejection fraction is abnormal on GB CCK cholescintigraphy and no obvious confounding factor
identified, consider referring the patient for a cholecystectomy.
5.2. Functional Sphincter of Oddi Disorder (SOD)
Sphincter of Oddi dysfunction implies that the basis is a motility disorder of the sphincter that
intermittently results in pain, elevated liver and/or pancreatic enzymes, a dilated common
duct and potentially pancreatitis. The Milwaukee classification originally categorizes SOD into
three types, separating functional biliary and pancreatic sphincter of Oddi disorders on the
basis of symptoms, laboratory tests and radiological imaging [8, 62-65] (Table 4). As these
require an invasive procedure, endoscopic cholangiopancreatography (ERCP), to measure
common duct size and biliary drainage, the criteria have been revised to use non-invasive
imaging for estimating duct size of on an abdominal ultrasound [64].
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Biliary type
Type I:
Typical biliary type pain
Liver enzymes (AST, ALT or ALP) > 2 times normal limit documented on at least 2 occasions during episodes of pain
Dilated CBD > 8 mm in diameter
Positive manometry for biliary SOD (seen in 65-95% of patients)
Type II:
Biliary type pain and one of the above criteria (laboratory or imaging)
Type III:




Amylase and/or lipase > 2 times upper normal limit on at least 2 occasions during episodes of pain
Dilated pancreatic duct (head > 6 mm, body > 5 mm)
Type II:
Pancreatic type pain, and one of the above criteria (laboratory or imaging)
Type III:
Pancreatic type pain only
Table 4. Modified Milwaukee Classification of Sphincter of Oddi dysfunction [8, 61, 62, 64-66].
As in biliary dyspepsia due to gallbladder dysfunction, patients with suspected SOD should
undergo evaluation with serum liver and pancreas biochemical tests, abdominal ultrasound,
and esophagogastroduodenoscopy to rule out underlying structural disease as a cause for their
abdominal symptoms. Consideration should also be given to magnetic resonance cholangio‐
pancreatography (MRCP) to eliminate structural lesions such as stones, strictures and tumors.
Dysfunction potentially might affect either or both segments of the sphincter of Oddi: biliary
versus pancreatic sphincters or both (e.g.; occurring simultaneously).
a. Functional Biliary Sphincter of Oddi Disorder
Type I manifest biliary pain; abnormal liver biochemistries (elevated aminotransferases,
alkaline phosphatase and/or bilirubin) >2 times normal on two or more occasions; plus a
dilated common bile duct > 8mm on abdominal ultrasound. Most will exhibit biliary SO
dysfunction on formal manometry. They are considered to have stenosis of the sphincter
causing structural outflow obstruction.
Type II patients with biliary sphincter dysfunction experience the biliary-type pain plus exhibit
one of either the laboratory or the imaging abnormalities.
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Figure 3. Algorithm for the diagnostic workup and management for biliary dyspepsia due to functional gallbladder
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and esophagogastroduodenoscopy to rule out underlying structural disease as a cause for their
abdominal symptoms. Consideration should also be given to magnetic resonance cholangio‐
pancreatography (MRCP) to eliminate structural lesions such as stones, strictures and tumors.
Dysfunction potentially might affect either or both segments of the sphincter of Oddi: biliary
versus pancreatic sphincters or both (e.g.; occurring simultaneously).
a. Functional Biliary Sphincter of Oddi Disorder
Type I manifest biliary pain; abnormal liver biochemistries (elevated aminotransferases,
alkaline phosphatase and/or bilirubin) >2 times normal on two or more occasions; plus a
dilated common bile duct > 8mm on abdominal ultrasound. Most will exhibit biliary SO
dysfunction on formal manometry. They are considered to have stenosis of the sphincter
causing structural outflow obstruction.
Type II patients with biliary sphincter dysfunction experience the biliary-type pain plus exhibit
one of either the laboratory or the imaging abnormalities.
Biliary Dyspepsia: Functional Gallbladder and Sphincter of Oddi Disorders
http://dx.doi.org/10.5772/56779
121
Type III patients only complain of the pain. There are no laboratory or imaging abnormalities
b. Functional Pancreatic Sphincter of Oddi Disorder [65, 66]
Pancreatic-type SOD encompasses patients with pancreatic-type pain, elevated serum amylase
or lipase plus pancreatic duct dilation.
Type I has pain, lipase elevation and pancreatic duct dilation
Type II has pain plus either lipase elevation or pancreatic duct dilation.
Type III has only pancreatic-type pain.
Investigations
1. ERCP Manometry.
The “gold” standard to diagnose SOD is sphincter of Oddi manometry. This entails endoscopic
retrograde cholangiopancreatography (ERCP) allowing passage of a manometric catheter
through the duct and measurement of basal sphincter pressures on slow withdrawal of the
catheter. A basal sphincter pressure of greater than or equal to 40 mmHg is used to diagnose
SOD [67]. Manometry is abnormal in 65-100% with type I, 50-65% with type II, and falls to
12-60% of biliary type III SOD patients [65, 67, 68]. Positive manometric findings, based on
type, are similar in both types of sphincter dysfunction. The distinction between types I, II,
and III SOD, however, is important as it may predict a favorable response to endoscopic
sphincterotomy and thus, guide further management. The algorithm for diagnosing and
treating functional biliary sphincter of Oddi dysfunction is outlined in Figure 4.
2. Non-invasive Methods
Additional non-invasive methods for diagnosing SOD have been studied, given the inherent
risk of complications in sphincter of Oddi manometry, particularly precipitating pancreatitis,
and the generally poor outcomes especially in patients with biliary type III SOD [69].
a. Ultrasonographic measurement of duct diameter
The common bile duct normally has a diameter of 6mm or less in healthy individuals whose
gallbladders are intact. Above 8mm indicates biliary obstruction. This value becomes some‐
what obscure following cholecystectomy, a situation in which dilation occurs to 10mm even
in those without symptoms [70]. Adding a fatty meal to release CCK seeks to show duct dilation
to indicate SO dysfunction but its diagnostic usefulness is limited.
b. Magnetic resonance pancreatography (MRCP)
Administration of the hormone secretin increases pancreatic exocrine secretion [71]. In
suspected SOD involving the pancreas, secretin improves MRCP visualization of the pancre‐
atic ducts to eliminate structural disease and elicits duct dilation [72]. Overall, secretin-
stimulated magnetic resonance cholangiopancreatography (ss-MRCP) is not sensitive in
predicting abnormal manometry results in patients with suspected SOD type III, though
somewhat accurate in predicting results in patients with SOD type II (73%) [73].
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c. Endosonography
Endoscopic ultrasound (EUS) generally has a low yield in diagnosing abnormalities in the
context of a normal upper endoscopy and imaging studies in patients with SOD Type III [72,
74]. Only 8% of patients with suspected SOD Type III (normal endoscopy and standard
imaging studies) have any pathology at EUS [74].
d. Hepatobiliary scintigraphy [10]
Nuclear medicine scanning of the biliary tract (choledochoscintigraphy) uses 99mTc HIDA as
the radiopharmaceutical to measure biliary emptying: the transit time from the liver to the
duodenum. Prolonged duodenal arrival reflects SO dysfunction [75]. Specificity approaches
90% but reported sensitivities are variable [76]. Although lacking controlled studies, choledo‐
Figure 4. Algorithm for the diagnostic workup and management of sphincter of Oddi disorder (SOD) [8] Patients with
biliary type pain should initially undergo non-invasive investigations including relevant laboratory work and an ab‐
dominal ultrasound. An endogastroduodenoscopy (EGD), endoscopic ultrasound (EUS) and a magnetic resonance
cholangiopancreatography (MRCP) should then be performed. Any structural abnormalities detected should be treat‐
ed by medical, endoscopic or surgical management. SOD should be classified as Type I, Type II and Type III according
to the Milwaukee classification described in the text,. Patients with Type I disease will benefit from an endoscopic
sphincterotomy (ES). Otherwise first line management should be medical. If there is no response, an ERCP with sphinc‐
ter of Oddi manometry (SO manometry) can be performed. If manometry is abnormal, ES is indicated. If normal, alter‐
native medical therapies can be attempted.
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sphincterotomy and thus, guide further management. The algorithm for diagnosing and
treating functional biliary sphincter of Oddi dysfunction is outlined in Figure 4.
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risk of complications in sphincter of Oddi manometry, particularly precipitating pancreatitis,
and the generally poor outcomes especially in patients with biliary type III SOD [69].
a. Ultrasonographic measurement of duct diameter
The common bile duct normally has a diameter of 6mm or less in healthy individuals whose
gallbladders are intact. Above 8mm indicates biliary obstruction. This value becomes some‐
what obscure following cholecystectomy, a situation in which dilation occurs to 10mm even
in those without symptoms [70]. Adding a fatty meal to release CCK seeks to show duct dilation
to indicate SO dysfunction but its diagnostic usefulness is limited.
b. Magnetic resonance pancreatography (MRCP)
Administration of the hormone secretin increases pancreatic exocrine secretion [71]. In
suspected SOD involving the pancreas, secretin improves MRCP visualization of the pancre‐
atic ducts to eliminate structural disease and elicits duct dilation [72]. Overall, secretin-
stimulated magnetic resonance cholangiopancreatography (ss-MRCP) is not sensitive in
predicting abnormal manometry results in patients with suspected SOD type III, though
somewhat accurate in predicting results in patients with SOD type II (73%) [73].
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c. Endosonography
Endoscopic ultrasound (EUS) generally has a low yield in diagnosing abnormalities in the
context of a normal upper endoscopy and imaging studies in patients with SOD Type III [72,
74]. Only 8% of patients with suspected SOD Type III (normal endoscopy and standard
imaging studies) have any pathology at EUS [74].
d. Hepatobiliary scintigraphy [10]
Nuclear medicine scanning of the biliary tract (choledochoscintigraphy) uses 99mTc HIDA as
the radiopharmaceutical to measure biliary emptying: the transit time from the liver to the
duodenum. Prolonged duodenal arrival reflects SO dysfunction [75]. Specificity approaches
90% but reported sensitivities are variable [76]. Although lacking controlled studies, choledo‐
Figure 4. Algorithm for the diagnostic workup and management of sphincter of Oddi disorder (SOD) [8] Patients with
biliary type pain should initially undergo non-invasive investigations including relevant laboratory work and an ab‐
dominal ultrasound. An endogastroduodenoscopy (EGD), endoscopic ultrasound (EUS) and a magnetic resonance
cholangiopancreatography (MRCP) should then be performed. Any structural abnormalities detected should be treat‐
ed by medical, endoscopic or surgical management. SOD should be classified as Type I, Type II and Type III according
to the Milwaukee classification described in the text,. Patients with Type I disease will benefit from an endoscopic
sphincterotomy (ES). Otherwise first line management should be medical. If there is no response, an ERCP with sphinc‐
ter of Oddi manometry (SO manometry) can be performed. If manometry is abnormal, ES is indicated. If normal, alter‐
native medical therapies can be attempted.
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choscintigraphy is a reasonable non-invasive test before embarking on an intrusive approach
with ERCP-manometry.
e. Morphine-prostigmine provocation (Nardi) test
The Nardi test assesses the response to an injection of morphine and prostigmine to provoke
biliary sphincter spasm and stimulate pancreatic enzyme secretion. A positive test should elicit
typical symptoms and/or increase in serum activities of pancreatic and/or liver enzymes. This
provocative test is not specific or sensitive: 60% of normal individuals and others with IBS
have a positive test [77]. Sphincterotomy decreases the pain and enzymatic response (amylase
and lipase) to such provocation in only about 50% of individuals [78].
6. Management
a. Functional Gallbladder Disorder
Medical
The medical options for management of functional biliary disorders are quite limited. The spice
turmeric (Curcuma longa) modulates multiple cell signalling pathways and is a putative
therapy for inflammatory bowel disease [79]. In patients with biliary dyspepsia, the extracts
of Curcuma seem to reduce abdominal pain at least during the first week of treatment [80].
Oddly, curcumin increases gallbladder contraction. Tenoten, an anxiolytic, appeared to
decrease the pain syndrome, burning and belching, and increase gallbladder contraction in a
small Russian study assessing patients with biliary dyskinesia and personality disorders [81].
Such reports have marked limitations including small patient numbers and unclear diagnostic
criteria for biliary dyspepsia. As such, further studies are needed to clarify any role for medical
therapy in biliary dyskinesia, including use of agents like tricyclic antidepressants that help
visceral hypersensitivity.
Surgical
Although there may be a rising tide of cholecystectomies being performed for biliary dyski‐
nesia, most reports touting efficacy are retrospective reviews with small sample sizes and lack
appropriate non-operative controls. One meta-analysis supported the notion of surgery in
adults that provided 98% symptomatic relief compared to 32% with non-operative manage‐
ment [59]. Although the success rate in pediatric patients may reach 80% in some reports, a
retrospective assessment of outcomes indicated no difference over a 2 year follow up: three-
quarters of both the surgical and non-surgical groups improved [82]. Further, gallbladder
emptying assessed by CCK-cholescintigraphy may not be a sensitive test that predicts a benefit
from cholecystectomy [83]. Certainly cholecystectomy for dyspeptic complaints of gassiness,
bloating, indigestion and fatty food intolerance is disappointing [84]. Despite the Rome III
consensus [8], the literature does not yet support cholecystectomy being done routinely for
biliary dyspepsia.
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b. Functional Sphincter of Oddi Disorder
The aim in patients with SOD is to reduce the resistance caused by the sphincter of Oddi to
the flow of bile and/or pancreatic juice [3]. This can be achieved by medical, endoscopic or
surgical methods.
Medical
Medical management of sphincter of Oddi dysfunction is also unclear. Therapy has been
primarily focused on the use of smooth muscle relaxants. Nifedipine, a calcium channel
antagonist, has previously been studied with conflicting results in the treatment of sphincter
of Oddi dysfunction. Nifedipine 20mg can significantly decrease the basal pressure in the
sphincter of Oddi and also reduce the amplitude, duration and frequency of phasic contrac‐
tions [85]. This effect is not seen at lower doses of nifedipine; unfortunately, hypotension is a
common side effect at the higher dose. Nevertheless, nifedipine use over 3 months decreases
pain, especially in patients with predominant antegrade propagation of phasic contractions
[86]. Once treatment ceases, the effect becomes lost in a week [86]. Nicardipine also appears
to have a similar effect on the sphincter of Oddi with a decrease in basal and phasic pressures
following a single infusion [87].
Trimebutine (a spasmolytic), sublingual nitrates or a combination of both agents provides
complete or partial relief of pain in most cases (64-71%) [88, 89]. All such studies however are
limited by small patient numbers.
Several other medications such as anticholinergics (e.g.; hyoscine butylbromide), antispas‐
modics (e.g.; tiropramide), opioid antagonists (e.g.; naloxone), alpha-2 adrenergic agonists
(e.g.; clonidine), and even corticosteroids may have a potential benefit in managing sphincter
of Oddi dysfunction or functional gallbladder disorder [90]. Nevertheless, reports are limited
in quality; well-done clinical trials are warranted.
Endoscopic Therapy
The goal of endoscopic therapy is to disable the dysfunctional sphincter through various
methods. Botulinum toxin, a neurotoxin, when injected directly into the ampulla of Vater at
endoscopy, improves symptoms in 44% of SOD patients for 6 to 12 weeks after the treatment
[91]. Unfortunately, repeated injections of botulinum toxin may be associated with antibody
formation and a subsequent reduced efficacy [90]. Hence, rather than being used to treat
sphincter of Oddi dysfunction, botulinum toxin injections appear more helpful in directing
further therapy, predicting the success of endoscopic sphincterotomy for pain relief [90, 91].
Endoscopic sphincterotomy (ES) is the current treatment for SOD Type I. At ERCP, deep
cannulation of the bile (or pancreatic) duct allows electrocautery to sever the biliary or the
pancreatic segment of the sphincter of Oddi. Pain relief after an ES is 90-95% in Type I patients,
85% in Type II patients with an abnormal sphincter of Oddi manometry and 55-60% in Type
III patients with an abnormal manometry [92, 93]. Conversely, in patients with a normal
manometry, the relief rates are much reduced: 35% for Type II and <20% in Type III patients,
respectively [92, 93]. Complications from this procedure are mostly due to pancreatitis, which
can be seen in up to 20% of patients [94]. ES as an indication of SOD results in a 2-5 fold increase
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decrease the pain syndrome, burning and belching, and increase gallbladder contraction in a
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Such reports have marked limitations including small patient numbers and unclear diagnostic
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therapy in biliary dyskinesia, including use of agents like tricyclic antidepressants that help
visceral hypersensitivity.
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adults that provided 98% symptomatic relief compared to 32% with non-operative manage‐
ment [59]. Although the success rate in pediatric patients may reach 80% in some reports, a
retrospective assessment of outcomes indicated no difference over a 2 year follow up: three-
quarters of both the surgical and non-surgical groups improved [82]. Further, gallbladder
emptying assessed by CCK-cholescintigraphy may not be a sensitive test that predicts a benefit
from cholecystectomy [83]. Certainly cholecystectomy for dyspeptic complaints of gassiness,
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consensus [8], the literature does not yet support cholecystectomy being done routinely for
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the flow of bile and/or pancreatic juice [3]. This can be achieved by medical, endoscopic or
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Medical
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tions [85]. This effect is not seen at lower doses of nifedipine; unfortunately, hypotension is a
common side effect at the higher dose. Nevertheless, nifedipine use over 3 months decreases
pain, especially in patients with predominant antegrade propagation of phasic contractions
[86]. Once treatment ceases, the effect becomes lost in a week [86]. Nicardipine also appears
to have a similar effect on the sphincter of Oddi with a decrease in basal and phasic pressures
following a single infusion [87].
Trimebutine (a spasmolytic), sublingual nitrates or a combination of both agents provides
complete or partial relief of pain in most cases (64-71%) [88, 89]. All such studies however are
limited by small patient numbers.
Several other medications such as anticholinergics (e.g.; hyoscine butylbromide), antispas‐
modics (e.g.; tiropramide), opioid antagonists (e.g.; naloxone), alpha-2 adrenergic agonists
(e.g.; clonidine), and even corticosteroids may have a potential benefit in managing sphincter
of Oddi dysfunction or functional gallbladder disorder [90]. Nevertheless, reports are limited
in quality; well-done clinical trials are warranted.
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The goal of endoscopic therapy is to disable the dysfunctional sphincter through various
methods. Botulinum toxin, a neurotoxin, when injected directly into the ampulla of Vater at
endoscopy, improves symptoms in 44% of SOD patients for 6 to 12 weeks after the treatment
[91]. Unfortunately, repeated injections of botulinum toxin may be associated with antibody
formation and a subsequent reduced efficacy [90]. Hence, rather than being used to treat
sphincter of Oddi dysfunction, botulinum toxin injections appear more helpful in directing
further therapy, predicting the success of endoscopic sphincterotomy for pain relief [90, 91].
Endoscopic sphincterotomy (ES) is the current treatment for SOD Type I. At ERCP, deep
cannulation of the bile (or pancreatic) duct allows electrocautery to sever the biliary or the
pancreatic segment of the sphincter of Oddi. Pain relief after an ES is 90-95% in Type I patients,
85% in Type II patients with an abnormal sphincter of Oddi manometry and 55-60% in Type
III patients with an abnormal manometry [92, 93]. Conversely, in patients with a normal
manometry, the relief rates are much reduced: 35% for Type II and <20% in Type III patients,
respectively [92, 93]. Complications from this procedure are mostly due to pancreatitis, which
can be seen in up to 20% of patients [94]. ES as an indication of SOD results in a 2-5 fold increase
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in complications compared to the risk when performing this procedure for ductal stones [95,
96]. Placing a temporary stent in the pancreatic duct helps lessen such complications.
Surgical
Surgical options include transduodenal biliary sphincteroplasty with a transampullary
septoplasty [97]. Due to the advances in endoscopic techniques, surgery is generally reserved
for patients who experience restenosis or when endoscopy is not available [97]. Endoscopy is
preferred with lower cost, morbidity and mortality compared to surgical procedures.
7. Summary
Functional gallbladder disease and sphincter of Oddi disorders can be quite frustrating for the
patient as well as the physician, in terms of arriving at a diagnosis and effective therapeutic
options. Initially, non-invasive investigations should be performed. Further, sphincter of Oddi
manometry requires specialized endoscopic equipment as well as physician expertise.
Unfortunately, this is not readily available in many centers. Perhaps with the procurement of
these resources in the future, physicians may be able to predict which patients with SOD will
benefit from endoscopic or surgical therapy. In terms of management, medical therapies
should be tried as first line. Further, surgical and endoscopic management in type II and type
III SOD should be initiated with caution. The suggested algorithm should assist the investi‐
gation and management of these patients (Figure 3 and 4).
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1. Introduction
Cardiovascular disease, primarily encompassing coronary heart disease, hypertensive heart
disease, heart failure, and stroke, is the number one cause of death globally, with 17.3 million
dying from such causes in 2008 and a projected 23.6 million dying from cardiovascular disease
in 2030 [1]. Cardiovascular disease affects 1 in every 3 Americans, or an estimated 83.6 million
people (myocardial infraction, 7.6 million; angina pectoris, 7.8 million; heart failure, 5.1 million;
and stroke of any kind, 6.8 million; high blood pressure, 77.9 million) [2]. Heart disease and
stroke results in over 500,000 and 160,000 deaths, respectively, each year in the United States;
giving rise to an enormous annual economic burden exceeding $312 billion in both direct and
indirect costs [1,2].
Upper gastrointestinal (or dyspeptic) symptoms, often sub-classified as ulcer-like (localized
epigastric pain or nocturnal/fasting pain), gastroesophageal-like (heartburn or regurgitation)
or dysmotility-like dyspepsia (postprandial fullness, early satiety, diffuse epigastric pain,
belching or abdominal distention) are also highly prevalent worldwide with an average 3-
month prevalence rate across an international sample of survey respondents of about 28%, but
with higher rates in some countries such as the United States (41.8%) [3] and lower rates in
others (Japan’s rate=9.4%). Clinically-relevant upper gastrointestinal symptoms have been
found to result in high healthcare utilization [4,5]; as noted in one study [4] which found 20%
of affected patients visited a physician’s office during the 3-months prior to being surveyed,
2% were hospitalized, nearly half used an over-the-counter medication and 27% were prescri‐
bed at least one medication to address their symptoms. Upper gastrointestinal symptoms have
© 2013 Coleman et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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also been associated with significant costs due to lost work productivity [4,5], with those
suffering symptoms having an 85% (95% confidence interval, 40%-145%) increased odds of
work absenteeism [5], 27% reporting at least one day of reduced or no productivity over a 3-
month period, and 89% of this subset of people reported more than one day affected [4]. In
addition to these direct and indirect costs, increased intangible costs (pain and suffering) are
also an important repercussion of upper gastrointestinal symptoms [6], with these symptoms
shown to be associated with significantly impaired wellbeing and patients’ ability to perform
activities of daily life (subjects reporting relevant upper gastrointestinal symptoms had
significantly worse Psychological General Well-Being Index (PGWBI) and Interference with
Daily Life Index (IDLI) scores compared with those reporting no or non-relevant symptoms
(PGWBI score 65.24 versus 77.91, p<0.0001; IDLI score 75.85 versus 98.57, p<0.0001). Both
cardiovascular disease and upper gastrointestinal symptoms are common diagnoses in daily
practice. According to the American Academy of Family Physicians, numerous diagnosis
codes for both cardiovascular disease and upper gastrointestinal symptoms are among the
most frequently billed for [7].
In addition, cardiovascular and upper gastrointestinal disorders are among the top 20 leading
diagnoses for direct health expenditures in the United States [2]. In 2008, approximately $95.6
billion dollars were spent treating heart conditions and $27.2 billion were spent treating upper
gastrointestinal disorders, making these two disease states the first and twelfth most costly
diagnoses, respectively, for direct healthcare expenditures. Since cardiovascular disease and
upper gastrointestinal symptoms are both common conditions, some overlap in the occurrence
of these conditions would naturally be expected.
Diagnosis description Diagnosis code (ICD-9-CM)
Cardiovascular disease
Atrial fibrillation 427.31
Chronic ischemic heart disease, unspec. 414.9
Heart failure, congestive, unspec. 428.0
Hypertension, benign 401.1
Hypertension, unspecified 401.9
Chest pain, unspec. 786.50
Upper gastrointestinal symptoms
Gastroenteritis, noninfectious, unspec. 558.9
Gastroesophageal reflux, no esophagitis 530.81
Nausea w/ vomiting 787.01
Table 1. International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Cardiovascular Disease
and Upper Gastrointestinal Symptoms Designated in the Top 100 According to the ’Family Practice Management Short
List’ [reference 7]
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Beyond both having relatively high frequencies in daily practice and large economic burdens,
there are clinical data supporting the hypothesis that upper gastrointestinal symptoms are
more prevalent in patients with cardiovascular disease. Previous studies have found upper
gastrointestinal symptoms to occur as much as twice as often [8] in patients suffering from a
cardiovascular disease [9-13], and moreover, some upper gastrointestinal disorder may
increase patients’ risk for cardiovascular disease [14-17].
Figure 1. Cardiovascular Disease and Upper Gastrointestinal Symptoms on the List of 20 Leading Diagnoses for Direct
Healthcare Expenditures (adapted from reference 2) Bars depicts the cost each diagnosis in 2008 US$, while the labels
above the bars provides each diagnosis’ ranking in direct healthcare expenditures.
The finding of higher prevalence rates of upper gastrointestinal symptoms in patients with
cardiovascular disease may exist for a number of reasons. First, there are a host of mutual risk
factors for developing both cardiovascular disease and upper gastrointestinal symptoms
[18-37]. Next, patients experiencing both health problems often complain of similar or
overlapping symptomatology, potentially resulting in the more frequent surveillance and
diagnosis of both [38]. Related to this, some studies have suggested that common means of
investigating upper gastrointestinal symptom origin can aggravate some cardiovascular
diseases or induce cardiovascular symptoms [39,40]. Finally, polypharmacy with drugs used
to manage cardiovascular diseases can cause upper gastrointestinal symptoms [8,41-46]
resulting in decreased adherence to their medications, and a perhaps initiating a cycle of
recurrence/worsening of cardiovascular disease. Moreover, some drugs to treat upper
gastrointestinal symptoms may increase cardiovascular disease risk either directly or through
drug-drug interactions.
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The aim of this chapter is to provide a detailed discussion of the evidence suggesting and
supporting an increased risk of upper gastrointestinal symptoms in populations suffering from
cardiovascular disease.
2. Evidence supporting the link between cardiovascular disease and upper
gastrointestinal symptoms
At least a half dozen published studies [8-13] have demonstrated a link between cardiovascular
diseases and an increased risk of upper gastrointestinal symptoms. Three of these studies have
assessed the association of upper gastrointestinal symptoms with general cardiovascular
diagnosis. A recent study created two cohorts of patients derived from health insurance claims
data from the Human Capital Management Services research database over a four year period
(2001-2004)[9]. The cohorts were based upon the presence or absence of functional dyspepsia
diagnosis codes, with the control cohort (n=83,450) being matched to the functional dyspepsia
cohort (n=1,669) using a propensity score that included variables such as age, sex, marital
status, salary, among others. This study demonstrated that employees with functional
dyspepsia were 1.8-fold more likely to suffer from circulatory system disease (preva‐
lence=39.19% in those with functional dyspepsia versus 22.37% in the control group; p<0.05).
Study, year
(N=)
Study Description Key Finding
Brook 2012
(N=275,875)
Retrospective database analysis of paid
health insurance claims within the Human
Capital Management Services research
database (USA); 275,875 eligible employees,
1,669 with functional dyspepsia diagnosis
codes
Higher prevalence of circulatory system disease in
those with functional dyspepsia versus controls
(ratio=1.8:1; prevalence=39.19% in those with




Respondents of the Domestic/International
Gastroenterology Surveillance Study which
surveyed urban, adult populations from 10
countries representing seven geographic
areas (Canada, the USA, Switzerland, The
Netherlands, Italy, Japan and the Nordic
countries) using a study-specific symptom
checklist; prevalence rate of upper
gastrointestinal symptoms=28%
Higher odds of cardiovascular condition (OR=2.0),
myocardial/endocardial/pericardial/valve condition
(OR=2.7) or vascular (extracardiac) condition
(OR=2.8) in patients with UGIS diagnosed by a
doctor
Higher odds of self-reported cardiovascular
symptoms (OR=1.5), or myocardial/endocardial/
pericardial/valve symptoms (OR=4.4) over previous
three months in patients with UGIS
Wallander 2007
(N=17,949)
Analysis UK General Practice Research
Database to identify patients with new onset
dyspepsia in 1996; overall incidence=15.3
Higher odds of chest pain (OR: 2.4, 95%CI 2.1-2.7) or
angina (OR=1.5, 95%CI=1.2-1.8) comorbidity in
dyspepsia cohort in the year prior to index date than
control cohort
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Study, year
(N=)
Study Description Key Finding
(95%CI 15.0-15.6) per 1000 person-years
(n=6,913)
Higher odds of having first time diagnosis of chest
pain (OR=2.3, 95%CI=2.0-2.8) or angina (OR=2.7,
95%CI=1.8-4.0) in dyspepsia group in the year after
index date than in control cohort
Lohr 1986
(N=4,962)
Respondents completing a questionnaire
enrolled in the Rand Health Insurance
Experiment from six sites (Dayton, Ohio;
Seattle, Washington; Fitchburg,
Massachusetts; Franklin County,
Massachusetts; Charleston, South Carolina;
and Georgetown County, South Carolina);
prevalence rate of ulcer-like symptoms per
100 (aged 18-61 years) men=3.8 and
women=3.8
Congestive heart failure and angina were associated
with a 3.6-fold (p<0.001) and 2.9-fold (p<0.05)
higher odds of ulcer-like symptoms
LaMori 2012
(N=1,297)
Respondents to the 2009 National Health
and Wellness Survey, a nationwide (USA) self-
administered internet-based questionnaire;
prevalence rate of dyspepsia=34%
Dyspepsia more likely among patients with higher
stroke risk (CHADS2 ≥2, OR=1.15)
Patients reporting dyspepsia in addition to AF had
higher mean CHADS2 scores (1.9 vs. 1.4, p<0.05)
Laliberte 2012
(N=413,168)
Retrospective database study of Thomson
Reuters MarketScan data from 2005 and
2009 to quantify the incidence of dyspeptic
events in patients with atrial fibrillation;
median follow-up of 563 days




Italian patients affected with congestive
heart failure and ischemic heart disease
studied to ascertain relation between
dyspeptic syndrome and acute cardiac
disorders
Data showed alterations of motility in esophagus,
stomach, duodenum in every patient and lesions of
gastric mucous membrane in more than half
AF=atrial fibrillation; FD=Functional dyspepsia; HLD=hyperlipidemia; HTN=hypertension; NA=not applicable; NR=not
reported; OR=odds ratio; UK=United Kingdom; UGIS=upper gastrointestinal symptoms; USA=United States of America
Table 2. Studies Assessing Upper Gastrointestinal Symptoms in Patients with Cardiovascular Disease
A second study, the large Domestic/International Gastroenterology Surveillance Study [8]
looked to investigate any association between upper gastrointestinal symptoms (gastroeso‐
phageal-, ulcer- or dysmotility-like) and lifestyle factors (including comorbidities) in a large
sample of patients experiencing dyspepsia in the prior 3-months. A sample of urban, adult
populations from seven geographic areas (Canada, United States, Switzerland, the Nether‐
lands, Italy, Japan and the Nordic countries) was obtained by door-to-door or telephone
recruitment. Subjects were divided into groups depending on whether gastrointestinal
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pain (OR=2.3, 95%CI=2.0-2.8) or angina (OR=2.7,
95%CI=1.8-4.0) in dyspepsia group in the year after
index date than in control cohort
Lohr 1986
(N=4,962)
Respondents completing a questionnaire
enrolled in the Rand Health Insurance
Experiment from six sites (Dayton, Ohio;
Seattle, Washington; Fitchburg,
Massachusetts; Franklin County,
Massachusetts; Charleston, South Carolina;
and Georgetown County, South Carolina);
prevalence rate of ulcer-like symptoms per
100 (aged 18-61 years) men=3.8 and
women=3.8
Congestive heart failure and angina were associated
with a 3.6-fold (p<0.001) and 2.9-fold (p<0.05)
higher odds of ulcer-like symptoms
LaMori 2012
(N=1,297)
Respondents to the 2009 National Health
and Wellness Survey, a nationwide (USA) self-
administered internet-based questionnaire;
prevalence rate of dyspepsia=34%
Dyspepsia more likely among patients with higher
stroke risk (CHADS2 ≥2, OR=1.15)
Patients reporting dyspepsia in addition to AF had
higher mean CHADS2 scores (1.9 vs. 1.4, p<0.05)
Laliberte 2012
(N=413,168)
Retrospective database study of Thomson
Reuters MarketScan data from 2005 and
2009 to quantify the incidence of dyspeptic
events in patients with atrial fibrillation;
median follow-up of 563 days




Italian patients affected with congestive
heart failure and ischemic heart disease
studied to ascertain relation between
dyspeptic syndrome and acute cardiac
disorders
Data showed alterations of motility in esophagus,
stomach, duodenum in every patient and lesions of
gastric mucous membrane in more than half
AF=atrial fibrillation; FD=Functional dyspepsia; HLD=hyperlipidemia; HTN=hypertension; NA=not applicable; NR=not
reported; OR=odds ratio; UK=United Kingdom; UGIS=upper gastrointestinal symptoms; USA=United States of America
Table 2. Studies Assessing Upper Gastrointestinal Symptoms in Patients with Cardiovascular Disease
A second study, the large Domestic/International Gastroenterology Surveillance Study [8]
looked to investigate any association between upper gastrointestinal symptoms (gastroeso‐
phageal-, ulcer- or dysmotility-like) and lifestyle factors (including comorbidities) in a large
sample of patients experiencing dyspepsia in the prior 3-months. A sample of urban, adult
populations from seven geographic areas (Canada, United States, Switzerland, the Nether‐
lands, Italy, Japan and the Nordic countries) was obtained by door-to-door or telephone
recruitment. Subjects were divided into groups depending on whether gastrointestinal
Upper Gastrointestinal Symptoms and Cardiovascular Disease
http://dx.doi.org/10.5772/56564
139
symptoms were reported and were analyzed for the association with comorbid conditions. In
total, 5,581 subjects were recruited, with 1,566 (28%) reporting relevant upper gastrointestinal
symptoms. In the previous three months, subjects reporting gastrointestinal symptoms self-
reported more general cardiovascular (odds ratio= 1.5) or vascular myocardial/endocardial/
pericardial and valve (odds ratio=4.4) symptoms or illnesses. Subjects with upper gastroin‐
testinal symptoms also had increased prevalence of clinician-diagnosed cardiovascular (odds
ratio=2.0) or myocardial/endocardial/pericardial and valve (odds ratio=2.7) conditions.
Two more large studies [10,11] have reported on a link between the prevalence of upper
gastrointestinal symptoms with angina and chest pain. The first, a cross-sectional study of
6,913 patients aged 20-79 with new diagnoses of dyspepsia and 11,036 age- and sex-matched
control patients from the United Kingdom-based General Practice Research Database,
demonstrated dyspeptic patients are at increased odds of having a diagnosis for chest pain
(odds ratio=2.4, 95% confidence interval=2.1-2.7) or angina (odds ratio=1.5, 95% confidence
interval=1.2-1.8) within the previous year. In addition, dyspeptic patients are also more likely
to receiving receive a first time diagnosis for chest pain (odds ratio=2.3, 95% confidence
interval=2.0-2.8) or angina (odds ratio=2.7, 95% confidence interval=1.8-4.0) [10]. In an older
study of 4,962 patients aged 18-61 who took part in the Rand Health Insurance Experiment, a
decade-long randomized controlled trial of the effects of alternative methods of financing
health care services, about 30% had one chronic illness, with an additional 16% having 2 or
more. Ulcer-like symptoms, defined by a previous diagnosis along with taking antacids daily,
frequent episodes of stomach pain relieved by milk, occurring one-half hour after eating or at
night, was significantly associated with angina (p<0.05) and congestive heart failure (p<0.001)
[11].
A single study sought to assess the prevalence of dyspepsia among patients with atrial
fibrillation [12]. The population (n=1,297) included a nationwide sample of American adults
(from the 2009 National Health and Wellness Survey) with atrial fibrillation divided into two
groups: those reporting dyspepsia (defined as any of the following: ulcers, abdominal bloating,
abdominal pain, gastroesophageal disease or heartburn) and those who did not. Of these atrial
fibrillation patients, 41% reported a diagnosis of a gastrointestinal condition while 34%
reported a diagnosis of dyspepsia. Patients with dyspepsia were associated with a significantly
higher mean CHADS2 score (1.9 vs. 1.4, p<0.05). Of note, while the CHADS2 score was
developed as a tool to determine atrial fibrillation patients’ risk for stroke, in this case, it can
also serve as a marker of the presence of cardiovascular diseases since 2 of 5 CHADS2 criteria
(eg, stroke and congestive heart failure) are in fact cardiovascular diseases and the remaining
3 criteria (eg, age, hypertension, diabetes) are potent risk factors for cardiovascular disease.
A retrospective database study sought to assess the risk of dyspepsia among patients with
atrial fibrillation [13]. Analysis of insurance claims from the MarketScan® database from
2005-2009 was conducted. The population (n=413,168) included patients ≥18 years at the date
of first atrial fibrillation diagnosis, with 180 days of continuous insurance coverage prior to
the index atrial fibrillation diagnosis, and no gastrointestinal event within 180 days of the index
atrial fibrillation diagnosis. The risk of dyspepsia was assessed with incidence rates (IRs; new
dyspepsia case per patient years of observation). During a mean follow-up of 563 days, the IR
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of dyspepsia for patients with atrial fibrillation was 14.7 events per 100 patient years. At
baseline, 62% of patients (n=257,357) had at least one medication which may cause gastroin‐
testinal tolerability issues. The authors conclude that atrial fibrillation was associated with a
40% risk of developing a gastrointestinal event, which was predominantly dyspepsia.
Finally in a small case series evaluating the relationship between dyspepsia and congestive
heart disease or ischemic heart disease in Italian patients, data showed alterations of motility
in the esophagus, stomach and duodenum in every cardiovascular disease patient evaluated
and lesions of the gastric mucous membrane in more than half [14].
In addition to the aforementioned data suggesting upper gastrointestinal symptoms are more
prevalent with patients with cardiovascular diseases; a body of literature suggesting upper
gastrointestinal symptoms may in fact induce cardiovascular disease has begun to take shape
[15-18]. In 2003, the first signal that gastro esophageal-like symptoms or disease could be linked
to the development of atrial fibrillation was published [15]. Clinicians in Australia looked at
18 patients with concomitant diagnoses of lone paroxysmal atrial fibrillation and gastroeso‐
phageal reflux disease and noted that after treatment with a proton pump inhibitor to treat the
upper gastrointestinal symptoms, 14 of 18 had a decrease or disappearance of at least one
paroxysmal atrial fibrillation symptom.
Since that time, 3 observational studies [16-18] have more thoroughly evaluated this link. In a
cohort study of 163,627 patients receiving care from the United States Army National Capitol
Area Military Healthcare System between 2001 and 2007 (5% had atrial fibrillation and 29%
had gastroesophageal-like symptoms), gastroesophageal symptoms were associated with an
increased risk of atrial fibrillation, even after adjusting for age, sex, race and atherosclerotic
risk factors (relative risk=1.19, 95% confidence interval=1.13-1.25) or further adjustment for
ischemic heart disease, cardiomyopathy, atrial septal defect and being status post-cardiac
bypass surgery (relative risk=1.08, 95% confidence interval=1.02-1.13) [16].
The second study [17] similarly sought to assess the relationship between gastroesophageal
reflux disease and atrial fibrillation; and the researchers assessed the risk for atrial fibrillation
over a follow-up period of greater than 11 years. A self-report survey was sent to 5,288 patients
aged 25-74 over the 6 year period of 1988-1994. Of these patients, 741 developed atrial
fibrillation. Contrary to the previous study, an inverse relationship with observed between
gastroesophageal reflux disease symptoms and atrial fibrillation risk (hazard ratio=0.81, 95%
confidence interval=0.68-0.96). However, the frequency of symptoms in those with gastroeso‐
phageal reflux (none, some, weekly, daily) was associated with an increased hazard of atrial
fibrillation (p<0.01 for overall association); with daily symptoms associated with the highest
hazard (hazard ratio=1.30, 95% Confidence interval=0.98-1.57) of developing atrial fibrillation
compared to no gastroesophageal symptoms (p=0.07 unadjusted and p>0.2 after adjustment
for confounders). The researchers cite an increase in medical attention in those experiencing
gastroesophageal reflux as a possible explanation for the lack of association between the
presence of symptoms and atrial fibrillation; hypothesizing that extra physician visits resulting
from gastroesophageal symptoms resulted in early and more frequent identification and
treatment of known atrial fibrillation risk factors, as well as a higher utilization of proton pump
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symptoms were reported and were analyzed for the association with comorbid conditions. In
total, 5,581 subjects were recruited, with 1,566 (28%) reporting relevant upper gastrointestinal
symptoms. In the previous three months, subjects reporting gastrointestinal symptoms self-
reported more general cardiovascular (odds ratio= 1.5) or vascular myocardial/endocardial/
pericardial and valve (odds ratio=4.4) symptoms or illnesses. Subjects with upper gastroin‐
testinal symptoms also had increased prevalence of clinician-diagnosed cardiovascular (odds
ratio=2.0) or myocardial/endocardial/pericardial and valve (odds ratio=2.7) conditions.
Two more large studies [10,11] have reported on a link between the prevalence of upper
gastrointestinal symptoms with angina and chest pain. The first, a cross-sectional study of
6,913 patients aged 20-79 with new diagnoses of dyspepsia and 11,036 age- and sex-matched
control patients from the United Kingdom-based General Practice Research Database,
demonstrated dyspeptic patients are at increased odds of having a diagnosis for chest pain
(odds ratio=2.4, 95% confidence interval=2.1-2.7) or angina (odds ratio=1.5, 95% confidence
interval=1.2-1.8) within the previous year. In addition, dyspeptic patients are also more likely
to receiving receive a first time diagnosis for chest pain (odds ratio=2.3, 95% confidence
interval=2.0-2.8) or angina (odds ratio=2.7, 95% confidence interval=1.8-4.0) [10]. In an older
study of 4,962 patients aged 18-61 who took part in the Rand Health Insurance Experiment, a
decade-long randomized controlled trial of the effects of alternative methods of financing
health care services, about 30% had one chronic illness, with an additional 16% having 2 or
more. Ulcer-like symptoms, defined by a previous diagnosis along with taking antacids daily,
frequent episodes of stomach pain relieved by milk, occurring one-half hour after eating or at
night, was significantly associated with angina (p<0.05) and congestive heart failure (p<0.001)
[11].
A single study sought to assess the prevalence of dyspepsia among patients with atrial
fibrillation [12]. The population (n=1,297) included a nationwide sample of American adults
(from the 2009 National Health and Wellness Survey) with atrial fibrillation divided into two
groups: those reporting dyspepsia (defined as any of the following: ulcers, abdominal bloating,
abdominal pain, gastroesophageal disease or heartburn) and those who did not. Of these atrial
fibrillation patients, 41% reported a diagnosis of a gastrointestinal condition while 34%
reported a diagnosis of dyspepsia. Patients with dyspepsia were associated with a significantly
higher mean CHADS2 score (1.9 vs. 1.4, p<0.05). Of note, while the CHADS2 score was
developed as a tool to determine atrial fibrillation patients’ risk for stroke, in this case, it can
also serve as a marker of the presence of cardiovascular diseases since 2 of 5 CHADS2 criteria
(eg, stroke and congestive heart failure) are in fact cardiovascular diseases and the remaining
3 criteria (eg, age, hypertension, diabetes) are potent risk factors for cardiovascular disease.
A retrospective database study sought to assess the risk of dyspepsia among patients with
atrial fibrillation [13]. Analysis of insurance claims from the MarketScan® database from
2005-2009 was conducted. The population (n=413,168) included patients ≥18 years at the date
of first atrial fibrillation diagnosis, with 180 days of continuous insurance coverage prior to
the index atrial fibrillation diagnosis, and no gastrointestinal event within 180 days of the index
atrial fibrillation diagnosis. The risk of dyspepsia was assessed with incidence rates (IRs; new
dyspepsia case per patient years of observation). During a mean follow-up of 563 days, the IR
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of dyspepsia for patients with atrial fibrillation was 14.7 events per 100 patient years. At
baseline, 62% of patients (n=257,357) had at least one medication which may cause gastroin‐
testinal tolerability issues. The authors conclude that atrial fibrillation was associated with a
40% risk of developing a gastrointestinal event, which was predominantly dyspepsia.
Finally in a small case series evaluating the relationship between dyspepsia and congestive
heart disease or ischemic heart disease in Italian patients, data showed alterations of motility
in the esophagus, stomach and duodenum in every cardiovascular disease patient evaluated
and lesions of the gastric mucous membrane in more than half [14].
In addition to the aforementioned data suggesting upper gastrointestinal symptoms are more
prevalent with patients with cardiovascular diseases; a body of literature suggesting upper
gastrointestinal symptoms may in fact induce cardiovascular disease has begun to take shape
[15-18]. In 2003, the first signal that gastro esophageal-like symptoms or disease could be linked
to the development of atrial fibrillation was published [15]. Clinicians in Australia looked at
18 patients with concomitant diagnoses of lone paroxysmal atrial fibrillation and gastroeso‐
phageal reflux disease and noted that after treatment with a proton pump inhibitor to treat the
upper gastrointestinal symptoms, 14 of 18 had a decrease or disappearance of at least one
paroxysmal atrial fibrillation symptom.
Since that time, 3 observational studies [16-18] have more thoroughly evaluated this link. In a
cohort study of 163,627 patients receiving care from the United States Army National Capitol
Area Military Healthcare System between 2001 and 2007 (5% had atrial fibrillation and 29%
had gastroesophageal-like symptoms), gastroesophageal symptoms were associated with an
increased risk of atrial fibrillation, even after adjusting for age, sex, race and atherosclerotic
risk factors (relative risk=1.19, 95% confidence interval=1.13-1.25) or further adjustment for
ischemic heart disease, cardiomyopathy, atrial septal defect and being status post-cardiac
bypass surgery (relative risk=1.08, 95% confidence interval=1.02-1.13) [16].
The second study [17] similarly sought to assess the relationship between gastroesophageal
reflux disease and atrial fibrillation; and the researchers assessed the risk for atrial fibrillation
over a follow-up period of greater than 11 years. A self-report survey was sent to 5,288 patients
aged 25-74 over the 6 year period of 1988-1994. Of these patients, 741 developed atrial
fibrillation. Contrary to the previous study, an inverse relationship with observed between
gastroesophageal reflux disease symptoms and atrial fibrillation risk (hazard ratio=0.81, 95%
confidence interval=0.68-0.96). However, the frequency of symptoms in those with gastroeso‐
phageal reflux (none, some, weekly, daily) was associated with an increased hazard of atrial
fibrillation (p<0.01 for overall association); with daily symptoms associated with the highest
hazard (hazard ratio=1.30, 95% Confidence interval=0.98-1.57) of developing atrial fibrillation
compared to no gastroesophageal symptoms (p=0.07 unadjusted and p>0.2 after adjustment
for confounders). The researchers cite an increase in medical attention in those experiencing
gastroesophageal reflux as a possible explanation for the lack of association between the
presence of symptoms and atrial fibrillation; hypothesizing that extra physician visits resulting
from gastroesophageal symptoms resulted in early and more frequent identification and
treatment of known atrial fibrillation risk factors, as well as a higher utilization of proton pump
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inhibitors (although the researchers did not have data medication use to test this hypothesis).
Finally, the most recently published study assessed the relationship between atrial fibrillation
and gastroesophageal reflux disease in 188 Japanese patients between 28-91 years of age [18].
Patients’ gastroesophageal reflux disease status was classified using the F-scale, a question‐
naire specifically designed to screen for gastroesophageal reflux disease. Almost half of
Study, year
(N=)
Study Description Key Finding
Weigl 2003
(N=18)
Endoscopic reports of 640 Austrian patients
searched for diagnosis of lone PAF and
mention of reflux esophagitis; 18 patients
invited to assess the effect of PPI therapy for
GERD on paroxysmal AF-related symptoms
PPI therapy led to a decrease or disappearance of




Cross-sectional cohort study of adults in the
United States Army National Capitol Area
Military Healthcare System database; 7,992
patients with diagnosis of AF; 47,845 with
diagnosis of GERD





Longitudinal survey study of Olmstead
County, Minnesota residents to assess long-
term risk of AF with symptomatic GERD; 2,577
(49%) reported GERD; 741 (14%) developed
AF over 11.4 year follow-up period
The presence of GERD was associated with a
decreased risk of AF (HR=0.81, 95%CI=0.68-0.96)
The frequency of symptoms in those with GERD
was associated with an increased hazard of AF
(p<0.01); with daily symptoms associated with the




Cross-sectional survey study of Japanese
patients completing screening questionnaire
for GERD based upon frequency of 12
common symptoms to evaluate the
relationship between AF and GERD; 46% with
AF
AF was associated with prevalence of GERD (F-
scale score≥8 points) (p<0.001 upon multivariate
analysis). The dyspeptic sub-score (2.05±0.29 vs.
0.94±0.12, p =0.018) and the total F-scale score
(3.98±0.51 vs. 2.12±0.21, p = 0.019) of AF patients
were significantly greater than those in normal
sinus rhythm.
*Widely used questionnaire in Japan to screen for gastroesophageal reflux disease based upon frequency of 12 common
symptoms
#Adjusted for age, sex, race, known atherosclerotic risk factors (hypertension, diabetes, hyperlipidemia, and tobacco use)
†Adjusted for strong correlates of AF: ischemic heart disease, cardiomyopathy, atrial septal defect, status post coronary
bypass surgery
AF= atrial fibrillation; aRR= adjusted relative risk; GERD= gastroesophageal reflux disorder; HR= hazard ratio; PAF=
paroxysmal atrial fibrillation; PPI= proton pump inhibitor; RR= relative risk; USA= United States of America
Table 3. Relationship Between Atrial Fibrillation and Gastroesophageal-Like Symptoms
Dyspepsia - Advances in Understanding and Management142
enrolled patients had a diagnosis of atrial fibrillation (n = 86), and while hypertension,
dyslipidemia or coronary artery disease were not associated with the prevalence of sympto‐
matic gastroesophageal reflux disease (defined as a total F-scale≥8 points) upon multivariate
analysis, atrial fibrillation did show a significant correlation with gastroesophageal reflux
disease (p<0.001). In addition, both the dyspeptic sub-score (p=0.018) and the total F-scale score
(p=0.019) of atrial fibrillation patients were significantly greater than those in normal sinus
rhythm.
Recognizing patients with both cardiovascular diseases and upper gastrointestinal conditions
is an important step in their medical care. As demonstrated in available evidence, the links
between the conditions are strong, and can impact therapeutic decisions.
3. Shared risk factors
The World Health Organization, World Heart Federation [1] and the American Heart Associ‐
ation [3] each agree on a set of risk factors for the development of cardiovascular diseases.
These risk factors include smoking, being overweight or obese, living a sedentary lifestyle, and
poor diet, as well as having pre-existing diagnoses of high cholesterol, hypertension and
diabetes.
In addition to significantly contributing to the risk of developing cardiovascular disease, these
same risk factors have also been found in epidemiologic studies to be associated with an
increased risk of reporting upper gastrointestinal symptoms. These risk factors are highly
prevalent both worldwide and in the United States [1,3].
Below we discuss the mechanism behind, and studies supporting, the association between
these risk factors and increased rates of upper gastrointestinal symptoms.
3.1. Current smoking
Over a billion people worldwide are thought to be current smokers. It is estimated that nearly
six million people die from tobacco-related deaths annually, and by 2030, this number is
projected to surpass 8 million. Smoking is the underlying cause of about 10% of cardiovascular
disease [1] and has been consistently found to be a strong and independent risk factor for
myocardial infarction and sudden death [2]. Similar findings have been observed with
cerebrovascular disease and smoking; with smokers having a 2 to 4 times increased risk of
stroke compared with nonsmokers [2]. Consequently, it is not surprising that a large number
of studies support the beneficial cardiovascular consequences of smoking cessation [1].
It is theorized that tobacco smoking/use induces upper gastrointestinal symptoms through its
effects on the gastric mucosa [19]. The nicotine in tobacco likely causes mucosal injury by
augmenting acid and pepsin release, causing duodenogastric reflux and producing free
radicals; while at the same time decreasing prostaglandin and mucus production. Addition‐
ally, smoking may reduce lower esophageal sphincter pressure and thus accentuate gastroe‐
sophageal-like dyspeptic symptoms.
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inhibitors (although the researchers did not have data medication use to test this hypothesis).
Finally, the most recently published study assessed the relationship between atrial fibrillation
and gastroesophageal reflux disease in 188 Japanese patients between 28-91 years of age [18].
Patients’ gastroesophageal reflux disease status was classified using the F-scale, a question‐
naire specifically designed to screen for gastroesophageal reflux disease. Almost half of
Study, year
(N=)
Study Description Key Finding
Weigl 2003
(N=18)
Endoscopic reports of 640 Austrian patients
searched for diagnosis of lone PAF and
mention of reflux esophagitis; 18 patients
invited to assess the effect of PPI therapy for
GERD on paroxysmal AF-related symptoms
PPI therapy led to a decrease or disappearance of




Cross-sectional cohort study of adults in the
United States Army National Capitol Area
Military Healthcare System database; 7,992
patients with diagnosis of AF; 47,845 with
diagnosis of GERD





Longitudinal survey study of Olmstead
County, Minnesota residents to assess long-
term risk of AF with symptomatic GERD; 2,577
(49%) reported GERD; 741 (14%) developed
AF over 11.4 year follow-up period
The presence of GERD was associated with a
decreased risk of AF (HR=0.81, 95%CI=0.68-0.96)
The frequency of symptoms in those with GERD
was associated with an increased hazard of AF
(p<0.01); with daily symptoms associated with the




Cross-sectional survey study of Japanese
patients completing screening questionnaire
for GERD based upon frequency of 12
common symptoms to evaluate the
relationship between AF and GERD; 46% with
AF
AF was associated with prevalence of GERD (F-
scale score≥8 points) (p<0.001 upon multivariate
analysis). The dyspeptic sub-score (2.05±0.29 vs.
0.94±0.12, p =0.018) and the total F-scale score
(3.98±0.51 vs. 2.12±0.21, p = 0.019) of AF patients
were significantly greater than those in normal
sinus rhythm.
*Widely used questionnaire in Japan to screen for gastroesophageal reflux disease based upon frequency of 12 common
symptoms
#Adjusted for age, sex, race, known atherosclerotic risk factors (hypertension, diabetes, hyperlipidemia, and tobacco use)
†Adjusted for strong correlates of AF: ischemic heart disease, cardiomyopathy, atrial septal defect, status post coronary
bypass surgery
AF= atrial fibrillation; aRR= adjusted relative risk; GERD= gastroesophageal reflux disorder; HR= hazard ratio; PAF=
paroxysmal atrial fibrillation; PPI= proton pump inhibitor; RR= relative risk; USA= United States of America
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enrolled patients had a diagnosis of atrial fibrillation (n = 86), and while hypertension,
dyslipidemia or coronary artery disease were not associated with the prevalence of sympto‐
matic gastroesophageal reflux disease (defined as a total F-scale≥8 points) upon multivariate
analysis, atrial fibrillation did show a significant correlation with gastroesophageal reflux
disease (p<0.001). In addition, both the dyspeptic sub-score (p=0.018) and the total F-scale score
(p=0.019) of atrial fibrillation patients were significantly greater than those in normal sinus
rhythm.
Recognizing patients with both cardiovascular diseases and upper gastrointestinal conditions
is an important step in their medical care. As demonstrated in available evidence, the links
between the conditions are strong, and can impact therapeutic decisions.
3. Shared risk factors
The World Health Organization, World Heart Federation [1] and the American Heart Associ‐
ation [3] each agree on a set of risk factors for the development of cardiovascular diseases.
These risk factors include smoking, being overweight or obese, living a sedentary lifestyle, and
poor diet, as well as having pre-existing diagnoses of high cholesterol, hypertension and
diabetes.
In addition to significantly contributing to the risk of developing cardiovascular disease, these
same risk factors have also been found in epidemiologic studies to be associated with an
increased risk of reporting upper gastrointestinal symptoms. These risk factors are highly
prevalent both worldwide and in the United States [1,3].
Below we discuss the mechanism behind, and studies supporting, the association between
these risk factors and increased rates of upper gastrointestinal symptoms.
3.1. Current smoking
Over a billion people worldwide are thought to be current smokers. It is estimated that nearly
six million people die from tobacco-related deaths annually, and by 2030, this number is
projected to surpass 8 million. Smoking is the underlying cause of about 10% of cardiovascular
disease [1] and has been consistently found to be a strong and independent risk factor for
myocardial infarction and sudden death [2]. Similar findings have been observed with
cerebrovascular disease and smoking; with smokers having a 2 to 4 times increased risk of
stroke compared with nonsmokers [2]. Consequently, it is not surprising that a large number
of studies support the beneficial cardiovascular consequences of smoking cessation [1].
It is theorized that tobacco smoking/use induces upper gastrointestinal symptoms through its
effects on the gastric mucosa [19]. The nicotine in tobacco likely causes mucosal injury by
augmenting acid and pepsin release, causing duodenogastric reflux and producing free
radicals; while at the same time decreasing prostaglandin and mucus production. Addition‐
ally, smoking may reduce lower esophageal sphincter pressure and thus accentuate gastroe‐
sophageal-like dyspeptic symptoms.
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While not consistently shown in every study [20-22], smoking’s correlation with an increased
upper gastrointestinal symptom prevalence (compared to abstainers) has been demonstrated
to exist in a fair number of observational studies [8,20,23-25].
In an Australian study of 592 survey respondents of which 78 were dyspeptic, smoking was
found to significantly increase this risk of reporting dyspeptic symptoms by more than 100%
[19]. The Domestic/International Gastroenterology Surveillance Study also demonstrated
smoking to be associated with a significantly greater prevalence of upper gastrointestinal
symptoms (16% increase in relative risk) compared to those whom abstained from smoking;
with the results of multivariate analysis suggesting smoking’s largest negative effect was on
heartburn and regurgitation (gastroesophageal-like) symptom prevalence [8].
Similar results were observed in two studies of United States veterans. In the first study,
tobacco  use  was  found  to  be  associated  with  more  symptoms  of  dyspepsia  (odds  ra‐












9.8% (men)/13.8% (women) 34.6%
Insufficient physical activity




(<4 of 5 DASH-diet components)
N/A 79.0%
High cholesterol






(Fasting glucose ≥126 mg/dL)
10% 11.8%
*Rates per the World Heart Federation/World Health Organization [1]
†Rates per the American Heart Association [2]
BMI=body mass index; DASH=Dietary Approaches to Stop Hypertension; DBP=diastolic blood pressure; N/A=not
available; SBP=systolic blood pressure
Table 4. Worldwide and United States-Specific Prevalence of Risk Factors for Cardiovascular Disease
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crease  in  dyspepsia  symptom  reporting  in  smokers  (41.4%)  compared  to  non-smokers
(25.6%) was observed.  Again,  as  in the Domestic/International  Gastroenterology Surveil‐
lance  Study [8],  subanalysis  of  the  latter  study suggested tobacco smoking may have a
more profound effect on heartburn and regurgitation symptoms, as evidenced by the fact
Study, Year
(N=)
Study Description Key Finding
Nandurkar 1998
(N=592)
Healthy blood donors in Sydney, Australia
completing the Bowel Symptoms Questionnaire;
prevalence rate of upper gastrointestinal
symptoms=13.2%
Smoking was an independent risk factor




Respondents of the Domestic/International
Gastroenterology Surveillance Study which
surveyed urban, adult populations from 10
countries representing seven geographic areas
(Canada, the USA, Switzerland, The Netherlands,
Italy, Japan and the Nordic countries) using a
study-specific symptom checklist; prevalence rate
of upper gastrointestinal symptoms=28%
Prevalence rate of upper gastrointestinal
symptoms were 30.8% for smokers and
26.5% for non-smokers, p=0.0003; Upon
multivariate regression analysis, p<0.05
only for the relationship between smoking
and gastroesophageal-like symptoms




Respondents completing surveys (modified
Bowel Disease Questionnaire) at one of 4
Durham, NC, USA Veterans Administration
clinics; prevalence rate of upper gastrointestinal
symptoms=30% (general medicine) to 53%
(gastroenterology) depending on site of
recruitment
Tobacco use was significantly associated




Cross-sectional survey study of Olmstead County,
Minnesota residents completing the
gastroesophageal reflux questionnaire;
prevalence rate of frequent upper
gastrointestinal symptoms=20%
Multivariate adjusted RR=1.3,
95%CI=0.8-2.1 for current vs. never
smokers and OR=1.6, 95% confidence
interval, 1.1-2.3 for past vs. never smoker
Shaib 2004
(N=465)
Employees of the Houston Veterans Affairs
Medical Center, Texas, USA, completing the
Gastro Esophageal Reflux Questionnaire;
prevalence rate of upper gastrointestinal
symptoms=31.4%
41.4% of dyspeptics (including those with
gastroesophageal-like symptoms) were
smokers vs. 25.6% non-dyspeptics; when
gastroesophageal-like symptoms were
excluded, no significant relationship
between dyspeptic symptoms and
smoking was seen (p=0.2)
CI=confidence interval; OR=odds ratio; RR=relative risk
Table 5. Summary of Studies Suggesting an Association Between Smoking and Upper Gastrointestinal Symptoms
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While not consistently shown in every study [20-22], smoking’s correlation with an increased
upper gastrointestinal symptom prevalence (compared to abstainers) has been demonstrated
to exist in a fair number of observational studies [8,20,23-25].
In an Australian study of 592 survey respondents of which 78 were dyspeptic, smoking was
found to significantly increase this risk of reporting dyspeptic symptoms by more than 100%
[19]. The Domestic/International Gastroenterology Surveillance Study also demonstrated
smoking to be associated with a significantly greater prevalence of upper gastrointestinal
symptoms (16% increase in relative risk) compared to those whom abstained from smoking;
with the results of multivariate analysis suggesting smoking’s largest negative effect was on
heartburn and regurgitation (gastroesophageal-like) symptom prevalence [8].
Similar results were observed in two studies of United States veterans. In the first study,
tobacco  use  was  found  to  be  associated  with  more  symptoms  of  dyspepsia  (odds  ra‐












9.8% (men)/13.8% (women) 34.6%
Insufficient physical activity




(<4 of 5 DASH-diet components)
N/A 79.0%
High cholesterol






(Fasting glucose ≥126 mg/dL)
10% 11.8%
*Rates per the World Heart Federation/World Health Organization [1]
†Rates per the American Heart Association [2]
BMI=body mass index; DASH=Dietary Approaches to Stop Hypertension; DBP=diastolic blood pressure; N/A=not
available; SBP=systolic blood pressure
Table 4. Worldwide and United States-Specific Prevalence of Risk Factors for Cardiovascular Disease
Dyspepsia - Advances in Understanding and Management144
crease  in  dyspepsia  symptom  reporting  in  smokers  (41.4%)  compared  to  non-smokers
(25.6%) was observed.  Again,  as  in the Domestic/International  Gastroenterology Surveil‐
lance  Study [8],  subanalysis  of  the  latter  study suggested tobacco smoking may have a
more profound effect on heartburn and regurgitation symptoms, as evidenced by the fact
Study, Year
(N=)
Study Description Key Finding
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study-specific symptom checklist; prevalence rate
of upper gastrointestinal symptoms=28%
Prevalence rate of upper gastrointestinal
symptoms were 30.8% for smokers and
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recruitment
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Multivariate adjusted RR=1.3,
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smokers and OR=1.6, 95% confidence
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Shaib 2004
(N=465)
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excluded, no significant relationship
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smoking was seen (p=0.2)
CI=confidence interval; OR=odds ratio; RR=relative risk
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that  the  relationship  between  smoking  and  upper  gastrointestinal  symptom  prevalence
was no longer statistically significant when patients suffering gastroesophageal-like symp‐
toms (~50% of the study population) were excluded from the analysis (p=0.2). This find‐
ing  is  further  supported  by  a  survey  study conducted  in  Olmstead  County,  Minnesota
where  residents  demonstrating  current  or  past  smoking  increased  respondents’  risk  of
gastroesophageal symptoms by 30-60% [25].
3.2. Overweight or obesity
Overweight (body mass index ≥25 kg/m2) or obesity (body mass index ≥30 kg/m2) are highly
prevalent disorders worldwide and are particular problems in the United States [1,3]. Obesity
is strongly related to major cardiovascular risk factors such as elevated blood pressure, glucose
intolerance, type 2 diabetes and dyslipidemia. Prospective studies have shown a significant
relationship between overweight or obesity and an increased rate of cardiovascular events. In
a collaborative meta-analysis of 58 cohorts (221,934 people from 17 countries, 14,297 incident
cardiovascular disease outcomes, 1.87 million person-years at risk), patients’ risk of coronary
heart disease, ischemic stroke and cardiovascular disease were found to increase by 29%, 20%
and 23%, respectively, for every 4.56 kg/m2 increase in body mass index after adjustment for
age, gender, and smoking status [26].
The mechanism behind the association between overweight/obesity and increased upper
gastrointestinal symptoms is likely multifactorial [22]. First, the poor diet (ie, increased intake
of fatty foods) [22] and lack of exercise that leads the overweight/obese state also promotes
increased upper gastrointestinal symptoms (see further discussion below). Next, it is possible
that abdominal obesity may lead to gastric compression by the surrounding adipose tissue.
This causes increased intragastric pressure and relaxation of the lower esophageal sphincter,
and ultimately heartburn and regurgitation. Obesity may also lead to the development of hiatal
hernia promoting regurgitation symptoms. Lastly, humoral mechanisms related to obesity
including increased levels of insulin, leptin, growth factors or hormones may contribute to
gastrointestinal symptoms as well [22,27].
Results of the Domestic/International Gastroenterology Surveillance Study [3] suggested that
the prevalence of upper gastrointestinal symptom reporting was higher in those with larger
body mass indices. However, consistent with the proposed mechanisms listed above, it
appeared the majority of the increased symptom burden related to increased body mass was
gastroesophageal-like in nature.
In a meta-analysis of 9 studies examining the association between body mass index and
gastroesophogeal-like symptoms, six (67%) found a statistically significant association.
Furthermore, data from 8 of the 9 studies demonstrated a “dose-response relationship”
between body mass index and gastroesophageal symptoms, with an increase in the pooled
adjusted odds ratios for symptoms of 1.43 (95% confidence interval, 1.158 to 1.774) for body
mass index of 25 kg/m2 to 30 kg/m2 and 1.94 (95% confidence interval, 1.468 to 2.566) for body
mass index ≥ 30 kg/m2 [28].
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3.3. Insufficient physical activity
Current guidance [1,29] recommends all adults should do at least 150 minutes a week of
moderate-intensity aerobic physical activity, 75 minutes a week of vigorous-intensity aerobic
physical activity, or some equivalent combination of both in order to reduce their risk of heart
disease and diabetes. In fact, maintaining this level of moderate- or vigorous-intensity physical
activity each week has been associated with as much as a 30% decrease in ischemic heart disease
risk and a similar reduction (27%) in the risk of developing diabetes. Unfortunately, nearly a
third of people worldwide and a fifth of Americans do not meet this goal [1,3]. While the
mechanism behind how insufficient physical activity/sedentary lifestyle is associated with
upper gastrointestinal symptoms is unclear, it may be that there is a higher rate of overweight/
obesity in those who do not engage in enough physical activity, or the failure of inactive people
to obtain the mental (reduced stress, reduced depressive symptoms and increased cognitive
function) and bodily health benefits borne from physical activity [29].
Limited data evaluating the impact of physical activity on the prevalence of upper gastroin‐
testinal symptoms have been published in the medical literature. In an internet survey of over
UGIS=upper gastrointestinal symptoms
Figure 2. Prevalence of Upper Gastrointestinal Symptoms (By Subtype) By Body Mass Index in the Domestic/Interna‐
tional Gastroenterology Surveillance Study [3] Gastroesophogeal-like symptoms are the only symptom subtype trend‐
ing upwards with increasing body mass index
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cardiovascular disease outcomes, 1.87 million person-years at risk), patients’ risk of coronary
heart disease, ischemic stroke and cardiovascular disease were found to increase by 29%, 20%
and 23%, respectively, for every 4.56 kg/m2 increase in body mass index after adjustment for
age, gender, and smoking status [26].
The mechanism behind the association between overweight/obesity and increased upper
gastrointestinal symptoms is likely multifactorial [22]. First, the poor diet (ie, increased intake
of fatty foods) [22] and lack of exercise that leads the overweight/obese state also promotes
increased upper gastrointestinal symptoms (see further discussion below). Next, it is possible
that abdominal obesity may lead to gastric compression by the surrounding adipose tissue.
This causes increased intragastric pressure and relaxation of the lower esophageal sphincter,
and ultimately heartburn and regurgitation. Obesity may also lead to the development of hiatal
hernia promoting regurgitation symptoms. Lastly, humoral mechanisms related to obesity
including increased levels of insulin, leptin, growth factors or hormones may contribute to
gastrointestinal symptoms as well [22,27].
Results of the Domestic/International Gastroenterology Surveillance Study [3] suggested that
the prevalence of upper gastrointestinal symptom reporting was higher in those with larger
body mass indices. However, consistent with the proposed mechanisms listed above, it
appeared the majority of the increased symptom burden related to increased body mass was
gastroesophageal-like in nature.
In a meta-analysis of 9 studies examining the association between body mass index and
gastroesophogeal-like symptoms, six (67%) found a statistically significant association.
Furthermore, data from 8 of the 9 studies demonstrated a “dose-response relationship”
between body mass index and gastroesophageal symptoms, with an increase in the pooled
adjusted odds ratios for symptoms of 1.43 (95% confidence interval, 1.158 to 1.774) for body
mass index of 25 kg/m2 to 30 kg/m2 and 1.94 (95% confidence interval, 1.468 to 2.566) for body
mass index ≥ 30 kg/m2 [28].
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risk and a similar reduction (27%) in the risk of developing diabetes. Unfortunately, nearly a
third of people worldwide and a fifth of Americans do not meet this goal [1,3]. While the
mechanism behind how insufficient physical activity/sedentary lifestyle is associated with
upper gastrointestinal symptoms is unclear, it may be that there is a higher rate of overweight/
obesity in those who do not engage in enough physical activity, or the failure of inactive people
to obtain the mental (reduced stress, reduced depressive symptoms and increased cognitive
function) and bodily health benefits borne from physical activity [29].
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testinal symptoms have been published in the medical literature. In an internet survey of over
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2,500 respondents complaining of functional dyspepsia (or other gastrointestinal symptoms),
only 6% of respondents reported exercising daily, 29% reported exercising at least once a week,
and a majority (54%) claimed almost never or never exercising [30]. This was significantly less
physical activity compared to a simultaneously surveyed control population (n=1,000)
(p<0.01), suggesting that a sedentary lifestyle may be associated with an increased prevalence
of upper gastrointestinal symptoms.
3.4. Poor diet patterns
Improper or poor diet has been shown to be an important risk factor for cardiovascular disease.
From a strict cardiovascular viewpoint an ideal diet consists the consumption of ≥4.5 cups per
day of fruits and vegetables, ≥2 servings a week of fish, and ≥3 servings per day of whole grains
and no more than 36 ounces per week of sugar-sweetened beverages and 1500 mg per day of
sodium [31]. In addition, other poor diet choices such as high dietary intake of saturated fat,
trans-fat and cholesterol have also been tied to poor cardiovascular outcomes [1].
The failure to meet the above-mentioned dietary and lifestyle goals not only hinders a person’s
ability to achieve a healthy body weight, desirable cholesterol profile, and blood pressure, but
has also been linked to increased rates of upper gastrointestinal complaints. In a retrospective
database analysis [9] of employed Americans with functional dyspepsia determined by having
an ICD-9 code of 536.8x (n=1,669) and matched controls (n=83,450), those found to have a
nutritional deficiency (defined by the Agency of Healthcare Research and Quality’s Clinical
Classifications Software grouping of relevant ICD-9 codes) were 3.8-times as likely to complain
of dyspeptic symptoms (p<0.05). Moreover, in the previously mentioned survey study of
>2,500 respondents complaining of dyspeptic or irritable bowel symptoms and 1,000 controls
[30], the irregular eating of meals was found to be associated with increased gastrointestinal
complaints (p<0.05).
A handful of observational studies have also more specifically evaluated the individual
contributions of various components of poor diet on upper gastrointestinal symptom preva‐
lence. An insufficient intake of vegetables has been found to be statistically significantly
associated with increased gastrointestinal complaints (p<0.05) [30]. Moreover, in a sample of
1,000 employees of the United States Veteran’s Administration system, a strong trend (p=0.09)
towards an increased prevalence of heartburn and regurgitation symptoms (adjusted odds
ratio=1.71, 95% confidence interval, 0.92-3.17) in those with high intake of saturated fat
(measured using the 100-item Block Food Frequency Questionnaire) was also observed [22].
3.5. High cholesterol and high blood pressure
Ten percent of the world’s adult population (and nearly 14% of the United States population)
have high cholesterol (total cholesterol ≥240 mg/dL) and more than one-third of all people have
high blood pressure (systolic and diastolic blood pressure ≥140 and 90 mm Hg, respectively),
including 77.9 million American adults. Approximately one third of the global burden of
ischemic heart disease can be attributed to high cholesterol, and each 20/10 mmHg increase in
blood pressure, starting at 115/75 mmHg, has been shown to double a patients’ risk of a
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cardiovascular event. The treatment of both high cholesterol and high blood pressure often
necessitates polypharmacy [32,33], and many of the drugs used to treat these conditions may
cause upper gastrointestinal symptoms (see further discussion below).
There are conflicting data regarding the association between high cholesterol, high blood
pressure and upper gastrointestinal symptoms. In one recent retrospective database analysis
of 4-years’ worth of data on 300,000 employees of companies in the United States-based,
patients with ICD-9 codes for functional dyspepsia symptoms (n=1,669) were found to have a
higher rate of both high cholesterol (prevalence rates of 21.2% versus 12.1%, p<0.05) and
essential hypertension (17.8% versus 12.4%, p<0.05) compared to matched controls without
upper gastrointestinal symptom coding (n=83,450) [9]. However, in a far older study examin‐
ing nearly 5,000 adults in the Rand Health Experiment, no statistically significant association
was observed between either hypercholesterolemia or hypertension and patient reporting of
“episodes or attacks of stomach pain or stomachache” in the prior 3-months [11].
3.6. Diabetes
In 2008, the global prevalence of diabetes (fasting plasma glucose ≥ 126 mg/dL) was estimated
to be 10%, resulting in approximately 1.3 million deaths. A diagnosis of diabetes increases
patients’ risk of cardiovascular disease by 2- to 3-fold, and consequently, cardiovascular
disease accounts for approximately 60% of all diabetes-related deaths [1].
Diabetes may increase peoples’ risk of having upper gastrointestinal complaints for a number
of reasons. First, many medications used to treat diabetes and hopefully reduce patient’s risk
of both cardiovascular and microvascular (retinopathy, neuropathy, nephropathy) complica‐
tions can cause upper gastrointestinal symptoms including biguanides, sulfonylureas and
alpha-glucosidase inhibitors [34]. Next, abnormal glucose regulation tends to occur in
conjunction with other cardiovascular risk factors such as obesity, elevated blood pressure,
low high-density lipoprotein cholesterol and a high triglyceride levels [1], as well as psychiatric
disorders [35]; all known to be risk factors for upper gastrointestinal symptoms. Finally, the
neuropathy associated with diabetes and resulting gastroparesis may cause diabetics to suffer
from more upper gastrointestinal problems [35]. A recent prospective cohort study of 782
individuals found that Helicobacter pylori infection (a common cause of upper gastrointestinal
symptoms) was associated with a 2.69-fold increased hazard of developing type II diabetes
(95% confidence interval=1.10-6.60) [36], suggesting the relationship between diabetes and
upper gastrointestinal symptoms may be bidirectional.
Some studies support the association between diabetes and upper gastrointestinal symptoms.
The Domestic/International Gastroenterology Surveillance Study demonstrated those suffer‐
ing from a metabolic or endocrine disorder (which would presumably include in large part,
diabetes) were 2.6- to 4.4-fold more likely to report upper gastrointestinal symptoms in the
prior three months (p<0.006)[8]. A study of Swedish type II diabetics (n=61) and non-diabetics
(n=106) asked to complete a gastrointestinal symptom checklist found type II diabetes were
more likely to report abdominal pain more often than once a month (28.3% versus 14.3%,
p<0.01) and heartburn (31.77% versus 14.0%, p<0.05) [37]. Interestingly, it appears that the
prevalence of upper gastrointestinal symptoms in diabetics may be linked to the extent/
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physical activity compared to a simultaneously surveyed control population (n=1,000)
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of dyspeptic symptoms (p<0.05). Moreover, in the previously mentioned survey study of
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[30], the irregular eating of meals was found to be associated with increased gastrointestinal
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A handful of observational studies have also more specifically evaluated the individual
contributions of various components of poor diet on upper gastrointestinal symptom preva‐
lence. An insufficient intake of vegetables has been found to be statistically significantly
associated with increased gastrointestinal complaints (p<0.05) [30]. Moreover, in a sample of
1,000 employees of the United States Veteran’s Administration system, a strong trend (p=0.09)
towards an increased prevalence of heartburn and regurgitation symptoms (adjusted odds
ratio=1.71, 95% confidence interval, 0.92-3.17) in those with high intake of saturated fat
(measured using the 100-item Block Food Frequency Questionnaire) was also observed [22].
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Ten percent of the world’s adult population (and nearly 14% of the United States population)
have high cholesterol (total cholesterol ≥240 mg/dL) and more than one-third of all people have
high blood pressure (systolic and diastolic blood pressure ≥140 and 90 mm Hg, respectively),
including 77.9 million American adults. Approximately one third of the global burden of
ischemic heart disease can be attributed to high cholesterol, and each 20/10 mmHg increase in
blood pressure, starting at 115/75 mmHg, has been shown to double a patients’ risk of a
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necessitates polypharmacy [32,33], and many of the drugs used to treat these conditions may
cause upper gastrointestinal symptoms (see further discussion below).
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pressure and upper gastrointestinal symptoms. In one recent retrospective database analysis
of 4-years’ worth of data on 300,000 employees of companies in the United States-based,
patients with ICD-9 codes for functional dyspepsia symptoms (n=1,669) were found to have a
higher rate of both high cholesterol (prevalence rates of 21.2% versus 12.1%, p<0.05) and
essential hypertension (17.8% versus 12.4%, p<0.05) compared to matched controls without
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was observed between either hypercholesterolemia or hypertension and patient reporting of
“episodes or attacks of stomach pain or stomachache” in the prior 3-months [11].
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In 2008, the global prevalence of diabetes (fasting plasma glucose ≥ 126 mg/dL) was estimated
to be 10%, resulting in approximately 1.3 million deaths. A diagnosis of diabetes increases
patients’ risk of cardiovascular disease by 2- to 3-fold, and consequently, cardiovascular
disease accounts for approximately 60% of all diabetes-related deaths [1].
Diabetes may increase peoples’ risk of having upper gastrointestinal complaints for a number
of reasons. First, many medications used to treat diabetes and hopefully reduce patient’s risk
of both cardiovascular and microvascular (retinopathy, neuropathy, nephropathy) complica‐
tions can cause upper gastrointestinal symptoms including biguanides, sulfonylureas and
alpha-glucosidase inhibitors [34]. Next, abnormal glucose regulation tends to occur in
conjunction with other cardiovascular risk factors such as obesity, elevated blood pressure,
low high-density lipoprotein cholesterol and a high triglyceride levels [1], as well as psychiatric
disorders [35]; all known to be risk factors for upper gastrointestinal symptoms. Finally, the
neuropathy associated with diabetes and resulting gastroparesis may cause diabetics to suffer
from more upper gastrointestinal problems [35]. A recent prospective cohort study of 782
individuals found that Helicobacter pylori infection (a common cause of upper gastrointestinal
symptoms) was associated with a 2.69-fold increased hazard of developing type II diabetes
(95% confidence interval=1.10-6.60) [36], suggesting the relationship between diabetes and
upper gastrointestinal symptoms may be bidirectional.
Some studies support the association between diabetes and upper gastrointestinal symptoms.
The Domestic/International Gastroenterology Surveillance Study demonstrated those suffer‐
ing from a metabolic or endocrine disorder (which would presumably include in large part,
diabetes) were 2.6- to 4.4-fold more likely to report upper gastrointestinal symptoms in the
prior three months (p<0.006)[8]. A study of Swedish type II diabetics (n=61) and non-diabetics
(n=106) asked to complete a gastrointestinal symptom checklist found type II diabetes were
more likely to report abdominal pain more often than once a month (28.3% versus 14.3%,
p<0.01) and heartburn (31.77% versus 14.0%, p<0.05) [37]. Interestingly, it appears that the
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severity of their disease, with a large (n=1,101) cross-sectional survey study demonstrating
higher adjusted odds of frequent abdominal pain (odds ratio=1.62, 95% confidence interval,
1.02-2.58), dysmotility-like dyspepsia (odds ratio=2.01, 95% confidence interval, 1.30-3.11),
ulcer-like dyspepsia (odds ratio=1.49, 95% confidence interval, 0.90-2.45) and gastroesopha‐
geal reflux symptoms (odds ratio=2.28, 95% confidence interval, 1.54-3.38) in patients experi‐
encing a diabetes-related complication compared to those whom did not, and higher adjusted
odds of dysmotility-like dyspepsia (odds ratio=1.32, 95% confidence interval, 1.08-1.60), ulcer-
like dyspepsia (odds ratio=1.36, 95% confidence interval, 1.06-1.75) in those with poorer
hemoglobin A1c control [38].
Appropriate management of the overlapping risk factors can result in additional benefit to the
patients. Of the many care management decisions to be made between the health care
providers and the patients, an understanding of the risk factor pattern can help with the
prioritization. These overlapping risk factors may deserve a higher priority, as they will
improve both the cardiovascular and upper gastrointestinal conditions at the same time.
4. Overlapping symptomatology and surveillance
As many as 40% of people will complain of chest pain (along with associated symptoms of
nausea, palpitations and shortness of breath) at least once in their lifetime [39,48]; however,
symptoms reported by patients are typically unreliable for differentiating between chest pain
of a cardiac or gastrointestinal (ie, dyspepsia, gastroesophageal reflux, peptic ulcer disease,
pancreatitis, cholecystitis) origin [39,49]. Hence, the birth of famous adages such as, “when a
young man complains of pain in his heart, it is usually his stomach; when an old man complains of pain
in his stomach, it is usually his heart” [39]. Upper gastrointestinal symptoms, particularly
gastroesophageal- or dysmotility-like dyspeptic symptoms, are a frequent cause of non-cardiac
chest pain (ie, recurrent episodes of substernal chest pain in patients lacking a cardiac diagnosis
after a comprehensive evaluation) [39]. This likely explains why as many as 55% of chest pain
suffers presenting to the emergency room for the first time are not ultimately diagnosed with
cardiovascular disease [50], and 30% of patients undergoing coronary angiography each year
show no signs of coronary heart disease [51]. However, despite the lack of a cardiac diagnosis,
up to 80% of non-cardiac chest pain sufferers continue to experience symptoms over time, and
25%-45% continue to take antianginal medications [52]. Thus, because of the critical and
continual need to differentiate between cardiovascular disease and upper gastrointestinal
symptoms in patients with chest pain, it would seem reasonable to assume the increased
surveillance of one of these disorders would result in a higher rate of diagnosis of the other.
It has been suggested that in areas with a high prevalence of H. pylori infection, a “search and
treat” strategy for ischemic heart disease patients with dyspepsia could significantly reduce
the need for urgent postoperative endoscopy due to major gastrointestinal events [53].
However, endoscopy has been shown to induce cardiovascular complications, including
myocardial ischemia [40,41,54]. Thus, this practice may serve as an additional explanation for
the frequent diagnosis of cardiovascular disease in patients experiencing upper gastrointesti‐
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nal symptoms. An early study [54] of 110,469 upper endoscopies performed by 82 gastroen‐
terologists and 12 internists found a rate of 5 cardiopulmonary complications (not specifically
defined) per 100,000 procedures performed. However, more recent studies in patients with
stable coronary disease or those at risk for cardiovascular disease have observed much higher
rates of cardiovascular complications following endoscopy. In a study of 71 patients with stable
coronary heart disease undergoing endoscopy for evaluation for the safety of secondary
prophylaxis with aspirin, 42% of patients experienced silent ischemia and one patient had a
symptomatic event [40]. A second study utilizing data from 9 hospitals in the United States
evaluated 602 charts for patients undergoing endoscopy and deemed to be at risk for cardio‐
vascular disease. The researchers found an overall cardiovascular complication (either an
arrhythmia, hypotension, chest pain or angina equivalent, or myocardial infarction requiring
intervention and occurring within one calendar day after the endoscopy) rate of one for every
325 procedures (or 308 complications per 100,000), and a rate as high as one complication for
every 94 procedures (1,063 complications per 100,000) at the worst performing hospital [41]; a
complication rate 2- to 70-fold higher than previously reported in the medical literature.
The awareness of how the symptoms of cardiovascular diseases and upper gastrointestinal
conditions overlap can improve the differential diagnosis, thus reducing the chance of
inappropriate procedures and medications.
5. Adverse effect of cardiovascular drugs
Optimal treatment of patients with cardiovascular disease [32,33] often requires the use of
multiple medications. Consequently, at least some of the burden of upper gastrointestinal
symptoms experienced in patients suffering from cardiovascular disease may be a result of
polypharmacy. In the aforementioned Domestic/International Gastroenterology Surveillance
Study [8], the occurrence of upper gastrointestinal symptoms was significantly higher in
respondents reporting the use of a prescribed medication for another health problem com‐
pared to those not prescribed a medication (10.6% versus 6.0%, 5.1% versus 3.5% and 19.1%
versus 13.3% for gastroesophogeal-, ulcer- and dysmotility-like symptoms, respectively,
multivariate p<0.007 for all). Likewise, the use of an over-the-counter medication was also
associated with a higher rate of upper gastrointestinal symptoms in general and dysmotility-
like symptoms (19.3% versus 13.2% and 33.9% versus 24.6%; p<0.0001 for both).
Numerous drugs indicated or commonly used to treat cardiovascular diseases including
antiplatelets, antiarrhythmics, antihypertensives, antianginals, cholesterol-lowering medica‐
tions, as well as drugs to manage heart failure, diabetes and chronic kidney disease have been
linked to the development of upper gastrointestinal symptoms.
Unfortunately, drug-induced dyspepsia can be difficult to identify because of the high
background reporting of upper gastrointestinal symptoms. To overcome this problem, two
studies [42,43,45] were conducted in a Dutch prescription database of over 1.5 million
prescriptions (92 million person-years of follow-up) to identify signals for drug-induced
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severity of their disease, with a large (n=1,101) cross-sectional survey study demonstrating
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nal symptoms. An early study [54] of 110,469 upper endoscopies performed by 82 gastroen‐
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like symptoms (19.3% versus 13.2% and 33.9% versus 24.6%; p<0.0001 for both).
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Unfortunately, drug-induced dyspepsia can be difficult to identify because of the high
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behind these types of analyses is that most patients complaining of drug-induced dyspeptic
symptoms are empirically treated with anti-ulcer and/or anti-dysmotility agents; therefore, a
drug’s propensity for causing upper gastrointestinal symptoms might be reflected in the
sequencing of anti-ulcer and/or anti-dysmotility agents relative to the other medication (eg,
an excess of patients presenting with their first prescription for an anti-ulcer or dysmotility
agent after compared to before the initiation of an index drug would suggest a possible
dyspepsia-causing effect of the index drug). These studies identified a handful of (index) drugs
to treat cardiovascular disease that were more often followed by (within 100-days), as
compared to preceded by a histmaine-2-antagonist, proton pump inhibitor, bismuth prepara‐
tion, sucralfate, cispiride or metoclopramide. Drugs used to treat heart failure were among the
drugs with the largest relative risks for upper gastrointestinal symptoms.
Cardiovascular Drug(s) Common Cardiovascular Indication(s)
Acetylsalicylic acid (and other NSAIDs) Antiplatelet
Amiodarone Antiarrhythmic
Amlodipine (and other calcium channel blockers) Antihypertensive, antianginal
Atorvastatin (and other statins) High cholesterol
Beta-blockers Antihypertensive, antianginal, heart failure
Bile acid sequestrants (less often with colesevelam) High cholesterol
Non-aspirin antiplatelet agents (ie, cilostazol, ticlopidine) Antiplatelet
Fibric acid derivatives (gemfibrozil>fenofibrate) High cholesterol
Fish oil preparations (ie, omega-3 fatty acids) High cholesterol, dietary supplement
Digoxin Atrial fibrillation, heart failure
Dronedarone Antiarrhythmic (atrial fibrillation)
Loop diuretics Heart failure, chronic kidney disease
Losartan Antihypertensive, heart failure, diabetes, chronic
kidney disease
Niacin and nicotinic acid derivatives High cholesterol
Nitrates Antianginal
Potassium supplements Dietary supplement
Ramipril (and other ACE inhibitors) Antihypertensive, heart failure, diabetes, chronic
kidney disease
This list was derived from searches of references 41,42,44,54,55
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ACE=angiotensin-converting enzyme; NSAID=non-steroidal anti-inflammatory
Table 6. Cardiovascular Drugs Commonly Associated With Upper Gastrointestinal Symptoms
While a plausible explanation or underlying mechanism by which the abovementioned
cardiovascular drugs can cause upper gastrointestinal symptoms is not always apparent, these
drugs likely induce symptoms through direct mucosal irritation or injury (ie, aspirin and other
non-steroidal anti-inflammatory drugs, potassium supplementation), facilitation of gastric
acid reflux (ie, calcium channel blockers, nitrates) or alteration of gastric motility (ie, drugs
targeting the renin-angiotensin system causing bradykinin-mediated dysmotility) [45,55]. Still
yet, other associations between cardiovascular drugs and upper gastrointestinal symptoms
may be “false” signals, representing nothing more than a link between a specific disease state
or other confounder and upper gastrointestinal symptoms. Such may be the case with
cholesterol-lowering medications. Patients with hypercholesterolemia may prefer frequent
consumption of high-fat meals a well-known independent predictors of higher gastroesopha‐
geal symptom prevalence rates. [22,42,43,45].
Similarly, while drugs commonly used to treat heart failure, including angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, loop diuretics and digoxin, have also been
demonstrated in prescription sequence symmetry analyses to be upper gastrointestinal
symptom-inducing; it is likely the symptoms attributed to them are a manifestation of heart
failure itself (which has previously been shown to increase the risk of ulcer-like symptoms by
as much as 3.6-fold [11]) and not the individual medications [11,57]. Of note, this may not
always be the case with digoxin, which has been associated with dyspeptic-like symptoms in
patients experiencing elevated/toxic blood concentrations (>2.0 ng/mL) [58].
Each year about 400,000 tons of aspirin (acetylsalicylic acid) are produced worldwide, and >50
million Americans take between 10 and 20 billion tablets for cardiovascular disease prevention
[59]. Aspirin becomes non-ionized in the acidic environment of the gastrointestinal tract
allowing it to penetrate mucosal tissue and cause irritation. Consequently it is not surprising
that numerous studies have demonstrated aspirin to increase patients’ relative risk of upper
gastrointestinal symptoms by more than 2-fold over non-users [19-21,24,44]. Because of
aspirin’s frequent use and its propensity to cause gastric mucosal injury, it is likely the biggest
drug-induced dyspepsia offender and one of the strongest links between upper gastrointesti‐
nal symptoms and cardiovascular disease. While it is best to stop aspirin in light of gastroin‐
testinal symptoms, there may be adverse cardiovascular consequences that need to be
considered. A double-blind, placebo-controlled study evaluating low-dose aspirin users who
experienced gastrointestinal bleeding compared continuation of aspirin with discontinuation
[60]. Seventy-eight patients received aspirin 80 mg daily while 78 received placebo daily for 8
weeks. All patients received intravenous followed by oral proton pump inhibitor therapy
(intravenous pantoprazole 80 mg bolus followed by 8 mg/hour for 72 hours then oral panto‐
prazole 40mg daily). Recurrent bleeding occurred in 10.3% of patients in the aspirin group vs.
5.4% of those in the placebo group (difference=4.9 points, 95% confidence interval=-3.6 to 13.4),
p=not significant), but patients who received aspirin had lower all-cause mortality rates than
patients who received placebo (1.3% vs. 12.9%, difference=11.6 points, 95% confidence
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non-steroidal anti-inflammatory drugs, potassium supplementation), facilitation of gastric
acid reflux (ie, calcium channel blockers, nitrates) or alteration of gastric motility (ie, drugs
targeting the renin-angiotensin system causing bradykinin-mediated dysmotility) [45,55]. Still
yet, other associations between cardiovascular drugs and upper gastrointestinal symptoms
may be “false” signals, representing nothing more than a link between a specific disease state
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cholesterol-lowering medications. Patients with hypercholesterolemia may prefer frequent
consumption of high-fat meals a well-known independent predictors of higher gastroesopha‐
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Similarly, while drugs commonly used to treat heart failure, including angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, loop diuretics and digoxin, have also been
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symptom-inducing; it is likely the symptoms attributed to them are a manifestation of heart
failure itself (which has previously been shown to increase the risk of ulcer-like symptoms by
as much as 3.6-fold [11]) and not the individual medications [11,57]. Of note, this may not
always be the case with digoxin, which has been associated with dyspeptic-like symptoms in
patients experiencing elevated/toxic blood concentrations (>2.0 ng/mL) [58].
Each year about 400,000 tons of aspirin (acetylsalicylic acid) are produced worldwide, and >50
million Americans take between 10 and 20 billion tablets for cardiovascular disease prevention
[59]. Aspirin becomes non-ionized in the acidic environment of the gastrointestinal tract
allowing it to penetrate mucosal tissue and cause irritation. Consequently it is not surprising
that numerous studies have demonstrated aspirin to increase patients’ relative risk of upper
gastrointestinal symptoms by more than 2-fold over non-users [19-21,24,44]. Because of
aspirin’s frequent use and its propensity to cause gastric mucosal injury, it is likely the biggest
drug-induced dyspepsia offender and one of the strongest links between upper gastrointesti‐
nal symptoms and cardiovascular disease. While it is best to stop aspirin in light of gastroin‐
testinal symptoms, there may be adverse cardiovascular consequences that need to be
considered. A double-blind, placebo-controlled study evaluating low-dose aspirin users who
experienced gastrointestinal bleeding compared continuation of aspirin with discontinuation
[60]. Seventy-eight patients received aspirin 80 mg daily while 78 received placebo daily for 8
weeks. All patients received intravenous followed by oral proton pump inhibitor therapy
(intravenous pantoprazole 80 mg bolus followed by 8 mg/hour for 72 hours then oral panto‐
prazole 40mg daily). Recurrent bleeding occurred in 10.3% of patients in the aspirin group vs.
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interval=3.7 to 19.5). As such, if aspirin must be part of the regimen, like in settings where dual
antiplatelet therapy is needed (cardiac stenting, post unstable angina and myocardial infarc‐
tion), treating the adverse gastrointestinal effects may be a superior strategy.
ACE=angiotensin-converting enzyme; ARR=adjusted rate ratios; CCBs=calcium channel blockers; CI=confidence inter‐
vals; H2A=histamine-2-antagonist; PPI=proton pump inhibitor; UGIS=upper gastrointestinal symptoms
Figure 3. Results of Cardiovascular Drug Sequence Symmetry Analyses Using Histmaine-2-Antagonists, Proton Pump
Inhibitors, Bismuth Preparations or Sucralfate, Cispiride or Metoclopramide. The cardiovascular sequence symmetry
analyses depicted above assumed the development of one or more upper gastrointestinal symptoms was followed by
(within 100 days) the prescription of a drug to treat it (eg, a histmaine-2-antagonist, proton pump inhibitors, bismuth
preparation or sucralfate, cispiride or metoclopramide). Results were reported as the adjusted rate ratio of individuals
with AN upper gastrointestinal symptom-treating drug prescribed last versus individuals with the upper gastrointesti‐
nal symptom-treating drug prescribed first. Ratios above 1.0 indicate a possible upper gastrointestinal symptom-in‐
ducing effect of the index cardiovascular drug.
Of note, while studies suggest enteric-coated or buffered formulations of aspirin provide no
significant protective effect against gastrointestinal complications [61], randomized trials of
patients taking aspirin suggest concomitant proton pump inhibitor therapy can both prevent
upper gastrointestinal symptoms (p<0.05) [62] and reduce their prevalence in patients already
suffering dyspeptic symptoms [44,62].
Aspirin is not, however, the only antithrombotic agent that has been associated with upper
gastrointestinal symptoms. In fact, both non-aspirin antiplatelet agents (including other non-
steroidals, P2Y12 platelet inhibitors and phosphodiesterase inhibitors) and anticoagulants
(particularly oral direct thrombin inhibitors) have been associated with clinically important
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rates of upper gastrointestinal symptoms [46,47,63]. In the largest systematic review to date
(92 controlled trials), non-steroidals were found to increase the risk of dyspepsia versus
placebo regardless of whether a strict (relative risk=1.36, 95% confidence interval=1.11-1.67) or
liberal definition (relative risk= 1.19, 95% confidence interval=1.03-1.39) was used; with a
placebo rate of 2.3% using the strict definition and 4.2% using the liberal definition [63].
In a systematic review of randomized controlled trials of adults with atrial fibrillation receiving
pharmacologic stroke prevention, not only were upper gastrointestinal adverse effects found
to be common place, but oral direct thrombin inhibitors were associated with highest inciden‐
ces of (~11%) and drug discontinuation due to these symptoms (~2%) [46]. The Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study found a statistically higher
incidence of dyspepsia in patients receiving the oral direct thrombin inhibitor, dabigatran,
compared to adjusted-dose warfarin (11.8% for dabigatran 110 mg, 11.3% for dabigatran 150
mg and 5.8% for warfarin, p<0.001 for the comparison of either dose of dabigatran versus
warfarin)[47]. The dyspepsia-provoking nature of dabigatran has been attributed to its
formulation which utilizes a tartaric acid core to lower the pH in the gastrointestinal tract and
thus increase the absorption of the drug [47]. Luckily, there are Factor Xa inhibitors as
therapeutic alternatives to direct thrombin inhibitors in those impacted by, or likely to be
impacted by, upper gastrointestinal symptoms [56,64].
Beyond the ability of cardiovascular drugs to provoke upper gastrointestinal symptoms, the
occurrence of these symptoms may adversely affect cardiovascular drug adherence, putting
UGIS PPI Group Placebo Group
Epigastric pain 83.9% 66.7%*
Epigastric burning 72.7% 58.1%
Epigastric discomfort 68.3% 50.9%*
Heartburn 89.7% 66.7%*




PPI=proton pump inhibitor; UGIS=upper gastrointestinal symptoms
Table 7. Percentages of Patients Taking Aspirin (75-325 mg/day) and Suffering Upper Gastrointestinal Symptoms
Reporting Resolution of Symptoms Following 26-Weeks of Proton Pump Inhibitor (Esomeprazole 20 mg/day) Therapy
or Placebo [62]
Upper Gastrointestinal Symptoms and Cardiovascular Disease
http://dx.doi.org/10.5772/56564
155
interval=3.7 to 19.5). As such, if aspirin must be part of the regimen, like in settings where dual
antiplatelet therapy is needed (cardiac stenting, post unstable angina and myocardial infarc‐
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patients at risk for adverse cardiovascular outcomes. Studies have demonstrated that gastro‐
intestinal side effects decrease medication adherence [66], and this likely plays an important
role in the poor adherence often seen across the spectrum cardiovascular medications [67].
6. Cardiovascular disease associated with upper gastrointestinal symptom
drug use
In addition to cardiovascular drugs provoking upper gastrointestinal symptoms, a number of
medications used to treat upper gastrointestinal symptoms have impacted cardiovascular
drug function or have been associated with poor cardiovascular outcomes through both
indirect and direct mechanisms.
6.1. Drug interactions impeding cardiovascular drug function
Proton pump inhibitors are frequently used to treat various gastrointestinal symptoms/
conditions including H. pylori infection. American College of Gastroenterology guidelines
recommended strategies for the eradication of H. pylori infection include treatment with at
Agent Mechanism of Action UGIS Nausea
Antiplatelet agents
ASA Blockade of COX-1 ++++ (>6%) ++++ (>6%)




Cilostazol PDE III blockade ++++ (~6%) ++++ (~7%)
Clopidogrel P2Y12 inhibition ++ (<2%) ++ (<2%)
Prasugrel P2Y12 inhibition ++ (<2%) +++ (~5%)
Ticagrelor P2Y12 inhibition ++ (~2%) +++ (~4%)
Ticlopidine P2Y12 inhibition ++++ (~7%) ++++ (~7%)
Anticoagulant agents
Warfarin Vitamin K antagonist ++++ (6%) ++ (1.5%)
Dabigatran Direct thrombin inhibition ++++ (11%) NA
Rivaroxaban Factor Xa inhibition ++ (≤2%) ++ (2%)
Apixaban Factor Xa inhibition NA +++ (3%)
++=minimal risk (≤2%); +++=moderate risk (3-5%); ++++=high risk (5-10%)
ASA=aspirin; COX=cyclooxygenase; NSAID=non-steroidal anti-inflammatory drug; NA=not available; PDE=phospho‐
diesterase; UGIS=upper gastrointestinal symptoms
Table 8. Cross-Comparison of Upper Gastrointestinal Symptoms Precipitated by Antithrombotics [46,47,56,65]
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least three drugs, and yield eradication rates of up to 90%. While the best H. pylori treatment
regimen may vary depending on patient characteristics, guidelines recommended four
different drug regimens including a proton pump inhibitor, clarithromycin, and amoxicillin,
or metronidazole (clarithromycin-based triple therapy) for 14 days, a proton pump inhibitor
or histamine-2-antagonist, bismuth, metronidazole, and tetracycline (bismuth quadruple
therapy) for 10–14 days, or sequential therapy consisting of a proton pump inhibitor and
amoxicillin for 5 days followed by a proton pump inhibitor, clarithromycin, and tinidazole for
an additional 5 days (as an alternative to clarithromycin-based triple or bismuth quadruple
therapy) [68].
Proton pump inhibitors competitively inhibit the cytochrome P450 2C19 isoenzyme
(CYP2C19). Based on in vitro and in vivo data, omeprazole and esomeprazole are the most
potent CYP2C19 inhibitors [69]. In vivo, omeprazole and esomeprazole induced 4 and 10 fold
functional inhibition of CYP2C19 versus less than 1.5 fold inhibition with lansoprazole and
pantoprazole [70]. Rabeprazole has in vitro data showing less inhibition of CYP2C19 than
omeprazole and lansoprazole but no in vivo data is available [69].
Clopidogrel is a CYP2C19 substrate and needs to be activated by this isoenzyme. When given
concurrently with proton pump inhibitors, there is a reduction in the produced active form of
clopidogrel and greater platelet reactivity (less platelet inhibition) [71,72].
Whether this platelet reactivity effect impacts clinical events has been controversial. A 2009
population-based study among Ontario residents aged 66 years or older used prescription
records to ascertain proton pump inhibitor use during clopidogrel therapy. The analysis
suggested that proton pump inhibitor use may be associated with an increased risk of
cardiovascular events [odds ratio for recurrent myocardial infarction within 90 days following
hospital discharge, 1.27 (1.03 to 1.57)], however, no effect on the risk of death was observed
[odds ratio of death within 90 days following hospital discharge 0.82 (0.57 to 1.18)] [73]. The
16,718 patient Clopidogrel Medco Outcomes Study was a cohort evaluation from an integrated
medical and pharmacy claims database. Patients had a clopidogrel prescription filled within
one month of a coronary stenting procedure (where dual aspirin and clopidogrel therapy is
frequently employed). Patients who concomitantly received a proton pump inhibitor were in
the active group while those without were in the control group in this observational non‐
randomized study. Those receiving a proton pump inhibitor had more cardiovascular events
(myocardial infarction, unstable angina, repeat coronary procedure) than those without (25%
vs. 18%, p<0.0001). Without randomization, however, it cannot be ascertained where it was
the underlying patient population with gastrointestinal symptoms that had a higher risk or if
the use of the proton pump inhibitor yielded the difference. When patients on each proton
pump inhibitor were analyzed separately, there were no differences in the percent of patients
with a cardiac event: omeprazole 25%, esomeprazole 25%, lansoprazole 24%, and pantoprazole
29%. Given the marked differences in CYP2C19 inhibition between omeprazole and esome‐
prazole versus lansoprazole and pantoprazole, qualitative differences between the groups
would have been expected [74]. Two other smaller analyses also supported the greater risk of
cardiac events with patients receiving concurrent proton pump inhibitors but again, whether
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patients at risk for adverse cardiovascular outcomes. Studies have demonstrated that gastro‐
intestinal side effects decrease medication adherence [66], and this likely plays an important
role in the poor adherence often seen across the spectrum cardiovascular medications [67].
6. Cardiovascular disease associated with upper gastrointestinal symptom
drug use
In addition to cardiovascular drugs provoking upper gastrointestinal symptoms, a number of
medications used to treat upper gastrointestinal symptoms have impacted cardiovascular
drug function or have been associated with poor cardiovascular outcomes through both
indirect and direct mechanisms.
6.1. Drug interactions impeding cardiovascular drug function
Proton pump inhibitors are frequently used to treat various gastrointestinal symptoms/
conditions including H. pylori infection. American College of Gastroenterology guidelines
recommended strategies for the eradication of H. pylori infection include treatment with at
Agent Mechanism of Action UGIS Nausea
Antiplatelet agents
ASA Blockade of COX-1 ++++ (>6%) ++++ (>6%)




Cilostazol PDE III blockade ++++ (~6%) ++++ (~7%)
Clopidogrel P2Y12 inhibition ++ (<2%) ++ (<2%)
Prasugrel P2Y12 inhibition ++ (<2%) +++ (~5%)
Ticagrelor P2Y12 inhibition ++ (~2%) +++ (~4%)
Ticlopidine P2Y12 inhibition ++++ (~7%) ++++ (~7%)
Anticoagulant agents
Warfarin Vitamin K antagonist ++++ (6%) ++ (1.5%)
Dabigatran Direct thrombin inhibition ++++ (11%) NA
Rivaroxaban Factor Xa inhibition ++ (≤2%) ++ (2%)
Apixaban Factor Xa inhibition NA +++ (3%)
++=minimal risk (≤2%); +++=moderate risk (3-5%); ++++=high risk (5-10%)
ASA=aspirin; COX=cyclooxygenase; NSAID=non-steroidal anti-inflammatory drug; NA=not available; PDE=phospho‐
diesterase; UGIS=upper gastrointestinal symptoms
Table 8. Cross-Comparison of Upper Gastrointestinal Symptoms Precipitated by Antithrombotics [46,47,56,65]
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least three drugs, and yield eradication rates of up to 90%. While the best H. pylori treatment
regimen may vary depending on patient characteristics, guidelines recommended four
different drug regimens including a proton pump inhibitor, clarithromycin, and amoxicillin,
or metronidazole (clarithromycin-based triple therapy) for 14 days, a proton pump inhibitor
or histamine-2-antagonist, bismuth, metronidazole, and tetracycline (bismuth quadruple
therapy) for 10–14 days, or sequential therapy consisting of a proton pump inhibitor and
amoxicillin for 5 days followed by a proton pump inhibitor, clarithromycin, and tinidazole for
an additional 5 days (as an alternative to clarithromycin-based triple or bismuth quadruple
therapy) [68].
Proton pump inhibitors competitively inhibit the cytochrome P450 2C19 isoenzyme
(CYP2C19). Based on in vitro and in vivo data, omeprazole and esomeprazole are the most
potent CYP2C19 inhibitors [69]. In vivo, omeprazole and esomeprazole induced 4 and 10 fold
functional inhibition of CYP2C19 versus less than 1.5 fold inhibition with lansoprazole and
pantoprazole [70]. Rabeprazole has in vitro data showing less inhibition of CYP2C19 than
omeprazole and lansoprazole but no in vivo data is available [69].
Clopidogrel is a CYP2C19 substrate and needs to be activated by this isoenzyme. When given
concurrently with proton pump inhibitors, there is a reduction in the produced active form of
clopidogrel and greater platelet reactivity (less platelet inhibition) [71,72].
Whether this platelet reactivity effect impacts clinical events has been controversial. A 2009
population-based study among Ontario residents aged 66 years or older used prescription
records to ascertain proton pump inhibitor use during clopidogrel therapy. The analysis
suggested that proton pump inhibitor use may be associated with an increased risk of
cardiovascular events [odds ratio for recurrent myocardial infarction within 90 days following
hospital discharge, 1.27 (1.03 to 1.57)], however, no effect on the risk of death was observed
[odds ratio of death within 90 days following hospital discharge 0.82 (0.57 to 1.18)] [73]. The
16,718 patient Clopidogrel Medco Outcomes Study was a cohort evaluation from an integrated
medical and pharmacy claims database. Patients had a clopidogrel prescription filled within
one month of a coronary stenting procedure (where dual aspirin and clopidogrel therapy is
frequently employed). Patients who concomitantly received a proton pump inhibitor were in
the active group while those without were in the control group in this observational non‐
randomized study. Those receiving a proton pump inhibitor had more cardiovascular events
(myocardial infarction, unstable angina, repeat coronary procedure) than those without (25%
vs. 18%, p<0.0001). Without randomization, however, it cannot be ascertained where it was
the underlying patient population with gastrointestinal symptoms that had a higher risk or if
the use of the proton pump inhibitor yielded the difference. When patients on each proton
pump inhibitor were analyzed separately, there were no differences in the percent of patients
with a cardiac event: omeprazole 25%, esomeprazole 25%, lansoprazole 24%, and pantoprazole
29%. Given the marked differences in CYP2C19 inhibition between omeprazole and esome‐
prazole versus lansoprazole and pantoprazole, qualitative differences between the groups
would have been expected [74]. Two other smaller analyses also supported the greater risk of
cardiac events with patients receiving concurrent proton pump inhibitors but again, whether
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the additional risk is due to the underlying differences in the populations versus the use of the
drug cannot be determined [75,76].
In the 13,608 patient TRITON-TIMI 38 Trial, a third of patients were on a concomitant proton
pump inhibitor (41% pantoprazole, 37% omeprazole, 14% esomeprazole, 10% lansoprazole,
1% rabeprazole). In a nested cohort analysis from this trial, there was no difference between
the proton pump inhibitor group and the control group for the composite endpoint of
cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke [77].
Given the profound effect of confounders, especially co-linear confounders, on the results of
observational trials, these trials cannot prove causality, regardless of their results. Randomized
and placebo controlled clinical trials eliminate many of these confounders and have much
stronger internal validity. The only major randomized evaluation of the impact of proton pump
inhibitors on cardiovascular events was the Clopidogrel and the Optimization of Gastrointes‐
tinal Events (COGENT) trial. Overall, 3761 patients starting dual antiplatelet therapy with
aspirin and clopidogrel were randomized to receive omeprazole or placebo. No difference was
found in the primary composite cardiovascular endpoint (p=0.98) but the rate of overt upper
gastrointestinal bleeding was reduced with omeprazole therapy versus placebo [hazard ratio
0.13 (0.03 to 0.56)] [78]. The use of omeprazole which is the most potent CYP2C19 inhibitor
was the best proton pump inhibitor choice to evaluate the balance of benefits to harms in this
population [56, 69].
The COGENT trial and TRITON-TIMI 38 analysis results led the American College of Cardi‐
ology, American College of Gastroenterology, and American Heart Association to issue
guidelines calling for the use of proton pump inhibitors when indicated for patients receiving
antiplatelet therapy for cardiovascular disease [79]. However, the package insert recommends
avoiding the use moderate to strong CYP2C19 inhibitors and to use alternative acid suppress‐
ing agents such as H2 antagonists or less potent CYP2C19 inhibiting proton pump inhibitors
where possible [56].
Aside from proton pump inhibitors, the histamine-2 antagonist cimetidine is ubiquitous
moderate CYP 1A2, 2C19, 2D6, and 3A4 inhibitor [56]. It raises the concentrations of all these
cardiovascular medications increasing the chances for cardiovascular adverse effects. As such
additional monitoring is suggested when added to amiodarone, beta-blockers (carvedilol,
nebivolol), calcium channel clockers (verapamil, diltiazem, nifedipine), procainamide,
propafenone, and ranolazine while selection of an alternative agent is specifically suggested
when quinidine is being used. Other drugs in this class do not have the same potency of
inhibition and are therapeutic alternatives [56].
6.2. QTc prolongation and Torsade de Pointes
Two classes of commonly used upper gastrointestinal drugs impact QTc prolongation and
arrhythmogenesis. The QTc interval is a marker of ventricular depolarization and repolariza‐
tion time and if the QTc interval reaches 500ms or is elevated by 60ms over baseline values,
the risk of the polymorphic ventricular arrhythmia Torsade de Pointes is elevated [80]. Torsade
de Pointes can be a life threatening arrhythmia and requires prompt detection and treatment.
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Cisapride is a promotility agent that enhances acetylcholine release at the myenteric plexus
[56]. In March of 2000, the Food and Drug Administration was notified that the manufacturer
would stop widespread manufacture of the drug due to elevated risk of QTc interval prolon‐
gation and the formation of the polymorphic ventricular tachycardia Torsade de Pointes. There
are 341 reports of heart rhythm abnormalities, likely Torsade de Pointes, and 80 deaths with
cisapride. It is still being made and distributed to individuals for whom other options have
failed but is contraindicated with QTc interval prolonging agents such as Vaughn Williams
Class Ia (quinidine, procainamide) or Class III (amiodarone, dronedarone, sotalol, dofetilide)
antiarrhythmic agents, macrolide antibiotics (erythromycin, clarithromycin, troleandomycin),
nefazodone, HIV protease inhibitors, and -azole antifungals. It is also contraindicated with
potent CYP3A4 inhibitors and prone individuals [56, 80]. While not classically considered a
gastrointestinal drug, erythromycin stimulates motilin receptors and can be an adjunctive
promotility agent in diabetic gastroparesis. Erythromycin blocks the rapid component of the
delayed rectifier potassium channel and prolongs the QTc interval and arrhythmogenic risk
as well [80].
The 5HT3 antagonists (dolasetron, granisetron, etc) prolong the QTc interval and when used
intravenously or in patients with other QTc interval prolonging drugs, hypokalemia or
hypomagnesemia, or congenital long QT syndrome; can induce the polymorphic ventricular
arrhythmia known as Torsade de Pointes [80]. Correcting electrolyte abnormalities before
starting a 5HT3 antagonist is important in preventing Torsade de Pointes but is also sometimes
difficult given the emesis the drugs are being used to control [56].
6.3. Bradycardia and atrioventricular blockade
The 5HT3 antagonists (dolasetron, granisetron, ondansetron, etc) and the histamine 2 receptor
antagonists (cimetidine, ranitidine) have been shown to rarely cause negative chronotropic
(reduced sinoatrial nodal firing rate) and dromotropic (reduced rate of impulse passage
through the atrioventricular node) effects when used in excessive doses or in intravenous
forms [56, 80]. Patients who are prone to develop bradycardia or heart block, such as those
with borderline low heart rates, elevated baseline PR intervals, or are receiving other negative
chronotropic or dromotropic drugs (beta-blockers, nondihydropyridine calcium channel
blockers, digoxin, Vaughn Williams Class Ic antiarrhythmic agents) are most at risk [56,80].
6.4. Hypertension
Metoclopramide is a complex dopaminergic agent with differing effects on blood pressure in
different individuals. When used as a sole agent in normotensive, essential hypertensive, and
type 2 diabetic subjects, there is no effect on systolic or diastolic blood pressure [81,82].
However, it can profoundly elevate blood pressure in patients with pheochromocytoma and
in patients developing serotonin syndrome while taking metoclopramide with select serotonin
reuptake inhibitors [83-86]. In addition, it has been shown to modestly attenuate the antihy‐
pertensive effects of bromocriptine and labetolol [87,88]. In this way, metoclopramide can
induce hypertensive urgencies and emergencies in prone individuals and alternative agents
should be utilized when appropriate.
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additional monitoring is suggested when added to amiodarone, beta-blockers (carvedilol,
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when quinidine is being used. Other drugs in this class do not have the same potency of
inhibition and are therapeutic alternatives [56].
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The consequences of these drug-disease interactions can be dire, with significant impact on
mortality and morbidities. As many of these interactions are unknown until a large population
has been using the offending medications, health care providers must remain vigilant in
identifying potential new problems.
7. Conclusions
There is growing evidence that patients with cardiovascular disease suffer a higher burden of
upper gastrointestinal symptoms and even that certain upper gastrointestinal complaints can
induce or promote cardiovascular disease. Knowledge of how these common conditions are
connected can bring forth therapeutic advantages. For instance, among patients with upper
gastrointestinal symptoms, their interactions with the health care system can increase the
chance of earlier diagnosis of cardiovascular conditions. Conversely, among patients with car‐
diovascular conditions, health care providers’ inquiry into gastrointestinal symptoms and side
effects of medications may aid in appropriate choice of therapy to enhance effectiveness and
patient adherence. Additional research is needed to clarify whether the cardiovascular pa‐
tients’ increased risk of upper gastrointestinal symptoms is a result of shared pathophysiology
or risk factors, increased surveillance due to overlapping symptoms, or induced by the fre‐
quent need for polypharmacy among suffers of both these disease states.
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1. Introduction
Gastrointestinal symptoms are frequently encountered in women diagnosed with endome‐
triosis. Women with endometriosis appear to complain more commonly of gastrointestinal
symptoms such as gastro-oesophageal reflux and dyspepsia. The psychological profile of
patients with endometriosis may promote these symptoms. As a reaction to high levels of
perceived stress, neuroendocrine-immune imbalance has been demonstrated in women
diagnosed with endometriosis. Pharmacological agents used to treat psychological dysfunc‐
tion, and symptoms of endometriosis such as dysmenorrhoea, may lead to undesirable
gastrointestinal symptoms.
Through neuroendocrine and immunological intermediaries, the gastrointestinal system may
also interact with the physiology of the female genital system. These variables have directed
some workers to suggest an interrelationship between both systems including the occurrence
of pathology. Gastrointestinal symptoms may act as a guide to dietary modification which
may result in improvement in the symptomatology of endometriosis.
2. Epidemiology of gastrointestinal symptoms and endometriosis
It is becoming apparent that although anatomically separate, gastrointestinal symptoms do
overlap with pelvic endometriosis. Endometriosis is the occurrence of endometrial tissue
outside the uterus. Endometriotic deposits are mainly found on the ovaries, utero-sacral
ligaments and pelvic peritoneum. Endometriosis affects one fourth of young women under
the age of 30 years with an overall incidence of 7% to 10 % of women. Subfertility has been
noted in 20-50% of women found to have endometriosis while more than 80% of women
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complaining of chronic pelvic pain have been diagnosed as having this condition. Conversely
endometriosis has been diagnosed in 20-50% of women who were completely asymptomatic,
unaware that they had this pelvic pathology [1].
Gastrointestinal symptoms appear more prevalent in women diagnosed with pelvic endome‐
triosis [2,3,]. Specific signs and symptoms result in frequent medical consultation are associ‐
ated with presence of endometriosis [4]. The anatomical separation between the
gastrointestinal tract and the female genital tract may prima facie, appear disparate without
any anatomical or physiological association. In a study by Muscat Baron et al [5,6] however,
gastrointestinal symptoms such as heartburn and dyspepsia were significantly more com‐
monly found in women with endometriosis as compared to a control group. This was a
prospective trial involving 57 menstrual women who had undergone laparoscopic examina‐
tion of the pelvis for a diverse number of abdominal and gynaecological symptoms. The
women recruited to the study were asked a comprehensive questionnaire which included
information on gastrointestinal symptoms, gynaecological symptoms, dietary intolerance and
general symptoms. During laparoscopy 23 women were diagnosed as having pelvic endome‐
triosis while in the other thirty-four this diagnosis was excluded. Upper gastrointestinal
symptoms such as heartburn and dyspepsia were found more commonly in the endometriosis
group reaching statistical significance (p <0.001). These results posed the enquiry as to why
two apparently anatomically distant systems, that is the gastrointestinal tract and the female
reproductive system, should influence each other [5,6].
Women diagnosed with endometriosis have been shown to have concomitant irritable bowel
syndrome symptoms. Ballard et al have shown that women with pelvic endometriosis were
also diagnosed with irritable bowel syndrome (OR 1.6 [95% CI: 1.3-1.8]) [4]. Lower gastro-
intestinal symptoms in the form of diarrhoea and loose stools have been found more commonly
found in women diagnosed with endometriosis. As opposed to the upper gastro-intestinal
tract, both the small and to a greater extent the large bowel is in close proximity with the female
genital tract. Both systems (intestinal and reproductive) throughout their physiological
functioning are likely to influence each other [5,6].
It must be kept in mind that gastrointestinal symptoms commonly occur in the general
population. Although estimates vary according to the diagnostic criteria used, 10–40% of the
adult population experience heartburn and dyspepsia in Western countries. Gastro-oesopha‐
geal reflux disease increases with age, rising sharply beyond the fourth decade. More than half
of the patients effected are aged between 45 and 64[7].
Dyspepsia also affects between 20% and 40% of the Western populations. A quarter of all cases
of dyspepsia are though to be related to gastric and duodenal ulcers [8]. Several studies from
the 1940’s to the 1980's reported that population prevalence of 18%[9], 26%[10] and 31% [11]
of people referred with dyspepsia were found to have peptic ulcers. Recently this percentage
has fallen to around 10–15%[7]. Although mortality in people with gastrointestinal disorders
is not raised compared with the general population, these disorders have a significant impact
on quality of life. It has been shown that 75% of people with heartburn and dyspepsia suffered
persistent symptoms and impaired quality of life over periods of 10 years or more; 30–50%
never returned to work and were unable to carry out household tasks [12].
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3. Pathogenesis of endometriosis and gastrointestinal symptoms
The enigmatic pathogenesis of endometriosis has led to the formulation of several hypotheses,
but none have been proven conclusively. The elusiveness of its pathology has directed some
workers to search beyond the female genital tract and concentrate their efforts at the gastro‐
intestinal system, the small and large bowel being in close anatomical proximity to the female
genital tract (Figure 1.)[5,6,13]. The overlap of symptoms between both the gastrointestinal
pathology and endometriosis influences clinical practice and in several women leads to
delayed or misdiagnosis (Figure 1.).









Sagittal Section: Retroposed Uterus due to 
Rectosigmoid Endometriosis
Figure 1. Following retrograde menstrual flow through the Fallopian tubes, endometriotic deposits colonize 
adjacent peritoneal structures. The peritoneal structures involved include ovaries, utero-sacral ligaments and 
adjacent bowel especially the rectosigmoid colon. Following endometriotic deposition adhesion formation results.  
This may lead to a retroverted uterus due to endometriosis-induced adhesions between rectosigmoid colon and 









Figure 1. Following retrograde menstrual flow thr ugh the Fallopian tubes, endrometri tic deposits colonize adja‐
cent peritoneal structur s. The peritoneal structur s involved include ovaries, utero- acral ligame ts and adjacent
bowel especially the rectosigmoid colon. Following endometriotic deposition adhesion formation results. This may
lead to a retroverted uterus due to endometriosis-included adhesions between rectosigmoid colon and posterior as‐
pect of uterus, with obliteration of the Pouch of Douglas.
Physiological studies indicate that gastric emptying does not appear to be affected by the
menstrual cycle. Abdominal symptoms related to the upper gastrointestinal tract appear more
commonly during the follicular phase. During the follicular phase the transit time in the small
bowel is longer. The normal menstrual cycle has no effect on gastric motility suggesting that
gastric emptying does not change significantly between the follicular and luteal phases [14].
Almost 50% of women with irritable bowel syndrome report a perimenstrual increase in
symptoms [15].
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4. Psychological background to the co-existence of endometriosis and
gastrointestinal symptoms
Emotional and mood disorders in women have been significantly detected in women suffering
from endometriosis. These disorders were found more commonly in women with endome‐
triosis (11/23 p < 0.03), admitting regular administration of anxiolytic and/or anti depressant
therapy for symptoms related to significant anxiety or depression [5].
In a prospective study by [16], out of 104 women diagnosed with pelvic endometriosis 87.5%
of women complained of anxiety. This anxiety state was mild in 24% and severe in 63.5% of
the subjects studied. Correlations between pain intensity and anxiety symptoms, were also
obtained using the State-Trait Anxiety Inventory (STAI) (state, P=0.009; trait, P=0.048) and the
Hamilton Rating Scale for Anxiety (HAMA) (P=0.0001). Moreover anxiolytic treatment with
benzodiazepines such as clonazepam has been used in women with endometriosis. A number
of these subjects also required prolonged treatment with serotonin selective serotonin re-
uptake inhibitors (SSRI’s) [16].
Depression has also been noted to be prevalent in women with pelvic endometriosis, a high
proportion of which require anti-depressant therapy. Depressive symptoms were observed in
86.5% of patients with pelvic endometriosis (mild in 22.1%, moderate in 31.7%, and severe in
32.7%) [16]. In a similar percentage (86%) of women, depression was detected in the women
with endometriosis complaining of chronic pelvic pain [17]. Work inhibition, dissatisfaction,
and sadness, were observed at a significantly higher rates in the group with abdominal pain
[17]
The above mentioned psychological profile of these women may have been moulded from a
very young age. The cyclical experience of the symptoms of severe dysmenorrhoea and
menstrual disorders from puberty, may have conditioned these women to acquire certain
personality traits as a reaction to the cyclical physical and subsequent psychological suffering
they sustained [16]. Lower quality of life indices correlated with high pain scores. Lower
quality of life status in psychological and environmental perspectives resulted in an inverse
relationship between pain scores and the psychological dimension of quality of life (r = -0.310,
P =.02)[18].
Mood disorders in adult women with endometriosis are associated with co-morbidities such
as pain syndromes including irritable bowel syndrome, vulvodynia, fibromyalgia and asthma
have been noted with in adult women with endometriosis. These co-morbidities appear to
have their conception early in reproductive life in adolescents and young women. A study by
Smorgick et al (2013) reviewing 138 adolescents/young women (younger than 24 years)
demonstrated a prevalence of comorbid pain syndromes 56% women, mood conditions in 66
(48%) women, and asthma in 31 (26%) women [19].
Exacerbations of gastrointestinal motility disorders such as gastro-oesophageal reflux and
irritable bowel syndrome are associated with the emergence of psychosocial stressors. Naliboff
et al [20] assessed 60 subjects with current heartburn symptoms and correlated for the
occurrence of stressful life events retrospectively over the preceding 6 months and prospec‐
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tively for 4 months. The occurrence of a severe, sustained life stress during the previous 6
months significantly predicted increased heartburn symptoms during the following 4 months.
Anxiety showed the strongest correlation to impaired quality of life and depression to
heartburn medication use. Similar to other chronic conditions such as irritable bowel syn‐
drome, heartburn severity appears to be most responsive to major life events. Both heartburn
and irritable bowel syndrome may be related to gastrointestinal motility disorders[20]. In the
upper gastrointestinal tract oesophageal acid exposure due to inhibition of gastric emptying
of acid may lead to heartburn. Alternatively motility disorders affecting the lower intestinal
tract lead to irritable bowel syndrome.
On further investigation of gynaecological complaints, once the diagnosis of endometriosis is
established, the phobia of infertility may set in, further compounding the psychological profile.
If infertility does occur in these women, then depressive symptoms are more likely to appear.
Self-reported depression was more common in subfertile women (n = 1,031), with endome‐
triosis (O.R. 5.43, C.I. 4.01-7.36) compared with fertile women (n = 4,905) [21].
5. Neuro-endocrine imbalance in association with Gastrointestinal
symptoms and Endometriosis
The majority of women suffering from endometriosis are well versed in their condition. With
easy access to medical literature, besides subfertility, the risk of inflammatory bowel disease
and ovarian cancer has now become universally known to most women suffering from
endometriosis [21]. All these factors exacerbate the tenuous emotional status of these women
(Figure 2.)
In response to high levels of perceived stress, neuroendocrine-immune imbalance has been
alluded to as a reaction to the symptoms of endometriosis. Serum prolactin levels were
significantly higher in infertile women with stage III-IV endometriosis (28.9 +/- 2.1 ng/mL) than
in healthy controls (13.2 +/- 2.1 ng/mL)[22]. Elevated serum cortisol levels were noted in
infertile women with stage III-IV endometriosis (20.1 +/- 1.3 ng/mL) compared to controls (10.5
+/- 1.4 ng/mL) [22]. Perception of stress has been noted to trigger or intensify the incidence or
exacerbation of diseases such as inflammatory bowel disease, immunological cutaneous
conditions, or pregnancy complications such as spontaneous miscarriage and pre-eclampsia.
The effect on the immunity of the intestinal mucosa by stress has been implicated as a potential
mechanism leading to irritable bowel syndrome. This is thought to be mediated through
altered function of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous
system. Both of these systems can modulate mucosal immune function. A study by Chang et
al indicated that basal adrenocorticotropin hormone levels were significantly blunted (P <
0.05), while basal and stimulated plasma cortisol levels were higher in patients with irritable
bowel syndrome. Patients with irritable bowel syndrome presenting with diarrhoea had
significantly decreased mRNA expression of mucosal cytokines [interleukin (IL)-2, IL-6] in the
sigmoid colon versus controls (P < 0.05) [24].
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of these subjects also required prolonged treatment with serotonin selective serotonin re-
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with endometriosis complaining of chronic pelvic pain [17]. Work inhibition, dissatisfaction,
and sadness, were observed at a significantly higher rates in the group with abdominal pain
[17]
The above mentioned psychological profile of these women may have been moulded from a
very young age. The cyclical experience of the symptoms of severe dysmenorrhoea and
menstrual disorders from puberty, may have conditioned these women to acquire certain
personality traits as a reaction to the cyclical physical and subsequent psychological suffering
they sustained [16]. Lower quality of life indices correlated with high pain scores. Lower
quality of life status in psychological and environmental perspectives resulted in an inverse
relationship between pain scores and the psychological dimension of quality of life (r = -0.310,
P =.02)[18].
Mood disorders in adult women with endometriosis are associated with co-morbidities such
as pain syndromes including irritable bowel syndrome, vulvodynia, fibromyalgia and asthma
have been noted with in adult women with endometriosis. These co-morbidities appear to
have their conception early in reproductive life in adolescents and young women. A study by
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Exacerbations of gastrointestinal motility disorders such as gastro-oesophageal reflux and
irritable bowel syndrome are associated with the emergence of psychosocial stressors. Naliboff
et al [20] assessed 60 subjects with current heartburn symptoms and correlated for the
occurrence of stressful life events retrospectively over the preceding 6 months and prospec‐
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tively for 4 months. The occurrence of a severe, sustained life stress during the previous 6
months significantly predicted increased heartburn symptoms during the following 4 months.
Anxiety showed the strongest correlation to impaired quality of life and depression to
heartburn medication use. Similar to other chronic conditions such as irritable bowel syn‐
drome, heartburn severity appears to be most responsive to major life events. Both heartburn
and irritable bowel syndrome may be related to gastrointestinal motility disorders[20]. In the
upper gastrointestinal tract oesophageal acid exposure due to inhibition of gastric emptying
of acid may lead to heartburn. Alternatively motility disorders affecting the lower intestinal
tract lead to irritable bowel syndrome.
On further investigation of gynaecological complaints, once the diagnosis of endometriosis is
established, the phobia of infertility may set in, further compounding the psychological profile.
If infertility does occur in these women, then depressive symptoms are more likely to appear.
Self-reported depression was more common in subfertile women (n = 1,031), with endome‐
triosis (O.R. 5.43, C.I. 4.01-7.36) compared with fertile women (n = 4,905) [21].
5. Neuro-endocrine imbalance in association with Gastrointestinal
symptoms and Endometriosis
The majority of women suffering from endometriosis are well versed in their condition. With
easy access to medical literature, besides subfertility, the risk of inflammatory bowel disease
and ovarian cancer has now become universally known to most women suffering from
endometriosis [21]. All these factors exacerbate the tenuous emotional status of these women
(Figure 2.)
In response to high levels of perceived stress, neuroendocrine-immune imbalance has been
alluded to as a reaction to the symptoms of endometriosis. Serum prolactin levels were
significantly higher in infertile women with stage III-IV endometriosis (28.9 +/- 2.1 ng/mL) than
in healthy controls (13.2 +/- 2.1 ng/mL)[22]. Elevated serum cortisol levels were noted in
infertile women with stage III-IV endometriosis (20.1 +/- 1.3 ng/mL) compared to controls (10.5
+/- 1.4 ng/mL) [22]. Perception of stress has been noted to trigger or intensify the incidence or
exacerbation of diseases such as inflammatory bowel disease, immunological cutaneous
conditions, or pregnancy complications such as spontaneous miscarriage and pre-eclampsia.
The effect on the immunity of the intestinal mucosa by stress has been implicated as a potential
mechanism leading to irritable bowel syndrome. This is thought to be mediated through
altered function of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous
system. Both of these systems can modulate mucosal immune function. A study by Chang et
al indicated that basal adrenocorticotropin hormone levels were significantly blunted (P <
0.05), while basal and stimulated plasma cortisol levels were higher in patients with irritable
bowel syndrome. Patients with irritable bowel syndrome presenting with diarrhoea had
significantly decreased mRNA expression of mucosal cytokines [interleukin (IL)-2, IL-6] in the
sigmoid colon versus controls (P < 0.05) [24].
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The association between psychological status and the gastrointestinal tract is well established.
Dr William Beaumont in 1833 demonstrated the influence of psychological stress on gastric
mucosal changes. Acclaimed as the Father of Gastric Physiology, Dr Beaumont carried out
observations and experiments on an individual known as Alexis St Martin. St Martin had
sustained a gastric fistula followed gunshot wound to the stomach, exposing a sliver of gastric
mucosa. Beaumont observed that the exposed gastric mucosa instantly reddened when St
Martin was angered, connecting the neuroendocrine-emotional status with gastric physiology
[25].
Heartburn and dyspepsia are acknowledged symptoms related with psychological and mood
disorders. Gastro-oesophageal reflux disease can be anatomically traced back to dysfunction
of the gastro-oesophageal junction, however psychological factors can play an important role
in the exacerbation of heart-burn. Well defined personality factors modulate the effect of stress
on the gastro-oesophageal junction, just as they can influence the perception and assessment
of symptoms. Gastric and small intestinal motor disorders and stomach acid hypersecretion,
interact with psychological and neurohormonal resulting in the pathogenesis of dyspepsia.
Greater proximal extension of acid during reflux episodes has been demonstrated in patients
with proven gastro-oesophageal reflux disease. These patients describe a shorter history of
symptom onset and worse anxiety scores. Endoscopic investigation depict findings compatible
with gastritis [26].
Altered secretion of gastric acid in the stomach has been linked with a vast array of modulators
supporting the neuro-endocrinological connection. Central neurotransmitters and/or neuro‐
modulators may excite or inhibit gastric acid secretion. Excitatory neuro-endocrine modulators
such as gamma-aminobutyric acid (GABA), acetylcholine, thyrotropin releasing hormone,
Increased Prolactin and 
Cortisol secretion
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secretion of gastric acid. This compounded by dietary indiscretion and injudicious ingestion of nonsteroidal inflammatory 
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oxytocin have been cited. On the contrary, noradrenaline, adenosine, bombesin, calcitonin-
gene related peptide, corticotropin releasing factor, beta-endorphin, neurotensin, neuropep‐
tide Y, insulin-like growth factor II and prostaglandins have been shown to inhibit gastric acid
secretion.
Several of these neuro-endocrine mediators have also been noted in endometriosis. Deep
infiltrating endometriosis is associated with severe and frequent chronic pelvic pain. In these
cases significantly more nerve fibres are detected histologically, than in superficial peritoneal
endometriotic lesions. Deep infiltrating endometriotic lesions were shown to be innervated
abundantly by sensory nerve fibres utilizing acetylcholine and norepinephrine as neurotrans‐
mitters [27]. Women with endometriosis have been noted to have lower levels of progesterone
in serum in the follicular phase and progesterone levels were inversely correlated to pain
scores. Progesterone receptor positive peritoneal lymphocytes of CD56(+) and CD8(+) type
were increasing found in advanced endometriosis. Cytokine secretion by peritoneal cells, was
higher in cells derived from endometriosis patients and could be further heightened by
corticotrophin releasing hormone mediated inflammation. Peripheral corticotrophin releasing
hormone increasing with anxiety and emotional stress, might contribute to the peritoneal
inflammation present in endometriosis [28,29].
6. Gastrointestinal symptoms, the menstrual cycle and endometriosis
An increase in the prevalence of gastro-intestimal symptoms are noted around the time of
menses and early menopause [30]. These are periods in the reproductive cycle whereby a
significant decline or low level of ovarian hormones in serum are noted. These observations
suggest that estrogen and progesterone withdrawal may contribute either directly or indirectly
to the occurrence of gastrointestinal symptoms and possibly to pathology [30].
Due to significant overlap between the symptoms of endometriosis and symptoms related to
endometriotic deposits on the gastrointestinal system, endometriosis has been referred to the
great masquerader. Moreover the menstrual cycle may also impact on gastrointestinal
function. As confirmed in the general literature, the presence of frequent menstruation in our
study in patients with endometriosis increased the likelihood of related gastrointestinal
symptoms.
Abdominal symptoms are significantly more pronounced at the beginning of the menstrual
cycle in the follicular phase [14]. Around 30% of otherwise asymptomatic women may
experience gastrointestinal symptoms at the time of menstruation, and almost fifty percent of
women with irritable bowel syndrome complain of a perimenstrual increase in symptoms.
Nausea, epigastric pain, and loose stools diarrhoea are more prevalent at the time of menses
in women complaining of bowel dysfunction. Patients complaining of bowel motility symp‐
toms indicate that stomach pain was higher throughout the menstrual cycle. Patients with
endometriosis complained of cramping pain more commonly in the perimenstrual phase [31].
Intestinal motility disorders may be associated with the genesis of endometriosis and con‐
versely endometriosis may influence intestinal motility. Preclinical studies have shown
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significantly more colonic damage, myeloperoxidase activity, and leucocyte count numbers
than controls did. Increased tension in the longitudinal muscle correlated with leuccytosis and
colonic damage. Mabrouk et al have shown that in deep infiltrating endometriosis, internal
anal sphincter tone was increased in 20 of 25 patients. Responses to a defaecatory function
questionnaire, indicated that incomplete evacuation was the most common symptom [32].
Premenstrual symptoms may be affected by dietary components. Soy products have not been
shown to alter Moos Menstrual Distress scores significantly during premenstrual phase [33].
However the ingestion of total saturated and monounsaturated fats were significantly
correlated with change in Moos Menstrual Distress scores which assesses a number of
premenstrual and menstrual symptomatology and subscale 'pain' in the premenstrual phase
after controlling for the covariates. The consumption of cereals/potatoes/starches was signifi‐
cantly inversely correlated with a change in total Moos Menstrual Distress scores in the
premenstrual phase [33].
Presumably due to hormonal and menstrual differences twice as many women as men seek
health services for irritable bowel syndrome as men. The presence of dyspepsia in women,
was found to be a significant independent risk factor for new-onset irritable bowel syndrome
( [OR] = 2.14; 95% CI, 1.56–2.94). The majority of women with irritable bowel syndrome
requesting medical consultation are of reproductive age experiencing the hormonal fluctua‐
tions of the menstrual cycle. However, after the age of 50 most population surveys have
reported a decline in the prevalence of irritable bowel syndrome[34]. Both oestrogen and
progesterone influence 5-hydroxytryptamine, an amine which is known to effect intestinal
motor-sensory function. During menstruation where oestrogen and progesterone levels reach
their lowest levels in the menstrual cycle, the platelet-depleted plasma concentration of 5-
hydroxytryptamine in irritable bowel syndrome patients with diarrhoea were similar to
healthy controls [35]. Compared to males, females with irritable bowel syndrome more
commonly display non-painful gastrointestinal symptoms, constipation and somatic discom‐
fort. There appear to be different gender-related pathways in sympathetic nervous system
responses to rectosigmoid stimulation. In a study by Chang et al 58 patients with irritable
bowel syndrome underwent barostat-assisted distensions of the rectum and sigmoid colon.
Women with irritable bowel syndrome had significantly lower rectal discomfort thresholds
compared with men with irritable bowel syndrome and healthy women who were the least
sensitive. There were no significant differences in rectal discomfort thresholds between men
with irritable bowel syndrome and healthy men. In both irritable bowel syndrome and control
groups, women demonstrated significantly lower discomfort thresholds after noxious sigmoid
stimulation (P<0.01) compared to men. [36].
Oral contraception results in relatively strict regulation of the menstrual cycle. Moreover the
use of oral contraception is associated with reduced menstrual loss and diminished levels of
dysmenorrhoea. During menstruation, women with irritable bowel syndrome using oral
contraceptives complain of less cognitive, anxiety, and depression symptoms (p < 0.05) but no
differences were seen for most symptoms of irritable bowel syndrome [37]. There may be a
differential effect of oral contraception depending on gastrointestinal symptom pattern.
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The presentation of endometriosis may mimic that of inflammatory bowel disease. Cramping
pain of dysmenorrhea is due to contraction of uterine smooth muscle under the influence of
prostaglandins, released by the endometrium during menstruation. The inflammatory process
in active inflammatory bowel disease is intimately related to prostaglandin levels. Elevated
prostaglandin levels increase contractility of intestinal smooth muscle resulting in diarrhoea
and abdominal pain.
There is critical importance in the clinical distinction between the diagnosis of endometriosis
and inflammatory bowel disease. Nonsteroidal anti-inflammatory drugs are administered to
relieve the symptoms of dysmenorrhoea in the presence and absence of endometriosis.
However Nonsteroidal anti-inflammatory drugs are contraindicated in inflammatory bowel
disease due to the risk of exacerbation of inflammatory bowel disease.
Dietary components in relation to symptomatic Endometriosis and Gastrointestinal symptoms
Psychological stress is also related to injudicious ingestion of dietary components that may
irritate the gastrointestinal tract. Somatization, state and trait anxiety and binge eating are
significant predictors of coexistent gastrointestinal disorders.
Nutrition research suggests that vitamins, minerals, and other dietary components are
important underpinnings of general physical and mental health. Moreover, dietary modifica‐
tion may even be useful in treating mood disorder by providing a more favourable risk-benefit
ratio than contemporary psychotropic agents [38].
The body mass index of women who experience depression is significantly higher than
controls. Meta-analyses confirm a reciprocal link between depressive states and obesity. Self-
confirmed depression, and clinically diagnosed depression are strongly associated with high
body mass index.
6.1. Pharmacological treatment of endometriosis and gastrointestinal symptoms
Anxiety states have been shown to result in excessive ingestion of benzodiazepines, relaxing
lower oesophageal sphincter pressure and subsequently facilitating gastro-oesophageal reflux.
Depression treated with clomipramine was associated with an increased risk of oesophageal
reflux (OR 4.6, 95% CI 2.0-10.6) in a duration- and dose-dependent manner [39].
Moreover, depression and its therapy were found to be predictive of developing obesity. Early
during the first 6 weeks of nortriptyline treatment, weight gain commences, reaching on
average 1.2 kg at 12 weeks with a resultant 0.44% increase in body mass index [40].
Chronic consumption of nonsteroidal anti-inflammatory agents to counter endometriosis-
induced dysmenorrhoea and menorrhagia may lead to ulceration of the gastric mucosa. The
degree of nonsteroidal anti-inflammatory gastropathy may be severe enough to develop
gastric and duodenal ulceration. It appears that there is sufficient evidence to indicate that
administration of nonsteroidal anti-inflammatory drugs could be considerably attenuated and
adverse effects, avoided if medical practitioners were persuaded to change their prescribing
practices [41].
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There appears to be co-existence of gastrointestinal symptoms and endometriosis. The linkage
between gastrointestinal symptoms and endometriosis may be due the psychological back‐
ground and neuro-endocrine mediation. Gastrointestinal symptoms have been related to both
dietary indiscretion and psychological stress both of which may, for a variety of reasons, be
commonly encountered in women with endometriosis. Moreover treatment of the symptoms
of endometriosis may aggravate gastrointestinal symptoms.
In suspected endometriosis, meticulous consultation carefully assessing the woman’s symp‐
tomatology is required to avoid delay or possibly misdiagnosis. A delay or misdiagnosis may
further exacerbate the psychological background of anxiety and depression, together with the
incidence of gastrointestinal symptoms. The co-existence of gastrointestinal conditions and
endometriosis may require a multi-disciplinary approach to enact effective treatment.
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1. Introduction
Opioid analgesics are commonly and in most cases effectively used to manage chronic pain
of moderate to severe intensity. Apart from analgesia, opioids exert numerous adverse ef‐
fects, several of which impact the gastrointestinal (GI) tract. The chronic use of opioid anal‐
gesics in fact is commonly associated with adverse effects on the gastrointestinal tract. [1]
Opioid–induced bowel dysfunction (OIBD) comprises gastrointestinal symptoms such as
dry mouth, anorexia, gastroesophageal reflux (GERD), delayed digestion, abdominal pain,
flatulence, bloating, nausea, vomiting, and constipation with hard stool and incomplete
evacuation. Further, side effects from long–term opioid therapy may result in more serious
intestinal complications such as faecal impaction with overflow diarrhea and incontinence,
pseudo–obstruction (causing anorexia, nausea and vomiting), disturbance of drug absorp‐
tion, and urinary retention and incontinence. OIBD may also lead to inappropriate opioid
dosing and in consequence, insufficient analgesia. As a result, OIBD significantly deteriorate
patients’ quality of life and compliance with their treatment. Approximately one-third of pa‐
tients treated with opioid analgesics do not adhere to the prescribed opioid regimen or sim‐
ply quit the treatment due to OIBD symptoms [2].
Several strategies have been advocated to prevent or treat OIBD. Use of traditional laxatives
is limited by their effectiveness, yet conveys their own adverse effects. Other possibilities
comprise an opioid switch or changing the opioid administration route. New therapies now
target opioid receptors in the gut as they represent a main source of OIBD symptoms. A
combination of an opioid and opioid antagonist (oxycodone/naloxone) in prolonged release
tablets and purely peripherally acting opioid receptor antagonist (methylnaltrexone) availa‐
ble in subcutaneous injections are currently available treatment options. This chapter re‐
views the pathophysiological basis and possible treatment strategies for OIBD.
© 2013 Leppert; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Pathophysiological mechanism of opioid–induced bowel dysfunction
Opioids produce widespread effects throughout the gastrointestinal tract though several
central and peripheral mechanisms. Such effects are a mixture of inhibitory and excitatory
actions. Opioid peptides and their receptors are found throughout the gastrointestinal tract,
especially in the gastric antrum and proximal duodenum. The basis for OIBD is therefore
complex. The peripheral opioid effect on μ–opioid receptors in the gut wall likely plays a
major role, but central effects may also be important [3]. μ–opioid receptors at a high density
reside in neurons of myenteric and submucosal plexus and immune cells in the lamina
propria [4]. Opioid receptors (predominantly μ, also κ and δ) are located in the gut wall in
the myenteric plexus and in the submucosal plexus. The former are responsible for gut mo‐
tility and the latter for secretion. These μ–opioid receptors are activated in the wall of the
stomach, small and large intestine by both endogenous (e.g. enkephalins, endorphins and
dynorphins) and exogenous (e.g. morphine, oxycodone, methadone) opioids and modify
gastrointestinal function. Activation of μ–opioid receptors inhibits excitatory and inhibitory
neural pathways within the enteric nervous system that coordinates motility. Inhibition of
excitatory neural pathways depresses peristaltic contractions. On the other hand, the block‐
ade of inhibitory neural pathways increases gut muscle activity, elevates resting muscle
tone, and results in spasm and non–propulsive motility patterns. These mechanisms give
rise to delayed gastric emptying and slowed intestinal transit [5].
Activation of opioid receptors in the submucosa inhibits water and electrolyte secretion into
the gut lumen and increases fluid absorption from the intestine and accelerates blood flow
in the gut wall [6]. Opioids increase activity in the sympathetic nervous system and thereby
decrease secretion. Endocrine cells located in the epithelium also may play a role in regulat‐
ing motor activity and secretion in the gut. Interms of motility, peripheral μ–opioid recep‐
tors inhibit intestinal transit independent of central μ–opioid receptors [7]. Moreover,
opioids increase ileocaecal and anal sphincter tones and impair defecation reflex through re‐
duced sensitivity to distension and increased internal anal sphincter tone [8]. Morphine ad‐
ministration leads to sphincter contraction and to a decreased emptying of pancreatic juice
and bile [9], which may impair digestion. The anal sphincter dysfunction is an important
factor in the sensation of anal blockage [10,11].
The central mechanism of opioid effects on the gastrointestinal tract is supported by the re‐
sults of animal studies in which intracerebroventricular administration of morphine inhibit‐
ed GI propulsion [12]. This effect was reversed by intracerebroventricular administration of
naloxone [13] and vagotomy [14]. Intrathecal administration of morphine reduced gastro‐
duodenal motility while intramuscular morphine gave additional effects. Thus, it seems that
both central and peripheral opioid effects play a role in opioid GI effects [15]. The indirect
evidence of both central and peripheral components of opioid effects on bowel function may
be the observed 50–60% response rate to the treatment of OIBD with methylnaltrexone
(MNTX), which displays only peripheral μ–opioid receptor antagonist effect in the treat‐
ment of patients with OIBD [16,17]. The stool remains in the gut lumen for a longer time,
allowing greater absorption of fluid. Enhanced absorption combined with opioid inhibition
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of secretomotor neurons in the epithelium of the gut [18] leads to the stool becomes hard
and dry. In summary, OIBD is the consequence of reduced gastrointestinal motility, in‐
creased absorption of fluids from the gut and decreased epithelial secretion.
3. Dyspepsia
Dysfunction of the upper gastrointestinal tract (esophagus, stomach and duodenum) often
manifests as dyspepsia. Dyspepsia represents a constellation of symptoms rather than a sin‐
gle disease entity. Its diverse symptoms may be expressed as epigastric pain, anorexia,
belching, heartburn, bloating, nausea and vomiting, post–prandial fullness, early satiety,
and/or regurgitation [19].
Two types of dyspepsia may be diagnosed:
• Structural (organic) dyspepsia for which a structural change can be demonstrated, often due
to acid–related disease such as a gastric ulcer. In advanced cancer patients, symptoms
may arise from NSAID, corticosteroid and bisphosphonate administration.
• Functional dysmotility (non–ulcer dyspepsia) due to dysmotility and/or altered sensitivity of
the upper GI tract affecting the esophagus, stomach and duodenum. Esophageal and gas‐
troduodenal dysmotility can be differentiated.
In  cancer  patients,  it  may be  iatrogenic  (e.g.;  opioid–induced delayed gastric  emptying)
and associated with  disease-related complications  like  hepatomegaly  or  massive  ascites.
Furthermore,  paraneoplastic  visceral  autonomic  neuropathy seems to  play an important
role. Opioids and other drugs such as anticholinergics, tricyclic antidepressants, benzodia‐
zepines,  nitrates and calcium channel blockers may decrease lower esophageal sphincter
tone and lead to reflux (GERD) that would be aggravated secondarily by delayed gastric
emptying.  Gastric  secretory and motor activity may be also affected by chronic alcohol‐
ism, diabetes, uremia, anxiety and depression. Gastroparesis is a symptomatic chronic dis‐
order  characterized  by  impaired  gastric  emptying  in  the  absence  of  a  structural  cause.
This occurs as a component of paraneoplastic syndromes, most commonly in the course
of small cell lung, breast, ovarian cancer, Hodgkin disease or multiple myeloma. In addi‐
tion to opioid adversely affecting gastric emptying, other drugs such as anticholinergics,
neuroleptics or tricyclic  antidepressants can aggravate gastroparesis.  Meanwhile,  concur‐
rent conditions such as diabetes, prior gastric surgery, and neuromuscular disorders may
further impair gastric emptying. Lastly, gastric or pancreatic tumors can inflict a mechani‐
cal outlet obstruction.
Another component that might co-exist is gastroesophageal reflux disease (GERD) due to re‐
flux of gastric contents into the esophagus, causing mucosal damage and heartburn.
The prevalence of functional dyspepsia is high in the normal population (24–34%) and even
higher in cancer patients (70%) [20]. Opioids adversely affect the esophagus. This class of
drugs impairs esophageal inhibitory innervation and so induces spastic esophageal dysfunc‐
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ment of patients with OIBD [16,17]. The stool remains in the gut lumen for a longer time,
allowing greater absorption of fluid. Enhanced absorption combined with opioid inhibition
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of secretomotor neurons in the epithelium of the gut [18] leads to the stool becomes hard
and dry. In summary, OIBD is the consequence of reduced gastrointestinal motility, in‐
creased absorption of fluids from the gut and decreased epithelial secretion.
3. Dyspepsia
Dysfunction of the upper gastrointestinal tract (esophagus, stomach and duodenum) often
manifests as dyspepsia. Dyspepsia represents a constellation of symptoms rather than a sin‐
gle disease entity. Its diverse symptoms may be expressed as epigastric pain, anorexia,
belching, heartburn, bloating, nausea and vomiting, post–prandial fullness, early satiety,
and/or regurgitation [19].
Two types of dyspepsia may be diagnosed:
• Structural (organic) dyspepsia for which a structural change can be demonstrated, often due
to acid–related disease such as a gastric ulcer. In advanced cancer patients, symptoms
may arise from NSAID, corticosteroid and bisphosphonate administration.
• Functional dysmotility (non–ulcer dyspepsia) due to dysmotility and/or altered sensitivity of
the upper GI tract affecting the esophagus, stomach and duodenum. Esophageal and gas‐
troduodenal dysmotility can be differentiated.
In  cancer  patients,  it  may be  iatrogenic  (e.g.;  opioid–induced delayed gastric  emptying)
and associated with  disease-related complications  like  hepatomegaly  or  massive  ascites.
Furthermore,  paraneoplastic  visceral  autonomic  neuropathy seems to  play an important
role. Opioids and other drugs such as anticholinergics, tricyclic antidepressants, benzodia‐
zepines,  nitrates and calcium channel blockers may decrease lower esophageal sphincter
tone and lead to reflux (GERD) that would be aggravated secondarily by delayed gastric
emptying.  Gastric  secretory and motor activity may be also affected by chronic alcohol‐
ism, diabetes, uremia, anxiety and depression. Gastroparesis is a symptomatic chronic dis‐
order  characterized  by  impaired  gastric  emptying  in  the  absence  of  a  structural  cause.
This occurs as a component of paraneoplastic syndromes, most commonly in the course
of small cell lung, breast, ovarian cancer, Hodgkin disease or multiple myeloma. In addi‐
tion to opioid adversely affecting gastric emptying, other drugs such as anticholinergics,
neuroleptics or tricyclic  antidepressants can aggravate gastroparesis.  Meanwhile,  concur‐
rent conditions such as diabetes, prior gastric surgery, and neuromuscular disorders may
further impair gastric emptying. Lastly, gastric or pancreatic tumors can inflict a mechani‐
cal outlet obstruction.
Another component that might co-exist is gastroesophageal reflux disease (GERD) due to re‐
flux of gastric contents into the esophagus, causing mucosal damage and heartburn.
The prevalence of functional dyspepsia is high in the normal population (24–34%) and even
higher in cancer patients (70%) [20]. Opioids adversely affect the esophagus. This class of
drugs impairs esophageal inhibitory innervation and so induces spastic esophageal dysfunc‐
Dyspepsia and Opioid–Induced Bowel Dysfunction: The Role of Opioid Receptor Antagonists
http://dx.doi.org/10.5772/56624
185
tion while impairing lower esophageal relaxation, leading to swallowing difficulties (dys‐
phagia). Opioids also reduce the lower esophageal sphincter (LES) pressure, thereby
decreasing the barrier pressure between the stomach and the esophagus, producing acid-re‐
flux symptoms. This effect is reversed by naloxone. Opioids inhibit gastric emptying, a
product of enhanced gastric relaxation and heightened pyloric tone. This decrease in gastric
emptying results from both central and peripheral effects, although a peripheral μ–opioid
receptor mechanism is dominant. Opioid administration increases duodenal motility by
generating patterns of contractions resembling migrating motor complex (MMC) phase III
patterns. Endorphins in humans decrease antral phasic pressure activity and increase pylor‐
ic phasic pressure activity and induce MMC III–like bursts of contractile activity in the prox‐
imal gut followed by motor quiescence. Exogenous and endogenous opioids impair gastric
emptying [21, 22].
The evaluation of patients with functional dyspepsia and gastroparesis is based on a careful
history taking and physical examination that allow differentiating between functional and
structural dyspepsia and GERD. The symptoms of gastroparesis, as quantified by the Gas‐
troparesis Cardinal Symptom Index (GCSI), consists of 9 symptoms, each graded from 0
(none) to 5 (very severe), divided into 3 subscales: postprandial fullness/early satiety, nau‐
sea/vomiting, and bloating [23]. Upper endoscopy is usually needed to exclude mechanical
obstruction and to assess for mucosal lesions. It is recommended in patients with alarming
symptoms e.g.; those suspected for gastrointestinal bleeding. Endoscopy may be also con‐
ducted when symptoms develop with NSAIDs administration and when treatment with an‐
tisecretory drugs or antacids is unsuccessful. Blood tests assessing complete blood count
and biochemistry might be useful. An ultrasound or CT abdominal scan is helpful to assess
for cancer spread. In some patients, solid phase gastric scintigraphic emptying studies or
breath tests may be needed to confirm gastroparesis. Other investigations such as electro‐
gastrography, antroduodenal manometry are infrequently used in cancer patients.
4. Management of opioid–induced bowel dysfunction
4.1. The management of dyspepsia
a. Non–pharmacological measures
Treatment should be directed at cause of symptoms. Functional dyspepsia may be treated
with non–pharmacological measures and drugs. The former comprise explanation and edu‐
cation of patients and families. Advice on the diet may play an important role. Fatty foods
should be avoided as lipids impair gastric emptying, while lipids entering the duodenum
may aggravate impaired gastric accommodation and gastric hypersensitivity. Medications
that may cause dyspepsia (e.g. NSAIDs) should be discontinued when possible [24].
b. Pharmacological approach
Pharmacological treatment is usually needed. First-line therapy for dyspepsia is usually acid
suppression. Proton pomp inhibitors (PPIs) such as omeprazole, esomeprazole or pantopra‐
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zole are used once daily in doses 20–40 mg, best given 30 minutes before breakfast. In cancer
patients, prokinetic agents are commonly administered, aiming to counteract opioid–in‐
duced motility disorders.
Typically, metoclopramide is prescribed (commonly as 10 mg t.i.d.) for patients with func‐
tional dyspepsia, especially when symptoms arise from gastroparesis. Metoclopramide
works mostly in the upper GI tract through blocking dopaminergic receptors. As metoclo‐
pramide also acts centrally, its use is associated with the added risk of extra–pyramidal ef‐
fects, particularly in younger patients and children. Metoclopramide also inhibits the
cytochrome, CYP2D6 enzyme [25]. The most common adverse effects of metoclopramide are
restlessness, drowsiness and fatigue. Concomitant use of antidepressants, such as tricyclics,
selective serotonin reuptake inhibitors (SSRIs) and newer serotonin–noradrenalin reuptake
inhibitors (venlafaxine, duloxetine), may aggravate the adverse effects of metoclopramide
[26]. Extrapyramidal effects are unlikely to occur when using domperidone, which does not
cross blood–brain barrier [27]. Cisapride is a 5HT4 receptor agonist, affecting the entire GI
tract; however, its cardiotoxicity has limited use [28].
Itopride works through peripheral blocking dopaminergic receptors. It inhibits acetylcholi‐
nesterase and so increases acetylcholine levels. Itopride works through the whole GI tract. It
is devoid of activity at 5–HT4 and 5–HT3 receptors. Itopride is metabolized through monoox‐
idase system. Thus, it has no significant risk of pharmacokinetic interactions with other
drugs. Itopride does not cross blood–brain barrier and in consequence does not induce ex‐
trapyramidal effects. The dose usually equals 50 mg t. i. d. [29]
Prucalopride, a new prokinetic agent, is a highly selective 5HT4 receptor agonist that stimu‐
lates gut motility in vitro and in vivo. Prucalopride at 2–4 mg daily accelerates whole gut,
gastric, small bowel and colonic transit in constipated patients [30]. The recommended dose
is 1–2 mg once daily. Prucalopride is used in managing chronic constipation predominantly
in women, but has not been evaluated in gastroparesis as yet [31]. Treatment is usually well-
tolerated; typical adverse effects are headaches (present in 25–30% of treated patients), nau‐
sea (12–24%), abdominal pain or cramps (16–23%) and diarrhea (12–19%) [32]. Both itopride
and prucapolpride appear safe relative to cardiac function.
Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist that appears quite
effective for chronic constipation and the irritable bowel syndrome [33,34]. It looks promis‐
ing in the treatment of gastroparesis and so may have a role in OBID.
Lubiprostone, a bicyclic fatty acid derived from prostaglandin E1, acts by specifically acti‐
vating chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a
chloride-rich fluid secretion. These secretions soften the stool, increase intestinal motility,
and so promote spontaneous bowel movements. Lubiprostone thus has value in treating
functional constipation.
4.2. Oral and rectal laxatives for Opioid-induced Bowel Dysfunction
General measures to be taken in patients with OIBD and OIC include the assessment and
applying prophylactic measures matched to the patient’s general condition [35]. Change of
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tion while impairing lower esophageal relaxation, leading to swallowing difficulties (dys‐
phagia). Opioids also reduce the lower esophageal sphincter (LES) pressure, thereby
decreasing the barrier pressure between the stomach and the esophagus, producing acid-re‐
flux symptoms. This effect is reversed by naloxone. Opioids inhibit gastric emptying, a
product of enhanced gastric relaxation and heightened pyloric tone. This decrease in gastric
emptying results from both central and peripheral effects, although a peripheral μ–opioid
receptor mechanism is dominant. Opioid administration increases duodenal motility by
generating patterns of contractions resembling migrating motor complex (MMC) phase III
patterns. Endorphins in humans decrease antral phasic pressure activity and increase pylor‐
ic phasic pressure activity and induce MMC III–like bursts of contractile activity in the prox‐
imal gut followed by motor quiescence. Exogenous and endogenous opioids impair gastric
emptying [21, 22].
The evaluation of patients with functional dyspepsia and gastroparesis is based on a careful
history taking and physical examination that allow differentiating between functional and
structural dyspepsia and GERD. The symptoms of gastroparesis, as quantified by the Gas‐
troparesis Cardinal Symptom Index (GCSI), consists of 9 symptoms, each graded from 0
(none) to 5 (very severe), divided into 3 subscales: postprandial fullness/early satiety, nau‐
sea/vomiting, and bloating [23]. Upper endoscopy is usually needed to exclude mechanical
obstruction and to assess for mucosal lesions. It is recommended in patients with alarming
symptoms e.g.; those suspected for gastrointestinal bleeding. Endoscopy may be also con‐
ducted when symptoms develop with NSAIDs administration and when treatment with an‐
tisecretory drugs or antacids is unsuccessful. Blood tests assessing complete blood count
and biochemistry might be useful. An ultrasound or CT abdominal scan is helpful to assess
for cancer spread. In some patients, solid phase gastric scintigraphic emptying studies or
breath tests may be needed to confirm gastroparesis. Other investigations such as electro‐
gastrography, antroduodenal manometry are infrequently used in cancer patients.
4. Management of opioid–induced bowel dysfunction
4.1. The management of dyspepsia
a. Non–pharmacological measures
Treatment should be directed at cause of symptoms. Functional dyspepsia may be treated
with non–pharmacological measures and drugs. The former comprise explanation and edu‐
cation of patients and families. Advice on the diet may play an important role. Fatty foods
should be avoided as lipids impair gastric emptying, while lipids entering the duodenum
may aggravate impaired gastric accommodation and gastric hypersensitivity. Medications
that may cause dyspepsia (e.g. NSAIDs) should be discontinued when possible [24].
b. Pharmacological approach
Pharmacological treatment is usually needed. First-line therapy for dyspepsia is usually acid
suppression. Proton pomp inhibitors (PPIs) such as omeprazole, esomeprazole or pantopra‐
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zole are used once daily in doses 20–40 mg, best given 30 minutes before breakfast. In cancer
patients, prokinetic agents are commonly administered, aiming to counteract opioid–in‐
duced motility disorders.
Typically, metoclopramide is prescribed (commonly as 10 mg t.i.d.) for patients with func‐
tional dyspepsia, especially when symptoms arise from gastroparesis. Metoclopramide
works mostly in the upper GI tract through blocking dopaminergic receptors. As metoclo‐
pramide also acts centrally, its use is associated with the added risk of extra–pyramidal ef‐
fects, particularly in younger patients and children. Metoclopramide also inhibits the
cytochrome, CYP2D6 enzyme [25]. The most common adverse effects of metoclopramide are
restlessness, drowsiness and fatigue. Concomitant use of antidepressants, such as tricyclics,
selective serotonin reuptake inhibitors (SSRIs) and newer serotonin–noradrenalin reuptake
inhibitors (venlafaxine, duloxetine), may aggravate the adverse effects of metoclopramide
[26]. Extrapyramidal effects are unlikely to occur when using domperidone, which does not
cross blood–brain barrier [27]. Cisapride is a 5HT4 receptor agonist, affecting the entire GI
tract; however, its cardiotoxicity has limited use [28].
Itopride works through peripheral blocking dopaminergic receptors. It inhibits acetylcholi‐
nesterase and so increases acetylcholine levels. Itopride works through the whole GI tract. It
is devoid of activity at 5–HT4 and 5–HT3 receptors. Itopride is metabolized through monoox‐
idase system. Thus, it has no significant risk of pharmacokinetic interactions with other
drugs. Itopride does not cross blood–brain barrier and in consequence does not induce ex‐
trapyramidal effects. The dose usually equals 50 mg t. i. d. [29]
Prucalopride, a new prokinetic agent, is a highly selective 5HT4 receptor agonist that stimu‐
lates gut motility in vitro and in vivo. Prucalopride at 2–4 mg daily accelerates whole gut,
gastric, small bowel and colonic transit in constipated patients [30]. The recommended dose
is 1–2 mg once daily. Prucalopride is used in managing chronic constipation predominantly
in women, but has not been evaluated in gastroparesis as yet [31]. Treatment is usually well-
tolerated; typical adverse effects are headaches (present in 25–30% of treated patients), nau‐
sea (12–24%), abdominal pain or cramps (16–23%) and diarrhea (12–19%) [32]. Both itopride
and prucapolpride appear safe relative to cardiac function.
Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist that appears quite
effective for chronic constipation and the irritable bowel syndrome [33,34]. It looks promis‐
ing in the treatment of gastroparesis and so may have a role in OBID.
Lubiprostone, a bicyclic fatty acid derived from prostaglandin E1, acts by specifically acti‐
vating chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a
chloride-rich fluid secretion. These secretions soften the stool, increase intestinal motility,
and so promote spontaneous bowel movements. Lubiprostone thus has value in treating
functional constipation.
4.2. Oral and rectal laxatives for Opioid-induced Bowel Dysfunction
General measures to be taken in patients with OIBD and OIC include the assessment and
applying prophylactic measures matched to the patient’s general condition [35]. Change of
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diet (increased food and fluid intake), more physical activity, assuming a sitting position
during bowel movement and obtaining privacy during defecation process are recommend‐
ed [36]. Patients treated with opioids should be considered for prokinetic administration
[37]. Any reversible causes such as hypercalcaemia should also be treated. Discontinuing or
decreasing doses of drugs that may aggravate constipation (e.g. tricyclics, neuroleptics, anti‐
cholinergics) should also be considered. Patients and families should be educated about the
means to prevent and treat OIBD [9].
In most patients with OIBD, laxatives are necessary. The general recommendation is to com‐
bine orally administered osmotic agents – usually lactulose or macrogol (PEG – polyethy‐
lene glycol) which have an osmotic effect in the colon [10] with stimulants activating on
neurons in the myenteric and submucosal plexus in colon and reducing absorption of water
and electrolytes from the intraluminal contents: anthracenes (senna), polyphenolics (bisa‐
codyl) or sodium picosulphate. Unfortunately, these drugs exhibit limited efficacy in pa‐
tients suffering from OIBD. Moreover, they may cause several adverse effects and must be
administered on a regular basis [38]. Other classes of laxatives are faecal lubricants (liquid
paraffin), stool softeners (surfactants: sodium docusate); however, they are usually ineffec‐
tive when administered alone [39]. The use of bulk–forming agents such as fibre, bran,
methylcellulose and psyllium seeds has limited role in patients with advanced constipation
and warrant ingesting adequate fluids (at least 2 liters per day) [40–42]. Castor oil is not rec‐
ommended due to its sudden stimulating effect on bowel motility and the risk of developing
severe abdominal cramps [43]. If oral laxatives are found to be ineffective, rectal treatment
should be considered.
Rectal laxatives comprise suppositories increasing intestinal motility through direct stimula‐
tion of the nerve endings in the myenteric ganglia of the colon, thus inducing peristalsis (bi‐
sacodyl) or using osmotic drugs (glycerol), which act by irritating the rectal mucosa and also
enhance the colonic motility that subsequently triggers the defecation reflex. The next step if
these agents prove ineffective is rectal enemas, either as normal saline (100–200 ml) or phos‐
phates (120–150 ml).
The management of faecal impaction depends on the severity of symptoms (rectal pain, ab‐
dominal colicky pain, protruding hard faeces and faecal leakage). If the symptoms are not
severe in case of soft faeces, administer bisacodyl 10–20 mg once daily either rectally or oral‐
ly until bowel movements are achieved. If hard faeces are present, use glycerol and bisacod‐
yl suppositories or osmotic enemas. Enemas of arachis oil (130 ml) or of decussate sodium
(100 ml) followed by a phosphate enema next day may be appropriate. Macrogol (PEG) re‐
duces the need for digital disimpaction. Digital stool evacuation may be necessary in cases
of severe symptoms, when neither oral nor rectal treatment gives a desired effect and faecal
impaction is not relieved, causing significant distress to the patient. As the procedure is
quite painful and distressing, it should be performed with great caution and only when nec‐
essary and sometimes necessitating intravenous sedation with midazolam combined with
opioids plus topical analgesics [44].
Polyethylene glycol (PEG) and sodium picosulphate are more effective than lactulose in OIC
in cancer pain patients [45]. PEG specifically appears to be more effective than lactulose in
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terms of weekly bowel movement frequency, patient satisfaction, ease of defecation and re‐
duced constipation symptoms with similar treatment tolerance and slightly higher lactulose
costs [46]. For palliative care patients, different laxative regimens have no real differences.
Overall, there is limited efficacy of traditional laxatives; well-done randomised controlled
trials are lacking [47].
4.3. Opioid switch
The possibility of opioid switch for OIBD should be considered as one of the available treat‐
ment options. Opioids, which seem to be more often associated with constipation, are co‐
deine and dihydrocodeine (opioids for mild to moderate pain), morphine, oxycodone and
hydromorphone (opioids for moderate to severe pain). These opioids may be switched to
other opioids belonging to the same group but having less constipating effect: codeine or di‐
hydrocodeine may be switched to tramadol; morphine, oxycodone or hydromorphone to
transdermal opioids (fentanyl, buprenorphine) or to methadone [48,49]. The most convinc‐
ing evidence supporting the benefits of the opioid switch as regards constipation relief
comes from the morphine to transdermal fentanyl switch [50–53]. In contrast to clinical stud‐
ies, observational surveys do not provide evidence for advantages of transdermal fentanyl
over other opioid analgesics with respect to bowel function. [54-55] Other studies report
similar or less intense constipating effects with transdermal buprenorphine compared to CR
morphine [56] and after a switch from morphine to methadone [57–59]. There may be a ben‐
efit to administering tramadol rather than small morphine doses [60–62] or dihydrocodeine
[63] with respect to the constipation intensity. However, no differences were found in con‐
stipation in cancer patients with pain between transdermal opioids (buprenorphine and fen‐
tanyl) and oral controlled release hydromorphone [64].
4.4. Targeted treatment of opioid–induced bowel dysfunction
Few clinical studies compared the efficacy of different laxatives [65] and controlled studies
are lacking [66]. Certainly traditional laxatives do not target the cause of OIBD, which is pre‐
dominantly associated with opioid analgesics binding and activating μ–opioid receptors in
the GI tract [67]. Treatment directed at the cause of OIBD involves either using a combina‐
tion of opioid analgesics with opioid receptor antagonists, which act both centrally and pe‐
ripherally, or administering opioid receptor antagonists, which act exclusively peripherally.
An important advantage of this approach is the fact that it is targeted treatment of OIBD and
that it may be combined with oral laxatives, if necessary. Finally, this approach may elimi‐
nate the need for rectal measures, which patients tolerate poorly.
Apart from opioid antagonists with exclusively peripheral effects, opioid receptor antago‐
nists with a central mode of action are naloxone, naltrexone and nalmefene. The majority of
studies performed so far have used immediate release formulation of oral naloxone (IR na‐
loxone). In spite of high IR naloxone efficacy in the treatment of OIBD, some patients experi‐
ence opioid withdrawal symptoms and attenuation of analgesia, rendering IR naloxone less
useful when administered alone [68–70]. Nalmefene [71] and nalmefene glucuronide [72] be‐
have similarly.
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essary and sometimes necessitating intravenous sedation with midazolam combined with
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hydromorphone (opioids for moderate to severe pain). These opioids may be switched to
other opioids belonging to the same group but having less constipating effect: codeine or di‐
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comes from the morphine to transdermal fentanyl switch [50–53]. In contrast to clinical stud‐
ies, observational surveys do not provide evidence for advantages of transdermal fentanyl
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are lacking [66]. Certainly traditional laxatives do not target the cause of OIBD, which is pre‐
dominantly associated with opioid analgesics binding and activating μ–opioid receptors in
the GI tract [67]. Treatment directed at the cause of OIBD involves either using a combina‐
tion of opioid analgesics with opioid receptor antagonists, which act both centrally and pe‐
ripherally, or administering opioid receptor antagonists, which act exclusively peripherally.
An important advantage of this approach is the fact that it is targeted treatment of OIBD and
that it may be combined with oral laxatives, if necessary. Finally, this approach may elimi‐
nate the need for rectal measures, which patients tolerate poorly.
Apart from opioid antagonists with exclusively peripheral effects, opioid receptor antago‐
nists with a central mode of action are naloxone, naltrexone and nalmefene. The majority of
studies performed so far have used immediate release formulation of oral naloxone (IR na‐
loxone). In spite of high IR naloxone efficacy in the treatment of OIBD, some patients experi‐
ence opioid withdrawal symptoms and attenuation of analgesia, rendering IR naloxone less
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4.5. Combined opioid receptor agonist with its antagonist
One  of  methods  to  decrease  the  frequency  of  constipation  in  patients  requiring  strong
opioids is using formulation composed of an opioid and opioid receptor antagonist. The
formulation combining oxycodone and naloxone is available in the form of prolonged re‐
lease (PR) tablets containing both drugs in the ratio of 2:1 (PR oxycodone/PR naloxone 5
mg/2.5  mg,  10 mg/5 mg,  20 mg/10 mg,  40 mg/20 mg) [73].  The optimal  2:1  ratio  of  PR
oxycodone/PR naloxone tablets was demonstrated in a phase II study rendering effective
analgesia and improvement in bowel function with good treatment toleration in patients
with severe chronic pain [74]. PR oxycodone/PR naloxone is registered for the indication
of severe pain, which may only be successfully treated with opioid analgesics. In this for‐
mulation,  naloxone  counteracts  the  development  of  OIBD  through  inhibition  of  oxyco‐
done  effect  on  opioid  receptors  in  the  gut  wall  [75].  The  starting  PR  oxycodone/PR
naloxone  doses  in  opioid–naive  patients  is  5  mg/2.5  mg  b.i.d.  Patients  unsuccessfully
treated with opioids for mild to moderate pain (tramadol, codeine, dihydrocodeine) may
start with the dose 10 mg/5 mg b.i.d. When rotating from other opioids for moderate to
severe  pain  to  PR oxycodone/PR naloxone,  the  starting  dose  is  established individually
depending on the  amount  of  previously  administered opioid,  analgesia  and adverse  ef‐
fects. The maximal daily dose of PR oxycodone/PR naloxone recommended equals 40 mg/
20 mg twice  daily.  However,  in  a  study conducted in  cancer  patients  with  pain higher
daily  doses  up  to  120  mg/60  mg were  effective  and  well–tolerated  while  symptoms  of
OIBD were decreased, compared to PR oxycodone administered alone [76].
Following oral administration, oxycodone displays high bioavailability (60 – 87%) and pro‐
vides effective analgesia [77,78]. Naloxone exhibits low bioavailability after oral administra‐
tion (< 2%) and undergoes extensive first–pass metabolism in the liver with the formation of
naloxone–3–glucuronide [79]. Analgesic effect is not reversed by naloxone and no symp‐
toms of opioid withdrawal occur. This effect of orally administered naloxone depends on
normal liver function. Thus, any hepatic impairment should be carefully considered. In pa‐
tients suffering from decompensated liver disease, PR oxycodone/PR naloxone administra‐
tion is not recommended. There is a clinically observed difference between the
administration of IR and PR formulations of naloxone. IR naloxone in some patients may at‐
tenuate analgesia or induce opioid withdrawal symptoms. The PR naloxone formulation
prevents saturation of hepatic enzyme system responsible for naloxone metabolism and re‐
duces the risk of opioid antagonism in the CNS [3].
PR oxycodone/PR naloxone provides similar analgesic efficacy to oxycodone with improve‐
ment in bowel function, a lower consumption of laxatives and more frequent spontaneous
bowel movements [82]. during treatment with PR oxycodone/PR naloxone in comparison to
PR oxycodone therapy [80–82]. Long–term therapy (up to 52 weeks) with PR oxycodone/PR
naloxone in daily doses up to 80 mg/40 mg appears effective and safe [83]. Analgesia is ef‐
fective while bowel function and quality of life improved with PR oxycodone/PR naloxone
(20 mg/10 mg to 40 mg/20 mg) treatment in patients with severe neuropathic non–malignant
pain [84]. Even at quite high doses, PR oxycodone/PR naloxone doses exhibited a benefit
compared to PR oxycodone administered alone [85]. PR oxycodone/PR naloxone in doses up
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to 120 mg/60 mg per day provides effective analgesia while improving bowel function [76].
Adverse effects of PR oxycodone/PR naloxone and PR oxycodone are similar; the frequency
of diarrhea is slightly higher in PR oxycodone/PR naloxone compared to PR oxycodone ad‐
ministered alone (5.2% vs. 2.6%) [81]. However, PR oxycodone/PR naloxone less frequency
induces nausea (6.3% vs. 10.5%), vomiting (1.3% vs. 4.3%), abdominal pain (1.3% vs. 4.3%)
and dyspepsia (0.6% vs. 2.5%) in comparison to PR oxycodone administered alone [82].
These differences might be explained by naloxone antagonist effect on gastric and gut
opioid receptors and in consequence, naloxone prokinetic properties [86]. PR oxycodone/PR
naloxone studies were performed mainly in patients with chronic, non–malignant pain [80–
83,85,89]. Opioid switch to PR oxycodone/PR naloxone for cancer patients generally pro‐
vides adequate analgesia and improved bowel function [87], but in some requiring height‐
ened analgesia, very high doses of PR up to 240 mg per day oxycodone administered alone
may be necessary[88].
The contraindications for PR oxycodone/PR naloxone comprise bowel obstruction, acute ab‐
dominal conditions, diarrhea and an allergy to the drug. PR oxycodone/PR naloxone is
available in several European countries. One pack contains 60 PR oxycodone/PR naloxone
tablets of 5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg, 40 mg/20 mg strength. Direct treatment
costs for PR oxycodone/PR naloxone in patients with moderate–to–severe non–malignant
pain and opioid–induced constipation is slightly higher compared to oxycodone PR. When
analysing constipation treatment costs and benefits of PR oxycodone/PR naloxone in terms
of improved quality–adjusted life–years, PR oxycodone/PR naloxone appears to be cost–ef‐
fective option in the UK [90]. Government and other insurance schemes however may not
reimburse PR oxycodone/PR naloxone tablets.
4.6. Purely peripherally acting opioid receptor antagonists
Methylnaltrexone (MNTX), a derivative of naltrexone, is a peripheral μ–opioid receptor an‐
tagonist, which does not cross blood–brain barrier [91]. Because of its low oral bioavailabili‐
ty, MNTX is administered subcutaneously or intravenously [92]. However, MNTX taken
orally prevents the delay in oro–ceacal transit time that follows intravenous morphine ad‐
ministration [93]. MNTX plasma half–life equals 105 to 140 minutes. 50% is excreted un‐
changed in the urine. MNTX is a weak CYP2D6 inhibitor with no significant drug
interactions [94]. MNTX is used to treat OIC in adult patients with advanced diseases when
constipation does not respond to conventional oral laxatives. The drug is available in am‐
poules containing 12 mg MNTX bromide in the volume of 0.6 ml and is applied via subcuta‐
neous injections. The recommended single MNTX dose is 8 mg in patients with body weight
38–61 kg or 12 mg if the body mass is 62–114 kg [95]. Those falling outside of this range
should receive a dose of 0.15 mg/kg. No dose adjustment is necessary for patients with mild
to moderate hepatic or renal impairment. However, in patients with severe renal failure
(creatinine clearance < 30 mL/min) the MNTX dose should be reduced by one–half [96].
A bowel movement within 4 h after MNTX injection is observed in 50–60% patients (the me‐
dian time to bowel movement after the drug administration is 30 minutes). If no therapeutic
effect is observed, the injection may be repeated every other day. MNTX adverse effects
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4.5. Combined opioid receptor agonist with its antagonist
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comprise abdominal pain (28% of the treated patients), flatulence (13%), nausea (11%), dizzi‐
ness (7%) and diarrhoea (5%) [16]. However, the administration of MNTX may be associated
with an increased risk of gastrointestinal perforation in patients with diseases that decrease
gut wall integrity (cancer, peptic ulceration and Ogilvie’s syndrome) or on concomitant
medications (NSAIDs, bevacizumab). GI perforation occur at different possible locations
(duodenum, small and large bowel). A possible contributing factor might be the prokinetic
effect of MNTX. It is not known if dose and duration of the treatment with MNTX relate to
this complication [95]. As MNTX does not cross the blood–brain barrier, there is no attenua‐
tion of analgesia nor is there an opioid withdrawal syndrome [17]. The use of MNTX is con‐
traindicated in patients with mechanical bowel obstruction, in acute abdominal conditions
and in case of allergy to the drug. MNTX may be used in palliative care patients with OIBD
not amenable to the treatment with oral laxatives. Several clinical studies have demonstrat‐
ed the effectiveness of MNTX in patients with advanced diseases and with OIBD
[16,17,95,96,98–100]. Peripherally active opioid receptor antagonists in the treatment of
OIBD are effective and safe in [101-4]. Long–term efficacy and safety of opioid antagonists is
not yet clearly established, in part due to a limited number of randomized studies [105-6].].
The Expert Working Group of the Polish Association for Palliative Medicine developed a
three step ladder for the management of OIC (Fig. 1) [43]. This updated version of the ladder
takes into account new therapies directed at the underlying mechanism of OIBD [107].
20





At the first step traditional oral laxatives and/or PR oxycodone/PR 
naloxone may be considered. PR oxycodone/PR naloxone targets the 
source of OIBD (prevention and treatment) as PR naloxone blocks opioid 
receptors in the gut and PR oxycodone provides effective analgesia. PR 
oxycodone/PR naloxone may be considered in cancer pain patients who 
are at high risk of OIBD development such as those with GI tumors, 
patients who require combined treatment with opioids and other drugs 
disturbing normal bowel function, e.g. advanced cancer patients. At the 
second step subcutaneous administration of MNTX may be considered 
       Drug(s) of step I (oral): 
 Osmotic agents: 
lactulose or macrogol 
 Stimulants: antranoids 
or poliphenolics 
 Oxycodone/naloxone 
      Drug(s) of step II: 
 Rectal suppositories 
 PAMORA* 
(Methylnaltrexone – sc) 
      Invasive procedures of step III:  
 Rectal enema 
 Manual evacuation** 
Constipation persists or intensifies
Constipation persists or intensifies
* PAMORA–peripherally acting mu–opioid receptor antagonists (methylnaltrexone) indicated for patients who do not
respond to traditional oral laxatives without bowel obstruction and acute abdominal illness; ** This procedure should
be used only when other measures fail nd he f ecal impaction caus s significant pain and distress for th  patient. It
should be proceeded by a sedative and analgesics (local and systemic) administration that provide effective relief of
severe pain and distress associated with manual stool evacuation; s  – subcutaneous
Figure 1. The three-step ladder of the management of opioid–induced constipation [43,107]
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At the first step traditional oral laxatives and/or PR oxycodone/PR naloxone may be consid‐
ered. PR oxycodone/PR naloxone targets the source of OIBD (prevention and treatment) as
PR naloxone blocks opioid receptors in the gut and PR oxycodone provides effective analge‐
sia. PR oxycodone/PR naloxone may be considered in cancer pain patients who are at high
risk of OIBD development such as those with GI tumors, patients who require combined
treatment with opioids and other drugs disturbing normal bowel function, e.g. advanced
cancer patients. At the second step subcutaneous administration of MNTX may be consid‐
ered when traditional oral laxatives are ineffective, which may allow avoiding invasive and
often painful invasive procedures at step 3 of the ladder.
5. Conclusions
OIBD in patients diagnosed with chronic diseases is a challenging problem that health care
providers often underestimate. This is particularly important in patients regularly receiving
opioids for pain or other indications. Thanks to newly introduced drugs that target the
cause of OIBD, a more effective therapy is available. The experience with MNTX and PR
oxycodone/PR naloxone in patients suffering from OIBD is promising. Further clinical stud‐
ies are needed to develop more effective guidelines for the management of OIBD and to es‐
tablish more precisely the role of opioid receptor antagonists. The role of opioid receptor
antagonists as potential antiemetic and prokinetic agents should be further explored as sug‐
gested by experimental studies in animals. The cost-benefit from new therapies must be
carefully considered; overall resources may actually be saved from reduced use of tradition‐
al laxatives. The most important advantage of targeted therapies is to decrease patient suf‐
fering from OIBD, substantial reduce the need to perform invasive rectal procedures and
most importantly, improve quality of life.
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